<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005441.pub3" GROUP_ID="LIVER" ID="375205020710004161" MERGED_FROM="" MODIFIED="2014-02-24 10:17:39 +0000" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="01" REVMAN_SUB_VERSION="5.2.8 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2014-02-24 11:14:43 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2012-06-06 09:22:42 +0200" MODIFIED_BY="[Empty name]">Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C</TITLE>
<CONTACT>
<PERSON ID="08E2F89082E26AA2002F1D7AD97D8A77" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Goran</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hauser</LAST_NAME>
<SUFFIX/>
<POSITION>Medical doctor</POSITION>
<EMAIL_1>ghauser@medri.hr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Gastroenterology</DEPARTMENT>
<ORGANISATION>Clinical Hospital Centre Rijeka</ORGANISATION>
<ADDRESS_1>Kresimirova 42</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rijeka</CITY>
<ZIP>51 000</ZIP>
<REGION/>
<COUNTRY CODE="HR">Croatia</COUNTRY>
<PHONE_1>385 51 658 122</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-02-24 11:14:43 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="08E2F89082E26AA2002F1D7AD97D8A77" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Goran</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hauser</LAST_NAME>
<SUFFIX/>
<POSITION>Medical doctor</POSITION>
<EMAIL_1>ghauser@medri.hr</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Gastroenterology</DEPARTMENT>
<ORGANISATION>Clinical Hospital Centre Rijeka</ORGANISATION>
<ADDRESS_1>Kresimirova 42</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rijeka</CITY>
<ZIP>51 000</ZIP>
<REGION/>
<COUNTRY CODE="HR">Croatia</COUNTRY>
<PHONE_1>385 51 658 122</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="F48AF30F82E26AA2009C393D2FDD6B25" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tahany</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Awad</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>tahany.awad@gmail.com</EMAIL_1>
<EMAIL_2>tahany.awad@gmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>The Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 354571</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="134056D182E26AA201B4268BAE08905F" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jesper</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Brok</LAST_NAME>
<SUFFIX>MD, Ph.D.</SUFFIX>
<POSITION/>
<EMAIL_1>jesperb5@hotmail.com</EMAIL_1>
<EMAIL_2>jesperb5@hotmail.com</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Paediatric Department 4072</DEPARTMENT>
<ORGANISATION>Rigshospitalet</ORGANISATION>
<ADDRESS_1>Blemdagsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>2100 Ø</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 40516963</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="7627681882E26AA20088EE035BF06853" ROLE="AUTHOR">
<PREFIX>Mr</PREFIX>
<FIRST_NAME>Kristian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Thorlund</LAST_NAME>
<SUFFIX/>
<POSITION>Assistant Professor</POSITION>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+1 604-780-0273</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Hamilton</CITY>
<ZIP/>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1>604-780-0273</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="95D6386382E26AA201C330AA55AD5845" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Davor</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>&#352;timac</LAST_NAME>
<SUFFIX>MD, Ph.D.</SUFFIX>
<POSITION/>
<EMAIL_1>davor.stimac@ri.t-com.hr</EMAIL_1>
<EMAIL_2>davor.stimac@medri.uniri.hr</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Gastroenterology</DEPARTMENT>
<ORGANISATION>Clinical Hospital Centre Rijeka</ORGANISATION>
<ADDRESS_1>Kresimirova 42</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rijeka</CITY>
<ZIP>51000</ZIP>
<REGION/>
<COUNTRY CODE="HR">Croatia</COUNTRY>
<PHONE_1>+385 516 58122</PHONE_1>
<PHONE_2/>
<FAX_1>+385 516 58826</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B8892A3682E26AA20046B37233D7D7C5" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Mahasen</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mabrouk</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>mahasen.mabrouk@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Endemic Medicine and Liver Department</DEPARTMENT>
<ORGANISATION>Faculty of Medicine, Cairo University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Cairo</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="EG">Egypt</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6439" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Christian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gluud</LAST_NAME>
<SUFFIX>M.D, Dr. Med. Sci.</SUFFIX>
<POSITION>Head of Department</POSITION>
<EMAIL_1>cgluud@ctu.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>The Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+ 45 3545 7175</PHONE_1>
<PHONE_2/>
<FAX_1>+ 45 3545 7101</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="A370F19282E26AA201ACDCB9FCA63E18" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Lise Lotte</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Gluud</LAST_NAME>
<SUFFIX>M.D., Dr.Med.Sci.</SUFFIX>
<POSITION/>
<EMAIL_1>liselottegluud@yahoo.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Gastro Unit, Medical Division</DEPARTMENT>
<ORGANISATION>Copenhagen University Hospital Hvidovre</ORGANISATION>
<ADDRESS_1>Kettegaards Alle</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hvidovre</CITY>
<ZIP>2650</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>31353212</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-02-24 11:02:31 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<UP_TO_DATE>
<DATE DAY="13" MONTH="2" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="27" MONTH="9" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="9" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2014"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2009-10-06 18:02:47 +0200" MODIFIED_BY="Dimitrinka Nikolova"/>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<INTERNAL_SOURCES MODIFIED="2012-09-25 15:56:30 +0200" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2012-09-25 15:56:30 +0200" MODIFIED_BY="[Empty name]">
<NAME>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen University Hospital</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<NAME>ERASMUS project</NAME>
<COUNTRY CODE="NONE">Other</COUNTRY>
<DESCRIPTION>
<UL>
<LI>ERASMUS project, Croatia Erasmus staff mobility was organised by the University of Rijeka and realised with the financial support of the European Commission under the auspices of the LLP Erasmus Programme.</LI>
</UL>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-02-24 11:06:49 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY MODIFIED="2014-02-20 09:34:21 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2013-11-18 21:21:59 +0100" MODIFIED_BY="[Empty name]">Peginterferon plus ribavirin is more effective than interferon plus ribavirin in clearing hepatitis C virus</TITLE>
<SUMMARY_BODY MODIFIED="2014-02-20 09:34:21 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>Importance of the review/background on the condition</I>
</B>
</P>
<P>Hepatitis C is a disease of the liver caused by the hepatitis C virus. Globally, an estimated 170 million people are chronically infected with the hepatitis C virus. Chronic hepatitis C can cause liver damage in the form of inflammation and scarring of the liver (cirrhosis). Liver damage can lead to liver failure and other complications, including liver cancer. The goal of treatment of chronic hepatitis C is to prevent complications of hepatitis C infection; this could possibly be achieved by clearing the virus from the blood of the patient (sustained virological response, that is, undetectable hepatitis C virus RNA in serum by sensitivity testing six months after the end of treatment). However, we still need to understand whether the sustained virological response outcome induced by antiviral treatment has any association with patient-relevant and clinically relevant outcomes. A combination of weekly injections of peginterferon and oral ribavirin represents the current standard of care.</P>
<P>
<B>
<I>Main findings of the review </I>
</B>
</P>
<P>The review identified and included 27 randomised clinical trials comparing peginterferon plus ribavirin versus interferon plus ribavirin in patients with chronic hepatitis C. All trials had high risk of bias, that is, overestimation of benefits and underestimation of harms. If we disregard bias from lack of blinding and industry support, then 14 trials were considered to have a lower risk of bias. All trials were able to inform on clearing virus from blood six months after the end of treatment (sustained virological response). We could not be certain that peginterferon plus ribavirin has an effect on liver-related morbidity plus all-cause mortality when compared with interferon plus ribavirin. Because so few events occurred, we cannot exclude major beneficial or detrimental effects<I>.</I> This review shows that peginterferon plus ribavirin compared with interferon plus ribavirin significantly increases the number of patients with sustained virological response (50.2% compared with 38.5%), but we do not yet know about any patient-relevant outcomes.</P>
<P>
<B>
<I>Adverse effects</I>
</B>
</P>
<P>Peginterferon plus ribavirin compared with interferon plus ribavirin significantly increased the risk of adverse events such as neutropenia (lack of white blood cells in the blood), thrombocytopenia (lack of blood platelets in the blood), arthralgia (joint pain), injection site reaction, and nausea, but adverse events leading to treatment discontinuation remained comparable for both treatments (12.3% versus 18.7%). Data about the influence of treatment on quality of life are insufficient.</P>
<P>
<B>
<I>Limitations of the review</I>
</B>
</P>
<P>This effect on virological response seems robust to analysis controlling for the risk of random errors ('play of chance'), but it may be due to the fact that all trials were considered at high risk of bias. Furthermore, we still need to have proof that sustained virological response induced by antiviral treatment has any association with patient-relevant and clinically relevant outcomes.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-02-20 22:04:11 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2014-01-06 13:14:32 +0100" MODIFIED_BY="[Empty name]">
<P>Pegylated interferon (peginterferon) plus ribavirin is the recommended treatment for patients with chronic hepatitis C, but systematic assessment of the effect of this treatment compared with interferon plus ribavirin is needed.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-06-06 09:27:29 +0200" MODIFIED_BY="[Empty name]">
<P>To systematically evaluate the benefits and harms of peginterferon plus ribavirin versus interferon plus ribavirin for patients with chronic hepatitis C.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-02-20 21:59:38 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL),<I> </I>MEDLINE, EMBASE, Science Citation Index-Expanded, and LILACS.<I> </I>We also searched conference abstracts, journals, and grey literature. The last searches were conducted in September 2013.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-02-07 12:04:33 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised clinical trials comparing peginterferon plus ribavirin versus interferon plus ribavirin with or without co-intervention(s) (e.g., other antiviral drugs) for chronic hepatitis C. Quasi-randomised and observational studies retrieved through the searches for randomised clinical trials were also considered for reports of harms. Our primary outcomes were liver-related morbidity, all-cause mortality, serious adverse events, adverse events leading to treatment discontinuation, other adverse events, and quality of life. Our secondary outcome was sustained virological response in serum, that is, undetectable hepatitis C virus RNA in serum by sensitive tests six months after the end of treatment.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-01-06 13:14:46 +0100" MODIFIED_BY="Tahany Awad">
<P>Two review authors independently used a standardised data collection form. We meta-analysed data with both fixed-effect and random-effects models. For each outcome, we calculated the odds ratio (OR) (for liver-related morbidity or all-cause mortality) or the risk ratio (RR) along with 95% confidence interval (CI) based on intention-to-treat analysis. We used domains of the trials to assess the risk of systematic errors (bias) and trial sequential analyses to assess the risk of random errors (play of chance).</P>
<P>For each outcome, we calculated the RR with 95% CI based on intention-to-treat analysis. Effects of interventions on outcomes were assessed according to GRADE.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-02-20 09:32:04 +0100" MODIFIED_BY="[Empty name]">
<P>We included 27 randomised trials with 5938 participants. All trials had high risk of bias. We considered that the risk of bias did not impact on the quality of evidence for liver-related mortality and adverse event outcomes, but it did for virological response. All trials compared peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin versus interferon plus ribavirin for participants with chronic hepatitis C. Three trials administered co-interventions (amantadine hydrochloride 200 mg daily to both intervention groups), and 24 trials were conducted without co-interventions. The effect observed between the two intervention groups regarding liver-related morbidity plus all-cause mortality (5/907 (0.55%) versus 4/882 (0.45%) was imprecise: OR 1.14 ( 95% CI 0.38 to 3.42; five trials; low quality of evidence), as was the risk of adverse events leading to treatment discontinuation (332/2692 (12.3%) versus 409/2176 (18.8%); RR 0.86, 95% CI 0.68 to 1.09; 15 trials; low quality of evidence) or regarding adverse events leading to treatment discontinuation (332/2692 (12.3%) versus 409/2176 (18.8%); RR 0.86, 95% CI 0.66 to 1.12; 17 trials; low quality of evidence). However, peginterferon plus ribavirin versus interferon plus ribavirin significantly increased the risk of neutropenia (332/2202 (15.1%) versus 117/1653 (7.1%); RR 2.15, 95% CI 1.76 to 2.61; 13 trials), thrombocytopenia (65/1113 (5.8%) versus 23/1082 (2.1%); RR 2.63, 95% CI 1.68 to 4.11; 10 trials), arthralgia (517/1740 (29.7%) versus 282/1194 (23.6%); RR 1.19, 95% CI 1.05 to 1.35; four trials), injection site reaction (627/1168 (53.7%) versus 186/649 (28.7%); RR 1.71, 95% CI 1.50 to 1.93; four trials), and nausea (606/1784 (34.0%) versus 354/1239 (28.6%); RR 1.13, 95% CI 1.01 to 1.26; four trials). The most frequent adverse event was fatigue, which occurred in 57% of participants (2024/3608). No significant difference was noted between peginterferon plus ribavirin versus interferon plus ribavirin in terms of fatigue (1177/2062 (57.1%) versus 847/1546 (54.8%); RR 1.01, 95% CI 0.96 to 1.07; 12 trials). No significant differences were reported between the two treatment groups regarding anaemia, headache, rigours, myalgia, pyrexia, weight loss, asthenia, depression, insomnia, irritability, alopecia, pruritus, skin rash, thyroid malfunction, decreased appetite, or diarrhoea. We were unable to identify any data on quality of life. Peginterferon plus ribavirin versus interferon plus ribavirin seemed to significantly increase the number of participants achieving sustained virological response (1673/3300 participants (50.7%) versus 1081/2804 patients (36.7%); RR 1.39, 95% CI 1.25 to 1.56; I<SUP>2</SUP> = 64%; 27 trials; very low<B> </B>quality of evidence). However, the risk of bias in the 13/27 (48.1%) trials reporting on this outcome was high and was considered only 'lower' in the remainder. Because the conventional meta-analysis did not reach its required information size (n = 14,486 participants), we used trial sequential analysis to control for risks of random errors. Again, in this analysis, the estimated effect was statistically significant in favour of peginterferon. Subgroup analyses according to risk of bias, viral genotype, baseline viral load, past treatment history, and type of intervention yielded similarly significant results favouring peginterferon over interferon on the outcome of sustained virological response.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-02-20 22:04:11 +0100" MODIFIED_BY="[Empty name]">
<P>Peginterferon plus ribavirin versus interferon plus ribavirin seems to significantly increase the proportion of patients with sustained virological response, as well as the risk of certain adverse events. However, we have insufficient evidence to recommend or reject peginterferon plus ribavirin for liver-related morbidity plus all-cause mortality compared with interferon plus ribavirin. The clinical consequences of achieved sustained virological response are unknown, as sustained virological response is still an unvalidated surrogate outcome. We found no evidence of the potential benefits on quality of life in patients with achieved sustained virological response. Further high-quality research is likely to have an important impact on our confidence in the estimate of patient-relevant outcomes and is likely to change our estimates.There is very low quality evidence that peginterferon plus ribavirin increases the proportion of patients with sustained virological response in comparison with interferon plus ribavirin. There is evidence that it also increases the risk of certain adverse events.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-02-24 11:01:15 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<BACKGROUND MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2014-01-06 13:16:06 +0100" MODIFIED_BY="[Empty name]">
<P>Globally, an estimated 170 million people are chronically infected with hepatitis C virus, and three to four million persons are infected each year (<LINK REF="REF-WHO-1999" TYPE="REFERENCE">WHO 1999</LINK>). In most patients, hepatitis C infection is asymptomatic in the initial phase. Hepatitis C infection generally is first recognised in the chronic phase (<LINK REF="REF-Hodgson-2003" TYPE="REFERENCE">Hodgson 2003</LINK>). Around 85% of patients who become infected with hepatitis C fail to clear the virus and become chronic carriers. A number of these individuals are reported to develop cirrhosis over a period of approximately 20 to 25 years (<LINK REF="REF-Seeff-2002" TYPE="REFERENCE">Seeff 2002</LINK>; <LINK REF="REF-Seeff-2009" TYPE="REFERENCE">Seeff 2009</LINK>). Patients with advanced fibrosis or cirrhosis develop liver complications such as hepatocellular carcinoma at the annual rate of approximately 2% to 4% (<LINK REF="REF-Benvegnu-2001" TYPE="REFERENCE">Benvegnu 2001</LINK>; <LINK REF="REF-Fattovich-2002" TYPE="REFERENCE">Fattovich 2002</LINK>). Chronic hepatitis C is the single most common indication for liver transplantation (<LINK REF="REF-OPTN-2008" TYPE="REFERENCE">OPTN 2008</LINK>). Chronic hepatitis C is expected to become a greater burden during the next decades.</P>
<P>Hepatitis C virus is an enveloped RNA virus that constitutes the genus <I>Hepacivirus</I> within the <I>Flaviviridae</I> family (<LINK REF="REF-van-Regenmortel-2000" TYPE="REFERENCE">van Regenmortel 2000</LINK>; <LINK REF="REF-Penin-2004" TYPE="REFERENCE">Penin 2004</LINK>). Hepatitis C virus is divided into six genotypes, which differ from each other by up to 30% in the nucleotide sequence (<LINK REF="REF-Rosenberg-2001" TYPE="REFERENCE">Rosenberg 2001</LINK>). Furthermore, hepatitis C virus genotypes differ by geographic region (<LINK REF="REF-Davis-1999" TYPE="REFERENCE">Davis 1999</LINK>). Although a genotype does not predict the outcome of the infection, it does predict the likelihood of virological response to treatment and in many cases determines the duration of treatment (<LINK REF="STD-Manns-2001" TYPE="STUDY">Manns 2001</LINK>; <LINK REF="STD-Fried-2002" TYPE="STUDY">Fried 2002</LINK>; <LINK REF="REF-Hadziyannis-2004" TYPE="REFERENCE">Hadziyannis 2004</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-02-12 23:36:14 +0100" MODIFIED_BY="[Empty name]">
<P>The goal of treatment of chronic hepatitis C is to prevent complications of hepatitis C infection; this is principally sought by eradication of the infection (<LINK REF="REF-Ghany-2009" TYPE="REFERENCE">Ghany 2009</LINK>). Accordingly, treatment is aimed at achieving a virological response, defined as the absence of hepatitis C virus RNA in serum by sensitive testssix months after the end of treatment (sustained virological response). It is not known whether this outcome bears any relevance to the patient regarding mortality, morbidity, or quality of life (<LINK REF="REF-Gluud-2007" TYPE="REFERENCE">Gluud 2007</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="[Empty name]">
<P>Interferons work through complicated cellular mechanisms, leading to a reduction of viral load in patients with chronic hepatitis C. Monotherapy with interferon produces sustained virological response in less than 20% of study participants (<LINK REF="REF-Myers-2002" TYPE="REFERENCE">Myers 2002</LINK>). The introduction of combination therapy with interferon plus ribavirin was considered a major advance because of its increased effect on sustained virological response. Combination therapy produces sustained virological response in approximately 40% of previously untreated participants, that is, participants who were previously naive to antiviral drugs (<LINK REF="REF-Brok-2009a" TYPE="REFERENCE">Brok 2009a</LINK>). A combination of weekly subcutaneous injections of long-acting peginterferon alpha plus oral ribavirin has achieved the highest overall sustained virological response of 56% of participants (<LINK REF="REF-Ghany-2009" TYPE="REFERENCE">Ghany 2009</LINK>). This represents the current standard of treatment according to the guidelines of the American Association for the Study of Liver Diseases (<LINK REF="REF-Ghany-2009" TYPE="REFERENCE">Ghany 2009</LINK>) and the European Association for the Study of the Liver (<LINK REF="REF-EASL-2012" TYPE="REFERENCE">EASL 2012</LINK>).</P>
<P>Pegylation involves the addition of polyethylene glycol molecules to the interferon molecule, thus altering metabolism, decreasing renal clearance, and increasing the half-life of the peginterferon molecule in the circulation, thereby necessitating fewer doses (<LINK REF="REF-Reddy-2001" TYPE="REFERENCE">Reddy 2001</LINK>). Currently, two licenced products of peginterferon are available: peginterferon alpha-2a (Pegasys<SUP>®</SUP>, Roche), which consists of a 40-kDa branched pegylated chain linked to the interferon molecule (<LINK REF="REF-Bailon-2001" TYPE="REFERENCE">Bailon 2001</LINK>), and peginterferon alpha-2b (Peg-Intron<SUP>®</SUP>, Merck Corporation), which consists of a 12-kDa linear pegylated chain linked to the interferon molecule (<LINK REF="REF-Glue-2000" TYPE="REFERENCE">Glue 2000</LINK>). The two forms of peginterferon differ substantially in terms of chemical and structural characteristics, as well as pharmacokinetic and pharmacodynamic properties (<LINK REF="REF-Foster-2004" TYPE="REFERENCE">Foster 2004</LINK>; <LINK REF="REF-Awad-2010" TYPE="REFERENCE">Awad 2010</LINK>; <LINK REF="REF-Hauser-2014" TYPE="REFERENCE">Hauser 2014</LINK>). In the present systematic review, we consider peginterferon alpha-2a and peginterferon alpha-2b as a single intervention, but in a subgroup analysis, we analyse them separately.</P>
</THEORY>
<IMPORTANCE MODIFIED="2014-01-23 16:34:23 +0100" MODIFIED_BY="[Empty name]">
<P>Previous reviews, including narrative reviews, meta-analyses, and health technology assessments, have compared pegylated interferon versus interferon given with or without co-interventions (<LINK REF="REF-Chander-2002" TYPE="REFERENCE">Chander 2002</LINK>; <LINK REF="REF-Zaman-2003" TYPE="REFERENCE">Zaman 2003</LINK>; <LINK REF="REF-Khuroo-2004" TYPE="REFERENCE">Khuroo 2004</LINK>; <LINK REF="REF-Shepherd-2005" TYPE="REFERENCE">Shepherd 2005</LINK>; <LINK REF="REF-Siebert-2005" TYPE="REFERENCE">Siebert 2005</LINK>). The overall conclusion of these review authors was that the combination of pegylated interferon plus ribavirin was more efficient than interferon plus ribavirin in obtaining sustained virological response. However, these reviews relied on a sparse number of included trials. Intervention research for hepatitis C is high-paced, and new trials have emerged since these reviews were completed. This Cochrane systematic review aimed to include and critically assess evidence obtained through extensive searches for randomised clinical trials.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-06-06 09:37:29 +0200" MODIFIED_BY="[Empty name]">
<P>To systematically evaluate the benefits and harms of peginterferon plus ribavirin versus interferon plus ribavirin for patients with chronic hepatitis C.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-02-20 22:04:55 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2014-02-20 22:04:55 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2014-01-12 21:08:18 +0100" MODIFIED_BY="Tahany Awad">
<P>We included randomised clinical trials, irrespective of language, publication status, sample size, or year of publication, for assessment of benefits and harms. We also included for assessment of harms quasi-randomised studies and observational studies that were identified during our searches for randomised trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-01-06 13:16:35 +0100" MODIFIED_BY="Tahany Awad">
<P>We included patients with chronic hepatitis C. The diagnosis was based on the presence of hepatitis C virus RNA for longer than six months, or the presence of hepatitis C virus RNA plus elevated transaminases in the blood for longer than six months, or histological evidence of chronic hepatitis C. Based on history of previous antiviral treatment, included patients were classified as treatment-naive (not previously treated with antiviral drugs), relapsers (patients with a transient response to previous treatment), or non-responders (patients without response to previous treatment). Patients who had undergone liver transplantation and patients with hepatitis B or human immunodeficiency virus coinfection were excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-01-06 13:16:35 +0100" MODIFIED_BY="[Empty name]">
<P>This review included randomised clinical trials comparing peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin versus interferon plus ribavirin for participants with chronic hepatitis C. Trials were included regardless of the type, the dose, or the duration of the interventions. Cointerventions were permitted if they were received by and applied equally to all intervention groups.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-02-20 22:04:55 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-02-20 22:04:55 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Liver-related morbidity plus all-cause mortality: number of participants who developed cirrhosis, ascites, variceal bleeding, hepatic encephalopathy, or hepatocellular carcinoma, or who died.</LI>
<LI>Adverse events leading to treatment discontinuation.</LI>
<UL>
<LI>Numbers and types of adverse events, defined as participants with any untoward medical occurrence not necessarily having a causal relationship to the treatment. We reported separately on adverse events that led to treatment discontinuation and those that did not lead to treatment discontinuation. We defined a serious adverse event according to the guidelines of the International Conference on Harmonisation (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>) as any event that leads to death, is life threatening, requires in-patient hospitalisation or prolongation of existing hospitalisation, or results in persistent or significant disability, as well as any important medical event that may have jeopardised the participant or required an intervention to prevent it. All other adverse events were considered non-serious.</LI>
<LI>Other adverse events: haematological effects, fatigue, flu-like symptoms, psychiatric symptoms, dermatological symptoms, thyroid malfunction, gastrointestinal symptoms (other than liver related).</LI>
</UL>
<LI>Quality of life.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-02-07 12:05:17 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Sustained virological response: number of participants with undetectable hepatitis C virus RNA in serum by sensitive tests six months after the end of treatment.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-01-06 13:16:53 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2014-01-06 13:16:53 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Hepato-Biliary Group Controlled Trials Register (<LINK REF="REF-Gluud-2013" TYPE="REFERENCE">Gluud 2013</LINK>)<I>, </I>the Cochrane Central Register of Controlled Trials (CENTRAL),<I> </I>MEDLINE, EMBASE, Science Citation Index-Expanded (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>), and LILACS, using the search strategies and time spans given in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>. The searches were conducted until September 2013.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-06-06 09:40:21 +0200" MODIFIED_BY="[Empty name]">
<P>We identified further trials by searching national and topic-specific databases, bibliographies, conference abstracts, journals, and grey literature. Furthermore, we reviewed the reference lists of the included trials and contacted the principal authors of the identified trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-02-20 21:58:18 +0100" MODIFIED_BY="[Empty name]">
<P>We performed the review and meta-analyses according to the recommendations of The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and the Cochrane Hepato-Biliary Group Module (<LINK REF="REF-Gluud-2013" TYPE="REFERENCE">Gluud 2013</LINK>). The analyses were performed using Review Manager 5.2 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>) and Trial Sequential Analysis version 0.9 (<LINK REF="REF-CTU-2011" TYPE="REFERENCE">CTU 2011</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>).</P>
<STUDY_SELECTION MODIFIED="2014-01-06 13:16:53 +0100" MODIFIED_BY="Tahany Awad">
<P>We listed the identified trials, and two of the review authors (GH and TA) independently assessed their fulfilment of the inclusion criteria. We listed the excluded trials along with the reasons for exclusion. Disagreements were resolved by discussion and were arbitrated with a third review author (CG).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2014-01-06 13:16:53 +0100" MODIFIED_BY="Tahany Awad">
<P>A standardised template or data collection form was used to extract data regarding source identification, eligibility, methods, participants, interventions, outcomes, and results obtained from published reports or by contact with the study authors. Two review authors (GH and TA) extracted all the data independently. Disagreements were resolved by discussion and were arbitrated with a third review author (CG). Any further information required of the original authors was requested by written correspondence, and any relevant information obtained in this manner was included in the review.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2014-02-06 14:27:11 +0100" MODIFIED_BY="[Empty name]">
<P>Methodological quality was defined as the level of confidence that the design and the report of the randomised clinical trial would restrict bias in the comparison of interventions (<LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>). According to empirical evidence (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-Lundh-2012" TYPE="REFERENCE">Lundh 2012</LINK>; <LINK REF="REF-Savovic-2012" TYPE="REFERENCE">Savovic 2012</LINK>; <LINK REF="REF-Savovic-2012a" TYPE="REFERENCE">Savovic 2012a</LINK>), the methodological quality of the trials, hence the risk of bias, was based on the following.</P>
<P>
<B>
<I>Sequence generation</I>
</B>
</P>
<UL>
<LI>Low risk of bias: Sequence generation was achieved by using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice are adequate if performed by an independent person not otherwise involved in the trial.</LI>
<LI>Uncertain risk of bias: The method of sequence generation was not specified.</LI>
<LI>High risk of bias: The sequence generation method was not random.</LI>
</UL>
<P>
<B>
<I>Allocation concealment </I>
</B>
</P>
<UL>
<LI>Low risk of bias: The participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g., if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes).</LI>
<LI>Uncertain risk of bias: The method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.</LI>
<LI>High risk of bias: The allocation sequence was likely to be known to the investigators who assigned the participants.</LI>
</UL>
<P>
<B>
<I>Blinding of outcome assessors<BR/>
</I>
</B>
</P>
<UL>
<LI>Low risk of bias: Blinding was performed adequately, or assessment of outcomes was not likely to be influenced by lack of blinding.</LI>
<LI>Uncertain risk of bias: Information was insufficient to permit assessment of whether blinding was likely to induce bias for the results.</LI>
<LI>High risk of bias: No blinding or incomplete blinding was performed, and assessment of outcomes was likely to be influenced by lack of blinding.</LI>
</UL>
<P>
<B>
<I>Incomplete outcome data</I>
</B>
</P>
<UL>
<LI>Low risk of bias: Missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, were employed in handling missing data.</LI>
<LI>Uncertain risk of bias: Information was insufficient to permit assessment of whether missing data in combination with the method used to handle missing data were likely to induce bias for the results.</LI>
<LI>High risk of bias: The results were likely to be biased as the result of missing data.</LI>
</UL>
<P>
<B>
<I>Selective outcome reporting</I>
</B>
</P>
<UL>
<LI>Low risk of bias: All outcomes were predefined and reported, or all clinically relevant and reasonably expected outcomes were reported.</LI>
<LI>Uncertain risk of bias: It is unclear whether all predefined and clinically relevant and reasonably expected outcomes were reported.</LI>
<LI>High risk of bias: One or more clinically relevant and reasonably expected outcomes were not reported, and data on these outcomes were likely to have been recorded.</LI>
</UL>
<P>
<B>
<I>Other sources of bias</I>
</B>
</P>
<UL>
<LI>Low risk of bias: The trial appears to be free of other components (e.g., academic bias) that could put it at risk of bias.</LI>
<LI>Uncertain risk of bias: The trial may or may not be free of other components that could put it at risk of bias.</LI>
<LI>High risk of bias: Other factors in the trial could put it at risk of bias (e.g., authors have conducted trials on the same topic).</LI>
</UL>
<P>The risk of bias of the trials was assessed independently by two review authors, and disagreements were resolved by discussion and were arbitrated with a third review author. Trials with adequate sequence generation and allocation concealment and free of incomplete outcome data and selective outcome reporting were considered trials with lower risk of bias, as we expected all or most trials to be unblinded and to have obtained industry support.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2014-01-06 13:17:20 +0100" MODIFIED_BY="Tahany Awad">
<P>
<B>
<I>Dichotomous data</I>
</B>
</P>
<P>Dichotomous data were expressed as risk ratios (RRs) and risk differences (RDs) with 95% confidence intervals (CIs). Furthermore, the number needed to treat for an additional beneficial outcome was derived from the RD in meta-analyses in which the 95% CI did not include zero. Rare events (morbidity and mortality) were estimated by using the odds ratio (OR) as a measure of effect.</P>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2014-02-07 12:05:23 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>We planned to perform all analyses according to the intention-to-treat method, including all participants, irrespective of compliance or follow-up. However, we performed analyses according to the intention-to-treat method only for dichotomous outcomes. For continuous outcomes, we performed available case analyses and included data only on those whose results were known. Regarding the primary outcome measures, we planned to include participants with incomplete or missing data in the sensitivity analyses by imputing them according to the two scenarios described below (<LINK REF="REF-Hollis-1999" TYPE="REFERENCE">Hollis 1999</LINK>; <LINK REF="REF-Gluud-2013" TYPE="REFERENCE">Gluud 2013</LINK>).</P>
<UL>
<LI>'Best-worst' case scenario analyses: Participants with missing outcomes are considered successes in the experimental group and failures in the control group. The denominator will include all participants in the trial.</LI>
<LI>'Worst-best' case scenario analyses: Participants with missing outcomes data are considered failures in the experimental group and successes in the control group. The denominator will include all participants in the trial.</LI>
</UL>
<P>As very few data were available, we decided not to conduct these extreme case scenario analyses. When sufficient data become available in the future, we will conduct such analyses.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2014-01-06 13:17:20 +0100" MODIFIED_BY="Tahany Awad">
<P>Heterogeneity was explored by the Chi<SUP>2</SUP> test, and the quantity of heterogeneity was measured by the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2002" TYPE="REFERENCE">Higgins 2002;</LINK> <LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). Sources of heterogeneity were assessed by subgroup analyses and meta-regression when possible. Subgroup analyses were carried out only when data from at least two trials were available for each subgroup. Meta-regression was carried out only for meta-analyses that included more than 10 trials. Whether sensitivity analyses needed to be performed was determined during the review process.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2014-01-06 13:17:20 +0100" MODIFIED_BY="Tahany Awad">
<P>Different types of reporting biases (e.g., publication bias, time lag bias, outcome reporting bias) were handled according to the recommendations of The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). For dichotomous outcomes with intervention effects measured as odds ratios, the arcsine test proposed by <LINK REF="REF-R_x00fc_cker-2008" TYPE="REFERENCE">Rücker 2008</LINK> was used to test for funnel plot asymmetry. Nevertheless, asymmetrical funnel plots are not necessarily caused by publication bias, and publication bias does not necessarily cause asymmetry in a funnel plot (<A HREF="http://archie.cochrane.org/sections/documents/view?document=0E5DDDFE82E26AA200AA39D65E0B0373&amp;format=REVMAN#REF-Egger-1997">Egger 1997</A>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2014-02-12 23:28:04 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Meta-analysis</B>
<BR/>For all analyses, we used both random-effects (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) and fixed-effect models (<LINK REF="REF-DeMets-1987" TYPE="REFERENCE">DeMets 1987</LINK>). Because of underlying assumptive differences, results from the random-effects model and from the fixed-effect model may differ to a non-ignorable extent. In case such discrepancies were observed, P values were ignored, and results were interpreted according to the implications of the subgroup and heterogeneity analyses according to confidence intervals of the two models.<BR/>
<BR/>
<B>Trial sequential analysis</B>
<BR/>Random errors may play an important role in the evaluation of cumulative meta-analyses as the result of sparse data and multiplicity from repetitive testing of accumulating data. To assess the reliability of inferences from our meta-analysis on sustained virological response, we calculated the diversity-adjusted required information size (DARIS). We defined DARIS as the required sample size for the meta-analysis to detect a 10% relative risk reduction in sustained virological response, assuming an average outcome proportion of 50% in the control group, a diversity observed in the meta-analysis, and statistical error levels of alpha = 5% and beta = 10% (90% power). Meta-analyses conducted before they surpassed the DARIS are considered analogous to interim analyses in a single randomised trial, and thus they necessitate adjustment of the threshold for statistical significance to maintain the predetermined maximum risk of obtaining a false positive (set to alpha = 5% in our analysis). Therefore, we substituted the conventional 5% threshold for statistical significance with those of Lan-DeMets trial sequential monitoring boundaries (<LINK REF="REF-Bangalore-2008" TYPE="REFERENCE">Bangalore 2008</LINK>; <LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>, <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>). To minimise the risk of random errors, we used trial sequential analysis (<LINK REF="REF-CTU-2011" TYPE="REFERENCE">CTU 2011</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>). On the basis of the required information size and the risk for type I (5%) and type II (10% or 20%) errors, trial sequential monitoring boundaries were constructed (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-CTU-2011" TYPE="REFERENCE">CTU 2011</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>). These boundaries determine the statistical inference that one may draw regarding the cumulative meta-analysis that has not reached the required information size. If the cumulative Z-score crosses a trial sequential monitoring boundary before the required information size is reached in a cumulative meta-analysis, firm evidence may have been established, and further trials may be superfluous, provided that systematic errors can be excluded. On the other hand, if the monitoring boundaries are not surpassed, it is most probably necessary to continue doing further trials to detect or reject a certain intervention effect. We used as default a type I error of 5%, a type II error of 10%, and adjusted information size for heterogeneity with diversity, unless otherwise stated (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-CTU-2011" TYPE="REFERENCE">CTU 2011</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>). Posthoc, we also challenged the trial sequential analysis on sustained virological response by a type I error of 1%.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2014-02-07 12:05:44 +0100" MODIFIED_BY="[Empty name]">
<P>The following subgroup analyses were considered and performed when feasible.<BR/>
</P>
<UL>
<LI>Risk of bias: trials assessed to have low risk of bias compared to trials with high risk of bias.</LI>
<LI>Participants: trials with treatment-naive participants compared to trials with relapsers or non-responders.</LI>
<LI>Genotype: comparisons of trials with participants infected with different hepatitis C virus genotypes.</LI>
<LI>Baseline viral load: trials assessed as having high or low risk of viral load on the basis of 800,000 IU (~ four million copies/mL) threshold.</LI>
<LI>Type of peginterferon: trials with peginterferon alpha-2a compared to trials with peginterferon alpha-2b.</LI>
</UL>
<P>We performed a test of interaction between subgroups within each of the five categories. We performed tests of interaction only between subgroups that both included at least three trials.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2014-02-20 21:58:18 +0100" MODIFIED_BY="[Empty name]">
<P>Suitable sensitivity analyses were identified during the review process. For example, if zero-event trials occurred, we employed a number of different continuity corrections according to the sensitivity analysis proposed by <LINK REF="REF-Bradburn-2006" TYPE="REFERENCE">Bradburn 2006</LINK> using the TSA programme (<LINK REF="REF-CTU-2011" TYPE="REFERENCE">CTU 2011</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>). We also carried out a sensitivity analysis from which we excluded trials that provided triple therapy with amantadine.</P>
<SUBSECTION>
<HEADING LEVEL="4">Summary of findings table</HEADING>
<P>To minimise wrong interpretations of our findings and recommendations, we planned to rate the available evidence for all outcomes following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) guidelines in order to prepare a Summary of Findings (SoFs) table (<LINK REF="REF-Guyatt-2008" TYPE="REFERENCE">Guyatt 2008</LINK>). A SoFs table consists of three parts: information about the review, a summary of the statistical results, and the grade of the quality of evidence. The quality assessment comprises three parts: the number of studies, the types of studies (randomised or observational), and the factors that affect the quality of the evidence (see below).</P>
<P>
<B>Factors that affect the quality of the evidence</B>
</P>
<TABLE COLS="2" ROWS="6">
<TR>
<TH>
<P>Decrease quality</P>
</TH>
<TH>
<P>Increase quality</P>
</TH>
</TR>
<TR>
<TD>
<P>Risk of bias</P>
</TD>
<TD>
<P>Large magnitude of effect</P>
</TD>
</TR>
<TR>
<TD>
<P>Inconsistency of results</P>
</TD>
<TD>
<P>Demonstrated effect reduced by all plausible confounding</P>
</TD>
</TR>
<TR>
<TD>
<P>Indirectness of evidence</P>
</TD>
<TD>
<P>Dose-response gradient</P>
</TD>
</TR>
<TR>
<TD>
<P>Imprecision</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>Publication bias</P>
</TD>
<TD>
<P> </P>
</TD>
</TR>
</TABLE>
</SUBSECTION>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-02-24 10:58:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDY_DESCRIPTION MODIFIED="2014-02-06 14:49:03 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2014-02-06 14:48:23 +0100" MODIFIED_BY="[Empty name]">
<P>We identified a total of 8089 references through electronic searches until September 2013. The Cochrane Hepato-Biliary Group Controlled Trials Register identified 923 references. We excluded 2459 duplicates and 3346 clearly irrelevant references by reading abstracts. Accordingly, 2284 references were retrieved for further assessment. We excluded 2225 references because they were not randomised clinical trials or because interventions or participants did not meet our inclusion criteria. <BR/>
<BR/>Fifty-nine references describing a total of 27 randomised clinical trials fulfilled our inclusion criteria (see the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table) (<LINK REF="STD-Manns-2001" TYPE="STUDY">Manns 2001</LINK>; <LINK REF="STD-Cariti-2002" TYPE="STUDY">Cariti 2002</LINK>; <LINK REF="STD-Fried-2002" TYPE="STUDY">Fried 2002</LINK>; <LINK REF="STD-Hinrichsen-2002" TYPE="STUDY">Hinrichsen 2002</LINK>; <LINK REF="STD-Esmat-2003" TYPE="STUDY">Esmat 2003</LINK>; <LINK REF="STD-Shobokshi-2003" TYPE="STUDY">Shobokshi 2003</LINK>; <LINK REF="STD-Thakeb-2003" TYPE="STUDY">Thakeb 2003</LINK>; <LINK REF="STD-Al_x002d_Faleh-2004" TYPE="STUDY">Al-Faleh 2004</LINK>; <LINK REF="STD-Bruno-2004" TYPE="STUDY">Bruno 2004</LINK>; <LINK REF="STD-Fargion-2004" TYPE="STUDY">Fargion 2004</LINK>; <LINK REF="STD-Izumi-2004" TYPE="STUDY">Izumi 2004</LINK>; <LINK REF="STD-Derbala-2005" TYPE="STUDY">Derbala 2005</LINK>; <LINK REF="STD-Dollinger-2005" TYPE="STUDY">Dollinger 2005</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Mangia-2005" TYPE="STUDY">Mangia 2005</LINK>; <LINK REF="STD-Napoli-2005" TYPE="STUDY">Napoli 2005</LINK>; <LINK REF="STD-PRETTY-2005" TYPE="STUDY">PRETTY 2005</LINK>; <LINK REF="STD-Scotto-2005" TYPE="STUDY">Scotto 2005</LINK>; <LINK REF="STD-Tsubota-2005" TYPE="STUDY">Tsubota 2005</LINK>; <LINK REF="STD-Derbala-2006" TYPE="STUDY">Derbala 2006</LINK>; <LINK REF="STD-Wakil-2006" TYPE="STUDY">Wakil 2006</LINK>; <LINK REF="STD-Rahman-2007a" TYPE="STUDY">Rahman 2007a</LINK>; <LINK REF="STD-Rahman-2007b" TYPE="STUDY">Rahman 2007b</LINK>; <LINK REF="STD-Sj_x00f6_gren-2007" TYPE="STUDY">Sjögren 2007</LINK>; <LINK REF="STD-Horsmans-2008" TYPE="STUDY">Horsmans 2008</LINK>; <LINK REF="STD-Roffi-2008" TYPE="STUDY">Roffi 2008</LINK>; <LINK REF="STD-Nevens-2010" TYPE="STUDY">Nevens 2010</LINK>). Accordingly, several of the trials were published multiple times. Seventeen trials were published as full-paper articles, and 10 trials were published in abstract form only.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-02-06 14:49:03 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Participants</HEADING>
<P>A total of 5938 participants were randomly assigned in the 27 trials. The number of participants in each trial ranged from 40 to 1530. Twenty-three trials included treatment-naive participants, and four trials included non-responders or relapsers. In 10 trials, all participants were infected with hepatitis C virus genotype one. In two trials, all participants were infected with genotype two or three. In seven trials, all participants were infected with genotype four. In eight trials, participants infected with different genotypes were included.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Experimental interventions</HEADING>
<P>The type of peginterferon was alpha-2a (nine trials) or alpha-2b (18 trials).</P>
<P>The dose of peginterferon alpha-2a was 180 &#956;g/wk (<LINK REF="STD-Cariti-2002" TYPE="STUDY">Cariti 2002</LINK>; <LINK REF="STD-Fried-2002" TYPE="STUDY">Fried 2002</LINK>; <LINK REF="STD-Shobokshi-2003" TYPE="STUDY">Shobokshi 2003</LINK>; <LINK REF="STD-Thakeb-2003" TYPE="STUDY">Thakeb 2003</LINK>; <LINK REF="STD-Fargion-2004" TYPE="STUDY">Fargion 2004</LINK>; <LINK REF="STD-Mangia-2005" TYPE="STUDY">Mangia 2005</LINK>; <LINK REF="STD-PRETTY-2005" TYPE="STUDY">PRETTY 2005</LINK>; <LINK REF="STD-Derbala-2006" TYPE="STUDY">Derbala 2006</LINK>; <LINK REF="STD-Nevens-2010" TYPE="STUDY">Nevens 2010</LINK>).</P>
<P>The dose of peginterferon alpha-2b was 1.0 &#956;g/kg/wk (<LINK REF="STD-Hinrichsen-2002" TYPE="STUDY">Hinrichsen 2002</LINK>; <LINK REF="STD-Esmat-2003" TYPE="STUDY">Esmat 2003</LINK>; <LINK REF="STD-Al_x002d_Faleh-2004" TYPE="STUDY">Al-Faleh 2004</LINK>) or 1.5 &#956;g/kg/wk (<LINK REF="STD-Manns-2001" TYPE="STUDY">Manns 2001</LINK>; <LINK REF="STD-Izumi-2004" TYPE="STUDY">Izumi 2004</LINK>; <LINK REF="STD-Derbala-2005" TYPE="STUDY">Derbala 2005</LINK>; <LINK REF="STD-Dollinger-2005" TYPE="STUDY">Dollinger 2005</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Napoli-2005" TYPE="STUDY">Napoli 2005</LINK>; <LINK REF="STD-Scotto-2005" TYPE="STUDY">Scotto 2005</LINK>; <LINK REF="STD-Tsubota-2005" TYPE="STUDY">Tsubota 2005</LINK>; <LINK REF="STD-Wakil-2006" TYPE="STUDY">Wakil 2006</LINK>; <LINK REF="STD-Rahman-2007a" TYPE="STUDY">Rahman 2007a</LINK>; <LINK REF="STD-Rahman-2007b" TYPE="STUDY">Rahman 2007b</LINK>; <LINK REF="STD-Sj_x00f6_gren-2007" TYPE="STUDY">Sjögren 2007</LINK>). In the <LINK REF="STD-Manns-2001" TYPE="STUDY">Manns 2001</LINK> trial, a third intervention group was given peginterferon alpha-2b 1.5 &#956;g/kg/wk for four weeks, followed by 0.5 &#956;g/kg/wk for an additional 44 weeks. In the <LINK REF="STD-Roffi-2008" TYPE="STUDY">Roffi 2008</LINK> trial, participants were given peginterferon alpha-2b 1.0 &#956;g/kg/wk for four weeks, followed by 0.5 &#956;g/kg/wk for an additional two weeks.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Control interventions</HEADING>
<P>The type of interferon was alpha-2a (eight trials), alpha-2b (14 trials), consensus interferon (four trials), or leucocyte interferon-alpha (one trial).</P>
<P>The dose of interferon alpha-2a was 3 MU (<LINK REF="STD-Thakeb-2003" TYPE="STUDY">Thakeb 2003</LINK>; <LINK REF="STD-Mangia-2005" TYPE="STUDY">Mangia 2005;</LINK> <LINK REF="STD-Derbala-2006" TYPE="STUDY">Derbala 2006</LINK>), 4.5 MU (<LINK REF="STD-Shobokshi-2003" TYPE="STUDY">Shobokshi 2003</LINK>), or 6 MU (<LINK REF="STD-Cariti-2002" TYPE="STUDY">Cariti 2002</LINK>; <LINK REF="STD-PRETTY-2005" TYPE="STUDY">PRETTY 2005</LINK>), given thrice weekly. In the <LINK REF="STD-Fargion-2004" TYPE="STUDY">Fargion 2004</LINK> trial, participants were given interferon alpha-2a 6 MU daily for four weeks, then 3 MU daily for an additional 20 weeks, and then 3 MU thrice weekly for an additional 24 weeks. In the <LINK REF="STD-Nevens-2010" TYPE="STUDY">Nevens 2010</LINK> trial, participants were given interferon alpha-2a at a dose of 6 MU for eight weeks, and then 3 MU for an additional 40 weeks.</P>
<P>The dose of interferon alpha-2b was 3 MU (<LINK REF="STD-Manns-2001" TYPE="STUDY">Manns 2001</LINK>; <LINK REF="STD-Fried-2002" TYPE="STUDY">Fried 2002</LINK>; <LINK REF="STD-Hinrichsen-2002" TYPE="STUDY">Hinrichsen 2002</LINK>; <LINK REF="STD-Esmat-2003" TYPE="STUDY">Esmat 2003</LINK>; <LINK REF="STD-Al_x002d_Faleh-2004" TYPE="STUDY">Al-Faleh 2004</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Scotto-2005" TYPE="STUDY">Scotto 2005</LINK>; <LINK REF="STD-Wakil-2006" TYPE="STUDY">Wakil 2006</LINK>), 5 MU (<LINK REF="STD-Wakil-2006" TYPE="STUDY">Wakil 2006</LINK>), or 6 MU (<LINK REF="STD-Bruno-2004" TYPE="STUDY">Bruno 2004</LINK>; <LINK REF="STD-Derbala-2005" TYPE="STUDY">Derbala 2005</LINK>; <LINK REF="STD-Scotto-2005" TYPE="STUDY">Scotto 2005</LINK>), given thrice weekly. In one trial (<LINK REF="STD-Izumi-2004" TYPE="STUDY">Izumi 2004</LINK>), interferon alpha-2b was given daily at a dose of 3 MU for the first two weeks, and then thrice weekly for an additional 46 weeks. In the <LINK REF="STD-Tsubota-2005" TYPE="STUDY">Tsubota 2005</LINK> trial, interferon alpha-2b was given daily at a dose of 6 MU for the first two weeks, and then thrice weekly for an additional 46 weeks. In the <LINK REF="STD-Bruno-2004" TYPE="STUDY">Bruno 2004</LINK> trial, peginterferon alpha-2b 100 µg was given to participants weighing 65 kg or more, and 80 µg to those weighing less than 65 kg, for the first eight weeks, followed by a fixed dose of 50 µg for the next 40 weeks.</P>
<P>The dose of consensus interferon was 9 µg (<LINK REF="STD-Rahman-2007a" TYPE="STUDY">Rahman 2007a</LINK>; <LINK REF="STD-Rahman-2007b" TYPE="STUDY">Rahman 2007b</LINK>) or 15 µg (<LINK REF="STD-Sj_x00f6_gren-2007" TYPE="STUDY">Sjögren 2007</LINK>) for 48 weeks. In the <LINK REF="STD-Dollinger-2005" TYPE="STUDY">Dollinger 2005</LINK> trial, consensus interferon was given at a dose of 18 µg/d for six weeks followed by 9 µg/d for 42 weeks.</P>
<P>In the <LINK REF="STD-Rahman-2007a" TYPE="STUDY">Rahman 2007a</LINK> trial, consensus interferon was given at a dose of 27 to 18 µg once a day for 12 weeks followed by 9 µg once a day for 36 weeks.The dose of leucocyte interferon-alpha was 6 MIU daily (<LINK REF="STD-Napoli-2005" TYPE="STUDY">Napoli 2005</LINK>).</P>
<P>Two trials (<LINK REF="STD-Shobokshi-2003" TYPE="STUDY">Shobokshi 2003</LINK>; <LINK REF="STD-Horsmans-2008" TYPE="STUDY">Horsmans 2008</LINK>) included three intervention groups. In the first trial (<LINK REF="STD-Shobokshi-2003" TYPE="STUDY">Shobokshi 2003</LINK>), group one was given peginterferon alpha-2a 180 µg plus ribavirin 800 mg for 48 weeks (n = 60); group two was given peginterferon alpha-2a 180 µg (n = 60); and group three was given interferon alpha-2a 4.5 MU plus ribavirin 800 mg for 48 weeks (n = 60). In the second trial (<LINK REF="STD-Horsmans-2008" TYPE="STUDY">Horsmans 2008</LINK>), group one was given daily interferon alpha-2b at a dose of 4 MIU for participants weighing more than 65 kg, and 0.06 MIU/kg for those weighing 65 kg or less; group two was given interferon alpha-2b three times a week at a dose of 3 MIU; and group three was given peginterferon alpha-2b at a dose of 100 mcg/wk for participants weighing more than 65 kg, and 1.5 mcg/kg/d for participants weighing 65 kg or less. Participants were followed up for 24 weeks after the end of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cointerventions in both intervention groups</HEADING>
<P>The dose of ribavirin was 600 mg, 800 mg, 1000 mg, or 1200 mg daily, based on body weight. Three trials also administered amantadine hydrochloride 200 mg daily to both intervention groups (<LINK REF="STD-Fargion-2004" TYPE="STUDY">Fargion 2004</LINK>; <LINK REF="STD-Mangia-2005" TYPE="STUDY">Mangia 2005</LINK>; <LINK REF="STD-PRETTY-2005" TYPE="STUDY">PRETTY 2005</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2014-01-06 13:29:34 +0100" MODIFIED_BY="[Empty name]">
<P>Seven publications were excluded for the reasons shown in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table (<LINK REF="STD-APRICOT-2004" TYPE="STUDY">APRICOT 2004</LINK>; <LINK REF="STD-Asahina-2004" TYPE="STUDY">Asahina 2004</LINK>; <LINK REF="STD-Gromova-2004" TYPE="STUDY">Gromova 2004</LINK>; <LINK REF="STD-Laguno-2004" TYPE="STUDY">Laguno 2004</LINK>; <LINK REF="STD-RIBAVIC-2004" TYPE="STUDY">RIBAVIC 2004</LINK>; <LINK REF="STD-ACTG-2005" TYPE="STUDY">ACTG 2005</LINK>; <LINK REF="STD-Ali-2010" TYPE="STUDY">Ali 2010</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-01-14 12:06:32 +0100" MODIFIED_BY="[Empty name]">
<P>The risk of bias was unclearly reported in a considerable number of included trials, hence giving them a high risk of bias (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Fourteen trials reported adequate sequence generation (generation of the allocation sequence ) (e.g., computer-generated random numbers, table of random numbers, minimisation). Fourteen trials used adequate allocation concealment (e.g., central independent unit, sealed opaque envelopes). None of the trials were blinded. It is unclear to what extent the outcome assessors or the participants were blinded; therefore, a risk of bias might be present in the registration of subjective outcome measures (e.g., diagnosis of complications, adverse events). Only one trial had adequate blinding for the outcome assessors for sustained virological response (<LINK REF="STD-Sj_x00f6_gren-2007" TYPE="STUDY">Sjögren 2007</LINK>). Nineteen trials addressed incomplete outcome data adequately. Protocols were not available for any of the included trials, but most trials reported on the primary outcomes of our review. Several trials had possible vested interest bias (<LINK REF="STD-Manns-2001" TYPE="STUDY">Manns 2001</LINK>; <LINK REF="STD-Fried-2002" TYPE="STUDY">Fried 2002</LINK>; <LINK REF="STD-Shobokshi-2003" TYPE="STUDY">Shobokshi 2003</LINK>; <LINK REF="STD-Al_x002d_Faleh-2004" TYPE="STUDY">Al-Faleh 2004</LINK>; <LINK REF="STD-Bruno-2004" TYPE="STUDY">Bruno 2004</LINK>; <LINK REF="STD-Dollinger-2005" TYPE="STUDY">Dollinger 2005</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Mangia-2005" TYPE="STUDY">Mangia 2005</LINK>; <LINK REF="STD-Horsmans-2008" TYPE="STUDY">Horsmans 2008</LINK>), and in the remainder, the risk of vested interest bias was unclear. The risk of bias was high in all of the trials from one or more domains.</P>
<P>Disregarding the risk of bias from lack of blinding and vested interests, we considered 14/27 trials (51.9%) as having a lower risk of bias according to the following domains: generation of the allocation sequence, allocation concealment, incomplete outcome reporting, and selective outcome reporting.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-02-24 10:58:27 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUBSECTION>
<HEADING LEVEL="3">Liver-related morbidity plus all-cause mortality</HEADING>
<P>Four deaths (suicide (suspected drug overdose), ruptured oesophageal varices, traffic-related, and unexplained) on peginterferon plus ribavirin versus three deaths (following surgery for colon cancer, hypertensive heart disease, and brain tumour) on interferon plus ribavirin were reported (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Two participants developed hepatocellular carcinoma, one on each intervention. No significant difference in liver-related morbidity or all-cause mortality was noted between participants receiving peginterferon plus ribavirin versus interferon plus ribavirin (Peto OR 1.14, 95% CI 0.38 to 3.42; five trials).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events</HEADING>
<P>Data from 17 trials yielded a non-significant difference regarding adverse events leading to treatment discontinuation of peginterferon plus ribavirin when compared with interferon plus ribavirin (332/2692 (12.3%) versus 409/2176 (18.8%); RR 0.86, 95% CI 0.66 to 1.12; 17 trials). When RR was used as the association measure of intervention effect, the Cochrane homogeneity test statistic yielded a P value of 0.003, and the heterogeneity was I<SUP>2 </SUP>= 56% (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Funnel plot visual inspection did not reveal significant evidence of publication bias (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).<BR/>
<BR/>Peginterferon plus ribavirin compared with interferon plus ribavirin significantly increased the risk of neutropenia (RR 2.15, 95% CI 1.76 to 2.61; 13 trials) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), thrombocytopenia (RR 2.63, 95% CI 1.68 to 4.11; 10 trials) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), arthralgia (RR 1.19, 95% CI 1.05 to 1.35; four trials) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>), injection site reaction (RR 1.71, 95% CI 1.50 to 1.93; four trials) (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>), or nausea (RR 1.13, 95% CI 1.01 to 1.26; four trials) (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).<BR/>
<BR/>The most frequent adverse event was fatigue, which overall occurred in 57% (2024/3608). No significant difference was seen between the effects of peginterferon plus ribavirin versus interferon plus ribavirin on fatigue (RR 1.01, 95% CI 0.96 to 1.07; 10 trials) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). No significant differences were noted between the two interventions regarding anaemia (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), headache, rigours, myalgia, pyrexia, weight loss, asthenia (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>), depression, insomnia, irritability (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>), alopecia, pruritus, skin rash (<LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>), thyroid malfunction (<LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>), or regarding decreased appetite and diarrhoea (<LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>Only one trial reported quality of life in the Methods section (<LINK REF="STD-Hinrichsen-2002" TYPE="STUDY">Hinrichsen 2002</LINK>). This trial is published only as an abstract, and we could not find the data in the Results section. We contacted the study authors to ask for further information, but no answer has been received.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Sustained virological response</HEADING>
<P>Peginterferon plus ribavirin seems to significantly increase the number of participants achieving sustained virological response compared with interferon plus ribavirin (1673/3300 (50.7%) versus 1081/2804 (38.6%); RR 1.39, 95% CI 1. 25 to 1.56; I<SUP>2</SUP> = 64%; 27 trials) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). When RR was used as the measure of effect, the Cochran homogeneity test statistic yielded a P value less than 0.00001 and the heterogeneity was I<SUP>2 </SUP>= 64%. The estimated number needed to treat for an additional beneficial outcome to achieve an extra participant with sustained virological response is seven participants (95% CI 5 to 10 participants) with peginterferon plus ribavirin versus interferon plus ribavirin. Funnel plot visual inspection did not reveal significant risk of publication bias (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>Because this meta-analysis did not reach its required information size of 14,486 participants based on the assumption of a maximum type I error of 5%, we used a trial sequential analysis to assess the statistical significance. Based on the assumption of a maximum type I error of 1%, the required information size was 20,513 participants. Again, the estimated effects were statistically significant in favour of peginterferon plus ribavirin (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>).</P>
<P>Subgroup analyses showed pronounced differences in comparative treatment effects according to the genotype of the virus (<LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>). Data from 16 trials (<LINK REF="STD-Manns-2001" TYPE="STUDY">Manns 2001</LINK>; <LINK REF="STD-Cariti-2002" TYPE="STUDY">Cariti 2002</LINK>; <LINK REF="STD-Fried-2002" TYPE="STUDY">Fried 2002</LINK>; <LINK REF="STD-Bruno-2004" TYPE="STUDY">Bruno 2004</LINK>; <LINK REF="STD-Izumi-2004" TYPE="STUDY">Izumi 2004</LINK>; <LINK REF="STD-Dollinger-2005" TYPE="STUDY">Dollinger 2005</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Mangia-2005" TYPE="STUDY">Mangia 2005</LINK>; <LINK REF="STD-Napoli-2005" TYPE="STUDY">Napoli 2005</LINK>; <LINK REF="STD-PRETTY-2005" TYPE="STUDY">PRETTY 2005</LINK>; <LINK REF="STD-Scotto-2005" TYPE="STUDY">Scotto 2005</LINK>; <LINK REF="STD-Tsubota-2005" TYPE="STUDY">Tsubota 2005</LINK>; <LINK REF="STD-Rahman-2007a" TYPE="STUDY">Rahman 2007a</LINK>; <LINK REF="STD-Sj_x00f6_gren-2007" TYPE="STUDY">Sjögren 2007</LINK>; <LINK REF="STD-Roffi-2008" TYPE="STUDY">Roffi 2008</LINK>; <LINK REF="STD-Nevens-2010" TYPE="STUDY">Nevens 2010</LINK>) for genotype one yielded RR 1.47, 95% CI 1.27 to 1.70, when the random-effects model was used. Data from nine trials (<LINK REF="STD-Manns-2001" TYPE="STUDY">Manns 2001</LINK>; <LINK REF="STD-Fried-2002" TYPE="STUDY">Fried 2002</LINK>; <LINK REF="STD-Hinrichsen-2002" TYPE="STUDY">Hinrichsen 2002</LINK>; <LINK REF="STD-Fargion-2004" TYPE="STUDY">Fargion 2004</LINK>; <LINK REF="STD-Mangia-2005" TYPE="STUDY">Mangia 2005</LINK>; <LINK REF="STD-Napoli-2005" TYPE="STUDY">Napoli 2005</LINK>; <LINK REF="STD-Rahman-2007b" TYPE="STUDY">Rahman 2007b</LINK>; <LINK REF="STD-Horsmans-2008" TYPE="STUDY">Horsmans 2008</LINK>; <LINK REF="STD-Roffi-2008" TYPE="STUDY">Roffi 2008</LINK>) for genotype two or three yielded RR 1.10, 95% CI 1.03 to 1.19, when the random-effects model was used. Data from nine trials (<LINK REF="STD-Manns-2001" TYPE="STUDY">Manns 2001</LINK>; <LINK REF="STD-Fried-2002" TYPE="STUDY">Fried 2002</LINK>; <LINK REF="STD-Esmat-2003" TYPE="STUDY">Esmat 2003</LINK>; <LINK REF="STD-Shobokshi-2003" TYPE="STUDY">Shobokshi 2003</LINK>; <LINK REF="STD-Thakeb-2003" TYPE="STUDY">Thakeb 2003</LINK>; <LINK REF="STD-Al_x002d_Faleh-2004" TYPE="STUDY">Al-Faleh 2004</LINK>; <LINK REF="STD-Derbala-2005" TYPE="STUDY">Derbala 2005</LINK>; <LINK REF="STD-Derbala-2006" TYPE="STUDY">Derbala 2006</LINK>; <LINK REF="STD-Wakil-2006" TYPE="STUDY">Wakil 2006</LINK>) for genotype four yielded RR 1.76, 95% CI 1.30 to 2.39, when the random-effects model was used. These differences were substantiated by tests of interaction that yielded statistically significant differences between genotype one and genotype two or three (P value &lt; 0.002) and between genotype two or three and genotype four (P value &lt; 0.029).<BR/>
</P>
<P>Subgroup analyses showed a pronounced difference in comparative treatment effects by type of peginterferon (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>; <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK>). Data from nine trials (<LINK REF="STD-Cariti-2002" TYPE="STUDY">Cariti 2002</LINK>; <LINK REF="STD-Fried-2002" TYPE="STUDY">Fried 2002</LINK>; <LINK REF="STD-Shobokshi-2003" TYPE="STUDY">Shobokshi 2003</LINK>; <LINK REF="STD-Thakeb-2003" TYPE="STUDY">Thakeb 2003</LINK>; <LINK REF="STD-Fargion-2004" TYPE="STUDY">Fargion 2004</LINK>; <LINK REF="STD-Mangia-2005" TYPE="STUDY">Mangia 2005</LINK>; <LINK REF="STD-PRETTY-2005" TYPE="STUDY">PRETTY 2005</LINK>; <LINK REF="STD-Derbala-2006" TYPE="STUDY">Derbala 2006</LINK>; <LINK REF="STD-Nevens-2010" TYPE="STUDY">Nevens 2010</LINK>) assessing peginterferon alpha-2a yielded RR 1.85 (95% CI 1.46 to 2.35) by using the random-effects model. Data from 18 trials (<LINK REF="STD-Manns-2001" TYPE="STUDY">Manns 2001</LINK>; <LINK REF="STD-Hinrichsen-2002" TYPE="STUDY">Hinrichsen 2002</LINK>; <LINK REF="STD-Esmat-2003" TYPE="STUDY">Esmat 2003</LINK>; <LINK REF="STD-Al_x002d_Faleh-2004" TYPE="STUDY">Al-Faleh 2004</LINK>; <LINK REF="STD-Bruno-2004" TYPE="STUDY">Bruno 2004</LINK>; <LINK REF="STD-Izumi-2004" TYPE="STUDY">Izumi 2004</LINK>; <LINK REF="STD-Derbala-2005" TYPE="STUDY">Derbala 2005</LINK>; <LINK REF="STD-Dollinger-2005" TYPE="STUDY">Dollinger 2005</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Napoli-2005" TYPE="STUDY">Napoli 2005</LINK>; <LINK REF="STD-Scotto-2005" TYPE="STUDY">Scotto 2005</LINK>; <LINK REF="STD-Tsubota-2005" TYPE="STUDY">Tsubota 2005</LINK>; <LINK REF="STD-Wakil-2006" TYPE="STUDY">Wakil 2006</LINK>; <LINK REF="STD-Rahman-2007a" TYPE="STUDY">Rahman 2007a</LINK>; <LINK REF="STD-Rahman-2007b" TYPE="STUDY">Rahman 2007b</LINK>; <LINK REF="STD-Sj_x00f6_gren-2007" TYPE="STUDY">Sjögren 2007</LINK>; <LINK REF="STD-Horsmans-2008" TYPE="STUDY">Horsmans 2008</LINK>; <LINK REF="STD-Roffi-2008" TYPE="STUDY">Roffi 2008</LINK>) assessing peginterferon alpha-2b yielded RR 1.14, 95% CI 1.06 to 1.22, when the random-effects model was used. These differences were substantiated by tests of interaction that yielded statistically significant differences between peginterferon alpha-2a plus ribavirin and peginterferon alpha-2b plus ribavirin (P &lt; 0.001).</P>
<P>Subgroup analyses on risk of bias (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), treatment history (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>), and baseline viral load (<LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>) using RR as the measure of effect yielded similar results favouring peginterferon over interferon. Tests of interactions of the latter subgroup analyses were non-significant.</P>
<P>A sensitivity analysis from which we excluded the three trials in which amantadine was used as triple therapy in both the peginterferon plus ribavirin group and the interferon plus ribavirin group yielded similar significant results favouring peginterferon (<LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings table</HEADING>
<P>We prepared a Summary of Findings (SoFs) table for all outcomes but one, ie, quality of life (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). The SoFs table presents that we can have low confidence in the current evidence on harms measured as morbidity plus mortality and adverse events leading to treatment discontinuation. The meta-analysis on morbidity plus mortality showed a very serious imprecision because only nine events were included in the meta-analysis with five trials. In the meta-analysis on adverse events, serious discrepancies across trials and lack of precision were evident. The proportions of observed adverse events differ substantially across the trials, and the direction of effect is heterogeneous. However, because the event proportion is still relatively low across the trials, all included trials may be subject to a considerable risk of random errors, thus explaining the apparent heterogeneity in direction of estimates. The observed treatment effects differ in magnitude as well, but most confidence intervals show considerable overlap. In addition, we can have a very low confidence in the current evidence on treatment benefits measured as sustained virological response.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-02-24 11:01:15 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SUMMARY_OF_RESULTS MODIFIED="2014-02-20 09:39:17 +0100" MODIFIED_BY="[Empty name]">
<P>A major obstacle to treatment and patient compliance is the association of combined antiviral therapy with frequent and sometimes serious adverse events. Timely recognition of adverse events has a crucial role in the continuation of antiviral therapy with a hope for successful virological treatment results. In clinical trials, approximately 10% to 15% of participants discontinue peginterferon and ribavirin therapy because of adverse effects; in clinical practice, the rate of treatment discontinuation has been reported as substantially higher (<LINK REF="REF-Sulkowski-2011" TYPE="REFERENCE">Sulkowski 2011</LINK>). The adverse effects of combined antiviral therapy are numerous and can be observed in many organ systems. The most common adverse effects are haematological, dermatological, neurological, immunological, gastrointestinal, pulmonary, cardiovascular, and ocular (<LINK REF="REF-Sulkowski-2011" TYPE="REFERENCE">Sulkowski 2011</LINK>). We are lacking data on direct comparisons of different types of interferons. Among the most frequent adverse effects is myelosuppression. Neutrophil count decreases by an average of 34% (<LINK REF="REF-Soza-2002" TYPE="REFERENCE">Soza 2002</LINK>), and mean platelet drop is around 42% (<LINK REF="REF-Roomer-2010" TYPE="REFERENCE">Roomer 2010</LINK>). Regarding haemoglobin levels, more than 50% of participants experienced a decrease in haemoglobin to around 30 g/L. Women are more prone to experiencing a haemoglobin level less than 100 g/L (<LINK REF="REF-Sulkowski-2004" TYPE="REFERENCE">Sulkowski 2004</LINK>). Many of those adverse effects usually require only adjustment of antiviral therapy. In some patients, application of growth factors is needed because of haematological disturbances. Psychiatric disturbances and mood alterations associated with long-term interferon therapy are well described. In some trials (<LINK REF="REF-Constant-2005" TYPE="REFERENCE">Constant 2005</LINK>), mood alterations occurred in 32% of participants, and significant depressive symptoms were noted in 21% to 58% of participants (<LINK REF="REF-Raison-2005" TYPE="REFERENCE">Raison 2005</LINK>). Retinopathy associated with pegylated interferon therapy has been reported in 21% of participants, but the vast majority of participants recovered without cessation of treatment (<LINK REF="REF-Lim-2010" TYPE="REFERENCE">Lim 2010</LINK>). Among the rare adverse events that could be linked to combined antiviral therapy are some potentially fatal disorders that are usually reported as case reports. Pulmonary complications such as pneumonitis and pulmonary hypertension are rare but require early detection and premature cessation of antiviral therapy (<LINK REF="REF-Kumar-2002" TYPE="REFERENCE">Kumar 2002</LINK>; <LINK REF="REF-Dhillon-2010" TYPE="REFERENCE">Dhillon 2010</LINK>; <LINK REF="REF-Slavenburg-2010" TYPE="REFERENCE">Slavenburg 2010</LINK>). In one trial, mortality secondary to pneumonitis was seen exclusively with peginterferon alpha-2b (<LINK REF="REF-Slavenburg-2010" TYPE="REFERENCE">Slavenburg 2010</LINK>).</P>
<P>In this systematic review, we have summarised the available evidence from randomised clinical trials comparing peginterferon alpha versus interferon alpha, both given in combination with ribavirin. Because of the high risk of bias in the trials, our results seem to suggest that the combination of peginterferon plus ribavirin is associated with a moderate or low beneficial effect on sustained virological response when compared with interferon plus ribavirin. Our results show that evidence on liver-related morbidity plus all-cause mortality is sparse, and that the meta-analysis is underpowered to detect any difference in risk of liver-related morbidity plus all-cause mortality. However, regarding adverse events, the two regimens seem to differ significantly, with interferon plus ribavirin causing less harm than peginterferon plus ribavirin.</P>
<P>Both peginterferon alpha-2a and peginterferon alpha-2b plus ribavirin were superior in terms of sustained virological response when compared with interferon plus ribavirin for participants with chronic hepatitis. Our subgroup analyses demonstrated that peginterferon alpha-2a was associated with a significantly higher sustained virological response than peginterferon alpha-2b versus interferon. This indirect observation is in harmony with our previous observations from head-to-head trials that peginterferon alpha-2a leads to sustained virological response in a greater number of participants than is seen with peginterferon alpha-2b (<LINK REF="REF-Awad-2010" TYPE="REFERENCE">Awad 2010</LINK>; <LINK REF="REF-Hauser-2014" TYPE="REFERENCE">Hauser 2014</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2014-02-24 11:01:15 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>The Summary of Findings table that we have prepared reveals that, in generalwe can have only low confidence in the current evidence on harms measured as liver-related morbidity plus all-cause mortality, and adverse events or adverse events leading to treatment discontinuation. In addition, we can have very low confidence in the current evidence on treatment benefits measured as sustained virological response (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). All trials had high risks of bias. If we disregarded bias due to lack of blinding and due to vested interests, about half of the trials could be considered trials with a lower risk of bias. Our sensitivity analyses, however, showed no important influence of bias risk on our estimates of intervention effects. This may be due to the fact that we were unable to identify trials with a lower risk of bias. In our study, trials that adequately reported on the methodology of trial performance are large trials that dominate the pooled estimates of effect. Therefore, it is less likely that the pooled estimates are biased. In the meta-analysis for sustained virological response, no serious inconsistencies were seen across trials, and the meta-analyses crossed the Lan-DeMets monitoring boundary, leaving out any random error. The only trial with blinded assessment of sustained virological response showed no significant differences between the two interventions but suffered from the fact that it was very small (<LINK REF="STD-Sj_x00f6_gren-2007" TYPE="STUDY">Sjögren 2007</LINK>).<BR/>
<BR/>Subgroup analyses for sustained virological response showed a pronounced difference in comparative treatment effects by genotype and type of peginterferon. Data from 16 trials for genotype one yielded RR 1.5, 95% CI 1.3 to 1.7. Data from nine trials for genotype two or three yielded RR 1.1, 95% CI 1.0 to 1.2. Data from nine trials for genotype four yielded RR 1.8, 95% CI 1.3 to 2.4. These differences were substantiated by tests of interaction that yielded statistically significant differences between genotype one and genotype two or three (P value 0.0002) and between genotype two or three and genotype four (P value 0.029). The larger effects of peginterferons versus interferons on sustained virological response were observed in participants infected with genotype one and genotype four, whereas the difference between peginterferon and interferon was least for participants infected with genotype two or three.<BR/>
<BR/>Moreover, peginterferon alpha-2a plus ribavirin seemed significantly more effective than peginterferon alpha-2b plus ribavirin when compared with interferon plus ribavirin in subgroup analyses. Data from nine trials for peginterferon alpha-2a yielded RR 1.9, 95% CI 1.5 to 2.4. Data from 18 trials for peginterferon alpha-2b yielded only RR 1.1, 95% CI 1.1 to 1.2. These differences were substantiated by tests of interaction that yielded statistically significant differences between peginterferon alpha-2a plus ribavirin and peginterferon alpha-2b plus ribavirin trials (P &lt; 0.0001). This is in accordance with our previous observations based on head-to-head randomised clinical trials comparing peginterferon alpha-2a versus peginterferon alpha-2b (<LINK REF="REF-Awad-2010" TYPE="REFERENCE">Awad 2010</LINK>; <LINK REF="REF-Hauser-2014" TYPE="REFERENCE">Hauser 2014</LINK>).<BR/>
<BR/>All other tests of interaction regarding risk of bias (lower risk of bias compared with high risk of bias), treatment history, and baseline viral load yielded non-significant results.<BR/>
<BR/>We found three trials that used amantadine cointervention, four trials that used consensus interferon, and one trial that used leucocyte interferon. However, the paucity of evidence precludes any firm conclusions on effects of triple therapy regimens with the use of amantadine, leucocyte interferon, or consensus interferon. Our analyses strengthen the evidence that peginterferon plus ribavirin increases sustained virological response for participants with chronic hepatitis C, irrespective of genotype, previous antiviral status, or viral load, and with or without amantadine as cointervention.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2014-02-06 15:12:25 +0100" MODIFIED_BY="[Empty name]">
<P>The methodological quality was unclearly reported in a considerable number of included trials. Only 14 of the 27 trials (51.9%) reported adequate randomisation and allocation concealment. Most trial reports described unclearly blinded outcome assessment. These aspects may be essential in minimising the risks of selection, performance, and ascertainment bias in individual trials (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-Lundh-2012" TYPE="REFERENCE">Lundh 2012</LINK>; <LINK REF="REF-Savovic-2012" TYPE="REFERENCE">Savovic 2012</LINK>; <LINK REF="REF-Savovic-2012a" TYPE="REFERENCE">Savovic 2012a</LINK>). However, we found no significant association between methodological quality and trial results <U>(</U>
<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).These findings may support the robustness of our results but do not exclude the possibility of bias, especially as we could not assess risk of bias from blinding and vested interests. Industry support is known to significantly bias trial results (<LINK REF="REF-Lundh-2012" TYPE="REFERENCE">Lundh 2012</LINK>). Regarding blinding, only one trial assessed sustained virological response with blinding and found no significant effect of pegylated interferon versus interferon (<LINK REF="STD-Sj_x00f6_gren-2007" TYPE="STUDY">Sjögren 2007</LINK>). However, this trial was small, and the confidence interval was accordingly wide (<LINK REF="STD-Sj_x00f6_gren-2007" TYPE="STUDY">Sjögren 2007</LINK>).</P>
<P>Selective outcome reporting was difficult to assess in this review. None of the included trials was adequately registered or had its protocol publicly available before trial completion (<LINK REF="REF-Krleza_x002d_Jeric-2005" TYPE="REFERENCE">Krleza-Jeric 2005</LINK>; <LINK REF="REF-WHO-2009" TYPE="REFERENCE">WHO 2009</LINK>). It is hoped that the initiation of the World Health Organization International Clinical Trials Registry Platform will facilitate such assessments for future trials (<LINK REF="REF-WHO-2009" TYPE="REFERENCE">WHO 2009</LINK>). Another limitation in this review was insufficient design and reporting. Investigators of future trials therefore are well advised to adhere to the guidelines of Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) (<LINK REF="REF-Chan-2013" TYPE="REFERENCE">Chan 2013</LINK>) and the Consolidated Standards for Reporting of Trials (CONSORT) (<LINK REF="REF-Moher-2012" TYPE="REFERENCE">Moher 2012</LINK>) to improve the quality of trials.</P>
<P>In general, we can have only low confidence in the current evidence on harms measured as morbidity plus mortality and adverse events leading to discontinuation, whereas we can have moderate confidence in the current evidence on treatment benefits measured as sustained virological response (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). In the meta-analysis for morbidity plus mortality, very serious imprecision was evident because only nine events were included in the meta-analysis from five trials (<LINK REF="STD-Fried-2002" TYPE="STUDY">Fried 2002</LINK>; <LINK REF="STD-Esmat-2003" TYPE="STUDY">Esmat 2003</LINK>; <LINK REF="STD-Al_x002d_Faleh-2004" TYPE="STUDY">Al-Faleh 2004</LINK>; <LINK REF="STD-Lee-2005" TYPE="STUDY">Lee 2005</LINK>; <LINK REF="STD-Nevens-2010" TYPE="STUDY">Nevens 2010</LINK>).<BR/>
<BR/>In the meta-analysis on adverse events, serious discrepancies across trials and lack of precision were noted. The proportions of observed adverse events differ substantially across trials, and the direction of effect is heterogeneous. However, because the event rate is still relatively low across trials, all of the included trials may be subject to considerable random error, thus explaining the apparent heterogeneity in direction of estimates. The observed treatment effects differ in magnitude as well, but most confidence intervals show considerable overlap. In the meta-analysis for sustained virological response, no serious inconsistencies across studies were evident, and the meta-analyses showed adequate precision (i.e., the TSA alpha-spending monitoring boundary for benefit was crossed, favouring pegylated interferon). Nonetheless, we had some concerns regarding bias (which was high in all trials) and indirectness, as all included randomised clinical trials had virological response as the predominant measure of benefit. Many of the trials measured sustained virological response, which is currently the commonly used surrogate outcome measure of benefit. Recent large cohort studies show a positive correlation between the presence of viraemia and mortality (<LINK REF="REF-Adeel-2009" TYPE="REFERENCE">Adeel 2009</LINK>; <LINK REF="REF-Hirofumi-2009" TYPE="REFERENCE">Hirofumi 2009</LINK>). However, it is important to remember that sustained virological response still is only a putative (unvalidated) surrogate outcome for the patient-relevant intervention effects of antivirals (<LINK REF="REF-Gluud-2007" TYPE="REFERENCE">Gluud 2007</LINK>; <LINK REF="REF-Koretz-2013" TYPE="REFERENCE">Koretz 2013</LINK>; <LINK REF="REF-Gurusamy-2013" TYPE="REFERENCE">Gurusamy 2013</LINK>). Because randomised clinical trials need to inform clinical practice, clinical outcomes such as risk of liver failure, hepatocellular carcinoma, mortality, and quality of life would be of greater interest to patients and clinicians. Such measures nevertheless require a follow-up of maybe up to five years. Currently, no randomised clinical trials assessing the two pegylated interferons are of such long duration.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2014-01-06 13:29:51 +0100" MODIFIED_BY="[Empty name]">
<P>The included meta-analyses had a seemingly reasonable mix of small and large studies, yielding fairly consistent results, thus causing little concern about the presence of publication bias.</P>
<P>The strengths of this Cochrane Hepato-Biliary Group systematic review are that it builds on a peer-reviewed published protocol, uses extensive searches until recently (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), considers risks of systematic errors (&#8216;bias&#8217;) (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-Lundh-2012" TYPE="REFERENCE">Lundh 2012</LINK>; <LINK REF="REF-Savovic-2012" TYPE="REFERENCE">Savovic 2012</LINK>; <LINK REF="REF-Savovic-2012a" TYPE="REFERENCE">Savovic 2012a</LINK>), and considers risks of random errors (&#8216;play of chance&#8217;) by adjusting the threshold for statistical significance according to the information and strength of evidence present in the cumulative meta-analysis (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>, <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>). Furthermore, to avoid publication and ascertainment bias, we included trials regardless of publication status and language, and all data were abstracted independently by at least two review authors to avoid information bias. However, our review has potential limitations that may lower our confidence in the estimates of intervention effect. First, we are aware of possible inclusion bias in excluding special patient groups (hepatitis B virus, human immunodeficiency virus, cancer, and liver-transplanted patients). Future systematic reviews should assess the intervention effects of antivirals in these patient groups. Second, a possible limitation of our review is the lack of availability of full reports of all included trials. Ten of the 27 included trials were available only as abstracts. However, including these abstracts in our systematic review may likely be a strength rather than a limitation. By including abstracts, we are looking at the complete available body of evidence. By excluding abstracts, we would have been looking only at a subset defined through present-day publication mechanisms, favouring trials that show beneficial effects. This would considerably increase the likelihood of publication bias. Third, in general, adverse events were reported insufficiently. Most of the participants treated with peginterferon alpha or interferon alpha experience one or more adverse effects (e.g., influenza-like symptoms, depression, neutropenia, thrombocytopenia). The proportions of observed adverse events differed greatly across trials, and the direction of effect was heterogeneous.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2014-02-07 12:06:50 +0100" MODIFIED_BY="[Empty name]">
<P>By comparing our results with those of the other meta-analyses, we have found two main differences. Our searches of the literature were much more detailed than searches previously conducted. In previous meta-analyses, authors usually did not perform grey literature searches and did not include meeting abstracts. Some authors excluded trials that were not published in English or used just two databases (<LINK REF="REF-Chander-2002" TYPE="REFERENCE">Chander 2002</LINK>; <LINK REF="REF-Zaman-2003" TYPE="REFERENCE">Zaman 2003</LINK>), performed only cost-effectives analysis (<LINK REF="REF-Shepherd-2005" TYPE="REFERENCE">Shepherd 2005</LINK>; <LINK REF="REF-Siebert-2005" TYPE="REFERENCE">Siebert 2005</LINK>), or evaluated only one genotype (<LINK REF="REF-Khuroo-2004" TYPE="REFERENCE">Khuroo 2004</LINK>; <LINK REF="REF-Aljumah-2013" TYPE="REFERENCE">Aljumah 2013</LINK>). Second, we performed several sensitivity analyses to ensure the robustness of the results of our systematic review; this procedure is lacking in previously published meta-analyses. Moreover, our number of included trials is much higher than the number included in the meta-analyses mentioned above. Fourth, we considered risk of bias. Fifth, we also took precautions to interpret the statistical inference according to the strength of the evidence. In this vein, we constructed adjusted thresholds for statistical significance by using TSA.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-02-19 21:51:09 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2014-01-06 13:30:04 +0100" MODIFIED_BY="[Empty name]">
<P>Moderate evidence shows that pegylated interferon plus ribavirin compared with interferon plus ribavirin increases sustained virological response for patients with chronic hepatitis C, irrespective of genotype, previous antiviral status, or viral load, and with or without amantadine as cointervention. However, evidence is insufficient with regard to the risk of liver-related morbidity plus all-cause mortality, adverse events, and quality of life. Therefore, in their best interest, patients must be informed and involved in the decision to treat and with what to treat. Once started, treatment should be monitored carefully to minimise the risk of harm for patients.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-02-19 21:51:09 +0100" MODIFIED_BY="[Empty name]">
<P>We can have very low confidence in the current evidence on treatment benefits measured as sustained virological response; thus, further research may not change our confidence in the estimate of effect. However, we lack knowledge about the clinical consequences of obtaining sustained virological response through antiviral treatment. We have only low confidence in the current evidence on harms measured as morbidity and mortality and adverse events leading to discontinuation; thus, further research is very likely to have an important impact on our confidence in the estimates of effect and is likely to change the estimates. Although we did not find differences regarding adverse events leading to treatment discontinuation between peginterferon plus ribavirin when compared with interferon plus ribavirin, an obvious trend was noted toward more adverse events among patients treated with pegylated interferons. Randomised clinical trials are needed to confirm or refute the effect of peginterferon plus ribavirin treatment in non-responders and relapsers. Longer follow-up assessment on existing trials and research on the long-term association between sustained virological response and liver-related morbidity and all-cause mortality seem warranted. Future trials ought to assess quality of life as well. Future trials should be designed according to the SPIRIT guidelines (<LINK REF="REF-Chan-2013" TYPE="REFERENCE">Chan 2013</LINK>) and reported according to the CONSORT guidelines (<A HREF="http://www.consort-statement.org">www.consort-statement.org</A>) (<LINK REF="REF-Moher-2012" TYPE="REFERENCE">Moher 2012</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-02-13 16:09:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Thanks to Marija Simin for drafting the previous version of this systematic review. Thanks to Sarah Klingenberg for advising on and conducting the search strategy.<BR/>Thanks to Esmat GH, Lee SD, Izumi N, Mangia A, Napoli N, Nevens F, and Tsubota A who provided us with additional information regarding their trials.</P>
<P>Peer reviewers: Jalal Poorolajal, Iran.<BR/>Contact editors: Bodil Als-Nielsen, Denmark; Ronald Koretz, USA.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-12-08 21:22:33 +0100" MODIFIED_BY="[Empty name]">
<P>Tahany Awad acted as an invited speaker for Roche and is now employed by AbbVie.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-02-24 11:06:49 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<P>Goran Hauser performed the literature search, performed data extraction, assessed the risk of bias in included trials, performed statistical analyses in RevMan including TSA, contributed to the interpretation of results, presented a Summary of Findings table, and drafted the review. Tahany Awad performed the literature search, performed data extraction, assessed the risk of bias in included trials, performed statistical analyses in RevMan, and contributed to the interpretation of results. Jesper Brok performed data extraction, assessed the risk of bias in included trials, contributed to the interpretation of results, and revised the review. Kristian Thorlund assessed the risk of bias associated with incomplete outcome data, performed statistical analyses in RevMan including TSA, contributed to the interpretation of results, and revised the review. Davor Stimac, Mahasen Mabrouk, Christian Gluud, and Lise Lotte Gluud acted as arbitrators for disagreements in data extraction and the bias risk assessment, contributed to the interpretation of results, and revised the review. All authors approved of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2014-02-20 21:55:39 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>We redefined risk of bias subgroup analysis as an analysis between trials that are assessed to be at low or high risk of bias instead of trials that are assessed to be at low, unclear, or high risk of bias. This is in accordance with the recommendation from the <I>Cochrane Handbook for Systematic Reviews of interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) and previous research on the topic (<LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-Savovic-2012" TYPE="REFERENCE">Savovic 2012</LINK>; <LINK REF="REF-Savovic-2012a" TYPE="REFERENCE">Savovic 2012a</LINK>).</LI>
<LI>We changed the outcome measure 'failure of sustained virological response' to 'sustained virological response'.</LI>
<LI>We changed the sequence of outcomes in accordance with recommendations of the <I>Cochrane Handbook for Systematic Reviews of interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</LI>
<LI>A Summary of findings table was planned at the review stage as guidelines about rating quality of evidence were issued after the protocol was published.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes of the protocol were as follows:</HEADING>
<UL>
<LI>Serum (or plasma) sustained virological response: number of participants with undetectable hepatitis C virus RNA in serum by sensitivity testing six months after the end of treatment.</LI>
<LI>Liver-related morbidity plus all-cause mortality: number of participants who developed cirrhosis, ascites, variceal bleeding, hepatic encephalopathy, or hepatocellular carcinoma, or who died.</LI>
<LI>Adverse events: numbers and types of adverse events, defined as participants with any untoward medical occurrence not necessarily having a causal relationship to the treatment. We will report separately on adverse events that led to treatment discontinuation and those that did not lead to treatment discontinuation. A serious adverse event is defined according to the guidelines of the International Conference on Harmonisation (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>) as any event that leads to death, is life threatening, requires in-patient hospitalisation or prolongation of existing hospitalisation, or results in persistent or significant disability, as well as any important medical event that may have jeopardised the participant or required intervention to prevent it. All other adverse events will be considered non-serious.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Updated outcomes became the following:</HEADING>
<UL>
<LI>Primary outcomes</LI>
</UL>
<UL>
<UL>
<LI>Liver-related morbidity plus all-cause mortality: number of participants who developed cirrhosis, ascites, variceal bleeding, hepatic encephalopathy, or hepatocellular carcinoma, or who died.</LI>
<LI>Adverse events leading to treatment discontinuation.</LI>
<LI>Other adverse events: haematological effects, fatigue and flu-like symptoms, psychiatric symptoms, dermatological symptoms, thyroid malfunction, gastrointestinal symptoms (other than liver related).</LI>
<LI>Quality of life.</LI>
</UL>
</UL>
<UL>
<LI>Secondary outcome</LI>
</UL>
<UL>
<UL>
<LI>Sustained virological response: number of participants with undetectable hepatitis C virus RNA in serum by sensitivity testing six months after the end of treatment.</LI>
</UL>
</UL>
<P>In our protocol, we included baseline imbalance and early stopping as potential bias components. According to updated guidelines from The Cochrane Collaboration, these two domains should no longer be used (<LINK REF="REF-Gluud-2013" TYPE="REFERENCE">Gluud 2013</LINK>).</P>
</SUBSECTION>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2014-02-20 10:22:47 +0100" MODIFIED_BY="Dimitrinka Nikolova"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-02-24 11:16:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<STUDIES MODIFIED="2014-01-23 16:18:37 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2014-01-23 16:18:37 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Al_x002d_Faleh-2004" MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" NAME="Al-Faleh 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alfaleh FZ, Hadad Q, Khuroo MS, Aljumah A, Algamedi A, Alashgar H, et al</AU>
<TI>Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4</TI>
<SO>Liver International</SO>
<YR>2004</YR>
<VL>24</VL>
<PG>568-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bruno-2004" MODIFIED="2013-05-28 12:20:01 +0200" MODIFIED_BY="Tahany Awad" NAME="Bruno 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-06-22 14:16:11 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bruno S, Camma C, Di Marco V, Rumi M, Vinci M, Camozzi M, et al</AU>
<TI>Peginterferon alfa-2b plus ribavirin for naive patients with genotype 1 chronic hepatitis C: a randomized controlled trial</TI>
<SO>Journal of Hepatology</SO>
<YR>2004</YR>
<VL>41</VL>
<PG>474-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:20:01 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bruno S, Camma C, Di Marco V, Rumi MG, Vinci M, Camozzi M, et al</AU>
<TI>Chronic hepatitis C (CH-C) genotype 1: an independent, multicenter RCT comparing PEG-IFN alfa-2b 12 kD plus ribavirin (RBV) and IFN alfa-2b plus RBV in naive patients</TI>
<SO>Journal of Hepatology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>Suppl 2</NO>
<PG>131-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cariti-2002" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Cariti 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cariti G, Andreoni M, Calleri G, Manca A, Rosina F, Sartori M, et al</AU>
<TI>PEG-INF alpha-2A (40KD) plus ribavirin (RBV) vs IFN alpha-2A (ROFERON-A) in naive patients with chronic hepatitis C (CHC) and genotype 1 [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>4 Pt 2</NO>
<PG>595A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Derbala-2005" MODIFIED="2011-06-01 13:29:38 +0200" MODIFIED_BY="[Empty name]" NAME="Derbala 2005" YEAR="2005">
<REFERENCE MODIFIED="2011-06-01 13:29:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Derbala M, Amer A, Bener B, Lopez A, Omar M, El Ghannam M</AU>
<TI>Pegylated interferon-alpha 2b- ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>4</NO>
<PG>380-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1111/j.1365-2893.2005.00604.x"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Derbala-2006" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Derbala 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Derbala MF, Kaabi SR, Dweik NZ, Pasic F, Butt MT, Yakoob R, et al</AU>
<TI>Treatment of hepatitis C virus genotype 4 with pegylated interferon alpha 2a:Impact of bilharziasis and fibrosis stage</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>35</NO>
<PG>5692-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dollinger-2005" MODIFIED="2013-05-28 12:20:42 +0200" MODIFIED_BY="Tahany Awad" NAME="Dollinger 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-05-28 12:20:42 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dollinger MM, Dridi Y, Lesske J, Behl S, Fleig WE</AU>
<TI>Efficacy of daily consensus interferon and ribavirin compared to peg-interferon alpha-2B and interferon in non-responders with chronic hepatitis C [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2005</YR>
<VL>42</VL>
<NO>4 Suppl 1</NO>
<PG>691-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Esmat-2003" MODIFIED="2013-05-28 12:21:32 +0200" MODIFIED_BY="Tahany Awad" NAME="Esmat 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-05-28 12:21:32 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Esmat GH, Abouzied A, Abdel-Hamid M, Mohamed MK, Zalata K, El Raziky MS, et al</AU>
<TI>Results of a randomized clinical trial of genotype-4 infected subjects when treated with standard or pegylated interferon alfa-2b in combination with ribavirin [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>4 Suppl 1</NO>
<PG>314A-315A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fargion-2004" MODIFIED="2013-05-28 12:22:16 +0200" MODIFIED_BY="Tahany Awad" NAME="Fargion 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-28 12:21:52 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fargion S, Borzio M, Cargnel A</AU>
<TI>End of treatment and sustained response to peginterferon alfa-2a (40kD) (Pegasys) plus ribavirin (RBV) (Copegus) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa-2a (Roferon-A) plus RBV and AMA in IFN/RBV nonresponders with chronic hepatitis C (CHC) [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>4 Suppl 1</NO>
<PG>733A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:22:04 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fargion S, Borzio M, Cargnel A</AU>
<TI>Peginterferon alfa-2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (Roferon-A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC) [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>4 Pt 2</NO>
<PG>572A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:22:09 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fargion S, Borzio M, Cargnel A</AU>
<TI>Peginterferon alfa-2a (40kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (Roferon-A) plus RBV and AMA in IFN/RBV nonresponder patients with chronic hepatitis C (CHC)</TI>
<SO>Journal of Hepatology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>Suppl 2</NO>
<PG>139-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:22:16 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fargion S, Borzio M, Maraschi A, Cargnel A</AU>
<TI>Sustained virological response (SVR) to peginterferon alfa-2a (40 kD) (Pegasys) plus ribavirin (RBV) and amantadine (AMA) vs induction therapy with interferon alfa-2a (Roferon-A) plus RBV and AMA in IFN/RBV non responders (NR) with chronic hepatitis C (CHC)</TI>
<SO>Journal of Hepatology</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>Suppl 1</NO>
<PG>140</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fried-2002" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Fried 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bosques-Padilla F, Trejo-Estrada R, Campollo-Rivas O, Cortez-Hernandez C, Dehesa-Violante M, Maldonado-Garza H, et al</AU>
<TI>Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: analysis of Mexican patients included in a multicenter international clinical trial</TI>
<SO>Annals of Hepatology</SO>
<YR>2003</YR>
<VL>2</VL>
<NO>3</NO>
<PG>135-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-06 09:31:31 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al</AU>
<TI>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection</TI>
<SO>New England Journal of Medicine</SO>
<YR>2002</YR>
<VL>347</VL>
<NO>13</NO>
<PG>975-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-31 14:20:20 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai M-Y, et al</AU>
<TI>The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C</TI>
<SO>Journal of Hepatology</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>4</NO>
<PG>675-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:22:55 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hassanein TI, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai M-Y, et al</AU>
<TI>Treatment with 40 kDa peginterferon alfa-2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alfa-2b plus ribavirin [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2001</YR>
<VL>34</VL>
<NO>4 Pt 2</NO>
<PG>243A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:25:59 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hassanein TI, Cooksley WGE, Sulkowski M, Smith C, Marinos G, Lai M-Y, et al</AU>
<TI>QOL benefits observed as early as week 2 with peginterferon alfa-2a (40kD) (Pegasys) in combination with ribavirin (RBV) versus interferon alfa-2b plus RBV [EASL abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>1</NO>
<PG>110</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-31 14:20:33 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Herrmann E, Lee J-H, Marinos G, Modi M, Zeuzem S</AU>
<TI>Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>6</NO>
<PG>1351-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-31 14:20:31 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lutchman G, Hoofnagle JH</AU>
<TI>Viral kinetics in hepatitis C</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>37</VL>
<NO>6</NO>
<PG>1257-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-31 14:20:28 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan SD, Craxi A, Alberti A, Giuliani G, De Carli C, Wintfeld N, et al</AU>
<TI>Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C</TI>
<SO>Pharmacoeconomics</SO>
<YR>2004</YR>
<VL>22</VL>
<NO>4</NO>
<PG>257-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-31 14:20:36 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan SD, Green J, Patel KK, Craxi A, Alberti A, Giuliani G, et al</AU>
<TI>A comparison of cost-effectiveness of peginterferon alfa-2a (40kD) (Pegasys) plus ribavirin (Copegus) vs interferon alfa-2b plus ribavirin as first treatment of chronic hepatitis C (CHC)</TI>
<SO>Journal of Hepatology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>Suppl 2</NO>
<PG>174-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-31 14:20:22 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan SD, Jensen DM, Bernstein DE, Hassanein TI, Foster GR, Lee SS, et al</AU>
<TI>Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2004</YR>
<VL>99</VL>
<PG>1490-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:26:51 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zeuzem S, Herrmann E, Lee J-H, Marinos G, Modi M, Roth WK</AU>
<TI>Effect of ribavirin on viral kinetics in hepatitis C virus genotype 1 infected patients treated with pegylated interferon alpha2a [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2001</YR>
<VL>34</VL>
<NO>4 Pt 2</NO>
<PG>558A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hinrichsen-2002" MODIFIED="2013-05-28 12:27:03 +0200" MODIFIED_BY="Tahany Awad" NAME="Hinrichsen 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-05-28 12:27:03 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hinrichsen H, Buggisch P, Nasser S, Foelsch UR</AU>
<TI>A prospective randomised 24 week trial of peg-interferon alpha2b plus ribavirin versus standard combination therapy in untreated hepatitis C genotype 2 and 3 patients [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>4 Pt 2</NO>
<PG>311A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Horsmans-2008" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Horsmans 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Horsmans Y, Colle I, Van Vlierberghe H, Langlet P, Adler M, Bourgeois N, et al</AU>
<TI>Weekly pegylated Interferon alpha-2b vs daily interferon a-2b versus standard regimen of Interferon a-2b in the treatment of patients with chronic hepatitis C virus infection</TI>
<SO>Acto Gastro-Enterologica Belgica</SO>
<YR>2008</YR>
<VL>71</VL>
<NO>3</NO>
<PG>293-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Izumi-2004" MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" NAME="Izumi 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Izumi N, Asahina Y, Kurosaki M, Uchihara M, Nishimura Y, Inoue K, et al</AU>
<TI>A comparison of the exponential decay slope between PEG-IFN alfa-2b/ribavirin and IFN alfa-2b/ribavirin combination therapy in patients with chronic hepatitis C</TI>
<SO>Intervirology</SO>
<YR>2004</YR>
<VL>47</VL>
<PG>102-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2005" MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" NAME="Lee 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, Hwang SJ, et al</AU>
<TI>Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2005</YR>
<VL>12</VL>
<PG>283-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mangia-2005" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Mangia 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mangia A, Ricci GL, Persico M, Minerva N, Caretta V, Bacca D, et al</AU>
<TI>A randomized controlled trial of peginterferon alpha-2a (40 kD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naive patients with chronic hepatitis C</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>3</NO>
<PG>292-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manns-2001" MODIFIED="2014-01-23 15:38:18 +0100" MODIFIED_BY="Tahany Awad" NAME="Manns 2001" YEAR="2001">
<REFERENCE MODIFIED="2014-01-23 15:38:18 +0100" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R</AU>
<TI>A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>687-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:29:33 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Condat B</AU>
<TI>Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b and ribavirin for the treatment of chronic hepatitis C: A randomized trial</TI>
<SO>Hepato-Gastroenterology</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>2</NO>
<PG>141-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:29:40 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gish R, Bzowej N, Brooks L, Brass C, Weng W</AU>
<TI>Treatment with pegylated interferon alfa-2b in combination with ribavirin improved health-related quality of life compared with interferon alfa-2b plus ribavirin in chronic hepatitis C [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>4 Pt 2</NO>
<PG>582A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jen J, Laughlin M, Chung C, Heft S, Affrime MB, Gupta SK, et al</AU>
<TI>Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2002</YR>
<VL>72</VL>
<NO>4</NO>
<PG>349-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:29:54 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manns MP, McHutchison JG, Gordon S, Rustgi V, Shiffman ML, Lee WM, et al</AU>
<TI>Peginterferon alfa-2b plus ribavirin compared to interferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C: 24 week treatment analysis of a multicenter, multinational phase III randomized controlled trial [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<NO>4 Pt 2</NO>
<PG>297A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-30 13:55:02 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al</AU>
<TI>Peginterferon alfa-2a plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>358</VL>
<PG>958-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-31 14:22:34 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McHutchison J, Manns M, Harvey J, Albrecht JK</AU>
<TI>Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peg-interferon alfa-2b plus ribavirin [abstract]</TI>
<SO>Journal of Hepatology</SO>
<YR>2001</YR>
<VL>34</VL>
<NO>1</NO>
<PG>2-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-31 14:22:32 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al</AU>
<TI>Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C</TI>
<SO>Gastroenterology</SO>
<YR>2002</YR>
<VL>123</VL>
<NO>4</NO>
<PG>1061-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:30:32 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McHutchison JG, Manns MP, Harvey J, Garaud J-J, Albrecht J</AU>
<TI>Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving peginterferon alfa 2b plus ribavirin</TI>
<SO>Hepatology</SO>
<YR>2001</YR>
<VL>34</VL>
<NO>4 Pt 2</NO>
<PG>417A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McHutchison JG, Manns MP, Ling M-H, Albrecht JK</AU>
<TI>Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C: is patient gender a confounding factor for sustained virological response when ribavirin dose is expressed as mg/kg of body weight? [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2001</YR>
<VL>34</VL>
<NO>4 Pt 2</NO>
<PG>329A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:30:46 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J</AU>
<TI>Biochemical markers as surrogate markers of liver fibrosis and activity in patients infected by hepatitis C virus: an example in a randomized trial of pegylated-interferon alpfa-2b and ribavirin combination [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>4 Pt 2</NO>
<PG>351A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-31 14:22:41 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J</AU>
<TI>Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>2</NO>
<PG>481-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-31 14:14:59 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al</AU>
<TI>Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>1</NO>
<PG>75-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-31 14:22:20 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al</AU>
<TI>Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C</TI>
<SO>Gut</SO>
<YR>2003</YR>
<VL>52</VL>
<PG>425-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-30 13:55:46 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK</AU>
<TI>Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>11</NO>
<PG>2354-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Napoli-2005" MODIFIED="2013-09-30 13:55:56 +0200" MODIFIED_BY="Tahany Awad" NAME="Napoli 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-30 13:55:56 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Napoli N, Giannelli G, Parisi CV, Antonaci A, Maddalena G, Antonaci S</AU>
<TI>Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C</TI>
<SO>New Microbiologica</SO>
<YR>2005</YR>
<VL>28</VL>
<PG>13-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nevens-2010" MODIFIED="2013-05-28 12:31:58 +0200" MODIFIED_BY="Tahany Awad" NAME="Nevens 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-05-28 12:31:58 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nevens F, Van Vlierberghe H, D'Heygere E, Delwaide J, Adler M, Henrion J, et al</AU>
<TI>A randomised, open-label, multicenter study evaluating the efficacy of peginterferon alfa-2a versus interferon alfa-2a, in combination with ribavirin, in naïve and relapsed chronic hepatitis C patients</TI>
<SO>Acta Gastroenterologica Belgica</SO>
<YR>2010</YR>
<VL>73</VL>
<PG>223-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PRETTY-2005" MODIFIED="2013-05-28 12:32:10 +0200" MODIFIED_BY="Tahany Awad" NAME="PRETTY 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-05-28 12:32:10 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mangia A, Cimino L, Persico M, Demelia L, Rumi M, Spinzi G, et al</AU>
<TI>Enhanced response to peginterferon-alpha-2a-based triple therapy in previously non-responsive chronic hepatitis C: final results of PRETTY study</TI>
<SO>Journal of Hepatology</SO>
<YR>2005</YR>
<VL>42</VL>
<NO>2</NO>
<PG>200-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rahman-2007a" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Rahman 2007a" YEAR="2007">
<REFERENCE MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rahman F, Schuchmann M, Lohr HF, Link R, Buggisch P, Fuchs M, et al</AU>
<TI>Daily consensus interferon versus peg-interferon alfa2b with weight based or 800 mg ribavirin in treatment-naive patients with chronic hepatitis C genotype 1</TI>
<SO>Hepatology</SO>
<YR>2007</YR>
<VL>46</VL>
<NO>4 Suppl 1</NO>
<PG>826A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rahman-2007b" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Rahman 2007b" YEAR="2007">
<REFERENCE MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rahman F, Schuchmann M, Lohr HF, Link R, Buggisch P, Fuchs M, et al</AU>
<TI>Daily consensus interferon versus peg-interferon alfa2b with weight based or 800 mg ribavirin in treatment-naive patients with chronic hepatitis C genotypes 2 or 3</TI>
<SO>Hepatology</SO>
<YR>2007</YR>
<VL>46</VL>
<NO>4 Suppl 1</NO>
<PG>826A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Roffi-2008" MODIFIED="2013-05-28 12:32:37 +0200" MODIFIED_BY="Tahany Awad" NAME="Roffi 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-05-28 12:32:37 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roffi L, Colloredo G, Del Poggio P, Fornaciari G, Castagnetti E, Ceriani R, et al</AU>
<TI>Efficacy and safety of low doses of interferon (IFN) alfa-2b plus ribavirin (RBV) in advanced HCV related liver disease [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>4 Suppl 1</NO>
<PG>322A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-06 09:34:00 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Roffi L, Colloredo G, Pioltelli P, Bellati G, Pozzpi M, Parravicini P, et al</AU>
<TI>Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis</TI>
<SO>Antiviral Therapy</SO>
<YR>2008</YR>
<VL>13</VL>
<NO>5</NO>
<PG>663-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scotto-2005" MODIFIED="2013-09-30 13:56:25 +0200" MODIFIED_BY="Tahany Awad" NAME="Scotto 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-09-30 13:56:25 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scotto G, Fazio V, Palumbo E, Cibelli DC, Saracino A, Angarano G</AU>
<TI>Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients</TI>
<SO>New Microbiologica</SO>
<YR>2005</YR>
<VL>28</VL>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shobokshi-2003" MODIFIED="2014-01-23 16:18:37 +0100" MODIFIED_BY="Tahany Awad" NAME="Shobokshi 2003" YEAR="2002">
<REFERENCE MODIFIED="2013-05-28 12:33:07 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shobokshi A, Serebour FE, Skakni L, Al-Jasser N, Tantawi AO, Sabah A, et al</AU>
<TI>Combination therapy of peginterferon alfa-2a (40kD) (Pegasys(R)) and ribavirin (Copegus(R)) significantly enhance sustained virological and biochemical response rate in chronic hepatitis C genotype 4 patients in Saudi Arabia [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>4 Suppl 1</NO>
<PG>636A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:33:15 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shobokshi O, Serebour F, Skakni L, Tantawi A, Dinish T, Al Quaiz M, et al</AU>
<TI>Efficacy of pegylated (40kDa) IFN alfa-2a (Pegasys) plus ribavirin in the treatment of hepatitis C genotype 4 chronic active patients in Saudi Arabia</TI>
<SO>Journal of Hepatology</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>Suppl 1</NO>
<PG>129</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-23 16:18:37 +0100" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shobokshi O, Serebour FE, Skakni L, Al-Jaser N, Tantawe AO, Sabah A, et al</AU>
<TI>Early virological response at week 12 has positive predictive value for end of treatment response for hepatitis C virus genotype 4 chronic active hepatitis cases treated with combination therapy of pegylated interferon plus ribavirin</TI>
<SO>Saudi Medical Journal</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>Suppl 2</NO>
<PG>S92-S93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:39:23 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shobokshi O, Serebour FE, Skakni L, Al-Jaser N, Tantawe AO, Sabah A, et al</AU>
<TI>Pegylated interferon alfa-2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients</TI>
<SO>Saudi Medical Journal</SO>
<YR>2003</YR>
<VL>24</VL>
<NO>Suppl 2</NO>
<PG>S92-S93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sj_x00f6_gren-2007" MODIFIED="2013-05-28 12:39:36 +0200" MODIFIED_BY="Tahany Awad" NAME="Sjögren 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-05-28 12:39:36 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sjogren MH, Sjogren R, Lyons MF, Ryan M, Santoro J, Smith C, et al</AU>
<TI>Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2007</YR>
<VL>52</VL>
<NO>6</NO>
<PG>1540-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thakeb-2003" MODIFIED="2009-04-28 11:38:42 +0200" MODIFIED_BY="[Empty name]" NAME="Thakeb 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-04-28 11:38:42 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thakeb FIA, Omar MM, El Awady MM, Isshak SY</AU>
<TI>Randomized controlled trial of peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus-genotype 4 among Egyptian patients [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>38</VL>
<NO>4 Suppl 1</NO>
<PG>278A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tsubota-2005" MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" NAME="Tsubota 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tsubota A, Arase Y, Someya T, Suzuki Y, Suzuki F, Saitoh S, et al</AU>
<TI>Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load</TI>
<SO>Journal of Medical Virology</SO>
<YR>2005</YR>
<VL>75</VL>
<PG>27-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wakil-2006" MODIFIED="2013-05-28 12:39:56 +0200" MODIFIED_BY="Tahany Awad" NAME="Wakil 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-05-28 12:39:56 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wakil RM, Montasser MF, Mansour MA, Salman TA, El-Batanony MH, Helail EH, et al</AU>
<TI>Peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for treatment of chronic hepatitis C in treatment-naive Egyptian patients</TI>
<SO>Journal of Clinical Virology</SO>
<YR>2006</YR>
<VL>36</VL>
<PG>S142-S143</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<STUDY DATA_SOURCE="PUB" ID="STD-ACTG-2005" MODIFIED="2013-05-28 12:40:39 +0200" MODIFIED_BY="Tahany Awad" NAME="ACTG 2005" YEAR="2004">
<REFERENCE MODIFIED="2009-03-31 14:16:16 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al</AU>
<TI>Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>5</NO>
<PG>451-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:40:39 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sherman KE, Shire NJ, Rouster SD, Peters MG, Koziel MJ, Chung RT, et al</AU>
<TI>Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients</TI>
<SO>Gastroenterology</SO>
<YR>2005</YR>
<VL>128</VL>
<NO>2</NO>
<PG>313-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ali-2010" MODIFIED="2013-09-30 13:59:37 +0200" MODIFIED_BY="[Empty name]" NAME="Ali 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-30 13:59:37 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ali S, Nazir G, Khan SA, Iram S, Fatima F</AU>
<TI>Comparative therapeutic response to pegylated interferon plus ribavirin versus interferon alpha-2b in chronic hepatitis C patients</TI>
<SO>Journal of Ayub Medical College</SO>
<YR>2010</YR>
<VL>22</VL>
<PG>127-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-APRICOT-2004" MODIFIED="2013-09-30 14:00:21 +0200" MODIFIED_BY="Tahany Awad" NAME="APRICOT 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-28 12:41:49 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mauss S, Valenti W, DePamphilis J, Duff F, Cupelli L, Passe S, et al</AU>
<TI>Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy</TI>
<SO>AIDS</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>13</NO>
<PG>F21-F25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-30 13:59:52 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Torriani FJ, Ribeiro RM, Gilbert TL, Schrenk UM, Clauson M, Pacheco DM, et al</AU>
<TI>Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) dynamics during HCV treatment in HCV/HIV coinfection</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2003</YR>
<VL>188</VL>
<PG>1498-507</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-09-30 14:00:21 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al</AU>
<TI>Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients</TI>
<SO>New England Journal of Medicine</SO>
<YR>2004</YR>
<VL>351</VL>
<NO>5</NO>
<PG>438-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asahina-2004" MODIFIED="2013-05-28 12:42:10 +0200" MODIFIED_BY="Tahany Awad" NAME="Asahina 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-28 12:42:10 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asahina Y, Izumi N, Onuki Y, Ueda K, Nishimura Y, Nakanishi H, et al</AU>
<TI>Enhanced interferon (IFN)-stimulated gene expression and HCV dynamics in patients treated with pegylated IFN alfa 2b and ribavirin: effect of pharmacokinetic change of IFN and ribavirin</TI>
<SO>Hepatology</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>4 Suppl 1</NO>
<PG>338A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gromova-2004" MODIFIED="2009-03-31 14:21:11 +0200" MODIFIED_BY="Tahany Awad" NAME="Gromova 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-03-31 14:21:11 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gromova NI, Bogomolov BP</AU>
<TI>Comparative efficacy of combined treatment with Intron a and Pegintron in combination with ribavirin in patients with chronic hepatitis C</TI>
<SO>Terapevticheskii Arkhiv</SO>
<YR>2004</YR>
<VL>76</VL>
<NO>2</NO>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laguno-2004" MODIFIED="2013-05-28 12:42:22 +0200" MODIFIED_BY="Tahany Awad" NAME="Laguno 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-05-28 12:42:22 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al</AU>
<TI>Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients</TI>
<SO>AIDS</SO>
<YR>2004</YR>
<VL>18</VL>
<NO>13</NO>
<PG>F27-F36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RIBAVIC-2004" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="RIBAVIC 2004" YEAR="2005">
<REFERENCE MODIFIED="2013-09-30 14:01:17 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al</AU>
<TI>Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>292</VL>
<NO>23</NO>
<PG>2839-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2013-05-28 12:42:33 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lunel F, Pivert A, Payan C</AU>
<TI>Comparison of HCV RNA and HCV core antigen kinetics in the follow up of a therapeutic protocol in HCV-HIV co-infected patients (RIBAVIC)</TI>
<SO>Journal of Hepatology</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>Suppl 1</NO>
<PG>144-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pol S, Carrat F, Bani-Sadr F, Rosenthal E, Lunel F, Morand P, et al</AU>
<TI>Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon alfa-2b plus ribavirin vs interferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected [AASLD abstract]</TI>
<SO>Hepatology</SO>
<YR>2004</YR>
<VL>40</VL>
<NO>4</NO>
<PG>315A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-03-31 14:25:18 +0200" MODIFIED_BY="Tahany Awad" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pol S, Carrat F, Bani-Sadr F, Rosenthal E, Lunel F, Morand P, et al</AU>
<TI>Final results of ANRS HC02-RIBAVIC: a randomized controlled trial of pegylated-interferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for naive HCV-HIV co-infected patients</TI>
<SO>Journal of Hepatology</SO>
<YR>2005</YR>
<VL>42</VL>
<NO>Suppl 2</NO>
<PG>10-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-06-04 17:43:51 +0200" MODIFIED_BY="Tahany Awad"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-02-24 11:16:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<ADDITIONAL_REFERENCES MODIFIED="2014-02-24 11:16:35 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<REFERENCE ID="REF-Adeel-2009" MODIFIED="2009-08-26 14:15:40 +0200" MODIFIED_BY="Tahany Awad" NAME="Adeel 2009" TYPE="JOURNAL_ARTICLE">
<AU>Adeel AB, Xiaoqiang Wang, Charity GM</AU>
<TI>Effect of hepatitis C virus and its treatment on survival</TI>
<SO>Hepatology</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>2</NO>
<PG>387-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Aljumah-2013" MODIFIED="2014-01-23 16:20:56 +0100" MODIFIED_BY="[Empty name]" NAME="Aljumah 2013" TYPE="JOURNAL_ARTICLE">
<AU>Aljumah AA, Murad MH</AU>
<TI>Pegylated versus standard interferon plus ribavirin in chronic hepatitis C genotype 4: a systematic review and meta-analysis</TI>
<SO>Hepatology Research</SO>
<YR>2013</YR>
<VL>43</VL>
<NO>12</NO>
<PG>1255-63</PG>
<IDENTIFIERS MODIFIED="2013-09-30 14:07:49 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-09-30 14:07:49 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=" 10.1111/hepr.12084"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Awad-2010" MODIFIED="2013-01-18 00:09:44 +0100" MODIFIED_BY="[Empty name]" NAME="Awad 2010" TYPE="JOURNAL_ARTICLE">
<AU>Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C</AU>
<TI>Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials</TI>
<SO>Hepatology</SO>
<YR>2010</YR>
<VL>51</VL>
<PG>1176-84</PG>
<IDENTIFIERS MODIFIED="2013-01-18 00:09:44 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-01-18 00:09:44 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/hep.23504."/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Bailon-2001" MODIFIED="2009-03-22 14:19:30 +0100" MODIFIED_BY="Tahany Awad" NAME="Bailon 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung W-J, Porter JE, et al</AU>
<TI>Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis</TI>
<SO>Bioconjugate Chemistry</SO>
<YR>2001</YR>
<VL>12</VL>
<NO>2</NO>
<PG>195-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bangalore-2008" MODIFIED="2013-09-30 14:08:17 +0200" MODIFIED_BY="Tahany Awad" NAME="Bangalore 2008" TYPE="JOURNAL_ARTICLE">
<AU>Bangalore S, Wetterslev J, Pranesh S, Sawhney S, Gluud C, Messerli F</AU>
<TI>Perioperative beta blockers in patients having non-cardiac surgery: a meta-analysis</TI>
<SO>Lancet</SO>
<YR>2008</YR>
<VL>372</VL>
<NO>9654</NO>
<PG>1962-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benvegnu-2001" MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" NAME="Benvegnu 2001" TYPE="JOURNAL_ARTICLE">
<AU>Benvegnu L, Alberti A</AU>
<TI>Patterns of hepatocellular carcinoma development in hepatitis B virus and hepatitis C virus-related cirrhosis</TI>
<SO>Antiviral Research</SO>
<YR>2001</YR>
<VL>52</VL>
<PG>199-207</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bradburn-2006" MODIFIED="2013-09-30 14:08:27 +0200" MODIFIED_BY="Tahany Awad" NAME="Bradburn 2006" TYPE="JOURNAL_ARTICLE">
<AU>Bradburn MJ, Deeks JJ, Berlin JA, Localio AR</AU>
<TI>Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events</TI>
<SO>Statistics in Medicine</SO>
<YR>2006</YR>
<VL>26</VL>
<NO>1</NO>
<PG>53-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2008" MODIFIED="2009-03-22 14:19:30 +0100" MODIFIED_BY="Tahany Awad" NAME="Brok 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>8</NO>
<PG>763-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2009" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Brok 2009" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>Apparently conclusive meta-analyses may be inconclusive&#8212;trial sequential analysis adjustment for random error risk in conclusive Cochrane neonatal meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>287-98</PG>
<IDENTIFIERS MODIFIED="2009-03-22 14:19:28 +0100" MODIFIED_BY="Tahany Awad">
<IDENTIFIER TYPE="DOI" VALUE="10.1093/ije/dyn188"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Brok-2009a" MODIFIED="2014-02-24 11:16:20 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Brok 2009a" TYPE="COCHRANE_REVIEW">
<AU>Brok J, Gluud LL, Gluud C</AU>
<TI>Ribavirin plus interferon versus interferon for chronic hepatitis C</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-05-28 14:08:38 +0200" MODIFIED_BY="Tahany Awad">
<IDENTIFIER MODIFIED="2013-05-28 14:08:38 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD005445.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Chan-2013" MODIFIED="2014-01-23 16:21:26 +0100" MODIFIED_BY="[Empty name]" NAME="Chan 2013" TYPE="JOURNAL_ARTICLE">
<AU>Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al</AU>
<TI>SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2013</YR>
<VL>8</VL>
<PG>346:e7586</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chander-2002" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Chander 2002" TYPE="JOURNAL_ARTICLE">
<AU>Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB, et al</AU>
<TI>Treatment of chronic hepatitis C: a systematic review</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>S1</NO>
<PG>135-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Constant-2005" MODIFIED="2013-09-30 14:09:08 +0200" MODIFIED_BY="[Empty name]" NAME="Constant 2005" TYPE="JOURNAL_ARTICLE">
<AU>Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes-Mainard J, et al</AU>
<TI>Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2005</YR>
<VL>66</VL>
<PG>105-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CTU-2011" MODIFIED="2014-01-23 16:21:40 +0100" MODIFIED_BY="[Empty name]" NAME="CTU 2011" TYPE="OTHER">
<AU>Copenhagen Trial Unit</AU>
<TI>TSA&#8212;Trial Sequential Analysis</TI>
<SO>ctu.dk/tsa/</SO>
<YR>2011 (accessed 28 May 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Davis-1999" MODIFIED="2009-08-19 14:18:29 +0200" MODIFIED_BY="Tahany Awad" NAME="Davis 1999" TYPE="JOURNAL_ARTICLE">
<AU>Davis GL</AU>
<TI>Hepatitis C virus genotypes and quasispecies</TI>
<SO>American Journal of Medicine</SO>
<YR>1999</YR>
<VL>107</VL>
<NO>6B</NO>
<PG>S21-S26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeMets-1987" MODIFIED="2009-03-22 14:19:30 +0100" MODIFIED_BY="Tahany Awad" NAME="DeMets 1987" TYPE="JOURNAL_ARTICLE">
<AU>DeMets DL</AU>
<TI>Methods of combining randomized clinical trials: strengths and limitations</TI>
<SO>Statistics in Medicine</SO>
<YR>1987</YR>
<VL>6</VL>
<NO>3</NO>
<PG>341-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2009-03-22 14:19:30 +0100" MODIFIED_BY="Tahany Awad" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dhillon-2010" MODIFIED="2013-09-30 14:09:42 +0200" MODIFIED_BY="[Empty name]" NAME="Dhillon 2010" TYPE="JOURNAL_ARTICLE">
<AU>Dhillon S, Kaker A, Dosanjh A, Japra D, Vanthiel DH</AU>
<TI>Irreversible pulmonary hypertension associated with the use of interferon alpha for chronic hepatitis C</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2010</YR>
<VL>55</VL>
<PG>1785-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EASL-2012" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" NAME="EASL 2012" TYPE="JOURNAL_ARTICLE">
<AU>European Association for the Study of the Liver</AU>
<TI>EASL Clinical Practice Guidelines: management of hepatitis C virus infection</TI>
<SO>Journal of Hepatology</SO>
<YR>2011</YR>
<VL>55</VL>
<PG>245-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Fattovich-2002" MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" NAME="Fattovich 2002" TYPE="JOURNAL_ARTICLE">
<AU>Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E; European Concerted Action on Viral Hepatitis (EUROHEP)</AU>
<TI>Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<NO>11</NO>
<PG>288-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Foster-2004" MODIFIED="2014-01-23 16:22:02 +0100" MODIFIED_BY="Tahany Awad" NAME="Foster 2004" TYPE="JOURNAL_ARTICLE">
<AU>Foster GR</AU>
<TI>Pegylated interferons: chemical and clinical differences</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>8</NO>
<PG>825-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ghany-2009" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Ghany 2009" TYPE="JOURNAL_ARTICLE">
<AU>Ghany MG, Strader DB, Wright T, Thomas DL, Seeff LB; American Association for the Study of Liver Disease</AU>
<TI>Diagnosis, management, and treatment of hepatitis C: an update</TI>
<SO>Hepatology</SO>
<YR>2009</YR>
<VL>49</VL>
<NO>4</NO>
<PG>1335-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glue-2000" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Glue 2000" TYPE="JOURNAL_ARTICLE">
<AU>Glue P, Fang JWS, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al</AU>
<TI>Pegylated interferon-[alpha]2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>2000</YR>
<VL>68</VL>
<NO>5</NO>
<PG>556-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2007" MODIFIED="2009-08-19 16:02:35 +0200" MODIFIED_BY="Tahany Awad" NAME="Gluud 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gluud C, Brok J, Gong Y, Koretz RL</AU>
<TI>Hepatology may have problems with putative surrogate outcome measures</TI>
<SO>Journal of Hepatology</SO>
<YR>2007</YR>
<VL>46</VL>
<NO>4</NO>
<PG>734-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2013" MODIFIED="2014-01-23 16:23:17 +0100" MODIFIED_BY="Tahany Awad" NAME="Gluud 2013" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al</AU>
<TI>Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>2013, Issue 12. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gurusamy-2013" MODIFIED="2014-01-23 16:24:27 +0100" MODIFIED_BY="[Empty name]" NAME="Gurusamy 2013" TYPE="JOURNAL_ARTICLE">
<AU>Gurusamy KS, Wilson E, Koretz RL, Allen VB, Davidson BR, Burroughs AK, et al</AU>
<TI>Is sustained virological response a marker of treatment efficacy in patients with chronic hepatitis C viral infection with no response or relapse to previous antiviral intervention?</TI>
<SO>PLoS ONE</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>12</NO>
<PG>e83313</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guyatt-2008" MODIFIED="2013-09-30 14:10:31 +0200" MODIFIED_BY="[Empty name]" NAME="Guyatt 2008" TYPE="JOURNAL_ARTICLE">
<AU>Guyatt GH, Oxman AD, Vist G, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al</AU>
<TI>Rating quality of evidence and strength of recommendations GRADE: an emerging consensus on rating quality of evidence and strength of recommendations</TI>
<SO>BMJ (Clinical Research Ed)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>924-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hadziyannis-2004" MODIFIED="2013-08-30 16:22:42 +0200" MODIFIED_BY="Tahany Awad" NAME="Hadziyannis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al</AU>
<TI>Peginterferon alfa-2a (40 kilodaltons) and ribavirin combination therapy in chronic hepatitis C: randomized study of the effect of treatment duration and ribavirin dose</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>140</VL>
<PG>346&#8211;55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hauser-2014" MODIFIED="2014-02-24 11:16:35 +0100" MODIFIED_BY="Dimitrinka Nikolova" NAME="Hauser 2014" TYPE="COCHRANE_REVIEW">
<AU>Hauser G, Awad T, Thorlund K, &#352;timac D, Mabrouk M, Gluud C</AU>
<TI>Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C (Review)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2014</YR>
<NO>2</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2002" MODIFIED="2009-03-22 14:19:30 +0100" MODIFIED_BY="Tahany Awad" NAME="Higgins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG</AU>
<TI>Quantifying heterogeneity in a meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2002</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1539-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hirofumi-2009" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Hirofumi 2009" TYPE="JOURNAL_ARTICLE">
<AU>Uto H, Sherri OS, Hayashi K, Kumagai K, Sasaki F, Kanmura S, et al</AU>
<TI>Increased rate of death related to presence of viremia among hepatitis C virus antibody-positive subjects in a community-based cohort study</TI>
<SO>Hepatology</SO>
<YR>2009</YR>
<VL>50</VL>
<NO>2</NO>
<PG>393-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hodgson-2003" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Hodgson 2003" TYPE="BOOK_SECTION">
<AU>Hodgson HJF</AU>
<TI>Viral hepatitis&#8212;clinical aspects</TI>
<SO>Oxford Textbook of Medicine</SO>
<YR>2003</YR>
<EN>4th</EN>
<ED>Warrell DA, Cox TM, Firth JD, Benz EJ Jr</ED>
<PB>Oxford University Press</PB>
<CY>Oxford/ New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hollis-1999" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" NAME="Hollis 1999" TYPE="JOURNAL_ARTICLE">
<AU>Hollis S, Campbell F</AU>
<TI>What is meant by intention to treat analysis? Survey of published randomised controlled trials</TI>
<SO>BMJ (Clinical Research Ed)</SO>
<YR>1999</YR>
<VL>319</VL>
<PG>670-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2013-05-28 12:56:54 +0200" MODIFIED_BY="Tahany Awad" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>PA 19063-2043, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Khuroo-2004" MODIFIED="2013-05-28 12:57:13 +0200" MODIFIED_BY="Tahany Awad" NAME="Khuroo 2004" TYPE="JOURNAL_ARTICLE">
<AU>Khuroo MS, Khuroo MS, Dahab ST</AU>
<TI>Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4</TI>
<SO>Alimentary Pharmacology and Therapeutics</SO>
<YR>2004</YR>
<VL>20</VL>
<NO>9</NO>
<PG>931-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodological quality and discrepancies between small and large randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Koretz-2013" MODIFIED="2013-05-28 12:58:00 +0200" MODIFIED_BY="[Empty name]" NAME="Koretz 2013" TYPE="COCHRANE_REVIEW">
<AU>Koretz RL, Pleguezuelo M, Arvaniti V, Barrera Baena P, Ciria R, Gurusamy KS</AU>
<TI>Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2013-05-28 12:57:52 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-28 12:57:52 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003617"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Krleza_x002d_Jeric-2005" MODIFIED="2014-02-06 15:16:56 +0100" MODIFIED_BY="Tahany Awad" NAME="Krleza-Jeric 2005" TYPE="JOURNAL_ARTICLE">
<AU>Krleza-Jeric K, Chan AW, Dickersin K, Sim I, Grimshaw J, Gluud C</AU>
<TI>Principles for international registration of protocol information and results from human trials of health related interventions: Ottawa statement</TI>
<SO>BMJ (Clinical Research Ed)</SO>
<YR>2005</YR>
<VL>330</VL>
<NO>7497</NO>
<PG>956-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kumar-2002" MODIFIED="2013-09-30 14:13:36 +0200" MODIFIED_BY="[Empty name]" NAME="Kumar 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kumar KS, Russo MW, Borczuk AC, Brown M, Esposito SP, Lobritto SJ, et al</AU>
<TI>Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C</TI>
<SO>American Journal of Gastroenterology</SO>
<YR>2002</YR>
<VL>97</VL>
<PG>2432-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lim-2010" MODIFIED="2013-08-29 21:02:57 +0200" MODIFIED_BY="[Empty name]" NAME="Lim 2010" TYPE="JOURNAL_ARTICLE">
<AU>Lim JW, Shin MC</AU>
<TI>Pegylated-interferon-associated retinopathy in chronic hepatitis patients</TI>
<SO>Ophtalmologica</SO>
<YR>2010</YR>
<VL>224</VL>
<PG>224-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lundh-2012" MODIFIED="2013-05-28 12:58:26 +0200" MODIFIED_BY="[Empty name]" NAME="Lundh 2012" TYPE="COCHRANE_REVIEW">
<AU>Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L</AU>
<TI>Industry sponsorship and research outcome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2013-05-28 12:58:26 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-05-28 12:58:26 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.MR000033.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2012" MODIFIED="2013-09-30 14:14:05 +0200" MODIFIED_BY="Tahany Awad" NAME="Moher 2012" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al</AU>
<TI>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</TI>
<SO>International Journal of Surgery</SO>
<YR>2012</YR>
<VL>10</VL>
<PG>28-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Myers-2002" MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" NAME="Myers 2002" TYPE="COCHRANE_REVIEW">
<AU>Myers RP, Regimbeau C, Thevenot T, Leroy V, Mathurin P, Opolon P, et al</AU>
<TI>Interferon for interferon naive patients with chronic hepatitis C</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2009-03-22 14:19:28 +0100" MODIFIED_BY="Tahany Awad">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD000370"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-OPTN-2008" MODIFIED="2014-01-23 16:25:15 +0100" MODIFIED_BY="Tahany Awad" NAME="OPTN 2008" TYPE="OTHER">
<AU>United Network for Organ Sharing</AU>
<TI>Chapter IV; Liver and Intestine Transplantation in the United States, 1998-2007</TI>
<SO>optn.transplant.hrsa.gov/ar2008/chapter_iv_AR_cd.htm?cp=5</SO>
<YR>(accessed 27 May 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Penin-2004" MODIFIED="2009-03-22 14:19:30 +0100" MODIFIED_BY="Tahany Awad" NAME="Penin 2004" TYPE="OTHER">
<AU>Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky J</AU>
<TI>Structural biology of hepatitis C virus</TI>
<SO>Hepatology</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>1</NO>
<PG>5-19</PG>
<IDENTIFIERS MODIFIED="2009-03-22 14:19:28 +0100" MODIFIED_BY="Tahany Awad">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/hep.20032"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Raison-2005" MODIFIED="2013-08-29 22:00:13 +0200" MODIFIED_BY="[Empty name]" NAME="Raison 2005" TYPE="JOURNAL_ARTICLE">
<AU>Raison CL, Demetrashvili M, Capuron L, Miller AH</AU>
<TI>Neuropsychiatric adverse effects of interferon-alpha: recognition and management</TI>
<SO>CNS Drugs</SO>
<YR>2005</YR>
<VL>19</VL>
<PG>105-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reddy-2001" MODIFIED="2013-09-30 14:26:37 +0200" MODIFIED_BY="Tahany Awad" NAME="Reddy 2001" TYPE="JOURNAL_ARTICLE">
<AU>Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R, et al</AU>
<TI>Efficacy and safety of pegylated (40-kd) interferonalpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C</TI>
<SO>Hepatology</SO>
<YR>2001</YR>
<VL>33</VL>
<NO>2</NO>
<PG>433&#8211;8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-05-28 13:00:38 +0200" MODIFIED_BY="Tahany Awad" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roomer-2010" MODIFIED="2013-09-30 14:27:42 +0200" MODIFIED_BY="[Empty name]" NAME="Roomer 2010" TYPE="JOURNAL_ARTICLE">
<AU>Roomer R, Hansen BE, Janssen HL, de Knegt RJ</AU>
<TI>Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C</TI>
<SO>Journal of Hepatology</SO>
<YR>2010</YR>
<VL>53</VL>
<PG>455-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rosenberg-2001" MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" NAME="Rosenberg 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rosenberg S</AU>
<TI>Recent advances in the molecular biology of hepatitis C virus</TI>
<SO>Journal of Molecular Biology</SO>
<YR>2001</YR>
<VL>313</VL>
<PG>451-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2009-03-22 14:19:30 +0100" MODIFIED_BY="Tahany Awad" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-R_x00fc_cker-2008" MODIFIED="2009-03-22 14:19:30 +0100" MODIFIED_BY="Tahany Awad" NAME="Rücker 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rücker G, Schwarzer G, Carpenter J</AU>
<TI>Arcsine test for publication bias in meta-analyses with binary outcomes</TI>
<SO>Statistics in Medicine</SO>
<YR>2008</YR>
<VL>27</VL>
<PG>746-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovic-2012" MODIFIED="2013-05-27 15:37:39 +0200" MODIFIED_BY="[Empty name]" NAME="Savovic 2012" TYPE="JOURNAL_ARTICLE">
<AU>Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Health Technology Assessment</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>35</NO>
<PG>1-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovic-2012a" MODIFIED="2013-05-27 15:37:39 +0200" MODIFIED_BY="[Empty name]" NAME="Savovic 2012a" TYPE="JOURNAL_ARTICLE">
<AU>Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>157</VL>
<NO>6</NO>
<PG>429-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2009-06-29 13:49:47 +0200" MODIFIED_BY="Tahany Awad" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Seeff-2002" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Seeff 2002" TYPE="OTHER">
<AU>Seeff LB, Hoofnagle JH</AU>
<TI>National institutes of health consensus development conference: management of hepatitis C: 2002</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>36</VL>
<NO>5 Suppl 1</NO>
<PG>S1-S2</PG>
<IDENTIFIERS MODIFIED="2009-03-22 14:19:28 +0100" MODIFIED_BY="Tahany Awad">
<IDENTIFIER TYPE="DOI" VALUE="10.1002/hep.1840360702"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Seeff-2009" MODIFIED="2009-08-19 13:18:58 +0200" MODIFIED_BY="Tahany Awad" NAME="Seeff 2009" TYPE="JOURNAL_ARTICLE">
<AU>Seeff LB</AU>
<TI>The history of the "natural history" of hepatitis C (1968-2009)</TI>
<SO>Liver International</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>S1</NO>
<PG>89-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shepherd-2005" MODIFIED="2013-05-28 13:02:35 +0200" MODIFIED_BY="Tahany Awad" NAME="Shepherd 2005" TYPE="JOURNAL_ARTICLE">
<AU>Shepherd J, Brodin H, Kan FT, Cave CB, Waugh NR, Price A, et al</AU>
<TI>Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>1</NO>
<PG>47-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siebert-2005" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NAME="Siebert 2005" TYPE="JOURNAL_ARTICLE">
<AU>Siebert U, Sroczynski G, German Hepatitis C Model GEHMO Group, HTA Expert Panel on Hepatitis C</AU>
<TI>Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned by the German Federal Ministry of Health and Social Security</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>1</NO>
<PG>55-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Slavenburg-2010" MODIFIED="2013-09-30 14:33:05 +0200" MODIFIED_BY="[Empty name]" NAME="Slavenburg 2010" TYPE="JOURNAL_ARTICLE">
<AU>Slavenburg S, Heijdra YF, Drenth JP</AU>
<TI>Pneumonitis as a consequence of (peg)interferon-ribavirin combination therapy for hepatitis C: a review of the literature</TI>
<SO>Digestive Diseases and Sciences</SO>
<YR>2010</YR>
<VL>55</VL>
<PG>579-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Soza-2002" MODIFIED="2013-09-30 14:33:19 +0200" MODIFIED_BY="[Empty name]" NAME="Soza 2002" TYPE="JOURNAL_ARTICLE">
<AU>Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, et al</AU>
<TI>Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C</TI>
<SO>Hepatology</SO>
<YR>2002</YR>
<VL>36</VL>
<PG>1273-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sulkowski-2004" MODIFIED="2014-01-23 16:30:48 +0100" MODIFIED_BY="[Empty name]" NAME="Sulkowski 2004" TYPE="JOURNAL_ARTICLE">
<AU>Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R</AU>
<TI>Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>2004</YR>
<VL>11</VL>
<PG>243-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sulkowski-2011" MODIFIED="2014-01-23 16:31:07 +0100" MODIFIED_BY="[Empty name]" NAME="Sulkowski 2011" TYPE="JOURNAL_ARTICLE">
<AU>Sulkowski MS, Cooper C, Hunyady B, Jia J, Ogurtsov P, Peck-Radosavljevic M, et al</AU>
<TI>Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C</TI>
<SO>Nature Reviews. Gastroenterology &amp; Hepatology</SO>
<YR>2011</YR>
<VL>8</VL>
<PG>212-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2009-03-22 14:19:30 +0100" MODIFIED_BY="Tahany Awad" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JPA, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses?</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS MODIFIED="2009-03-22 14:19:28 +0100" MODIFIED_BY="Tahany Awad">
<IDENTIFIER TYPE="DOI" VALUE="10.1093/ije/dyn179"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2010" MODIFIED="2013-05-27 15:37:51 +0200" MODIFIED_BY="[Empty name]" NAME="Thorlund 2010" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Anema A, Mills E</AU>
<TI>Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals</TI>
<SO>Clinical Epidemiology</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>57-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2014-01-23 16:31:18 +0100" MODIFIED_BY="[Empty name]" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual forTrial Sequential Analysis (TSA)</TI>
<SO>ctu.dk/tsa/files/tsa_manual.pdf</SO>
<YR>2011 (accessed 23 April 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Regenmortel-2000" MODIFIED="2013-05-28 13:04:14 +0200" MODIFIED_BY="Tahany Awad" NAME="van Regenmortel 2000" TYPE="BOOK_SECTION">
<AU>van Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, et al</AU>
<TI>Virus Taxonomy: The Classification and Nomenclature of Viruses</TI>
<SO>The Seventh Report of the International Committee on Taxonomy of Viruses</SO>
<YR>2000</YR>
<PG>599-621</PG>
<PB>Academic Press</PB>
<CY>San Diego</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2009-03-22 14:19:30 +0100" MODIFIED_BY="Tahany Awad" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<NO>1</NO>
<PG>64-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2013-05-28 13:04:28 +0200" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1999" MODIFIED="2009-08-19 13:11:51 +0200" MODIFIED_BY="Tahany Awad" NAME="WHO 1999" TYPE="JOURNAL_ARTICLE">
<AU>World Health Organization (WHO)</AU>
<TI>Global surveillance and control of hepatitis C</TI>
<SO>Journal of Viral Hepatitis</SO>
<YR>1999</YR>
<VL>6</VL>
<NO>1</NO>
<PG>35-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2009" MODIFIED="2013-05-28 13:05:11 +0200" MODIFIED_BY="Tahany Awad" NAME="WHO 2009" TYPE="OTHER">
<AU>WHO</AU>
<TI>International Clinical Trials Registry Platform (ICTRP)</TI>
<SO>www.who.int/ictrp/en/</SO>
<YR>(accessed 27 May 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2014-01-23 16:31:36 +0100" MODIFIED_BY="Tahany Awad" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zaman-2003" MODIFIED="2014-01-23 16:31:42 +0100" MODIFIED_BY="Tahany Awad" NAME="Zaman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Zaman A, Fennerty MB, Keeffe EB</AU>
<TI>Peginterferon vs. standard interferon in the treatment of chronic hepatitis C</TI>
<SO>Alimentary Pharmacology &amp; Therapeutics</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>7</NO>
<PG>661-70</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES MODIFIED="2009-03-31 15:12:44 +0200" MODIFIED_BY="Tahany Awad"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-02-12 23:42:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Al_x002d_Faleh-2004">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial with two parallel-group design.</P>
<P>Sample size calculation: performed, 48 participants estimated for each group.</P>
<P>Intention-to-treat analysis: used. Participants who discontinued treatment or were lost to follow-up were classified as non-responders.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Saudi Arabia.</P>
<P>Number of participants randomly assigned: 96; 54 men and 42 women.</P>
<P>All participants were treatment-naive.</P>
<P>Genotype: four.</P>
<P>Inclusion criteria.</P>
<UL>
<LI>Persistently raised ALT for at least six months.</LI>
<LI>Serum antibodies to HCV.</LI>
<LI>HCV RNA found by PCR.</LI>
<LI>Diagnosis of chronic hepatitis on liver biopsy sample taken in the preceding 12 months.</LI>
</UL>
<P>Exclusion criteria.</P>
<UL>
<LI>Age younger than 18 or older than 70 years.</LI>
<LI>Previous treatment with interferon or ribavirin.</LI>
<LI>Neutropenia (fewer than 1500 neutrophils/mm<SUP>3</SUP>).</LI>
<LI>Thrombocytopenia (fewer than 90,000 platelets/mm<SUP>3</SUP>).</LI>
<LI>Anaemia (less than 12 g of haemoglobin/dL in women and less than 13 g of haemoglobin/dL in men).</LI>
<LI>Serum creatinine greater than 1.5 times above the upper limit of normal.</LI>
<LI>Serum alpha-fetoproteins concentration above 25 ng/mL.</LI>
<LI>History of alcohol or haemolytic disease.</LI>
<LI>Decompensated cirrhosis.</LI>
<LI>Autoimmune hepatitis.</LI>
<LI>Hepatitis B infection.</LI>
<LI>HIV infection.</LI>
<LI>Current intravenous drug use; severe depressive illness; severe comorbid disease.</LI>
<LI>Organ transplant.</LI>
<LI>Pregnancy.</LI>
<LI>Unwillingness to practice contraception.</LI>
<LI>Hepatocellular cancer.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to two groups.</P>
<UL>
<LI>Group 1: peginterferon alpha-2b 100 µg plus ribavirin 800 mg for 48 weeks (n = 48).</LI>
<LI>Group 2: interferon alpha-2b 3 MU plus ribavirin 800 mg for 48 weeks (n = 48).</LI>
</UL>
<P>Participants were followed up for 24 weeks after the end of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcomes were biochemical and virological responses at the end of treatment and at the end of follow-up.</P>
<P>Other outcomes reported are adverse events.</P>
<P>Limit for hepatitis C virus RNA detection was 3200 copies/mL.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-02-12 23:42:55 +0100" MODIFIED_BY="[Empty name]">
<P>Author contacted for additional information, but no reply received.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-Bruno-2004">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial with two parallel-group design.</P>
<P>Sample size calculation: performed, 151 participants estimated for each group.</P>
<P>Intention-to-treat analysis: not used, although stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Country: Italy.</P>
<P>Number of participants randomly assigned: 323; 194 men and 117 women, and 12 excluded from analyses.</P>
<P>All participants were treatment-naive.</P>
<P>All participants were infected with HCV genotype one.</P>
<P>Inclusion criteria.</P>
<UL>
<LI>Previously untreated HCV RNA positive patients between 18 and 65 years of age with ALT values above 1.5 times the upper normal limit.</LI>
<LI>Liver biopsy performed within six months before enrolment and a diagnosis of chronic hepatitis with any degree of fibrosis.</LI>
<LI>Haemoglobin equal to 13 g/dL for males, equal to 12 g/dL for females, WBC count greater than 3000/mm<SUP>3</SUP>, granulocyte count greater than 1500/mm<SUP>3</SUP>, platelet count greater than 80,000/mm<SUP>3</SUP>, bilirubin, albumin and serum creatinine levels within normal limits.</LI>
</UL>
<P>Exclusion criteria.</P>
<UL>
<LI>Advanced cirrhosis, that is, large oesophageal varices (F2 or more), history of gastrointestinal bleeding, ascites or encephalopathy.</LI>
<LI>Hepatocellular carcinoma.</LI>
<LI>Anti-HIV or HBsAg positivity.</LI>
<LI>Alcohol abuse (equal to 80 mg/d).</LI>
<LI>Parenteral drug addiction if not abstaining for at least two years; and any other contraindications to interferon or ribavirin.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Participants were randomly assigned to two groups.</P>
<UL>
<LI>Group 1: peginterferon alpha-2b 100 µg for weight 65 kg or greater and 80 µg for weight below 65 kg, for the first eight weeks, followed by a fixed dose of 50 µg for the next 40 weeks plus ribavirin for 48 weeks (n = 163).</LI>
<LI>Group 2: non-pegylated interferon alpha-2b 6 MU plus ribavirin for 48 weeks (n = 148).</LI>
</UL>
<P>For both groups, ribavirin was given at a dose of 1000 mg for participants weighting 75 kg or less and 1200 mg for those weighing more than 75 kg.</P>
<P>Participants were withdrawn from treatment if they did not achieve a virological response that was defined as undetectable serum HCV RNA by PCR 24 weeks after starting treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcome was sustained virological response, defined as the absence of detectable HCV RNA by PCR 24 weeks after the end of treatment.</P>
<P>Other outcomes reported are end of treatment biochemical and virological response, sustained biochemical response, and frequency of discontinuations and dose reductions with causes.</P>
<P>Limit for hepatitis C virus RNA detection was 50 IU/mL.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-10 02:00:37 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-Cariti-2002">
<CHAR_METHODS MODIFIED="2013-11-10 02:01:13 +0100" MODIFIED_BY="Tahany Awad">
<P>Study design: randomised clinical trial.</P>
<P>Inclusion criteria: biopsy proven chronic hepatitis C, persistently elevated ALT, HCV RNA positive.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Country: Italy.</P>
<P>Total number (sample size): 117.</P>
<P>Age: 46.7 group A; 43.7 group B.</P>
<P>Sex (male): group A 73%, group B 76%.</P>
<P>Genotype: one.</P>
<P>Previous HCV treatment: naive.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Group A.</P>
<UL>
<LI>Drug: peginterferon alpha-2a.</LI>
<UL>
<LI>Dosage: 180 µg/wk.</LI>
<LI>Duration: 48 weeks.</LI>
</UL>
<LI>Ribavirin</LI>
<UL>
<LI>Dose: 800 to 1000 mg weight-based.</LI>
<LI>Duration: 48 weeks.</LI>
</UL>
</UL>
<P>Group B.</P>
<UL>
<LI>Drug: Interferon alpha-2a.</LI>
<UL>
<LI>Dosage: 6 MU thrice weekly.</LI>
<LI>Duration: 48 weeks.</LI>
</UL>
<LI>Ribavirin</LI>
<UL>
<LI>Dose: 800 mg to 1000 mg weight-based.</LI>
<LI>Duration: 48 weeks.</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-13 17:06:18 +0100" MODIFIED_BY="Tahany Awad">
<P>Sustained virological response.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Abstract form, study authors were contacted, but we received no reply. It is not clear whether Intention-to-treat analysis was used when participants discontinued treatment or were lost to follow-up. The trial included 150 participants, but data from only 117 are available.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Derbala-2005">
<CHAR_METHODS MODIFIED="2013-11-18 22:46:20 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Country: Egypt.</P>
<P>Total number (sample size): 70.</P>
<P>Age, years: 42.6 group A; 38.7 group B.</P>
<P>Sex (male): group A 27, group B 26.</P>
<P>Genotype: four.</P>
<P>Previous HCV treatment: naive.</P>
<P>Inclusion criteria: biopsy proven chronic hepatitis C, persistently elevated ALT, HCV RNA positive.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Group A: 35 participants</P>
<UL>
<LI>Drug: peginterferon alpha-2b.</LI>
</UL>
<UL>
<UL>
<LI>Dosage: 1.5 µg/kg.</LI>
<LI>Duration: 48 weeks.</LI>
</UL>
</UL>
<P>Group B: 35 participants.</P>
<UL>
<LI>Drug: interferon alpha-2b.</LI>
</UL>
<UL>
<UL>
<LI>Dosage: 6 MU thrice weekly.</LI>
<LI>Duration: 48 weeks.</LI>
</UL>
</UL>
<P>Ribavirin was given to both groups at a weight-based dose ranging from 800 mg to 1000 mg.</P>
<UL>
<LI>1200 mg (more than 75 kg).</LI>
<LI>1000 mg (less than 75 kg but more than 65 kg).</LI>
<LI>800 (less than 65 kg).</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Sustained virological response.</P>
<P>Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Abstract only, no data about inclusion and exclusion criteria are provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Derbala-2006">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Egypt.</P>
<P>Total number: 73 (seven participants did not continue the treatment).</P>
<P>Age, years: 45.5.</P>
<P>Sex (male): 31% to 33%.</P>
<P>Comorbidity: bilharziasis.</P>
<P>Genotype: four.</P>
<P>Previous HCV treatment: naïve.</P>
<P>Inclusion criteria: chronic active hepatitis C as evidenced by the following.</P>
<UL>
<LI>Positive serological test for HCV-Ab.</LI>
<LI>Detectable serum HCV-RNA.</LI>
<LI>Elevated serum alanine transaminases.</LI>
<LI>Histopathological criteria of chronic active hepatitis.</LI>
</UL>
<P>Exclusion criteria.</P>
<UL>
<LI>Patient with hepatocellular carcinoma.</LI>
<LI>Positive serum pregnancy test and breast feeders.</LI>
<LI>Coinfected patients with HBV, HIV.</LI>
<LI>Patient with other chronic liver disease.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Group A (n = 38).</P>
<UL>
<LI>Drug: peginterferon alpha-2a.</LI>
<LI>Dosage: 180 µg.</LI>
<LI>Ribavirin dose: 1200 mg daily.</LI>
</UL>
<P>Group B (n = 35).</P>
<UL>
<LI>Drug: INF 2a.</LI>
<LI>Dosage: 3 MU three times.</LI>
<LI>Ribavirin dose: 1200 mg daily.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-13 16:10:40 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcomes: end of treatment response, sustained virological response, adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-13 16:10:41 +0100" MODIFIED_BY="[Empty name]">
<P>Published article.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dollinger-2005">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised multicentre trial.</P>
<P>ITT analysis: performed.</P>
<P>Sample size calculation: not mentioned.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Germany.</P>
<P>Total number (sample size): 40.</P>
<P>Age: not mentioned.</P>
<P>Sex (male): not mentioned.</P>
<P>Comorbidity: not mentioned.</P>
<P>Genotype: one-b.</P>
<P>Previous HCV treatment: non-responders to previous combination treatment with IFN and RBV.</P>
<P>Inclusion criteria: chronic hepatitis C diagnosed by the following.</P>
<UL>
<LI>Histologically proven chronic hepatitis.</LI>
<LI>Hepatitis C, positive HCV-RNA.</LI>
<LI>Elevated transaminases.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Group A (n = 22).</P>
<UL>
<LI>Drug: peginterferon alpha-2b.</LI>
<UL>
<LI>1.5 µg/kg body weight.</LI>
<LI>Once weekly.</LI>
</UL>
</UL>
<P>Group B (n = 18).</P>
<UL>
<LI>Drug: consensus interferon (CIFN)</LI>
<UL>
<LI>18 mcg/d CIFN for six weeks followed by 9 µg/d CIFN for 42 weeks.</LI>
</UL>
<LI>Ribavirin</LI>
<UL>
<LI>Dose: &gt; 10.6 mg/kg body weight daily.</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Early response rate (24 weeks of treatment); end-of-treatment response rate (52 weeks of treatment); sustained response rate (six months after treatment); adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Esmat-2003">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial with two parallel-group design.</P>
<P>Sample size calculation: unclear, not described.</P>
<P>Intention-to-treat analysis: used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Country: Egypt.</P>
<P>Number of participants randomly assigned: 200; 158 men and 42 women.</P>
<P>All participants were treatment-naive.</P>
<P>Mean inflammatory histological activity index score was 7/18 ± 2 and fibrosis stage 2.7/6 ± 1.3 in both arms.</P>
<P>90% of participants were infected with HCV genotype four.</P>
<P>Inclusion and exclusion criteria: none stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to two groups:</P>
<UL>
<LI>Group 1: peginterferon alpha-2b 100 µg with weight-based ribavirin 800 mg or 1000 mg for 48 weeks (n = 100).</LI>
<LI>Group 2: interferon alpha-2b 3 MU with weight-based ribavirin 800 mg or 1000 mg for 48 weeks (n = 100).</LI>
</UL>
<P>If HCV RNA was detectable at week 24, the treatment was stopped. Participants were followed-up for an additional 24 weeks after the end of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcome was HCV RNA status at week 72 (end of follow-up).</P>
<P>Other outcomes reported were end of treatment virological response and adverse events.</P>
<P>Limit for hepatitis C virus RNA detection was 50 copies/mL.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>The report is abstract. Abstract only, no data about inclusion and exclusion criteria are provided.</P>
<P>Additional data were obtained through personal communication with the study author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fargion-2004">
<CHAR_METHODS MODIFIED="2013-11-18 22:53:25 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial with two parallel-group design.</P>
<P>Samlpe size calculation: not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy.</P>
<P>Number of participants randomly assigned: 185.</P>
<P>All participants were non-responders to previous interferon plus ribavirin treatment.</P>
<P>Inclusion and exclusion criteria: none stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to two groups.</P>
<UL>
<LI>Group 1: peginterferon alpha-2a 180 µg plus ribavirin 800 mg to 1000 mg plus amantadine hydrochloride 200 mg for 48 weeks.</LI>
<LI>Group 2: interferon alpha 2a 6 MU daily for four weeks, then 3 MU daily for additional 20 weeks, and then 3 MU thrice weekly for additional 24 weeks plus ribavirin 800 mg to 1000 mg plus amantadine hydrochloride 200 mg for 48 weeks.</LI>
</UL>
<P>Participants with detectable HCV RNA after 24 weeks of treatment were considered non-responders and therapy discontinued. Participants were followed-up for 24 weeks after the end of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcome was sustained virological response, defined as undetectable HCV RNA 24 weeks after the end of treatment.</P>
<P>Other outcome reported was end of treatment virological response.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>The report is abstract; because the study has not been published yet, no data about inclusion and exclusion criteria are provided.</P>
<P>Data were extracted from the primary reference and the previous abstract: Fargion S et al. End of treatment and sustained response to peginterferon alfa-2a (40 kD) (Pegasys) plus ribavirin (RBV) (Copegus) and amantadine (AMA), and to induction therapy with interferon (IFN) alfa-2A (Roferon-A) plus RBV and AMA in INF/RBV non-responders with chronic hepatitis C (CHC) [AASLD abstract]. Hepatology 2003;38(4, Suppl 1):733A.</P>
<P>Number of participants in each group is not reported, so we provisionally divided the total number of participants by two.</P>
<P>Study author contacted for additional information, but no data were obtained.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fried-2002">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial with three-group design.</P>
<P>Sample size calculation: unclear, not described.</P>
<P>Intention-to-treat analysis: not used, although stated (28 participants who were randomly assigned and did not receive allocated intervention were excluded from analyses). All participants who received at least one dose of study medication were included in all efficacy analyses, and if they had undergone at least one safety assessment after baseline, they were included in the safety analysis. All participants with follow-up of less than 20 weeks were considered to have had no response to treatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Country: 81 centres worldwide.</P>
<P>Number of participants randomly assigned: 1149; 800 men and 321 women, and 28 excluded from analyses.</P>
<P>All participants were treatment-naive.</P>
<P>Genotype: one.</P>
<P>Inclusion criteria.</P>
<UL>
<LI>Adult patients who had never received interferon and who had at least 2000 copies of HCV RNA per millilitre of serum according to a PCR assay.</LI>
<LI>Serum ALT activity above the upper limit of normal within six months before entry into the study; </LI>
<LI>Liver biopsy result consistent with the diagnosis of chronic hepatitis C.</LI>
</UL>
<P>Exclusion criteria.</P>
<UL>
<LI>Neutropenia (fewer than 1500 neutrophils per cubic millimetre). </LI>
<LI>Thrombocytopenia (fewer than 90,000 platelets per cubic millimetre).</LI>
<LI>Anaemia (less than 12 g of haemoglobin per decilitre in women and less than 13 g of haemoglobin per decilitre in men).</LI>
<LI>HIV infection.</LI>
<LI>Decompensated liver disease. </LI>
<LI>Serum creatinine level greater than 1.5 times the upper limit of normal.</LI>
<LI>Poorly controlled psychiatric disease.</LI>
<LI>Alcohol or drug dependence within one year before entry into the study.</LI>
<LI>Substantial coexisting medical conditions.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to three groups.</P>
<UL>
<LI>Group 1: peginterferon alpha-2a 180 µg plus ribavirin for 48 weeks (n = 453).</LI>
<LI>Group 2: interferon alpha-2b 3 MU plus ribavirin for 48 weeks (n = 444).</LI>
<LI>Group 3: peginterferon alpha-2a 180 µg plus placebo for 48 weeks (n = 224).</LI>
</UL>
<P>For two arms, ribavirin was given at a dose of 1000 mg for participants weighing 75 kg or less and 1200 mg for those weighing more than 75 kg.</P>
<P>Participants were withdrawn from treatment if they continued to have viraemia at week 24, if they missed four consecutive doses, or at the discretion of the investigator. Participants were followed for 24 weeks after the end of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcome was sustained virological response, defined as the absence of detectable HCV RNA at the end of follow-up according to a PCR assay.</P>
<P>Other outcomes reported are end of treatment virological response, incidence of treatment discontinuation, dose modification, and adverse events.</P>
<P>Limit for hepatitis C virus RNA detection was 50 IU/mL (100 copies/mL).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>The study was designed by the sponsor in collaboration with expert hepatologists. Data were collected by the Pegasys International Study Group. Data analysis was performed by the sponsor and the authors of the report; the authors had full access to the data, and the decision to publish was not limited by the sponsor.</P>
<P>Data were extracted from the primary reference and Hassanein T, et al. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. Journal of Hepatology 2004;40:675-81.</P>
<P>Study author contacted for additional information, but no reply obtained.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hinrichsen-2002">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial with two-group design.</P>
<P>Samlpe size calculation: unclear, not described.</P>
<P>Intention-to-treat analysis: used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Country: Germany.</P>
<P>Number of participants randomly assigned: 72; 41 men and 31 women.</P>
<P>All participants were treatment-naive.</P>
<P>All participants were infected with HCV genotype two and three.</P>
<P>Inclusion and exclusion criteria: none stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to two groups.</P>
<UL>
<LI>Group 1: peginterferon alpha-2b 100 µg with ribavirin 800 mg for 24 weeks (n = 36).</LI>
<LI>Group 2: interferon alpha-2b 3 MU with ribavirin 1000 mg to 1200 mg for 24 weeks (n = 36).</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcomes were sustained and end of treatment virological responses.</P>
<P>Other outcome reported is quality of life.</P>
<P>Limit for hepatitis C virus RNA detection was 50 IU/mL.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>The report is abstract; because the study has not been published yet, no data about inclusion and exclusion criteria are provided.</P>
<P>Study author contacted for additional information, but no data obtained.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-Horsmans-2008">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: multi-centre, controlled randomised trial comparing three groups.</P>
<P>ITT analysis: performed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Belgium.</P>
<P>Total number (sample size): 258 (initially 336, but 78 had not commenced treatment).</P>
<P>Age, years (STD) : 45, 46, and 45.</P>
<P>Sex (male, number): 63, 62, and 36.</P>
<P>Genotype: one, two, and three.</P>
<P>Previous HCV treatment: naive.</P>
<P>Inclusion criteria: chronic hepatitis C diagnosed by the following.</P>
<UL>
<LI>Elevated alanine aminotransferase (ALT) activity.</LI>
<LI>Presence of HCV RNA in serum.</LI>
</UL>
<P>Exclusion criteria.</P>
<UL>
<LI>Patients with decompensated liver cirrhosis.</LI>
<LI>Patients with other chronic liver disease (e.g., HBV).</LI>
<LI>Patients coinfected with HIV.</LI>
<LI>Active alcohol abuse and intravenous drug abuse.</LI>
<LI>Patients with contraindication to RBV.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Group 1 (n = 101).</P>
<UL>
<LI>Drug: interferon alpha-2b (daily) 4 MIU sc for participants &gt; 65 kg or 0.06 MIU/kg &#8804; 65 kg.</LI>
</UL>
<P>Group 2 (n = 98).</P>
<UL>
<LI>Drug:  peginterferon alpha-2b 100 µg/wk for participants &gt; 65 kg or 1.5 µg/kg/d for participants &#8804; 65 kg.</LI>
</UL>
<P>Group 3 (n = 59).</P>
<UL>
<LI>Drug: IFN-2b.</LI>
</UL>
<UL>
<UL>
<LI>Dosage: 3 MIU three times a week.</LI>
</UL>
</UL>
<UL>
<LI>Ribavirin.</LI>
</UL>
<UL>
<UL>
<LI>Dose: 1000 mg/d for participants weighing less than 75 kg or 1200 mg/d for participants weighing more than 75 kg.</LI>
</UL>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>End of treatment response; sustained virological response; adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Inconsistency in the figures across the study report is evident: total number (sample size): 258 (initially 336, but 78 had not commenced treatment).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Izumi-2004">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial with two parallel-group design.</P>
<P>Sample size calculation: unclear, not described.</P>
<P>Intention-to-treat analysis: unclear, not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Japan.</P>
<P>Number of participants randomly assigned: 49; 23 men and 26 women.</P>
<P>63% of participants were treatment-naive and 37% were retreated.</P>
<P>None of the participants had cirrhosis.</P>
<P>All participants were infected with HCV genotype one. Limit for hepatitis C virus RNA detection was 10 copies/mL.</P>
<P>Mean HCV RNA levels (kIU/mL) were 720 in peginterferon plus ribavirin group and 640 in interferon plus ribavirin group.</P>
<P>Inclusion criteria.</P>
<UL>
<LI>Biopsy-proven chronic hepatitis C.</LI>
<LI>Genotype one-b infection.</LI>
<LI>HCV RNA greater than 100 kIU/mL by Amplicore Monitor assay; Roche Molecular Diagnostics Co., Tokyo, Japan.</LI>
</UL>
<P>Exclusion criteria.</P>
<UL>
<LI>Cirrhosis.</LI>
<LI>Autoimmune hepatitis.</LI>
<LI>Alcoholic liver injury.</LI>
<LI>HBsAg or HIV antibody in serum.</LI>
<LI>Immunomodulatory therapy before enrolment in the study.</LI>
<LI>History of excessive alcohol drinking (more than 80 g/d).</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to two groups.</P>
<UL>
<LI>Group 1: peginterferon alpha-2b 1.5 µg/kg for 48 weeks (n = 23).</LI>
<LI>Group 2: interferon alpha-2b 6 MU intramuscularly, daily for the first two weeks and then thrice weekly for additional 46 weeks (n = 26).</LI>
</UL>
<P>Both arms received ribavirin 600 mg for participants who weighed less than 60 kg, 800 mg for participants who weighed between 60 and 80 kg, and 1000 mg for participants who weighed more than 80 kg.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcome was HCV RNA dynamics.</P>
<P>No other outcomes were reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Data were obtained through personal communication with the study author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-12 21:46:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2005">
<CHAR_METHODS MODIFIED="2014-01-12 21:46:07 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with two parallel-group design.</P>
<P>Sample size calculation: performed, 70 participants estimated for each group.</P>
<P>Intention-to-treat analysis: used (14 and five participants discontinued treatment in peginterferon plus ribavirin and interferon plus ribavirin groups).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Country: Taiwan.</P>
<P>Number of participants randomly assigned: 153; 105 men and 48 women.</P>
<P>All participants were treatment-naive.</P>
<P>Genotype: one, two, three, four.</P>
<P>Inclusion criteria.</P>
<UL>
<LI>HCV RNA detectable in serum by PCR assay.</LI>
<LI>Had undergone a liver biopsy within one year before entry that was consistent with chronic hepatitis.</LI>
<LI>Elevated serum ALT defined as two (upper limit of normal) for at least two measurements within six months preceding trial entry.</LI>
</UL>
<P>Exclusion criteria.</P>
<UL>
<LI>Positive HBsAg.</LI>
<LI>Previous liver transplantation. </LI>
<LI>Neutropenia (fewer than 1500/mm<SUP>3</SUP>).</LI>
<LI>Thrombocytopenia (fewer than 100,000/mm<SUP>3</SUP>).</LI>
<LI>Anaemia (less than 13 g/dL for men and less than 12 g/dL for women).</LI>
<LI>HIV infection.</LI>
<LI>Decompensated liver disease. </LI>
<LI>Other causes of liver disease. </LI>
<LI>Abnormal serum creatinine or alpha-fetoprotein level.</LI>
<LI>Abnormal thyroid function test.</LI>
<LI>Preexisting psychiatric disorders.</LI>
<LI>Haemoglobinopathies.</LI>
<LI>Autoimmune-type disease.</LI>
<LI>Poorly controlled coexisting medical conditions.</LI>
<LI>Unable to use contraception.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to two arms.</P>
<UL>
<LI>Group 1: peginterferon alpha-2b 1.5 µg/kg plus ribavirin 1000 mg to 1200 mg (n = 76).</LI>
<LI>Group 2: interferon alpha-2b 3 MU plus ribavirin 1000 mg to 1200 mg (n = 77).</LI>
</UL>
<P>The dose of ribavirin was based on body weight (1000 mg for weight 75 kg, and 1200 mg for weight greater than 75 kg). Participants were treated for 24 weeks and were followed for another 24 weeks after the end of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcomes were biochemical response, virological response, which was defined as the persistent disappearance of serum HCV RNA, and degree of histological improvement.</P>
<P>Other outcomes reported are adverse events.</P>
<P>Limit for hepatitis C virus RNA detection was 50 IU/mL.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>The trial was supported by research grants from Schering-Plough Limited, Taiwan.</P>
<P>Additional data were obtained through personal communication with the study author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mangia-2005">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with three parallel-group design.</P>
<P>Sample size calculation: performed, 118 participants estimated for each group.</P>
<P>Intention-to-treat analysis: used. Participants who discontinued treatment or were lost during follow-up were considered to be virological non-responders (i.e., no sustained virological response). 39 participants discontinued treatment in peginterferon plus ribavirin plus amantadine group, 46 in interferon plus ribavirin plus amantadine group, and 54 in interferon plus ribavirin group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy.</P>
<P>Number of participants randomly assigned: 362; 215 men and 147 women.</P>
<P>All participants were treatment-naive.</P>
<P>Genotype: one, two, three.</P>
<P>Mean HCV RNA levels (UI/mL × 1000) were 2817 ± 4318. 618 in peginterferon plus ribavirin plus amantadine group and 1998 ± 2255. 631 in interferon plus ribavirin plus amantadine group.</P>
<P>Inclusion criteria.</P>
<UL>
<LI>Previously untreated patients</LI>
<LI>Aged 18 to 70 years.</LI>
<LI>Histologically proven chronic hepatitis C.</LI>
<LI>Positive for anti-HCV and HCV RNA by PCR.</LI>
<LI>At least a 1.5-fold increase in ALT levels for at least six months before the start of the study.</LI>
<LI>Haemoglobin levels at least 13 g/dL in men and 12 g/dL in women.</LI>
<LI>Leukocyte counts at least 3000/mm<SUP>3</SUP>.</LI>
<LI>Platelet counts higher than 70,000/mm<SUP>3</SUP>.</LI>
</UL>
<P>Exclusion criteria.</P>
<UL>
<LI>Contraindications to interferon, ribavirin, and amantadine.</LI>
<LI>Immune suppression.</LI>
<LI>Concomitant liver disease; attributable to a cause other than HCV infection.</LI>
<LI>Severe systemic diseases.</LI>
<LI>Intravenous drug use.</LI>
<LI>Alcohol abuse.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to three groups.</P>
<UL>
<LI>Group 1: peginterferon alpha-2a 180 µg and amantadine hydrochloride 200 mg for 48 weeks (n = 121).</LI>
<LI>Group 2: interferon alpha-2a 3 MU and amantadine hydrochloride 200 mg for 48 weeks (n = 120).</LI>
<LI>Group 3: interferon alpha-2a 3 MU for 48 weeks (n = 121).</LI>
</UL>
<P>All participants received ribavirin 1000 mg (body weight less than 75 kg) or 1200 mg (body weight greater than 75 kg).</P>
<P>Participaants were evaluated for virological response at 24 weeks of treatment. Therapy was continued only in participants with undetectable HCV RNA at this time.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcome was sustained virological response, defined as undetectable HCV RNA 24 weeks after the end of treatment (study week 72).</P>
<P>Other outcomes reported included end of treatment virological response, sustained and end of treatment biochemical responses, and adverse events.<BR/>Limit for hepatitis C virus RNA detection was 50 copies/mL.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>The study was conducted by the Al-liver Study Group.</P>
<P>Data were extracted from the primary reference, and additional data were obtained through personal communication with the study author.</P>
<P>Dose reductions are reported only if they were greater than 20% of the prescribed drugs and for longer than 20% of the prescribed duration.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Manns-2001">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with three parallel-group design.</P>
<P>Sample size calculation: performed. This study was designed to include 525 participants per group.</P>
<P>Intention-to-treat analysis: used. As prospectively specified in the protocol, all safety and efficacy analyses, except for changes from baseline in the histological scores, were based on all participants who received at least one dose of study medication. Participants who were missing HCV RNA values during follow-up were classified as non-responders. Analyses of changes from baseline in histological scores were based on participants who had both a pretreatment and a post-treatment biopsy sample. 72 participants discontinued treatment in higher-dose peginterferon plus ribavirin group, 67 in lower-dose peginterferon plus ribavirin group, and 66 in interferon plus ribavirin group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: 62 centres in Europe, Canada, Argentina, and the USA.</P>
<P>Number of participants randomly assigned: 1530; 1003 men and 527 women.</P>
<P>All participants were treatment-naive.</P>
<P>Genotype: one, two, three.</P>
<P>Geometric mean HCV RNA levels (copies/mL × 1,000,000) were 2.7 in both peginterferon plus ribavirin arms, and 2.8 in interferon plus ribavirin group. Limit for hepatitis C virus RNA detection was 100 copies/mL.</P>
<P>Inclusion criteria.</P>
<UL>
<LI>Previously untreated adults.</LI>
<LI>HCV RNA detectable in serum by PCR.</LI>
<LI>Liver biopsy within one year before entry that was consistent with chronic hepatitis.</LI>
<LI>High serum values of ALT (above the upper limit of normal more than 43 IU/L for men, more than 34 IU/L for women).</LI>
<LI>Minimum haematological and biochemical values of: haemoglobin 120 g/L for women and 130 g/L for men; WBC count 3000 × 1,000,000/L; neutrophil count 1.5 × 1,000,000/L; platelet count 100 × 1,000,000/L.</LI>
<LI>Bilirubin, albumin, and creatinine within normal limits.</LI>
</UL>
<P>Exclusion criteria.</P>
<UL>
<LI>Decompensated cirrhosis.</LI>
<LI>Serum alpha-fetoprotein concentration greater than 50 µg/L.</LI>
<LI>HIV infection.</LI>
<LI>Previous organ transplantation. </LI>
<LI>Other causes of liver disease. </LI>
<LI>Preexisting psychiatric disease.</LI>
<LI>Seizure disorders.</LI>
<LI>Cardiovascular disease.</LI>
<LI>Haemoglobinopathies.</LI>
<LI>Haemophilia.</LI>
<LI>Poorly controlled diabetes. </LI>
<LI>Autoimmune-type disease. </LI>
<LI>Inability to use contraception.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to three groups.</P>
<UL>
<LI>Group 1: peginterferon alpha-2b 1.5 µg/kg plus ribavirin 800 mg for 48 weeks (n = 511).</LI>
<LI>Group 2: peginterferon alpha-2b 1.5 µg/kg for the first four weeks, followed by 0.5 µg/kg for the next 44 weeks plus ribavirin 1000 mg to 1200 mg for 48 weeks (n = 514).</LI>
<LI>Group 3: interferon alpha-2b 3 MU plus ribavirin 1000 mg to 1200 mg for 48 weeks (n = 505).</LI>
</UL>
<P>In the two arms receiving 1000 mg to 1200 mg of ribavirin, the dose was adjusted according to body weight (1000 mg for weight below 75 kg and 1200 mg for weight 75 kg or more).</P>
<P>Both drugs were started and stopped at the same time.</P>
<P>Participants were followed-up for 24 weeks after the end of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcome was sustained virological response, defined as undetectable HCV RNA in serum at the end of follow-up.</P>
<P>Other outcomes reported included end of treatment virological response, sustained and end of treatment biochemical responses, histological response, and rates of discontinuation of treatment, dose reductions, and adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-11-18 22:33:10 +0100" MODIFIED_BY="Tahany Awad">
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-12 21:46:17 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-Napoli-2005">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial with two-group design.</P>
<P>Sample size calculation: unclear, not described.</P>
<P>Intention-to-treat analysis: used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Country: Italy.</P>
<P>Number of participants randomly assigned: 64; 45 men and 19 women.</P>
<P>All participants were treatment-naive.</P>
<P>Inclusion criteria.</P>
<UL>
<LI>Positive for HCV RNA by PCR.</LI>
<LI>Serum levels of ALT above the upper limit of normal values for at least six months before treatment.</LI>
<LI>Histopathological confirmation of chronic hepatitis.</LI>
</UL>
<P>Exclusion criteria.</P>
<UL>
<LI>Decompensated liver cirrhosis.</LI>
<LI>Haematological abnormalities (haemoglobin level less than 12 g/dL in women and less than 13 g/dL in men; neutrophil count fewer than 1.5 × 1000 cells/mL; platelet count fewer than 90 × 1.000 cells/mL).</LI>
<LI>Preexisting severe psychiatric conditions.</LI>
<LI>Severe cardiac disease.</LI>
<LI>Haemoglobinopathies.</LI>
<LI>Haemophilia.</LI>
<LI>Autoimmune diseases.</LI>
<LI>HIV coinfection.</LI>
<LI>Previous liver transplantation.</LI>
<LI>Other causes of liver disease.</LI>
<LI>Women unable or unwilling to practice contraception.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Participants were randomly assigned to two arms:</P>
<UL>
<LI>Group 1: peginterferon alpha-2b 1.5 µg/kg plus ribavirin 800 mg to 1200 mg (n = 32).</LI>
<LI>Group 2: non-pegylated leucocyte interferon alpha 6 MU plus ribavirin 800 mg to 1200 mg (n = 32).</LI>
</UL>
<P>Dose of ribavirin depended on pretreatment body weight: 800 mg for weight less than 60 kg; 1000 mg for weight greater than and equal to 60 kg and less than 75 kg; 1200 mg for weight greater than and equal to 75 kg.</P>
<P>Duration of treatment was 48 weeks for participants infected with HCV genotype one and 24 weeks for participants infected with genotypes two and three.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-12 21:46:17 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcomes were end of treatment and sustained virological responses, defined as the absence of detectable HCV-RNA in the serum at the end of treatment and at week 24 of post-treatment follow-up.</P>
<P>Other outcomes reported are adverse events and dose reductions.</P>
<P>Limit for hepatitis C virus RNA detection was 3200 copies/mL.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>The study was supported by grants from Ministero dell Universita e della Ricerca Scientifica e Tecnologica, Rome, Italy.</P>
<P>Additional data were obtained through personal communication with the study author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-12 21:46:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nevens-2010">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with two parallel-group design.</P>
<P>Sample size calculation: unclear, not described.</P>
<P>Intention-to-treat analysis: used. All participants who received at least one dose of study medication were included in the analysis (ITT/e = exposed). Participants without measurements at the end of the 24-week untreated follow-up period were considered as non-responders.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Belgium.</P>
<P>Number of participants randomly assigned: 443; 241 men and 202 women.</P>
<P>78% of participants were treatment-naive and 22% were relapsers.</P>
<P>Inclusion criteria.</P>
<UL>
<LI>Patients 18 years of age or older.</LI>
<LI>Serologically proven chronic hepatitis C.</LI>
<LI>Quantifiable HCV RNA (more than 1000 IU/mL).</LI>
<LI>Compensated liver disease (Child-Pugh Grade A).</LI>
<LI>Naive to any therapy or had a relapse after previous interferon-based treatment.</LI>
</UL>
<P>Exclusion criteria: none stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to two groups.</P>
<UL>
<LI>Group 1: peginterferon alpha-2a 180 µg plus ribavirin 1000 mg to 1200 mg for 48 weeks (n = 230).</LI>
<LI>Group 2: interferon alpha-2a 6 MU for eight weeks, and then 3 MU for additional 40 weeks plus ribavirin 1000 mg to 1200 mg for 48 weeks (n = 213).</LI>
</UL>
<P>Participants were followed-up for 24 weeks after the end of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcome was sustained virological response, defined as undetectable HCV RNA at the end of follow-up.</P>
<P>Other outcomes reported are sustained biochemical response and adverse events.</P>
<P>Limit for hepatitis C virus RNA detection was 50 IU/mL.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-12 21:46:26 +0100" MODIFIED_BY="Tahany Awad">
<P>Follow-up: 71 and 119 participants discontinued treatment in peginterferon plus ribavirin and interferon plus ribavirin groups. Additional data were obtained through personal communication with the study author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PRETTY-2005">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial with two-group design.</P>
<P>Sample size calculation: unclear, not described.</P>
<P>Intention-to-treat analysis: unclear, not described.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy.</P>
<P>Number of participants randomly assigned: 178; 119 men and 59 women.</P>
<P>Genotype: one, two, three.</P>
<P>All participants were non-responders to previous interferon plus ribavirin treatment.</P>
<P>Inclusion and exclusion criteria: none stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to two arms:</P>
<UL>
<LI>Group 1: peginterferon alpha-2a 180 µg plus ribavirin 1000 mg to 1200 mg and amantadine hydrochloride 200 mg for 48 weeks.</LI>
<LI>Group 2: interferon alpha-2a 6 MU plus ribavirin 1000 mg to 1200 mg and amantadine hydrochloride 200 mg for 48 weeks.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcomes were biochemical and virological responses.</P>
<P>Other outcome reported was dose reduction.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>The report is abstract; because the study has not been published yet, no data about inclusion and exclusion criteria were provided.</P>
<P>We calculated sustained virological response based on reported proportions of participants because no absolute numbers of participants with sustained virological response were reported.</P>
<P>Number of participants in each group is not reported, so we provisionally divided the total number of participants by two.</P>
<P>Study author contacted for additional informations, but no reply obtained.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-12 21:15:40 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-Rahman-2007a">
<CHAR_METHODS MODIFIED="2013-12-13 16:40:53 +0100" MODIFIED_BY="Tahany Awad">
<P>Study design: randomised controlled trial.</P>
<P>ITT analysis: yes.</P>
<P>Sample size calculation: not mentioned.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Country: not known.</P>
<P>Total number (sample size): 310.</P>
<P>Genotype: one.</P>
<P>Previous HCV treatment: naive.</P>
<P>Inclusion criteria: chronic hepatitis C infection.</P>
<P>Exclusion criteria: not mentioned.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-12 21:15:40 +0100" MODIFIED_BY="Tahany Awad">
<P>Group 1: peginterferon alpha-2b induction plus ribavirin.</P>
<UL>
<LI>Dosage: induction two weeks interferon alpha-2b 10 -&gt; 5 MU qd followed by 36 weeks peginterferon alpha-2b 1.5 µg/kg,weekly.</LI>
</UL>
<P>Group 2: peginterferon alpha-2b  standard plus ribavirin.</P>
<UL>
<LI>Dosage: 1.5 µg/kg weekly.</LI>
</UL>
<P>Group 3: CIFN induction plus ribavirin.</P>
<UL>
<LI>Dosage: 12 weeks CIFN 27 -18 µg qd followed by 36 weeks CIFN 9 µg qd.</LI>
</UL>
<P>Group 4: CIFN plus ribavirin.</P>
<UL>
<LI>Dosage: 9 µg qd.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-13 16:35:19 +0100" MODIFIED_BY="Tahany Awad">
<P>Sustained virological response.</P>
<P>Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Only published abstract; no data about inclusion and exclusion criteria were provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-Rahman-2007b">
<CHAR_METHODS MODIFIED="2013-12-13 16:40:17 +0100" MODIFIED_BY="Tahany Awad">
<P>Study design: randomised clinical trial.</P>
<P>ITT analysis: yes.</P>
<P>Sample size calculation: not mentioned.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Country: not known.</P>
<P>Total number (sample size): 262.</P>
<P>Genotype: two, three.</P>
<P>Previous HCV treatment: naive.</P>
<P>Inclusion criteria: chronic hepatitis C infection.</P>
<P>Exclusion criteria: not mentioned.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Group 1: peginterferon alpha-2b  plus ribavirin.</P>
<UL>
<LI>Dosage: 1.5 µg/kg weekly.</LI>
</UL>
<P>Group 2: consensus interferon plus ribavirin.</P>
<UL>
<LI>Dosage: 9 µg qd.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-13 16:59:01 +0100" MODIFIED_BY="Tahany Awad">
<P>Sustained virological response.</P>
<P>Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Only published abstract; no data about inclusion and exclusion criteria provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-12 21:46:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roffi-2008">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with two parallel-group design.</P>
<P>Sample size calculation: yes.</P>
<P>Intention-to-treat analysis: yes.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy.</P>
<P>Number of participants randomly assigned: 91; 64 men and 27 women.</P>
<P>Participant status regarding previous antiviral therapy not described.</P>
<P>Genotype: one, two, three</P>
<P>All participants had bridging fibrosis or cirrhosis.</P>
<P>Inclusion criteria.</P>
<UL>
<LI>Participants with chronic hepatitis C.</LI>
<LI>Liver biopsy performed within 12 months before entry to the protocol.</LI>
<LI>Pathology report confirming a histological diagnosis of advanced disease: stage greater than four sec. Ishak; stage greater than three sec. Knodell.</LI>
<LI>Compensated liver disease.</LI>
<LI>Minimum biochemical criteria: haemoglobin 13 g/dL for men, 12 g/dL for women, WBC greater than 3000/mm<SUP>3</SUP>, granulocyte greater than 1500/mm<SUP>3</SUP>, platelets greater than 80,000/mm<SUP>3</SUP>, bilirubin within normal limits.</LI>
</UL>
<P>Exclusion criteria.</P>
<UL>
<LI>Decompensated.</LI>
<LI>Child-Pugh class B or C cirrhosis.</LI>
<LI>Medium-sized or large varices.</LI>
<LI>Coinfection with hepatitis B or HIV.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to two groups (n = 93):</P>
<UL>
<LI>Group 1: peginterferon alpha-2b 1.0 µg for four weeks, then 50 µg for up to 24 weeks plus ribavirin for 24 weeks (n = 57).</LI>
<LI>Group 2: interferon alpha-2b 3 MU plus ribavirin for 24 weeks (n = 36).</LI>
</UL>
<P>Ribavirin</P>
<UL>
<LI>Dose: 800 mg/d for participants weighing less than 65 kg, 1000 mg/d for participants weighing between 65 kg and 75 kg, or 1200 mg/d for participants weighing more than 75 kg.</LI>
</UL>
<P>Participants were followed-up for 48 weeks after the end of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcomes were end of treatment and sustained virological responses.</P>
<P>Other outcome reported is treatment discontinuation.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-12 21:46:36 +0100" MODIFIED_BY="Tahany Awad">
<P>Follow-up: Six and five participants discontinued treatment in peginterferon plus ribavirin and interferon plus ribavirin groups.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Scotto-2005">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with three parallel-group design.</P>
<P>Sample size calculation: not described.</P>
<P>Intention-to-treat analysis: used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Italy.</P>
<P>Number of participants randomly assigned: 78; 36 men and 42 women.</P>
<P>All participants were treatment-naive.</P>
<P>All participants were infected with HCV genotype one-b.</P>
<P>Mean histological activity index score was 13.7 ± 2.9 in peginterferon plus ribavirin group, 13.7 ± 3.8 in lower-dose interferon plus ribavirin group, and 13.9 ± 3.2 in higher-dose interferon plus ribavirin group.</P>
<P>Inclusion criteria.</P>
<UL>
<LI>Serum ALT levels at least twice the upper normal limit for at least six months before treatment.</LI>
<LI>Presence of anti-HCV antibodies determined by means of a third-generation enzyme-linked immunosorbent assay (HCV ELISA, Ortho Diagnostic System, Raritan, NJ, USA) and confirmed by additional third-generation recombinant immunoblot assay (RIBA, Ortho Diagnostic System, Raritan, NJ, USA).</LI>
<LI>Presence of measurable serum HCV RNA (Cobas Amplicor HCV Monitor test, Roche Molecular System, Basel, Suisse).</LI>
<LI>HCV genotype one-b (Inno-Lipa HCV II Kits, Innogenetics, Zwijmaarden, Belgium).</LI>
<LI>Leukocyte counts greater than 3000/mm<SUP>3</SUP>.</LI>
<LI>Platelet counts greater than 75,000/mm<SUP>3</SUP>.</LI>
<LI>Haemoglobin concentration greater than 13 g/dL for men and greater than 12 g/dL for women.</LI>
<LI>Liver biopsy performed within one year of the start of treatment with histological diagnosis of chronic hepatitis based on the histological activity index score as described by Knodell et al. and modified by Ishak et al.</LI>
</UL>
<P>Exclusion criteria.</P>
<UL>
<LI>Previous episodes of decompensated liver disease (i.e., ascites, bleeding from oesophageal varicose veins, encephalopathy).</LI>
<LI>HIV coinfection.</LI>
<LI>Active intravenous drug use.</LI>
<LI>Potential cause of liver disease other than HCV.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to three groups.:</P>
<UL>
<LI>Group 1: peginterferon alpha-2b 1.5 µg/kg for 52 weeks (n = 26).</LI>
<LI>Group 2: interferon alpha-2b 6 MU for 52 weeks (n = 26).</LI>
<LI>Group 3: interferon alpha-2b 3 MU daily for 52 weeks (n = 26).</LI>
</UL>
<P>All participants also received ribavirin at 800 to 1000 to 1200 mg according to body weight (less than 65 kg, 65 to 85 kg, and more than 85 kg).</P>
<P>Participants were followed up for 24 weeks after the end of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcomes were early, end of treatment, and sustained biochemical and virological responses.</P>
<P>Other outcomes reported are histological changes, adverse events, and treatment discontinuations.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Follow-up: Three participants discontinued treatment in peginterferon plus ribavirin group, four in lower-dose interferon plus ribavirin group, and eight in higher-dose interferon plus ribavirin group. Study author contacted for additional information, but no reply obtained.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shobokshi-2003">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial with three parallel-group design.</P>
<P>Sample size calculation: unclear, not described.</P>
<P>Intention-to-treat analysis: unclear, not described.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Saudi Arabia.</P>
<P>Number of participants randomly assigned: 180; 119 men and 61 women.</P>
<P>Participant status regarding previous antiviral therapy not described.</P>
<P>Histological activity index (22) mean was 6.9 in peginterferon plus ribavirin group and 8.1 in interferon plus ribavirin group.</P>
<P>All participants were infected with HCV genotype four.</P>
<P>Mean HCV RNA levels (UI/mL) were 459,590 in peginterferon plus ribavirin group and 411,028 in interferon plus ribavirin group.</P>
<P>Inclusion and exclusion criteria: none stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned in three groups to receive the following.</P>
<UL>
<LI>Group 1: peginterferon alpha-2a 180 µg plus ribavirin 800 mg for 48 weeks (n = 60).</LI>
<LI>Group 2: peginterferon alpha-2a 180 µg (n = 60).</LI>
<LI>Group 3: interferon alpha 2a 4.5 MU plus ribavirin 800 mg for 48 weeks (n = 60).</LI>
</UL>
<P>Participants were followed up for 24 weeks after the end of treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcomes were sustained and end of treatment virological responses.</P>
<P>Other outcomes reported are sustained and end of treatment biochemical responses.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>The report is abstract because the study has not been published yet.</P>
<P>The study was conducted by MOH PEG-IFN Clinical Trial Group.</P>
<P>Data were extracted from the primary reference and abstracts: Shobokshi, et al. Peginterferon alfa-2a (40KDA) as a monotherapy or in combination with ribavirin significantly improves end of treatment response rate in hepatitis C virus genotype 4 chronic active hepatitis patients. Saudi Medical Journal 2003;24(Suppl 2):S92-3; and Shobokshi et al. Early virological response at week 12 has positive predictive value for end of treatment response for hepatitis C virus genotype 4 chronic active hepatitis cases treated with combination therapy of peginterferon plus ribavirin. Saudi Medical Journal 2003;24(Suppl 2):S92-3. </P>
<P>Follow-up: Seven participants discontinued treatment in peginterferon plus ribavirin group, four in peginterferon group, and one in interferon plus ribavirin group.</P>
<P>Study author contacted for additional information, but no reply obtained.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-Sj_x00f6_gren-2007">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial with two parallel-group design.</P>
<P>Intention-to-treat analysis: used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="[Empty name]">
<P>Country: USA.</P>
<P>Number of participants randomly assigned: 59.</P>
<P>All participants are treatment-naive.</P>
<P>All participants are infected with HCV genotype one.</P>
<P>Inclusion criteria: HCV RNA positive patients with liver biopsy compatible with chronic HCV infection</P>
<P>Exclusion criteria: minimum haemoglobin 12g/L for women and 13g/L for men, WBC &lt; 3x10<SUP>3</SUP>/mm<SUP>3</SUP>, Neutrophil count &lt; 1,5x10<SUP>3</SUP>/mm<SUP>3</SUP>, platelet count &lt; 75x10<SUP>3</SUP>/mm<SUP>3</SUP>, prothrombin time &gt; 2 sec above the upper limit of normal, severe psychiatric conditions, other causes of liver disease than HCV infection</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Participants are randomly assigned to two groups.</P>
<UL>
<LI>Group 1: peginterferon 1.5 µg/kg and ribavirin 1000 mg or 1200 mg (n = 29).</LI>
<LI>Group 2: non-pegylated consensus interferon 15 µg and ribavirin 1000 mg or 1200 mg (n = 30).</LI>
</UL>
<P>Treatment is planned for 48 weeks if serum HCV RNA is undetectable at week 24; otherwise, drugs are to be discontinued.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcome is sustained virological response, which will be determined at week 72.</P>
<P>Other outcomes reported include end of treatment virological response and adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>An ongoing study with interim results. No new publications regarding this data.</P>
<P>Study author contacted for additional information, but no reply obtained.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-Thakeb-2003">
<CHAR_METHODS MODIFIED="2013-12-13 16:38:21 +0100" MODIFIED_BY="[Empty name]">
<P>Study design: randomised clinical trial.</P>
<P>ITT analysis: performed.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: not known.</P>
<P>Total number (sample size): 100.</P>
<P>Genotype: four.</P>
<P>Previous HCV treatment.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Group A (n = 51).</P>
<UL>
<LI>Drug: peginterferon alpha-2a.</LI>
<LI>Dosage: 180 µg.</LI>
</UL>
<P>Group B (n = 49).</P>
<UL>
<LI>Drug: IFN-2a.</LI>
<LI>Dosage: 3 MU.</LI>
</UL>
<P>Ribavirin.</P>
<UL>
<LI>1000 or 1200 mg depending on body weight.</LI>
</UL>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-13 16:37:54 +0100" MODIFIED_BY="[Empty name]">
<P>Sustained virological response.</P>
<P>Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Published abstract only; no data about inclusion and exclusion criteria were provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tsubota-2005">
<CHAR_METHODS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial with two parallel-group design.</P>
<P>Sample size calculation: not described.</P>
<P>Intention-to-treat analysis: used.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Country: Japan.</P>
<P>Number of participants randomly assigned: 48; 31 men and 17 women.</P>
<P>All participants were treatment-naive.</P>
<P>None of the participants had cirrhosis.</P>
<P>All participants were infected with HCV genotype one.</P>
<P>Mean HCV RNA levels (kIU/mL) were 540 (120 to 2100) in peginterferon plus ribavirin group and 700 (250 to 2800) in interferon plus ribavirin group.</P>
<P>Inclusion criteria.</P>
<UL>
<LI>HCV genotype one-b confirmed by PCR.</LI>
<LI>Serum HCV RNA levels greater than 100,000 IU/mL on quantitative PCR assay (defined as &#8216;&#8216;high&#8217;&#8217; viral load, Amplicor HCV Monitor Version 2.0, Roche Diagnostics, Tokyo, Japan).</LI>
<LI>Serum ALT concentrations above the upper limit of normal (greater than 45 IU/L).</LI>
<LI>Diagnosis of chronic hepatitis on a liver biopsy specimen obtained within the preceding year, using the ranking system for grading of necrotic inflammation activity and staging of fibrosis.</LI>
<LI>Haemoglobin concentration 12.0 g/dL.</LI>
<LI>Neutrophil count 1500/mL.</LI>
<LI>Platelet count greater than 100,000/mL.</LI>
<LI>Creatinine clearance greater than 51 mL/min.</LI>
<LI>Body weight between 40 and 100 kg.</LI>
<LI>Older than 20 years of age.</LI>
</UL>
<P>Exclusion criteria.</P>
<UL>
<LI>Liver cancer or severe liver failure.</LI>
<LI>Other forms of liver disease.</LI>
<LI>Coexisting serious psychiatric or medical illness, including seizure disorders, diabetes mellitus, cardiovascular or lung disease, and autoimmune-type disease.</LI>
<LI>Previous organ transplantation.</LI>
<LI>Treatment with any other antiviral or immunomodulatory agent administered within the previous 180 days.</LI>
<LI>History of interferon monotherapy or combination therapy with ribavirin.</LI>
<LI>Positive test for HBsAg.</LI>
<LI>Hypersensitivity to interferon, peginterferon, or ribavirin.</LI>
<LI>Pregnancy or lactation, including patients&#8217; partners.</LI>
<LI>Inability to use contraception.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Participants were randomly assigned to two groups.</P>
<UL>
<LI>Group 1: peginterferon alpha-2b 1.5 µg/kg plus ribavirin for 48 weeks (n = 28).</LI>
<LI>Group 2: interferon alpha-2b 6 MU intramuscularly, daily with ribavirin for the initial two weeks, followed thrice weekly for 46 weeks (n = 20).</LI>
</UL>
<P>For both treatment groups, ribavirin at the total dose of 600 mg to 1000 mg was administered for 48 weeks; the dose was adjusted according to body weight (600 mg for weight 60 kg or less, 800 mg for weight 60 kg to 80 kg, and 1000 mg for weight 80 kg to 100 kg).</P>
<P>Both non-pegylated peginterferon and ribavirin were concurrently initiated.</P>
<P>Treatment was provided for 48 weeks, with a subsequent 24-weeks follow-up period.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Primary outcome was viral kinetics.</P>
<P>Other outcomes reported include biochemical and virological responses.</P>
<P>Limit for hepatitis C virus RNA detection was 50 IU/mL.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Additional data were obtained through personal communication with the study author.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-Wakil-2006">
<CHAR_METHODS MODIFIED="2013-12-13 16:37:18 +0100" MODIFIED_BY="Tahany Awad">
<P>Study design: randomised trial.</P>
<P>ITT analysis: not mentioned.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>County: Egypt.</P>
<P>Total number (sample size): 50.</P>
<P>Age, years: 38.24 ± 8.56.</P>
<P>Sex (male): not stated.</P>
<P>Genotype: four.</P>
<P>Previous HCV treatment: naive.</P>
<P>Inclusion criteria: treatment-naive chronic hepatitis C patients.</P>
<P>Exclusion criteria: not mentioned.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Group 1 (n = 18).</P>
<UL>
<LI>Drug: peginterferon alpha-2b.</LI>
<LI>Dosage: 1.5 µg/kg weekly.</LI>
</UL>
<P>Group 2 (n = 17).</P>
<UL>
<LI>Drug: IFN alpha-2b.</LI>
<LI>Dosage: 3 MU thrice weekly.</LI>
</UL>
<P>Group 3 (n = 15).</P>
<UL>
<LI>Drug: IFN alpha-2b.</LI>
<LI>Dosage: 5 MU thrice weekly.</LI>
</UL>
<P>All three groups were given weight-based ribavirin (1000 mg to 1200 mg).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-13 16:36:37 +0100" MODIFIED_BY="Tahany Awad">
<P>Sustanied virological response.</P>
<P>Adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Published abstract only; no data about inclusion and exclusion criteria were provided.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ALT = alanine aminotransferase.<BR/>CIFN = consensus interferon.<BR/>HCV = hepatitis C virus.<BR/>HIV = human immunodeficiency virus.<BR/>IFN = interferon.<BR/>ITT = intention-to-treat analysis.<BR/>MU = mega units.<BR/>PCR = polymerase chain reaction.<BR/>PEG IFN = pegylated interferon.<BR/>WBC = white blood cells.<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-02-13 16:16:02 +0100" MODIFIED_BY="Tahany Awad" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2014-02-13 16:16:02 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-ACTG-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-13 16:16:02 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial in HIV co-infected participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ali-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised clinical trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-13 16:16:00 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-APRICOT-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-13 16:16:00 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial in HIV co-infected participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-Asahina-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad">
<P>Not reported whether the trial was randomised.<BR/>First study author contacted for additional information, but no reply obtained.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-03-31 14:59:50 +0200" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-Gromova-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-03-31 14:59:50 +0200" MODIFIED_BY="Tahany Awad">
<P>Pilot study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-13 16:15:58 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-Laguno-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-13 16:15:58 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial in HIV co-infected participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-02-13 16:15:56 +0100" MODIFIED_BY="Tahany Awad" STUDY_ID="STD-RIBAVIC-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-02-13 16:15:56 +0100" MODIFIED_BY="Tahany Awad">
<P>Randomised clinical trial in HIV co-infected participants.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-06-04 17:43:51 +0200" MODIFIED_BY="Tahany Awad" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 10:20:24 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Al_x002d_Faleh-2004">
<DESCRIPTION>
<P>Quote: randomly generated numbers by a computer program.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-13 13:32:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruno-2004">
<DESCRIPTION>
<P>Quote: computer-generated scheme. Patients were stratified according to centre and randomised in blocks of four to the peginterferon plus ribavirin or interferon plus ribavirin group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Cariti-2002">
<DESCRIPTION>
<P>Quote: "patients where randomised".</P>
<P>Comments: Method used to perform sequence generation is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:00:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Derbala-2005">
<DESCRIPTION>
<P>Comments: Method used to perform sequence generation is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:01:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Derbala-2006">
<DESCRIPTION>
<P>Comments: Method used to perform sequence generation is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dollinger-2005">
<DESCRIPTION>
<P>Comments: Method of sequence generation is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Esmat-2003">
<DESCRIPTION>
<P>Comment: A computer programme randomly allocated participants to one of the two treatment groups in blocks of 10.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fargion-2004">
<DESCRIPTION>
<P>Comments: Method of sequence generation is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fried-2002">
<DESCRIPTION>
<P>Comments: Sequence generation was performed by a computer programme.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:03:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hinrichsen-2002">
<DESCRIPTION>
<P>Comments: Method used to perform sequence generation is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Horsmans-2008">
<DESCRIPTION>
<P>Comments: Method of sequence generation is not mentioned. Randomisation process is not well described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:06:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Izumi-2004">
<DESCRIPTION>
<P>Comments: Method used to perform sequence generation is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>Comments: Sequence generation was performed by a computer programme.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mangia-2005">
<DESCRIPTION>
<P>Comments: Sequence generation was performed by a computer programme.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manns-2001">
<DESCRIPTION>
<P>Comment: computer generated. Eligible participants were randomly assigned the three study treatments in equal proportions, stratified by HCV genotype (one versus others) and the presence or absence of cirrhosis. The randomisation schedule, balanced within each country participating in the study, used a block size of three for each stratum and was generated by the study sponsor (Schering Plough Research Institute).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Napoli-2005">
<DESCRIPTION>
<P>Comments: Sequence generation was performed by a computer programme.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Nevens-2010">
<DESCRIPTION>
<P>Quote: &#8220;Randomisation was stratified according to pre-treatment status (treatment naïve versus relapse) and presence of cirrhosis&#8221;.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:25:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PRETTY-2005">
<DESCRIPTION>
<P>Comments: Method used to perform sequence generation is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:26:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2007a">
<DESCRIPTION>
<P>Comments: Method used to perform sequence generation is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:26:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2007b">
<DESCRIPTION>
<P>Comments: Method used to perform sequence generation is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Roffi-2008">
<DESCRIPTION>
<P>Comments: Sequence generation was performed by a computer programme.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Scotto-2005">
<DESCRIPTION>
<P>Comment: Randomisation was performed using a matrix of casual numbers, which generated the random allocation sequence table.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Shobokshi-2003">
<DESCRIPTION>
<P>Comment: Method of sequence generation was not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Sj_x00f6_gren-2007">
<DESCRIPTION>
<P>Quote: "Patients were randomised using a computerized system".</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Thakeb-2003">
<DESCRIPTION>
<P>Comments: Method of sequence generation is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Tsubota-2005">
<DESCRIPTION>
<P>Comment: Randomisation was achieved through computer-generated random numbers.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Wakil-2006">
<DESCRIPTION>
<P>Comments: Method of sequence generation is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-13 13:30:13 +0200" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Al_x002d_Faleh-2004">
<DESCRIPTION>
<P>Quote: performed in a central unit and were distributed in opaque sealed envelopes to individual centres.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-24 13:51:39 +0200" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Bruno-2004">
<DESCRIPTION>
<P>Comment: central randomisation centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cariti-2002">
<DESCRIPTION>
<P>Comment: Method of allocation concealment is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Derbala-2005">
<DESCRIPTION>
<P>Comment: Method of allocation concealment is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:01:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Derbala-2006">
<DESCRIPTION>
<P>Comments: Allocation concealment is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:02:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dollinger-2005">
<DESCRIPTION>
<P>Comments: Allocation concealment is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:02:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Esmat-2003">
<DESCRIPTION>
<P>Comment: The group assignment was concealed in opaque sealed envelopes that were not opened until all study entry criteria were met.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:03:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fargion-2004">
<DESCRIPTION>
<P>Comments: Allocation concealment is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:03:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fried-2002">
<DESCRIPTION>
<P>Comments: Central allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:03:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hinrichsen-2002">
<DESCRIPTION>
<P>Comments: Allocation concealment is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Horsmans-2008">
<DESCRIPTION>
<P>Comments: The allocation concealment process is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:06:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Izumi-2004">
<DESCRIPTION>
<P>Comments: Allocation concealment is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:06:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>Comments: Central allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:17:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mangia-2005">
<DESCRIPTION>
<P>Comments: Central allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manns-2001">
<DESCRIPTION>
<P>Comment: Randomisation of participants to treatment was done by an independent central randomisation centre (Information Management Systems, Silver Springs, MD, USA). When a participant was found to be eligible for participation in the study, the study site sent a fax to the randomisation centre documenting the participant's eligibility; the centre sent a return fax with the participant's treatment assignment and identification number for the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Napoli-2005">
<DESCRIPTION>
<P>Comments: central allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nevens-2010">
<DESCRIPTION>
<P>Comment: no data about allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:25:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PRETTY-2005">
<DESCRIPTION>
<P>Comments: Allocation concealment is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:26:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2007a">
<DESCRIPTION>
<P>Comments: Allocation concealment is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2007b">
<DESCRIPTION>
<P>Comments: Allocation concealment is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-03 14:36:00 +0200" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Roffi-2008">
<DESCRIPTION>
<P>Comments: central allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-11 14:04:10 +0200" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Scotto-2005">
<DESCRIPTION>
<P>Comments: central allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Shobokshi-2003">
<DESCRIPTION>
<P>Comments: Allocation concealment is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-11 14:05:25 +0200" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Sj_x00f6_gren-2007">
<DESCRIPTION>
<P>Comments: central allocation concealment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Thakeb-2003">
<DESCRIPTION>
<P>Comments: Method of allocation concealment is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsubota-2005">
<DESCRIPTION>
<P>Comment: Randomisation of eligible participants to treatment was carried out by an independent randomisation centre.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Wakil-2006">
<DESCRIPTION>
<P>Comments: Method of allocation concealment is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Faleh-2004">
<DESCRIPTION>
<P>Comment: It is mentioned only that the pathologists were blinded to the treatment allocation of the participant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Bruno-2004">
<DESCRIPTION>
<P>Comment: It is mentioned only that the slides of liver biopsy specimens were coded and read by a single pathologist, who was unaware of clinical data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cariti-2002">
<DESCRIPTION>
<P>Comment: It is mentioned only that the pathologists were blinded to the treatment allocation of the participant.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Derbala-2005">
<DESCRIPTION>
<P>Comment: It is not mentioned whether outcome assessors were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-06 10:01:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Derbala-2006">
<DESCRIPTION>
<P>Comments: Blinding to the outcome assessor is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-06 10:02:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dollinger-2005">
<DESCRIPTION>
<P>Comments: Blinding to outcome assessors is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Esmat-2003">
<DESCRIPTION>
<P>Comment: Participants were not blinded; however, it is mentioned whether outcome assessors were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-06 10:03:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fargion-2004">
<DESCRIPTION>
<P>Comments: Blinding to outcome assessors is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Fried-2002">
<DESCRIPTION>
<P>Comments:Method of blinding was not described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-06 10:03:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hinrichsen-2002">
<DESCRIPTION>
<P>Comments: Blinding is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Horsmans-2008">
<DESCRIPTION>
<P>Coments: open-label trial.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-06 10:06:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Izumi-2004">
<DESCRIPTION>
<P>Comments: Blinding to outcome assessors is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>Comment: It is mentioned only that the liver histology was analysed by a single pathologist, who was unaware of the participant's identity, treatment regimen, response or timing of the biopsy relative to treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mangia-2005">
<DESCRIPTION>
<P>Comment: It is mentioned only that the liver histology was analysed by a single pathologist, who was unaware of the participant's identity, treatment regimen, response, or timing of the biopsy relative to treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Manns-2001">
<DESCRIPTION>
<P>Comment: It is mentioned only that the liver histology was analysed by a single pathologist, who was unaware of the participant's identity, treatment regimen, response, or timing of the biopsy relative to treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2013-12-13 16:34:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Napoli-2005">
<DESCRIPTION>
<P>Comments: Blinding is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Nevens-2010">
<DESCRIPTION>
<P>Comment: open-label study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-06 10:25:55 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PRETTY-2005">
<DESCRIPTION>
<P>Comments: Blinding to outcome assessors is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2012-06-06 10:26:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2007a">
<DESCRIPTION>
<P>Comments: Blinding to outcome assessors is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2007b">
<DESCRIPTION>
<P>Comments: Blinding to outcome assessors is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Roffi-2008">
<DESCRIPTION>
<P>Comments: It is mentioned only that the pathologists reviewed the biopsy specimens in a blinded manner.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Scotto-2005">
<DESCRIPTION>
<P>Comments: Blinding to the outcome assessor is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Shobokshi-2003">
<DESCRIPTION>
<P>Comments: Blinding to the outcome assessor is not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Sj_x00f6_gren-2007">
<DESCRIPTION>
<P>Quote: "HCV RNA and HCV genotype were tested at a central laboratory". However, it is not clear whether adverse event outcome assessors were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Thakeb-2003">
<DESCRIPTION>
<P>Comments: It is not mentioned whether outcome assessors were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Tsubota-2005">
<DESCRIPTION>
<P>Comments: It is not mentioned whether outcome assessors were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Wakil-2006">
<DESCRIPTION>
<P>Comments: It is not mentioned whether outcome assessors were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-02-13 16:10:19 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-12 21:45:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Al_x002d_Faleh-2004">
<DESCRIPTION>
<P>It is clearly stated that treatment was discontinued in three and eight participants in peginterferon plus ribavirin and interferon plus ribavirin groups. Intention-to-treat analysis was used when participants who discontinued treatment or were lost to follow-up were classified as non-responders.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-12 21:45:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Bruno-2004">
<DESCRIPTION>
<P>Comment: The number of participants lost to follow-up is mentioned. Treatment was discontinued in 31 and 46 participants in peginterferon plus ribavirin and interferon plus ribavirin groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Cariti-2002">
<DESCRIPTION>
<P>Comment: It is not clear whether Intention-to-treat analysis was used when participants discontinued treatment or were lost to follow-up. The trial included 150 participants, but the data from only 117 are available.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Derbala-2005">
<DESCRIPTION>
<P>Comment: The number and reasons for participant dropout were clearly specified. Intention-to-treat analysis did not change the estimates for sustained virological response.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Derbala-2006">
<DESCRIPTION>
<P>Comments: Incomplete outcome data were addressed adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Dollinger-2005">
<DESCRIPTION>
<P>Comments: Incomplete outcome data were addressed adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Esmat-2003">
<DESCRIPTION>
<P>Comment: The number of participants lost to follow-up is stated. 67 participants discontinued treatment in peginterferon plus ribavirin group and 69 in interferon plus ribavirin group. Intention-to-treat analysis was employed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-02-13 16:10:19 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Fargion-2004">
<DESCRIPTION>
<P>Comments: No post randomisation dropouts were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Fried-2002">
<DESCRIPTION>
<P>Comments: No postrandomisation dropouts were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hinrichsen-2002">
<DESCRIPTION>
<P>Comment: The trial seems to have addressed incomplete outcome data adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Horsmans-2008">
<DESCRIPTION>
<P>Comment: 78 participants had not commenced treatment; it is not clear whether the trial adhered to the intention-to-treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Izumi-2004">
<DESCRIPTION>
<P>Comments: Incomplete outcome data were addressed adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>Comments: Incomplete outcome data were addressed adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Mangia-2005">
<DESCRIPTION>
<P>Comments: Incomplete outcome data were addressed adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manns-2001">
<DESCRIPTION>
<P>Comment: As prospectively specified in the protocol, all safety and efficacy analyses, except for changes from baseline in histological scores, were based on all participants who received at least one dose of study medication. Participants who were missing HCV RNA values during follow-up were classified as non-responders. Analyses of changes from baseline in histological scores were based on participants who had both a pretreatment and a post-treatment biopsy sample.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Napoli-2005">
<DESCRIPTION>
<P>Comments: Incomplete outcome data were addressed adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nevens-2010">
<DESCRIPTION>
<P>Comments: Incomplete outcome data were addressed adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-PRETTY-2005">
<DESCRIPTION>
<P>Comment: Information was insufficient to permit assessment of whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2007a">
<DESCRIPTION>
<P>Comment: Information was insufficient to permit assessment of whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2007b">
<DESCRIPTION>
<P>Comment: Information was insufficient to permit assessment of whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Roffi-2008">
<DESCRIPTION>
<P>Comments: Incomplete outcome data were addressed adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Scotto-2005">
<DESCRIPTION>
<P>Comments: Incomplete outcome data were addressed adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Shobokshi-2003">
<DESCRIPTION>
<P>Comment: Information was insufficient to permit assessment of whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Sj_x00f6_gren-2007">
<DESCRIPTION>
<P>Comments: Incomplete outcome data were addressed adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Thakeb-2003">
<DESCRIPTION>
<P>Comment: Information was insufficient to permit assessment of whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Tsubota-2005">
<DESCRIPTION>
<P>Comments: Incomplete outcome data were addressed adequately.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Wakil-2006">
<DESCRIPTION>
<P>Comment: Information was insufficient to permit assessment of whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-18 22:34:51 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Al_x002d_Faleh-2004">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-18 00:03:23 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Bruno-2004">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-26 09:15:47 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Cariti-2002">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-08 21:25:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Derbala-2005">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:16:10 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Derbala-2006">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:16:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Dollinger-2005">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:21:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Esmat-2003">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:21:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fargion-2004">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:21:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fried-2002">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:21:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hinrichsen-2002">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:22:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Horsmans-2008">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:22:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Izumi-2004">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:22:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:22:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mangia-2005">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:22:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Manns-2001">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Napoli-2005">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:22:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nevens-2010">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:23:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PRETTY-2005">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:23:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2007a">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:23:15 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Rahman-2007b">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:23:20 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Roffi-2008">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:23:26 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Scotto-2005">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:23:35 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Shobokshi-2003">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-17 23:23:41 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Sj_x00f6_gren-2007">
<DESCRIPTION>
<P>Comment: All clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Thakeb-2003">
<DESCRIPTION>
<P>Comment: It is unclear whether all predefined and clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Tsubota-2005">
<DESCRIPTION>
<P>Comment: It is unclear whether all predefined and clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Wakil-2006">
<DESCRIPTION>
<P>Comment: It is unclear whether all predefined and clinically relevant and reasonably expected outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Al_x002d_Faleh-2004">
<DESCRIPTION>
<P>Conflict of interest bias might be present. The study was supported in part by a grant from Schering-Plough, Saudi Arabia.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Bruno-2004">
<DESCRIPTION>
<P>Comment: Conflict of interest bias might be present. Schering-Plough Italy supplied peginterferon alpha-2b, and the other drugs were provided by the National Health System.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Cariti-2002">
<DESCRIPTION>
<P>Comment: The trial seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:00:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Derbala-2005">
<DESCRIPTION>
<P>Comment: The trial seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:01:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Derbala-2006">
<DESCRIPTION>
<P>Comment: The trial seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Dollinger-2005">
<DESCRIPTION>
<P>Quote: "The study was supported by a grant of Yamanouchi and Essexpharma, Germany".</P>
<P>Comments: The study may contain conflict of interest risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:02:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Esmat-2003">
<DESCRIPTION>
<P>Comments: The trial seem to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:03:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Fargion-2004">
<DESCRIPTION>
<P>Comments: The trial seem to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Fried-2002">
<DESCRIPTION>
<P>The trial was sponsored by Roche. Designed by the sponsor in collaboration with expert hepatologists. Data were collected by the Pegasys International Study Group. Data analysis was performed by the sponsor and the authors of the report; the authors had full access to the data, and the decision to publish was not limited by the sponsor. This trial may contain conflict of interest bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-13 17:04:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hinrichsen-2002">
<DESCRIPTION>
<P>Comment: The trial seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Horsmans-2008">
<DESCRIPTION>
<P>All medication was provided by Schering-Plough.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:06:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Izumi-2004">
<DESCRIPTION>
<P>Comments: The trial seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-06 10:06:51 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2005">
<DESCRIPTION>
<P>Comment: The trial was supported by research grants from Schering-Plough Limited, Taiwan. The study may have conflict of interest bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Mangia-2005">
<DESCRIPTION>
<P>Comment: No conflict of interest statement was provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Manns-2001">
<DESCRIPTION>
<P>Comment: The study may contain conflict of interest bias. The study was supported by research grants from Schering Plough Research Institute, Kenilworth, NJ, and by clinical research centre grants from Massachusetts General Hospital, Scripps Clinic, and University of Florida. Study authors received grants from Schering Corp as part of their participation in current clinical trials. The study was conducted by International Hepatitis Interventional Therapy Group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Napoli-2005">
<DESCRIPTION>
<P>Comment: The study seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Nevens-2010">
<DESCRIPTION>
<P>Comment: The study seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-PRETTY-2005">
<DESCRIPTION>
<P>Comment: It was not possible to assess whether the trial was free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rahman-2007a">
<DESCRIPTION>
<P>Comment: The trial seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Rahman-2007b">
<DESCRIPTION>
<P>Comment: The trial seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Roffi-2008">
<DESCRIPTION>
<P>Comment: The study seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Scotto-2005">
<DESCRIPTION>
<P>Comment: The study seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="UNKNOWN" STUDY_ID="STD-Shobokshi-2003">
<DESCRIPTION>
<P>Comment: The trial may have conflict of interest bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sj_x00f6_gren-2007">
<DESCRIPTION>
<P>Comment: The trial seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Thakeb-2003">
<DESCRIPTION>
<P>Comment: The study seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Tsubota-2005">
<DESCRIPTION>
<P>Comment: The study seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" RESULT="YES" STUDY_ID="STD-Wakil-2006">
<DESCRIPTION>
<P>Comment: The study seems to be free of other sources of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-02-24 10:58:55 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-02-24 10:58:55 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" READONLY="YES">
<TITLE MODIFIED="2009-09-15 20:22:55 +0200" MODIFIED_BY="Grade Profiler">Peginterferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C</TITLE>
<TABLE COLS="7" ROWS="10">
<TR>
<TD COLSPAN="7">
<P>
<B>Peginterferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> patients with chronic hepatitis C.<BR/>
<B>Settings:</B> mainly outpatients.<BR/>
<B>Intervention:</B> peginterferon.<BR/>
<B>Comparison: </B>non-pegylated.</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Non-pegylated<B> </B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Peginterferon </B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Liver-related morbidity plus all-cause mortality</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>Five per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>Six per 1000</B>
<BR/>(two to 17)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>OR 1.14 </B>
<BR/>(0.38 to 3.42)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>1789<BR/>(five studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>1</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Adverse events leading to treatment discontinuation</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>207 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>178 per 1000</B>
<BR/>(141 to 226)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>RR 0.86 </B>
<BR/>(0.68 to 1.09)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>4571<BR/>(15 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
<SUP>2,3</SUP>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P/>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Sustained virological response</B>
</P>
</TD>
<TD>
<P>
<B>386 per 1000</B>
</P>
</TD>
<TD>
<P>
<B>537 per 1000</B>
<BR/>(482 to 602)</P>
</TD>
<TD>
<P>
<B>RR 1.39 </B>
<BR/>(1.25 to 1.56)</P>
</TD>
<TD>
<P>6104<BR/>(27 studies)</P>
</TD>
<TD>
<P>&#8853;&#8861;&#8861;&#8861;<SUP>4,5</SUP>
<BR/>
<B>very low</B>
</P>
</TD>
<TD>
<P>All trials had high risks of bias.</P>
<P>Only an unvalidated surrogate outcome.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g., the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> Confidence interval; <B>RR:</B> Risk ratio; <B>OR:</B> Odds ratio.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence.<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<SUP>1</SUP>Low due to imprecision and indirectness wide confidence interval. The meta-analysis included only nine events.</P>
<P>
<SUP>2</SUP>Low due to imprecision and indirectness.The proportions of observed adverse events differ substantially across trials, and the direction of effect is heterogeneous. However, because the event rate is still relatively low across trials, all of the included trials may be subject to considerable random error, thus explaining the apparent heterogeneity in the direction of estimates.<BR/>
<SUP>3</SUP>The observed treatment effects differ in both direction and magnitude, but most confidence intervals have considerable overlap. Low due to indirectness.</P>
<P>
<SUP>4</SUP>Sustained virological response does not seem to be a valid surrogate marker for assessing hepatitis C virus treatment efficacy of interferon treatment. Very low due to high risk of bias in all trials and imprecision and indirectness due to surrogate<BR/>
<SUP>5</SUP>Only randomised clinical trials were included.<BR/>
<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2010-05-27 22:59:24 +0200" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-02-24 11:01:15 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<COMPARISON ID="CMP-001" MODIFIED="2014-02-24 11:01:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1">
<NAME>Peginterferon plus ribavirin versus non-pegylated interferon plus ribavirin</NAME>
<DICH_OUTCOME CHI2="3.599906649051081" CI_END="3.4227949004455445" CI_START="0.38006968064616753" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.14057028048677" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.5343808762709747" LOG_CI_START="-0.42013677405187627" LOG_EFFECT_SIZE="0.05712205110954925" METHOD="MH" MODIFIED="2014-02-24 11:01:15 +0100" MODIFIED_BY="Dimitrinka Nikolova" NO="1" P_CHI2="0.4628508382154448" P_Q="1.0" P_Z="0.8145318267619118" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="YEAR" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="907" TOTAL_2="882" WEIGHT="100.0" Z="0.23458374574824256">
<NAME>Liver-related morbidity plus all-cause mortality</NAME>
<GROUP_LABEL_1>PEGINF+RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF+RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEG + RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INF + RBV</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.023488767880952" CI_START="0.013244235885636347" EFFECT_SIZE="0.32598309445056967" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9043632489802693" LOG_CI_START="-1.8779730928763316" LOG_EFFECT_SIZE="-0.48680492194803127" MODIFIED="2009-04-01 11:05:24 +0200" MODIFIED_BY="Tahany Awad" ORDER="390" O_E="0.0" SE="1.6343581399935843" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="2.6711265297632885" WEIGHT="25.32304117771374"/>
<DICH_DATA CI_END="16.212320916498346" CI_START="0.06168148318494964" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2098451918427227" LOG_CI_START="-1.2098451918427224" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-04-01 11:05:11 +0200" MODIFIED_BY="Tahany Awad" ORDER="389" O_E="0.0" SE="1.4213381090374029" STUDY_ID="STD-Esmat-2003" TOTAL_1="100" TOTAL_2="100" VAR="2.0202020202020203" WEIGHT="16.565791898990817"/>
<DICH_DATA CI_END="4.101465781568586" CI_START="0.008964856192129998" EFFECT_SIZE="0.19175257731958764" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6129390925935767" LOG_CI_START="-2.0474566726902337" LOG_EFFECT_SIZE="-0.7172587900483285" MODIFIED="2009-04-01 11:04:58 +0200" MODIFIED_BY="Tahany Awad" ORDER="388" O_E="0.0" SE="1.562729641699138" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="2.4421239330451168" WEIGHT="41.40594243975751"/>
<DICH_DATA CI_END="76.78574480868221" CI_START="0.12350126612899952" EFFECT_SIZE="3.0794701986754967" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8852806012090648" LOG_CI_START="-0.9083285900154958" LOG_EFFECT_SIZE="0.4884760055967845" MODIFIED="2009-04-01 11:05:38 +0200" MODIFIED_BY="Tahany Awad" ORDER="391" O_E="0.0" SE="1.640979867513828" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="2.692814925585701" WEIGHT="8.15065029894954"/>
<DICH_DATA CI_END="127.92743628614066" CI_START="0.337338057825861" EFFECT_SIZE="6.569230769230769" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.106963696549389" LOG_CI_START="-0.4719346597850529" LOG_EFFECT_SIZE="0.8175145183821683" MODIFIED="2009-04-01 11:05:51 +0200" MODIFIED_BY="Tahany Awad" ORDER="392" O_E="0.0" SE="1.5148576602635986" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="2.2947937308593045" WEIGHT="8.55457418458838"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="36.61403776867315" CI_END="1.1151787875807107" CI_START="0.6644547999373231" CI_STUDY="95" CI_TOTAL="95" DF="16" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8608053776529789" ESTIMABLE="YES" EVENTS_1="332" EVENTS_2="409" I2="56.30091359743572" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.04734449988210673" LOG_CI_START="-0.17753455694166292" LOG_EFFECT_SIZE="-0.0650950285297781" METHOD="MH" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="0.0023757445948592304" P_Q="1.0" P_Z="0.256505609121779" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="17" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.11128865463125395" TOTALS="YES" TOTAL_1="2692" TOTAL_2="2176" WEIGHT="100.00000000000001" Z="1.134689137289967">
<NAME>Adverse events leading to treatment discontinuation</NAME>
<GROUP_LABEL_1>PEGINF+RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF+RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEGINF+RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INF+RBV</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.328860833262457" CI_START="0.10582372245463406" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.12347950125058388" LOG_CI_START="-0.9754169657951461" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2009-08-31 14:20:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="1550" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.4166666666666667" WEIGHT="3.3050349371579273"/>
<DICH_DATA CI_END="0.9866735375665624" CI_START="0.44350548998087774" EFFECT_SIZE="0.6615097359295812" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="46" LOG_CI_END="-0.005826519353101646" LOG_CI_START="-0.35310099983756726" LOG_EFFECT_SIZE="-0.17946375959533445" MODIFIED="2009-08-31 14:18:58 +0200" MODIFIED_BY="Tahany Awad" ORDER="1551" O_E="0.0" SE="0.20399074887297775" STUDY_ID="STD-Bruno-2004" TOTAL_1="163" TOTAL_2="160" VAR="0.04161222562575827" WEIGHT="11.412038826820572"/>
<DICH_DATA CI_END="71.27082870516693" CI_START="1.3193507499812704" EFFECT_SIZE="9.696969696969697" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="1" LOG_CI_END="1.852911808607375" LOG_CI_START="0.12036026827666237" LOG_EFFECT_SIZE="0.9866360384420185" MODIFIED="2009-08-31 14:15:14 +0200" MODIFIED_BY="Tahany Awad" ORDER="1552" O_E="0.0" SE="1.0177093510587014" STUDY_ID="STD-Cariti-2002" TOTAL_1="99" TOTAL_2="60" VAR="1.0357323232323232" WEIGHT="1.5212544633648368"/>
<DICH_DATA CI_END="4.270009242102193" CI_START="0.3659242665317408" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6304288150225976" LOG_CI_START="-0.4366087890064849" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-08-31 14:26:09 +0200" MODIFIED_BY="Tahany Awad" ORDER="1566" O_E="0.0" SE="0.6267831705280087" STUDY_ID="STD-Derbala-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.39285714285714285" WEIGHT="3.4611233314668786"/>
<DICH_DATA CI_END="1.9423192528417736" CI_START="0.08237574732676249" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.28832061504272793" LOG_CI_START="-1.084200632386803" LOG_EFFECT_SIZE="-0.3979400086720376" MODIFIED="2009-08-31 14:25:33 +0200" MODIFIED_BY="Tahany Awad" ORDER="1553" O_E="0.0" SE="0.8062257748298549" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.6499999999999999" WEIGHT="2.2920488457735533"/>
<DICH_DATA CI_END="1.0313341541319931" CI_START="0.018030083894549468" EFFECT_SIZE="0.13636363636363635" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.013399400281876517" LOG_CI_START="-1.744002252486964" LOG_EFFECT_SIZE="-0.8653014261025438" MODIFIED="2009-08-31 14:08:05 +0200" MODIFIED_BY="Tahany Awad" ORDER="1554" O_E="0.0" SE="1.0323064301148985" STUDY_ID="STD-Dollinger-2005" TOTAL_1="22" TOTAL_2="18" VAR="1.0656565656565657" WEIGHT="1.4825760384339315"/>
<DICH_DATA CI_END="3.703386572816602" CI_START="0.480041103682485" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5685990476364001" LOG_CI_START="-0.31872157441980037" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2009-08-31 14:08:05 +0200" MODIFIED_BY="Tahany Awad" ORDER="1555" O_E="0.0" SE="0.5212165257037296" STUDY_ID="STD-Esmat-2003" TOTAL_1="100" TOTAL_2="100" VAR="0.2716666666666666" WEIGHT="4.556434354363263"/>
<DICH_DATA CI_END="1.1393160812556071" CI_START="0.6750189260054569" EFFECT_SIZE="0.8769606134541652" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="95" LOG_CI_END="0.05664422741676568" LOG_CI_START="-0.17068405036229986" LOG_EFFECT_SIZE="-0.05701991147276709" MODIFIED="2009-08-31 14:08:05 +0200" MODIFIED_BY="Tahany Awad" ORDER="1556" O_E="0.0" SE="0.13353375566054665" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.017831263900810572" WEIGHT="13.513877657185404"/>
<DICH_DATA CI_END="1.1938065652127032" CI_START="0.6163884702653898" EFFECT_SIZE="0.8578161822466615" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="67" LOG_CI_END="0.07693396291870586" LOG_CI_START="-0.2101454934885798" LOG_EFFECT_SIZE="-0.06660576528493696" MODIFIED="2009-08-31 14:22:11 +0200" MODIFIED_BY="Tahany Awad" ORDER="1557" O_E="0.0" SE="0.16863189375986748" STUDY_ID="STD-Horsmans-2008" TOTAL_1="114" TOTAL_2="182" VAR="0.028436715593039237" WEIGHT="12.48814570573018"/>
<DICH_DATA CI_END="5.059848364757751" CI_START="0.2525535758407554" EFFECT_SIZE="1.1304347826086956" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.7041375019513142" LOG_CI_START="-0.5976464780448641" LOG_EFFECT_SIZE="0.05324551195322505" MODIFIED="2009-08-31 14:19:48 +0200" MODIFIED_BY="Tahany Awad" ORDER="1558" O_E="0.0" SE="0.7646743537843825" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="0.584726867335563" WEIGHT="2.50699981117843"/>
<DICH_DATA CI_END="7.4886281895222" CI_START="1.0746525166590457" EFFECT_SIZE="2.836842105263158" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.874402268395638" LOG_CI_START="0.0312680600721815" LOG_EFFECT_SIZE="0.4528351642339098" MODIFIED="2009-08-31 14:21:03 +0200" MODIFIED_BY="Tahany Awad" ORDER="1559" O_E="0.0" SE="0.4952612075508402" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.24528366370471638" WEIGHT="4.893567706800988"/>
<DICH_DATA CI_END="1.9900007752432387" CI_START="0.4942406997833874" EFFECT_SIZE="0.9917355371900827" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="14" LOG_CI_END="0.2988532455975434" LOG_CI_START="-0.3060614941351939" LOG_EFFECT_SIZE="-0.003604124268825242" MODIFIED="2009-08-31 14:20:19 +0200" MODIFIED_BY="Tahany Awad" ORDER="1560" O_E="0.0" SE="0.35532991249526424" STUDY_ID="STD-Mangia-2005" TOTAL_1="121" TOTAL_2="120" VAR="0.12625934671389216" WEIGHT="7.345508159476337"/>
<DICH_DATA CI_END="1.9660084076000937" CI_START="0.532586898135754" EFFECT_SIZE="1.023264540337711" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="13" LOG_CI_END="0.293585370752739" LOG_CI_START="-0.2736095215946614" LOG_EFFECT_SIZE="0.009987924579038776" MODIFIED="2009-08-31 14:08:05 +0200" MODIFIED_BY="Tahany Awad" ORDER="1561" O_E="0.0" SE="0.3331730874248615" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.11100430618421442" WEIGHT="7.849599806251021"/>
<DICH_DATA CI_END="0.6935262841990474" CI_START="0.44021352776320216" EFFECT_SIZE="0.5525392765801973" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="119" LOG_CI_END="-0.15893707479791672" LOG_CI_START="-0.3563366157067045" LOG_EFFECT_SIZE="-0.2576368452523106" MODIFIED="2009-08-31 14:08:05 +0200" MODIFIED_BY="Tahany Awad" ORDER="1562" O_E="0.0" SE="0.11595346747330862" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.013445206619083641" WEIGHT="13.989070527096697"/>
<DICH_DATA CI_END="1.8081714334452272" CI_START="0.22060517016296838" EFFECT_SIZE="0.631578947368421" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.25723960372215654" LOG_CI_START="-0.6563843135325648" LOG_EFFECT_SIZE="-0.19957235490520417" MODIFIED="2009-08-31 14:21:49 +0200" MODIFIED_BY="Tahany Awad" ORDER="1563" O_E="0.0" SE="0.5366672115067519" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="0.2880116959064327" WEIGHT="4.369920486667288"/>
<DICH_DATA CI_END="1.9945684140604976" CI_START="0.18049017394551037" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.2998489372813018" LOG_CI_START="-0.7435464365140146" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2009-08-31 14:08:05 +0200" MODIFIED_BY="Tahany Awad" ORDER="1564" O_E="0.0" SE="0.6128956074577674" STUDY_ID="STD-Scotto-2005" TOTAL_1="26" TOTAL_2="52" VAR="0.3756410256410257" WEIGHT="3.58349645306557"/>
<DICH_DATA CI_END="55.1698914760233" CI_START="0.8881656042643342" EFFECT_SIZE="7.0" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.7417021296635475" LOG_CI_START="-0.051506049635034135" LOG_EFFECT_SIZE="0.8450980400142568" MODIFIED="2009-08-31 14:10:12 +0200" MODIFIED_BY="Tahany Awad" ORDER="1565" O_E="0.0" SE="1.0533393610436332" STUDY_ID="STD-Shobokshi-2003" TOTAL_1="60" TOTAL_2="60" VAR="1.1095238095238096" WEIGHT="1.4293028891671224"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="71.52516562416292" CI_END="1.5593889685670195" CI_START="1.245901989062741" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3938600423500724" ESTIMABLE="YES" EVENTS_1="1673" EVENTS_2="1081" I2="63.64915792489047" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.19295445760851365" LOG_CI_START="0.09548387917433794" LOG_EFFECT_SIZE="0.14421916839142582" METHOD="MH" MODIFIED="2012-09-14 15:41:57 +0200" MODIFIED_BY="Tahany Awad" NO="3" P_CHI2="3.968843961588142E-6" P_Q="1.0" P_Z="6.6317366396289284E-9" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04235474272055203" TOTALS="YES" TOTAL_1="3300" TOTAL_2="2804" WEIGHT="100.0" Z="5.79999381286943">
<NAME>Sustained virological response</NAME>
<GROUP_LABEL_1>PEG INF+RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF+RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INF+RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PEG INF+RBV</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.587460148665582" CI_START="0.8695786101905303" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.4128736696348625" LOG_CI_START="-0.06069115152350007" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-07-09 18:09:08 +0200" MODIFIED_BY="Tahany Awad" ORDER="372" O_E="0.0" SE="0.2781743201320934" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.07738095238095238" WEIGHT="2.7377806584848634"/>
<DICH_DATA CI_END="1.8820793587258766" CI_START="1.0156744853200899" EFFECT_SIZE="1.3825989960959286" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="44" LOG_CI_END="0.27463793170022405" LOG_CI_START="0.006754542711053098" LOG_EFFECT_SIZE="0.1406962372056386" MODIFIED="2009-06-03 15:39:53 +0200" MODIFIED_BY="Tahany Awad" ORDER="373" O_E="0.0" SE="0.15735602873640067" STUDY_ID="STD-Bruno-2004" TOTAL_1="163" TOTAL_2="148" VAR="0.024760919779690957" WEIGHT="4.884255894485923"/>
<DICH_DATA CI_END="3.5357884851784527" CI_START="1.4846729778611794" EFFECT_SIZE="2.291176470588235" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="17" LOG_CI_END="0.5484862771364655" LOG_CI_START="0.17163080412415313" LOG_EFFECT_SIZE="0.3600585406303093" MODIFIED="2009-07-09 12:38:08 +0200" MODIFIED_BY="Tahany Awad" ORDER="136" O_E="0.0" SE="0.22136677031210955" STUDY_ID="STD-Cariti-2002" TOTAL_1="60" TOTAL_2="57" VAR="0.04900324699841427" WEIGHT="3.588192682298972"/>
<DICH_DATA CI_END="2.7902971569505266" CI_START="0.5599762004229086" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.44565045658963615" LOG_CI_START="-0.2518304305735233" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-07-09 12:38:09 +0200" MODIFIED_BY="Tahany Awad" ORDER="137" O_E="0.0" SE="0.4097037257057139" STUDY_ID="STD-Derbala-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.16785714285714284" WEIGHT="1.5594269052782943"/>
<DICH_DATA CI_END="5.180388604362314" CI_START="1.489473082428314" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" LOG_CI_END="0.7143623393591298" LOG_CI_START="0.1730326591062955" LOG_EFFECT_SIZE="0.44369749923271273" MODIFIED="2009-07-09 12:21:50 +0200" MODIFIED_BY="Tahany Awad" ORDER="45" O_E="0.0" SE="0.3179797338056486" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.10111111111111112" WEIGHT="2.284934438572249"/>
<DICH_DATA CI_END="3.2554443304763296" CI_START="0.3212990204096413" EFFECT_SIZE="1.0227272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5126102731205879" LOG_CI_START="-0.4930905985422754" LOG_EFFECT_SIZE="0.00975983728915624" MODIFIED="2009-07-07 17:39:32 +0200" MODIFIED_BY="Tahany Awad" ORDER="42" O_E="0.0" SE="0.5907536703143696" STUDY_ID="STD-Dollinger-2005" TOTAL_1="22" TOTAL_2="18" VAR="0.34898989898989896" WEIGHT="0.8376505904012875"/>
<DICH_DATA CI_END="1.6490129785229268" CI_START="0.850420578189295" EFFECT_SIZE="1.1842105263157894" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="38" LOG_CI_END="0.21722407376380887" LOG_CI_START="-0.07036623944674189" LOG_EFFECT_SIZE="0.07342891715853349" MODIFIED="2009-07-09 18:09:09 +0200" MODIFIED_BY="Tahany Awad" ORDER="374" O_E="0.0" SE="0.16893197357488735" STUDY_ID="STD-Esmat-2003" TOTAL_1="100" TOTAL_2="100" VAR="0.02853801169590643" WEIGHT="4.624027841455053"/>
<DICH_DATA CI_END="2.1462413599066443" CI_START="0.7112332211862739" EFFECT_SIZE="1.2355072463768115" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.3316785598393653" LOG_CI_START="-0.14798796598480524" LOG_EFFECT_SIZE="0.09184529692728" MODIFIED="2009-07-09 12:38:10 +0200" MODIFIED_BY="Tahany Awad" ORDER="375" O_E="0.0" SE="0.2817584916567142" STUDY_ID="STD-Fargion-2004" TOTAL_1="92" TOTAL_2="93" VAR="0.07938784762066668" WEIGHT="2.6926490496083364"/>
<DICH_DATA CI_END="1.4477692368960238" CI_START="1.111778062982932" EFFECT_SIZE="1.2686993646418125" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="197" LOG_CI_END="0.16069934423037288" LOG_CI_START="0.04601810051792744" LOG_EFFECT_SIZE="0.10335872237415017" MODIFIED="2009-06-03 16:52:25 +0200" MODIFIED_BY="Tahany Awad" ORDER="376" O_E="0.0" SE="0.06736433023800226" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.004537952988414626" WEIGHT="6.990642470495825"/>
<DICH_DATA CI_END="1.5453227913002832" CI_START="0.770119130661838" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.18901920986974008" LOG_CI_START="-0.11344208809094057" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2009-07-09 18:09:10 +0200" MODIFIED_BY="Tahany Awad" ORDER="377" O_E="0.0" SE="0.1776672636296754" STUDY_ID="STD-Hinrichsen-2002" TOTAL_1="36" TOTAL_2="36" VAR="0.031565656565656575" WEIGHT="4.4346360861757335"/>
<DICH_DATA CI_END="1.4710974778935566" CI_START="0.8843842405219245" EFFECT_SIZE="1.1406206318143697" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="73" LOG_CI_END="0.16764145091153848" LOG_CI_START="-0.05335900502971767" LOG_EFFECT_SIZE="0.057141222940910424" MODIFIED="2009-06-04 16:08:56 +0200" MODIFIED_BY="Tahany Awad" ORDER="43" O_E="0.0" SE="0.1298167617897941" STUDY_ID="STD-Horsmans-2008" TOTAL_1="98" TOTAL_2="160" VAR="0.016852391641588145" WEIGHT="5.536665027124785"/>
<DICH_DATA CI_END="2.965569021857373" CI_START="0.6732913166880276" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4721080364330698" LOG_CI_START="-0.17179698651050676" LOG_EFFECT_SIZE="0.1501555249612815" MODIFIED="2009-06-03 20:33:38 +0200" MODIFIED_BY="Tahany Awad" ORDER="378" O_E="0.0" SE="0.37823299785832587" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="0.14306020066889633" WEIGHT="1.767980855192466"/>
<DICH_DATA CI_END="1.32831790191945" CI_START="0.83714450752687" EFFECT_SIZE="1.0545112781954886" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="49" LOG_CI_END="0.12330202573004048" LOG_CI_START="-0.07719956780781415" LOG_EFFECT_SIZE="0.023051228961113182" MODIFIED="2009-06-03 20:43:53 +0200" MODIFIED_BY="Tahany Awad" ORDER="379" O_E="0.0" SE="0.11777562854303061" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.013871098678705927" WEIGHT="5.830238588185288"/>
<DICH_DATA CI_END="2.603101809315667" CI_START="1.47378725784399" EFFECT_SIZE="1.9586776859504131" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="40" LOG_CI_END="0.4154911540329175" LOG_CI_START="0.1684347973543901" LOG_EFFECT_SIZE="0.29196297569365376" MODIFIED="2009-07-09 12:38:12 +0200" MODIFIED_BY="Tahany Awad" ORDER="380" O_E="0.0" SE="0.14512212686165601" STUDY_ID="STD-Mangia-2005" TOTAL_1="121" TOTAL_2="120" VAR="0.021060431704850578" WEIGHT="5.169268604074464"/>
<DICH_DATA CI_END="1.213964321130765" CI_START="0.9715225770566696" EFFECT_SIZE="1.0859989621172808" ESTIMABLE="YES" EVENTS_1="518" EVENTS_2="235" LOG_CI_END="0.08420592284819177" LOG_CI_START="-0.012547102447421674" LOG_EFFECT_SIZE="0.035829410200385034" MODIFIED="2009-06-04 15:34:20 +0200" MODIFIED_BY="Tahany Awad" ORDER="382" O_E="0.0" SE="0.05683320599384272" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.00323001330353856" WEIGHT="7.1912213373676686"/>
<DICH_DATA CI_END="2.9224114694732757" CI_START="1.0479359364655019" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.4657413636656654" LOG_CI_START="0.02033473370692358" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2009-07-07 17:39:35 +0200" MODIFIED_BY="Tahany Awad" ORDER="383" O_E="0.0" SE="0.26163405923614175" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.06845238095238093" WEIGHT="2.9583844369675147"/>
<DICH_DATA CI_END="2.465187633311933" CI_START="1.4892241124860108" EFFECT_SIZE="1.9160419790104948" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="58" LOG_CI_END="0.3918499804127436" LOG_CI_START="0.17296005939892112" LOG_EFFECT_SIZE="0.2824050199058324" MODIFIED="2009-07-09 12:38:19 +0200" MODIFIED_BY="Tahany Awad" ORDER="384" O_E="0.0" SE="0.12857702312610314" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.016532050875970462" WEIGHT="5.566784165991645"/>
<DICH_DATA CI_END="2.7755764012248623" CI_START="0.7696039905850021" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.44335318633323517" LOG_CI_START="-0.11373268904125085" LOG_EFFECT_SIZE="0.16481024864599217" MODIFIED="2009-07-09 12:38:21 +0200" MODIFIED_BY="Tahany Awad" ORDER="381" O_E="0.0" SE="0.32723500081453055" STUDY_ID="STD-PRETTY-2005" TOTAL_1="89" TOTAL_2="89" VAR="0.1070827457580858" WEIGHT="2.193626736613686"/>
<DICH_DATA CI_END="1.6137622339028166" CI_START="0.8924743107464483" EFFECT_SIZE="1.2001005530417295" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="51" LOG_CI_END="0.20783954766570586" LOG_CI_START="-0.04940427590106791" LOG_EFFECT_SIZE="0.07921763588231896" MODIFIED="2009-07-22 12:22:52 +0200" MODIFIED_BY="Tahany Awad" ORDER="82" O_E="0.0" SE="0.15110629534058637" STUDY_ID="STD-Rahman-2007a" TOTAL_1="156" TOTAL_2="154" VAR="0.022833112491556513" WEIGHT="5.02869850699198"/>
<DICH_DATA CI_END="1.2131071622648262" CI_START="0.8569730573893487" EFFECT_SIZE="1.0196078431372548" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="85" LOG_CI_END="0.08389916683905466" LOG_CI_START="-0.06703283176532913" LOG_EFFECT_SIZE="0.008433167536862764" MODIFIED="2009-07-22 12:21:36 +0200" MODIFIED_BY="Tahany Awad" ORDER="83" O_E="0.0" SE="0.08865820310565761" STUDY_ID="STD-Rahman-2007b" TOTAL_1="132" TOTAL_2="130" VAR="0.007860276977924036" WEIGHT="6.5281278818076025"/>
<DICH_DATA CI_END="2.274740625322729" CI_START="0.7610986148420958" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.3569318838885388" LOG_CI_START="-0.11855906845012143" LOG_EFFECT_SIZE="0.11918640771920867" MODIFIED="2009-07-09 18:09:12 +0200" MODIFIED_BY="Tahany Awad" ORDER="47" O_E="0.0" SE="0.2793057391219034" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="0.07801169590643274" WEIGHT="2.7234341558864434"/>
<DICH_DATA CI_END="2.3142093919110254" CI_START="0.8091645396612035" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.3644026517796553" LOG_CI_START="-0.0919631577436773" LOG_EFFECT_SIZE="0.136219747017989" MODIFIED="2009-06-04 17:15:42 +0200" MODIFIED_BY="Tahany Awad" ORDER="385" O_E="0.0" SE="0.2680715355611962" STUDY_ID="STD-Scotto-2005" TOTAL_1="26" TOTAL_2="52" VAR="0.07186234817813765" WEIGHT="2.870061455775532"/>
<DICH_DATA CI_END="2.6453240320969122" CI_START="1.0500708964473708" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.42247887740424933" LOG_CI_START="0.021218621828463496" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2009-07-09 12:38:22 +0200" MODIFIED_BY="Tahany Awad" ORDER="386" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Shobokshi-2003" TOTAL_1="60" TOTAL_2="60" VAR="0.05555555555555555" WEIGHT="3.348065279657441"/>
<DICH_DATA CI_END="2.138945474742073" CI_START="0.595420689890192" EFFECT_SIZE="1.128526645768025" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3301997138279745" LOG_CI_START="-0.22517607840776227" LOG_EFFECT_SIZE="0.052511817710106094" MODIFIED="2009-07-07 17:39:39 +0200" MODIFIED_BY="Tahany Awad" ORDER="97" O_E="0.0" SE="0.32623048951378114" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="29" TOTAL_2="30" VAR="0.10642633228840126" WEIGHT="2.2033048904869976"/>
<DICH_DATA CI_END="8.136576897762474" CI_START="2.1715317787493897" EFFECT_SIZE="4.203431372549019" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" LOG_CI_END="0.9104417332569528" LOG_CI_START="0.336766189320866" LOG_EFFECT_SIZE="0.6236039612889093" MODIFIED="2009-08-20 13:38:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="44" O_E="0.0" SE="0.3369798542477986" STUDY_ID="STD-Thakeb-2003" TOTAL_1="51" TOTAL_2="49" VAR="0.11355542216886758" WEIGHT="2.102557395225906"/>
<DICH_DATA CI_END="2.128278660395544" CI_START="0.5393838715932618" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.328028490516341" LOG_CI_START="-0.2681020437614546" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2009-06-04 17:40:30 +0200" MODIFIED_BY="Tahany Awad" ORDER="387" O_E="0.0" SE="0.35017002672851316" STUDY_ID="STD-Tsubota-2005" TOTAL_1="28" TOTAL_2="20" VAR="0.12261904761904761" WEIGHT="1.9870433327884411"/>
<DICH_DATA CI_END="3.9220926091785993" CI_START="1.1603782889930911" EFFECT_SIZE="2.1333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.593517844094743" LOG_CI_START="0.06459959443370657" LOG_EFFECT_SIZE="0.32905871926422475" MODIFIED="2009-06-22 14:23:03 +0200" MODIFIED_BY="Tahany Awad" ORDER="465" O_E="0.0" SE="0.3106891980384542" STUDY_ID="STD-Wakil-2006" TOTAL_1="18" TOTAL_2="32" VAR="0.0965277777777778" WEIGHT="2.3603407326055965"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="Tahany Awad" NO="2">
<NAME>Adverse events</NAME>
<DICH_OUTCOME CHI2="78.27897923430571" CI_END="1.6486146652868325" CI_START="1.3339054813211524" CI_STUDY="95" CI_TOTAL="95" DF="35" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4829349745058085" ESTIMABLE="YES" EVENTS_1="791" EVENTS_2="431" I2="55.28812416518932" I2_Q="94.5951823068564" ID="CMP-002.01" LOG_CI_END="0.21711915880067117" LOG_CI_START="0.12512505717051423" LOG_EFFECT_SIZE="0.1711221079855927" METHOD="MH" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="3.741617467500902E-5" P_Q="9.219065510990276E-9" P_Z="3.062423789696111E-13" Q="37.004023327875494" RANDOM="NO" SCALE="38.19" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5517" TOTAL_2="4387" WEIGHT="300.0" Z="7.291623325128258">
<NAME>Haematological effects</NAME>
<GROUP_LABEL_1>PEG + RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF+ RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEG + RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INF + RBV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.27379424464856" CI_END="1.2732933676902305" CI_START="0.9773693169194976" DF="12" EFFECT_SIZE="1.1155616831970911" ESTIMABLE="YES" EVENTS_1="394" EVENTS_2="291" I2="26.26181811321564" ID="CMP-002.01.01" LOG_CI_END="0.10492847693760313" LOG_CI_START="-0.009941299134033788" LOG_EFFECT_SIZE="0.04749358890178466" MODIFIED="2013-01-22 00:38:57 +0100" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="0.17901529585116405" P_Z="0.10507825520100326" STUDIES="13" TAU2="0.0" TOTAL_1="2202" TOTAL_2="1652" WEIGHT="100.00000000000001" Z="1.6207174232845654">
<NAME>Anaemia</NAME>
<DICH_DATA CI_END="1.755544598182172" CI_START="0.957186783822807" EFFECT_SIZE="1.2962962962962963" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.24441186683947572" LOG_CI_START="-0.019003306456899054" LOG_EFFECT_SIZE="0.11270428019128832" MODIFIED="2009-08-31 14:57:07 +0200" MODIFIED_BY="Tahany Awad" ORDER="1567" O_E="0.0" SE="0.15473137672042778" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.02394179894179894" WEIGHT="8.542997649171701"/>
<DICH_DATA CI_END="2.0215547644461873" CI_START="0.9261195010732345" EFFECT_SIZE="1.3682840676705708" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="33" LOG_CI_END="0.3056855109799205" LOG_CI_START="-0.03333297086861335" LOG_EFFECT_SIZE="0.13617627005565358" MODIFIED="2009-08-31 14:57:07 +0200" MODIFIED_BY="Tahany Awad" ORDER="1568" O_E="0.0" SE="0.1991411344063791" STUDY_ID="STD-Bruno-2004" TOTAL_1="163" TOTAL_2="160" VAR="0.03965719141265954" WEIGHT="10.538420904688587"/>
<DICH_DATA CI_END="3.6851354381687162" CI_START="0.2713604470659396" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5664534539232672" LOG_CI_START="-0.5664534539232672" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-31 15:26:17 +0200" MODIFIED_BY="Tahany Awad" ORDER="1690" O_E="0.0" SE="0.6654751256486924" STUDY_ID="STD-Derbala-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.44285714285714284" WEIGHT="1.2656292813587706"/>
<DICH_DATA CI_END="2.076837721370986" CI_START="0.5650952402464904" EFFECT_SIZE="1.0833333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.31740256323395694" LOG_CI_START="-0.24787835071553313" LOG_EFFECT_SIZE="0.03476210625921191" MODIFIED="2009-08-31 15:45:46 +0200" MODIFIED_BY="Tahany Awad" ORDER="2033" O_E="0.0" SE="0.33204880703958306" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.11025641025641025" WEIGHT="3.796887844076312"/>
<DICH_DATA CI_END="4.279214572856113" CI_START="1.2469811712289252" EFFECT_SIZE="2.31" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="12" LOG_CI_END="0.631364063878412" LOG_CI_START="0.09585989590587662" LOG_EFFECT_SIZE="0.36361197989214433" MODIFIED="2009-08-31 14:57:07 +0200" MODIFIED_BY="Tahany Awad" ORDER="1569" O_E="0.0" SE="0.3145577990554501" STUDY_ID="STD-Esmat-2003" TOTAL_1="100" TOTAL_2="99" VAR="0.09894660894660895" WEIGHT="3.815967682488756"/>
<DICH_DATA CI_END="1.3439690177221952" CI_START="0.8228340638682072" EFFECT_SIZE="1.0516004415011038" ESTIMABLE="YES" EVENTS_1="103" EVENTS_2="96" LOG_CI_END="0.12838925712005417" LOG_CI_START="-0.08468773758527061" LOG_EFFECT_SIZE="0.021850759767391748" MODIFIED="2009-08-31 14:57:07 +0200" MODIFIED_BY="Tahany Awad" ORDER="1570" O_E="0.0" SE="0.12516248143804232" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.015665646759728286" WEIGHT="30.679869669860768"/>
<DICH_DATA CI_END="17.065106640316344" CI_START="0.07488279005022852" EFFECT_SIZE="1.1304347826086956" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.2321090065411875" LOG_CI_START="-1.125617982634737" LOG_EFFECT_SIZE="0.05324551195322505" MODIFIED="2009-08-31 14:57:07 +0200" MODIFIED_BY="Tahany Awad" ORDER="1571" O_E="0.0" SE="1.3849405043787608" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="1.9180602006688963" WEIGHT="0.2970354435842013"/>
<DICH_DATA CI_END="2.438571412486936" CI_START="0.8782546811432665" EFFECT_SIZE="1.463450292397661" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="18" LOG_CI_END="0.3871354782359282" LOG_CI_START="-0.05637952671752331" LOG_EFFECT_SIZE="0.16537797575920243" MODIFIED="2009-08-31 14:57:07 +0200" MODIFIED_BY="Tahany Awad" ORDER="1572" O_E="0.0" SE="0.26052290934433947" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.06787218629323892" WEIGHT="5.658107375486269"/>
<DICH_DATA CI_END="4.712180139139888" CI_START="0.5343303370225955" EFFECT_SIZE="1.5867768595041323" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.6732218844825765" LOG_CI_START="-0.27219016770837734" LOG_EFFECT_SIZE="0.20051585838709954" MODIFIED="2009-08-31 14:57:07 +0200" MODIFIED_BY="Tahany Awad" ORDER="1573" O_E="0.0" SE="0.5553397193221005" STUDY_ID="STD-Mangia-2005" TOTAL_1="121" TOTAL_2="120" VAR="0.30840220385674927" WEIGHT="1.5886010689254277"/>
<DICH_DATA CI_END="1.0743040126465966" CI_START="0.605016846303763" EFFECT_SIZE="0.8062084257206208" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="66" LOG_CI_END="0.031127197873443976" LOG_CI_START="-0.21823253252950542" LOG_EFFECT_SIZE="-0.09355266732803072" MODIFIED="2009-08-31 14:57:07 +0200" MODIFIED_BY="Tahany Awad" ORDER="1574" O_E="0.0" SE="0.1464751399892653" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.021454966634874867" WEIGHT="27.98033362219635"/>
<DICH_DATA CI_END="8.383428283463806" CI_START="0.2683866222650336" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9234216534894845" LOG_CI_START="-0.5712391353781221" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-08-31 15:50:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="1575" O_E="0.0" SE="0.8779711460710615" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.7708333333333333" WEIGHT="0.6328146406793853"/>
<DICH_DATA CI_END="2.994633116961709" CI_START="0.6116431344339862" EFFECT_SIZE="1.3533834586466165" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="7" LOG_CI_END="0.4763436230395212" LOG_CI_START="-0.2135018947670807" LOG_EFFECT_SIZE="0.13142086413622026" MODIFIED="2009-08-31 15:57:30 +0200" MODIFIED_BY="Tahany Awad" ORDER="2037" O_E="0.0" SE="0.4052186719499842" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="0.1642021720969089" WEIGHT="2.714978942269621"/>
<DICH_DATA CI_END="1.5327265729660113" CI_START="0.17455079672374207" EFFECT_SIZE="0.5172413793103449" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="8" LOG_CI_END="0.1854646868548305" LOG_CI_START="-0.7580781645413801" LOG_EFFECT_SIZE="-0.28630673884327484" MODIFIED="2009-08-31 16:17:09 +0200" MODIFIED_BY="Tahany Awad" ORDER="2044" O_E="0.0" SE="0.5542417415225751" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="29" TOTAL_2="30" VAR="0.307183908045977" WEIGHT="2.488355875213854"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="23.5521061132164" CI_END="2.6116055216175558" CI_START="1.762306585740015" DF="12" EFFECT_SIZE="2.145332051245589" ESTIMABLE="YES" EVENTS_1="332" EVENTS_2="117" I2="49.04914260187487" ID="CMP-002.01.02" LOG_CI_END="0.41690757814559026" LOG_CI_START="0.24608146418535295" LOG_EFFECT_SIZE="0.3314945211654716" MODIFIED="2009-09-14 10:10:36 +0200" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="0.023388122206877138" P_Z="2.8103477295372088E-14" STUDIES="13" TAU2="0.0" TOTAL_1="2202" TOTAL_2="1653" WEIGHT="100.0" Z="7.606768163185027">
<NAME>Neutropenia</NAME>
<DICH_DATA CI_END="4.981310590503257" CI_START="0.4516883577365299" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.6973436213421815" LOG_CI_START="-0.3451611032308191" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-08-31 14:58:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="1576" O_E="0.0" SE="0.6123724356957945" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.375" WEIGHT="3.0324722417551375"/>
<DICH_DATA CI_END="3.982341232824634" CI_START="0.7409730003874966" EFFECT_SIZE="1.7177914110429449" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.6001384704536771" LOG_CI_START="-0.13019761657715428" LOG_EFFECT_SIZE="0.23497042693826142" MODIFIED="2009-08-31 14:58:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="1577" O_E="0.0" SE="0.42900303274384677" STUDY_ID="STD-Bruno-2004" TOTAL_1="163" TOTAL_2="160" VAR="0.18404360210341805" WEIGHT="6.121275237227089"/>
<DICH_DATA CI_END="6.445158746541576" CI_START="0.43098671219980617" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.809233618647991" LOG_CI_START="-0.3655361194152783" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2009-08-31 15:30:32 +0200" MODIFIED_BY="Tahany Awad" ORDER="1691" O_E="0.0" SE="0.6900655593423543" STUDY_ID="STD-Derbala-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.47619047619047616" WEIGHT="2.2743541813163533"/>
<DICH_DATA CI_END="1.7150491773009116" CI_START="0.7122866588128807" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="19" LOG_CI_END="0.23427657751244324" LOG_CI_START="-0.14734518995026258" LOG_EFFECT_SIZE="0.043465693781090345" MODIFIED="2009-08-31 15:46:06 +0200" MODIFIED_BY="Tahany Awad" ORDER="2034" O_E="0.0" SE="0.2241665152658087" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.05025062656641604" WEIGHT="14.404243148336903"/>
<DICH_DATA CI_END="3.3463886208508744" CI_START="0.2988296080643896" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.5245763747885444" LOG_CI_START="-0.5245763747885444" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-31 14:58:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="1578" O_E="0.0" SE="0.6162775184914503" STUDY_ID="STD-Esmat-2003" TOTAL_1="99" TOTAL_2="99" VAR="0.3797979797979798" WEIGHT="3.790590302193922"/>
<DICH_DATA CI_END="5.786021378703327" CI_START="2.499498919836507" EFFECT_SIZE="3.8029139072847684" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="25" LOG_CI_END="0.762380033984576" LOG_CI_START="0.3978529534074144" LOG_EFFECT_SIZE="0.5801164936959952" MODIFIED="2009-08-31 14:58:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="1579" O_E="0.0" SE="0.2141250115691752" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.04584952057949942" WEIGHT="19.14311490405626"/>
<DICH_DATA CI_END="8.777517355740464" CI_START="0.01602104493795524" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.94337169686651" LOG_CI_START="-1.795309161411072" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2009-08-31 14:58:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="1580" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="1.0702843206194603"/>
<DICH_DATA CI_END="8.866417991126994" CI_START="1.338332111483168" EFFECT_SIZE="3.444736842105263" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.9477482014682662" LOG_CI_START="0.1265638983996251" LOG_EFFECT_SIZE="0.5371560499339456" MODIFIED="2009-08-31 14:58:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="1581" O_E="0.0" SE="0.4823677245503783" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.23267862168790965" WEIGHT="3.7658152021795828"/>
<DICH_DATA CI_END="9.72971884267666" CI_START="0.7188345209175901" EFFECT_SIZE="2.644628099173554" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9881002907474601" LOG_CI_START="-0.14337107474054822" LOG_EFFECT_SIZE="0.42236460800345593" MODIFIED="2009-08-31 14:58:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="1582" O_E="0.0" SE="0.664631880961245" STUDY_ID="STD-Mangia-2005" TOTAL_1="121" TOTAL_2="120" VAR="0.44173553719008257" WEIGHT="2.2837913355956743"/>
<DICH_DATA CI_END="2.4597495931709537" CI_START="1.2612355986790853" EFFECT_SIZE="1.761341463414634" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="40" LOG_CI_END="0.39089089741257266" LOG_CI_START="0.10079622031540261" LOG_EFFECT_SIZE="0.24584355886398768" MODIFIED="2009-08-31 14:58:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="1583" O_E="0.0" SE="0.1704030493186887" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.02903719921710745" WEIGHT="40.63116402351655"/>
<DICH_DATA CI_END="7.312180366174348" CI_START="0.5470324581302356" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8640468953992082" LOG_CI_START="-0.2619869040712458" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2009-08-31 15:51:02 +0200" MODIFIED_BY="Tahany Awad" ORDER="1584" O_E="0.0" SE="0.6614378277661477" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.4375" WEIGHT="2.2743541813163533"/>
<DICH_DATA CI_END="64.59535547231174" CI_START="0.1575020377938322" EFFECT_SIZE="3.189655172413793" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8102012925266522" LOG_CI_START="-0.8027138228464988" LOG_EFFECT_SIZE="0.5037437348400765" MODIFIED="2009-08-31 15:57:58 +0200" MODIFIED_BY="Tahany Awad" ORDER="2038" O_E="0.0" SE="1.534839272908609" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="2.355731593662628" WEIGHT="0.46285102637315256"/>
<DICH_DATA CI_END="62.151490235474135" CI_START="1.0995356268830494" EFFECT_SIZE="8.266666666666667" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.7934515463852898" LOG_CI_START="0.04120930582781786" LOG_EFFECT_SIZE="0.9173304261065539" MODIFIED="2009-08-31 14:58:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="1585" O_E="0.0" SE="1.029275765842438" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="30" TOTAL_2="31" VAR="1.0594086021505376" WEIGHT="0.7456898955135584"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.111282608491159" CI_END="4.106715264822647" CI_START="1.6817579041798507" DF="9" EFFECT_SIZE="2.6280222329408733" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="23" I2="31.35683007723898" ID="CMP-002.01.03" LOG_CI_END="0.6134945925047078" LOG_CI_START="0.22576347752244869" LOG_EFFECT_SIZE="0.41962903501357823" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NO="3" P_CHI2="0.1576352219662731" P_Z="2.2112910089684584E-5" STUDIES="10" TAU2="0.0" TOTAL_1="1113" TOTAL_2="1082" WEIGHT="99.99999999999999" Z="4.242413176108102">
<NAME>Thrombocytopenia</NAME>
<DICH_DATA CI_END="5.6416496128421665" CI_START="0.31511665909399916" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7514061098352028" LOG_CI_START="-0.501528636618603" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2009-08-31 14:58:37 +0200" MODIFIED_BY="Tahany Awad" ORDER="1586" O_E="0.0" SE="0.7359800721939871" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.5416666666666665" WEIGHT="11.955456309692948"/>
<DICH_DATA CI_END="2.6421210976840315" CI_START="0.09117001918754336" EFFECT_SIZE="0.49079754601226994" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.4219527189752111" LOG_CI_START="-1.0401479537992395" LOG_EFFECT_SIZE="-0.30909761741201425" MODIFIED="2009-08-31 14:58:37 +0200" MODIFIED_BY="Tahany Awad" ORDER="1587" O_E="0.0" SE="0.8588451727027676" STUDY_ID="STD-Bruno-2004" TOTAL_1="163" TOTAL_2="160" VAR="0.7376150306748467" WEIGHT="16.08866359942168"/>
<DICH_DATA CI_END="4.038645960707643" CI_START="0.009904309609993965" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6062357833382839" LOG_CI_START="-2.0041757920103214" LOG_EFFECT_SIZE="-0.6989700043360187" MODIFIED="2009-08-31 15:46:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="2035" O_E="0.0" SE="1.5333686811054679" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="2.351219512195122" WEIGHT="9.962880258077456"/>
<DICH_DATA CI_END="10.647390071989383" CI_START="0.8284565457224657" EFFECT_SIZE="2.97" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="1.0272431649350453" LOG_CI_START="-0.08173026630062062" LOG_EFFECT_SIZE="0.4727564493172124" MODIFIED="2009-08-31 15:50:57 +0200" MODIFIED_BY="Tahany Awad" ORDER="1588" O_E="0.0" SE="0.6514164830148484" STUDY_ID="STD-Esmat-2003" TOTAL_1="100" TOTAL_2="99" VAR="0.4243434343434343" WEIGHT="12.015533979590904"/>
<DICH_DATA CI_END="145.43953935615338" CI_START="2.6420865314751216" EFFECT_SIZE="19.602649006622517" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="1" LOG_CI_END="2.1626824903594826" LOG_CI_START="0.42194703717205584" LOG_EFFECT_SIZE="1.2923147637657693" MODIFIED="2009-08-31 14:59:14 +0200" MODIFIED_BY="Tahany Awad" ORDER="1593" O_E="0.0" SE="1.0225166219817572" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="1.045540242228984" WEIGHT="4.02513690694233"/>
<DICH_DATA CI_END="78.99765620166416" CI_START="0.14418940444159714" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8976142063058348" LOG_CI_START="-0.8410666519717473" LOG_EFFECT_SIZE="0.5282737771670437" MODIFIED="2009-08-31 14:59:14 +0200" MODIFIED_BY="Tahany Awad" ORDER="1589" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="1.8753656956381095"/>
<DICH_DATA CI_END="5.395423468655351" CI_START="1.1890736260450236" EFFECT_SIZE="2.5328947368421053" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="8" LOG_CI_END="0.7320255366709862" LOG_CI_START="0.07520874645646998" LOG_EFFECT_SIZE="0.40361714156372813" MODIFIED="2009-08-31 14:59:14 +0200" MODIFIED_BY="Tahany Awad" ORDER="1590" O_E="0.0" SE="0.3858174338675546" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.1488550922761449" WEIGHT="31.67284285966585"/>
<DICH_DATA CI_END="132.97714812896132" CI_START="0.36246839487416016" EFFECT_SIZE="6.942622950819672" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.1237770146949604" LOG_CI_START="-0.4407298553830433" LOG_EFFECT_SIZE="0.8415235796559587" MODIFIED="2009-08-31 14:59:14 +0200" MODIFIED_BY="Tahany Awad" ORDER="1591" O_E="0.0" SE="1.506404029997561" STUDY_ID="STD-Mangia-2005" TOTAL_1="121" TOTAL_2="120" VAR="2.2692531015928927" WEIGHT="2.000775953062469"/>
<DICH_DATA CI_END="6.670714447920194" CI_START="0.14990898018604015" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8241723502842975" LOG_CI_START="-0.8241723502842975" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-31 14:59:14 +0200" MODIFIED_BY="Tahany Awad" ORDER="1592" O_E="0.0" SE="0.9682458365518543" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.9375" WEIGHT="7.970304206461965"/>
<DICH_DATA CI_END="103.56435381087164" CI_START="0.31828940337380157" EFFECT_SIZE="5.741379310344827" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.0152102997416987" LOG_CI_START="-0.4971778198549338" LOG_EFFECT_SIZE="0.7590162399433825" MODIFIED="2009-08-31 15:58:42 +0200" MODIFIED_BY="Tahany Awad" ORDER="2039" O_E="0.0" SE="1.4757892179728278" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="2.1779538158848504" WEIGHT="2.433040231446284"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="104.32651814050557" CI_END="1.0684737916876448" CI_START="1.0018917569321941" CI_STUDY="95" CI_TOTAL="95" DF="44" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0346473236760136" ESTIMABLE="YES" EVENTS_1="5425" EVENTS_2="3538" I2="57.82472109273178" I2_Q="41.423930091446586" ID="CMP-002.02" LOG_CI_END="0.02876387393571825" LOG_CI_START="8.208034609913613E-4" LOG_EFFECT_SIZE="0.014792338698354831" METHOD="MH" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="8.267268785111526E-7" P_Q="0.10220613441316062" P_Z="0.03797648301034107" Q="11.950272544621235" RANDOM="NO" SCALE="37.27" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="13792" TOTAL_2="9454" WEIGHT="800.0" Z="2.075108468993469">
<NAME>Fatigue and flu-like symptoms</NAME>
<GROUP_LABEL_1>PEG + RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF + RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEG+RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INF + RBV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.3012562860163" CI_END="1.073313426581178" CI_START="0.9566401760424404" DF="10" EFFECT_SIZE="1.0132989417508207" ESTIMABLE="YES" EVENTS_1="1177" EVENTS_2="847" I2="0.0" ID="CMP-002.02.01" LOG_CI_END="0.030726562187858245" LOG_CI_START="-0.01925138400435937" LOG_EFFECT_SIZE="0.005737589091749457" MODIFIED="2009-09-14 10:11:21 +0200" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="0.87016692890793" P_Z="0.6526980319522369" STUDIES="11" TAU2="0.0" TOTAL_1="2062" TOTAL_2="1546" WEIGHT="100.00000000000001" Z="0.45001721097814606">
<NAME>General fatigue</NAME>
<DICH_DATA CI_END="2.019978687398658" CI_START="0.6981045190214401" EFFECT_SIZE="1.1875" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.3053467872713827" LOG_CI_START="-0.1560795506775743" LOG_EFFECT_SIZE="0.07463361829690418" MODIFIED="2009-08-31 15:00:50 +0200" MODIFIED_BY="Tahany Awad" ORDER="1594" O_E="0.0" SE="0.2710441150084277" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.07346491228070176" WEIGHT="1.6906861432133882"/>
<DICH_DATA CI_END="1.237312590638159" CI_START="0.8629814210708537" EFFECT_SIZE="1.0333333333333334" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="30" LOG_CI_END="0.09247943223969134" LOG_CI_START="-0.06399855401047076" LOG_EFFECT_SIZE="0.014240439114610285" MODIFIED="2009-08-31 15:37:21 +0200" MODIFIED_BY="Tahany Awad" ORDER="2027" O_E="0.0" SE="0.09191594370186937" STUDY_ID="STD-Derbala-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.00844854070660522" WEIGHT="3.170036518525103"/>
<DICH_DATA CI_END="1.0492736688573092" CI_START="0.9530402121774677" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="40" LOG_CI_END="0.020888774536551257" LOG_CI_START="-0.020888774536551274" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-31 15:41:00 +0200" MODIFIED_BY="Tahany Awad" ORDER="2030" O_E="0.0" SE="0.024540339127743588" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="6.022282445046628E-4" WEIGHT="4.279549300008889"/>
<DICH_DATA CI_END="1.0964280620727447" CI_START="0.8618674381152823" EFFECT_SIZE="0.972098577787428" ESTIMABLE="YES" EVENTS_1="242" EVENTS_2="244" LOG_CI_END="0.039980142379484024" LOG_CI_START="-0.06455952689250449" LOG_EFFECT_SIZE="-0.012289692256510217" MODIFIED="2009-08-31 15:00:50 +0200" MODIFIED_BY="Tahany Awad" ORDER="1595" O_E="0.0" SE="0.06140711921007478" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.0037708342896803347" WEIGHT="26.041655627321937"/>
<DICH_DATA CI_END="8.777517355740464" CI_START="0.01602104493795524" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.94337169686651" LOG_CI_START="-1.795309161411072" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2009-08-31 15:00:50 +0200" MODIFIED_BY="Tahany Awad" ORDER="1596" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="0.14917818910706368"/>
<DICH_DATA CI_END="1.1659701631834578" CI_START="0.6832652493976967" EFFECT_SIZE="0.8925619834710744" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="60" LOG_CI_END="0.0666874371034622" LOG_CI_START="-0.16541066676246297" LOG_EFFECT_SIZE="-0.04936161482950037" MODIFIED="2009-08-31 15:34:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="2025" O_E="0.0" SE="0.13633557511498784" STUDY_ID="STD-Mangia-2005" TOTAL_1="121" TOTAL_2="120" VAR="0.018587389041934493" WEIGHT="6.366380394050414"/>
<DICH_DATA CI_END="1.1438977660343395" CI_START="0.9645563236015776" EFFECT_SIZE="1.0504065040650405" ESTIMABLE="YES" EVENTS_1="646" EVENTS_2="303" LOG_CI_END="0.058387211842352627" LOG_CI_START="-0.015672407403018014" LOG_EFFECT_SIZE="0.021357402219667306" MODIFIED="2009-08-31 15:00:50 +0200" MODIFIED_BY="Tahany Awad" ORDER="1597" O_E="0.0" SE="0.04350298694575846" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.001892509873202831" WEIGHT="42.899088964746575"/>
<DICH_DATA CI_END="1.7855937216654156" CI_START="0.7087978551019752" EFFECT_SIZE="1.125" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" LOG_CI_END="0.2517826502352742" LOG_CI_START="-0.14947760534051163" LOG_EFFECT_SIZE="0.05115252244738129" MODIFIED="2009-08-31 15:00:50 +0200" MODIFIED_BY="Tahany Awad" ORDER="1598" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.05555555555555555" WEIGHT="1.6906861432133882"/>
<DICH_DATA CI_END="1.3069710718352923" CI_START="0.7996389878950948" EFFECT_SIZE="1.0223037831733484" ESTIMABLE="YES" EVENTS_1="85" EVENTS_2="77" LOG_CI_END="0.1162659751235129" LOG_CI_START="-0.09710603919760155" LOG_EFFECT_SIZE="0.009579967962955693" MODIFIED="2009-08-31 15:00:50 +0200" MODIFIED_BY="Tahany Awad" ORDER="1599" O_E="0.0" SE="0.12533577742072785" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.015709057101658236" WEIGHT="8.448660156972096"/>
<DICH_DATA CI_END="1.55656724339959" CI_START="0.6875093783588958" EFFECT_SIZE="1.0344827586206897" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="29" LOG_CI_END="0.19216788686022115" LOG_CI_START="-0.16272137321880836" LOG_EFFECT_SIZE="0.014723256820706378" MODIFIED="2009-08-31 15:34:03 +0200" MODIFIED_BY="Tahany Awad" ORDER="2026" O_E="0.0" SE="0.2084637081005915" STUDY_ID="STD-Scotto-2005" TOTAL_1="26" TOTAL_2="52" VAR="0.043457117595048625" WEIGHT="2.0429124230495104"/>
<DICH_DATA CI_END="1.046159064818269" CI_START="0.8289035598384039" EFFECT_SIZE="0.9312169312169312" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="31" LOG_CI_END="0.01959772250526416" LOG_CI_START="-0.08149599522345283" LOG_EFFECT_SIZE="-0.030949136359094347" MODIFIED="2009-08-31 16:12:55 +0200" MODIFIED_BY="Tahany Awad" ORDER="1600" O_E="0.0" SE="0.05938295021582182" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="29" TOTAL_2="31" VAR="0.0035263347763347733" WEIGHT="3.2211661397916367"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="12.83525792972239" CI_END="1.0723649881459831" CI_START="0.9319311744107104" DF="5" EFFECT_SIZE="0.9996851318289243" ESTIMABLE="YES" EVENTS_1="962" EVENTS_2="645" I2="61.04480309334818" ID="CMP-002.02.02" LOG_CI_END="0.030342626176917156" LOG_CI_START="-0.030616160261216198" LOG_EFFECT_SIZE="-1.3676704214949642E-4" MODIFIED="2009-09-14 10:12:12 +0200" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="0.024972515837613396" P_Z="0.9929828995794594" STUDIES="6" TAU2="0.0" TOTAL_1="1845" TOTAL_2="1301" WEIGHT="100.0" Z="0.008794744533083354">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.0274067117923718" CI_START="0.7869304966028408" EFFECT_SIZE="0.8991649870429024" ESTIMABLE="YES" EVENTS_1="211" EVENTS_2="230" LOG_CI_END="0.011742398535359057" LOG_CI_START="-0.1040636237715836" LOG_EFFECT_SIZE="-0.04616061261811227" MODIFIED="2009-08-31 15:01:25 +0200" MODIFIED_BY="Tahany Awad" ORDER="1601" O_E="0.0" SE="0.06802503075215377" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.004627404808831467" WEIGHT="31.020701882596217"/>
<DICH_DATA CI_END="2.598276822466223" CI_START="1.117446997657916" EFFECT_SIZE="1.7039473684210527" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="22" LOG_CI_END="0.41468541927935765" LOG_CI_START="0.04822693299360098" LOG_EFFECT_SIZE="0.23145617613647929" MODIFIED="2009-08-31 15:01:25 +0200" MODIFIED_BY="Tahany Awad" ORDER="1602" O_E="0.0" SE="0.21525952884301636" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.04633666475771739" WEIGHT="2.91852130078393"/>
<DICH_DATA CI_END="1.1309031525824036" CI_START="0.9456373157651659" EFFECT_SIZE="1.0341296928327646" ESTIMABLE="YES" EVENTS_1="615" EVENTS_2="293" LOG_CI_END="0.05342541473981328" LOG_CI_START="-0.024275398443422143" LOG_EFFECT_SIZE="0.014575008148195581" MODIFIED="2009-08-31 15:01:25 +0200" MODIFIED_BY="Tahany Awad" ORDER="1603" O_E="0.0" SE="0.04564184228906093" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.0020831777675395105" WEIGHT="52.422542443656326"/>
<DICH_DATA CI_END="1.7244072565977273" CI_START="0.7243851145473846" EFFECT_SIZE="1.1176470588235294" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="17" LOG_CI_END="0.23663984177041422" LOG_CI_START="-0.1400304826213041" LOG_EFFECT_SIZE="0.048304679574555046" MODIFIED="2009-08-31 15:01:25 +0200" MODIFIED_BY="Tahany Awad" ORDER="1604" O_E="0.0" SE="0.22125801309587212" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.04895510835913312" WEIGHT="2.270057985448266"/>
<DICH_DATA CI_END="1.327064553029063" CI_START="0.7511898642238981" EFFECT_SIZE="0.9984375" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="64" LOG_CI_END="0.12289204897026873" LOG_CI_START="-0.1242502806212428" LOG_EFFECT_SIZE="-6.791158254870203E-4" MODIFIED="2009-08-31 15:01:25 +0200" MODIFIED_BY="Tahany Awad" ORDER="1605" O_E="0.0" SE="0.1451726277763157" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.02107509185548071" WEIGHT="8.874054852157345"/>
<DICH_DATA CI_END="1.027062388333158" CI_START="0.34924311782603357" EFFECT_SIZE="0.5989110707803993" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="19" LOG_CI_END="0.01159682537515202" LOG_CI_START="-0.456872143322947" LOG_EFFECT_SIZE="-0.22263765897389756" MODIFIED="2009-08-31 16:14:54 +0200" MODIFIED_BY="Tahany Awad" ORDER="1606" O_E="0.0" SE="0.27518099117205813" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="29" TOTAL_2="30" VAR="0.07572457790243634" WEIGHT="2.4941215353579156"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="20.476299165390003" CI_END="1.0839228029691927" CI_START="0.8806842567123496" DF="3" EFFECT_SIZE="0.977033135603133" ESTIMABLE="YES" EVENTS_1="607" EVENTS_2="383" I2="85.34891497839249" ID="CMP-002.02.03" LOG_CI_END="0.03499835283120494" LOG_CI_START="-0.05517976712228278" LOG_EFFECT_SIZE="-0.010090707145538932" MODIFIED="2009-09-15 19:06:19 +0200" MODIFIED_BY="Tahany Awad" NO="3" P_CHI2="1.3521760544565886E-4" P_Z="0.6609295250889342" STUDIES="4" TAU2="0.0" TOTAL_1="1584" TOTAL_2="1057" WEIGHT="100.0" Z="0.4386301819997607">
<NAME>Rigours</NAME>
<DICH_DATA CI_END="0.8153601182025997" CI_START="0.5370719823750112" EFFECT_SIZE="0.661745476019741" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="157" LOG_CI_END="-0.08865053505718903" LOG_CI_START="-0.269967503028162" LOG_EFFECT_SIZE="-0.17930901904267557" MODIFIED="2009-08-31 15:02:02 +0200" MODIFIED_BY="Tahany Awad" ORDER="1607" O_E="0.0" SE="0.10650648451961622" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.01134363124472725" WEIGHT="34.829039918145945"/>
<DICH_DATA CI_END="2.134770054434712" CI_START="0.767217402496221" EFFECT_SIZE="1.2797783933518005" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="19" LOG_CI_END="0.32935110209249374" LOG_CI_START="-0.11508155479155857" LOG_EFFECT_SIZE="0.10713477365046759" MODIFIED="2009-08-31 15:02:02 +0200" MODIFIED_BY="Tahany Awad" ORDER="1608" O_E="0.0" SE="0.26106194263082466" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.06815333789017998" WEIGHT="4.145833477081456"/>
<DICH_DATA CI_END="1.2819667194435245" CI_START="1.0012245481963618" EFFECT_SIZE="1.132932720631554" ESTIMABLE="YES" EVENTS_1="476" EVENTS_2="207" LOG_CI_END="0.10787675080710318" LOG_CI_START="5.314891738240712E-4" LOG_EFFECT_SIZE="0.05420411999046363" MODIFIED="2009-08-31 15:02:02 +0200" MODIFIED_BY="Tahany Awad" ORDER="1609" O_E="0.0" SE="0.06305513805100302" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.003975950434631048" WEIGHT="60.91705110801647"/>
<DICH_DATA CI_END="73.15840614780981" CI_START="0.131085556818331" EFFECT_SIZE="3.096774193548387" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.864264235230413" LOG_CI_START="-0.8824451568198217" LOG_EFFECT_SIZE="0.49090953920529573" MODIFIED="2009-08-31 15:02:02 +0200" MODIFIED_BY="Tahany Awad" ORDER="1610" O_E="0.0" SE="1.613430693321079" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="30" TOTAL_2="31" VAR="2.6031586021505375" WEIGHT="0.10807549675613014"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.958622798773928" CI_END="1.352794962941708" CI_START="1.052194965519819" DF="3" EFFECT_SIZE="1.193064981209253" ESTIMABLE="YES" EVENTS_1="517" EVENTS_2="282" I2="0.0" ID="CMP-002.02.04" LOG_CI_END="0.13123197752086962" LOG_CI_START="0.02209621947958487" LOG_EFFECT_SIZE="0.07666409850022726" MODIFIED="2009-09-14 10:12:28 +0200" MODIFIED_BY="Tahany Awad" NO="4" P_CHI2="0.3980489918040323" P_Z="0.005894125088781906" STUDIES="4" TAU2="0.0" TOTAL_1="1740" TOTAL_2="1194" WEIGHT="99.99999999999999" Z="2.7536139330399028">
<NAME>Arthralgia</NAME>
<DICH_DATA CI_END="1.32100130773744" CI_START="0.8487914260463921" EFFECT_SIZE="1.0588930936613057" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="112" LOG_CI_END="0.12090324754857178" LOG_CI_START="-0.07119901605245887" LOG_EFFECT_SIZE="0.02485211574805646" MODIFIED="2009-08-31 15:03:55 +0200" MODIFIED_BY="Tahany Awad" ORDER="1611" O_E="0.0" SE="0.11284182056078648" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.012733276467472734" WEIGHT="34.09658315932375"/>
<DICH_DATA CI_END="1.4368095573222635" CI_START="1.0350192946312773" EFFECT_SIZE="1.2194775990313094" ESTIMABLE="YES" EVENTS_1="349" EVENTS_2="141" LOG_CI_END="0.15739920815849923" LOG_CI_START="0.014948445902877232" LOG_EFFECT_SIZE="0.08617382703068824" MODIFIED="2009-08-31 15:03:55 +0200" MODIFIED_BY="Tahany Awad" ORDER="1616" O_E="0.0" SE="0.08367628289159794" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.0070017203185547255" WEIGHT="56.942774734313964"/>
<DICH_DATA CI_END="2.371745990672961" CI_START="0.6071476480461607" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.37506817509858015" LOG_CI_START="-0.2167056830033305" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2009-08-31 15:03:55 +0200" MODIFIED_BY="Tahany Awad" ORDER="1617" O_E="0.0" SE="0.3476108935769035" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.12083333333333335" WEIGHT="3.014096016035301"/>
<DICH_DATA CI_END="2.888163257042801" CI_START="1.007652259362659" EFFECT_SIZE="1.705949656750572" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="19" LOG_CI_END="0.46062173863059347" LOG_CI_START="0.003310683006589487" LOG_EFFECT_SIZE="0.2319662108185915" MODIFIED="2009-08-31 15:03:55 +0200" MODIFIED_BY="Tahany Awad" ORDER="1618" O_E="0.0" SE="0.26862677779977423" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.07216034575108929" WEIGHT="5.946546090326981"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.743924219662381" CI_END="1.0625439636930305" CI_START="0.904586015581687" DF="4" EFFECT_SIZE="0.9803889077796888" ESTIMABLE="YES" EVENTS_1="821" EVENTS_2="559" I2="40.68735250111914" ID="CMP-002.02.05" LOG_CI_END="0.02634690841108611" LOG_CI_START="-0.04355013049972997" LOG_EFFECT_SIZE="-0.008601611044321953" MODIFIED="2009-09-14 10:12:35 +0200" MODIFIED_BY="Tahany Awad" NO="5" P_CHI2="0.1500555886165863" P_Z="0.6295282839734424" STUDIES="5" TAU2="0.0" TOTAL_1="1816" TOTAL_2="1271" WEIGHT="100.0" Z="0.4823909029223328">
<NAME>Myalgia</NAME>
<DICH_DATA CI_END="0.9721630146607919" CI_START="0.7293041558054145" EFFECT_SIZE="0.8420228777844672" ESTIMABLE="YES" EVENTS_1="189" EVENTS_2="220" LOG_CI_END="-0.012260905411517779" LOG_CI_START="-0.13709131168283056" LOG_EFFECT_SIZE="-0.07467610854717416" MODIFIED="2009-08-31 15:04:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="1619" O_E="0.0" SE="0.07332599856424586" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.005376702065443786" WEIGHT="34.260013214932954"/>
<DICH_DATA CI_END="1.6683907750512152" CI_START="0.6152568900628688" EFFECT_SIZE="1.013157894736842" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.22229777985790486" LOG_CI_START="-0.21094351407452383" LOG_EFFECT_SIZE="0.005677132891690489" MODIFIED="2009-08-31 15:04:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="1620" O_E="0.0" SE="0.25448808063490086" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.06476418318523582" WEIGHT="3.3697984690132725"/>
<DICH_DATA CI_END="1.1578245408960126" CI_START="0.9378764079842449" EFFECT_SIZE="1.0420634920634921" ESTIMABLE="YES" EVENTS_1="533" EVENTS_2="252" LOG_CI_END="0.06364275050178732" LOG_CI_START="-0.027854388557954374" LOG_EFFECT_SIZE="0.017894180971916473" MODIFIED="2009-08-31 15:04:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="1621" O_E="0.0" SE="0.05374587240183521" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.002888618800234352" WEIGHT="52.05854931495982"/>
<DICH_DATA CI_END="1.8617126298232212" CI_START="0.757451084238442" EFFECT_SIZE="1.1875" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="16" LOG_CI_END="0.2699126450052951" LOG_CI_START="-0.12064540841148672" LOG_EFFECT_SIZE="0.07463361829690418" MODIFIED="2009-08-31 15:04:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="1622" O_E="0.0" SE="0.22941573387056177" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.05263157894736842" WEIGHT="2.466885960569525"/>
<DICH_DATA CI_END="1.527046420150385" CI_START="0.7868919866731577" EFFECT_SIZE="1.096184560780834" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="49" LOG_CI_END="0.18385223922324476" LOG_CI_START="-0.10408487731210787" LOG_EFFECT_SIZE="0.039883680955568455" MODIFIED="2009-08-31 15:04:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="1623" O_E="0.0" SE="0.1691356875645801" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.028606880807943255" WEIGHT="7.84475304052442"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="39.14220797045611" CI_END="1.182115385860433" CI_START="0.9921582166956839" DF="5" EFFECT_SIZE="1.0829799135551026" ESTIMABLE="YES" EVENTS_1="775" EVENTS_2="507" I2="87.22606552043788" ID="CMP-002.02.06" LOG_CI_END="0.07265986994347355" LOG_CI_START="-0.0034190665969471836" LOG_EFFECT_SIZE="0.03462040167326318" MODIFIED="2009-09-14 10:12:39 +0200" MODIFIED_BY="Tahany Awad" NO="6" P_CHI2="2.223353390284899E-7" P_Z="0.07445643919124767" STUDIES="6" TAU2="0.0" TOTAL_1="1873" TOTAL_2="1307" WEIGHT="100.0" Z="1.7837983414464484">
<NAME>Pyrexia</NAME>
<DICH_DATA CI_END="0.8852857898886485" CI_START="0.6763342161316719" EFFECT_SIZE="0.7737887765772046" ESTIMABLE="YES" EVENTS_1="195" EVENTS_2="247" LOG_CI_END="-0.05291650677605936" LOG_CI_START="-0.16983864081466019" LOG_EFFECT_SIZE="-0.11137757379535979" MODIFIED="2009-08-31 15:05:25 +0200" MODIFIED_BY="Tahany Awad" ORDER="1624" O_E="0.0" SE="0.06868064030817196" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.004717030353140495" WEIGHT="43.93867768759611"/>
<DICH_DATA CI_END="1.7064459271937547" CI_START="1.0815843756650843" EFFECT_SIZE="1.3585526315789473" ESTIMABLE="YES" EVENTS_1="59" EVENTS_2="44" LOG_CI_END="0.2320925311769576" LOG_CI_START="0.0340604049183369" LOG_EFFECT_SIZE="0.13307646804764728" MODIFIED="2009-08-31 15:05:25 +0200" MODIFIED_BY="Tahany Awad" ORDER="1625" O_E="0.0" SE="0.11632505123914848" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.01353151754579052" WEIGHT="7.698730350144529"/>
<DICH_DATA CI_END="1.5665394117227303" CI_START="1.1807626536726024" EFFECT_SIZE="1.3600408938221118" ESTIMABLE="YES" EVENTS_1="461" EVENTS_2="167" LOG_CI_END="0.194941325536519" LOG_CI_START="0.07216260840138713" LOG_EFFECT_SIZE="0.1335519669689531" MODIFIED="2009-08-31 15:05:25 +0200" MODIFIED_BY="Tahany Awad" ORDER="1626" O_E="0.0" SE="0.07212082620962817" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.005201413573159391" WEIGHT="39.408796880561894"/>
<DICH_DATA CI_END="1.5139717084603916" CI_START="0.5850922734148978" EFFECT_SIZE="0.9411764705882353" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="17" LOG_CI_END="0.18011775959315712" LOG_CI_START="-0.2327756370378554" LOG_EFFECT_SIZE="-0.026328938722349152" MODIFIED="2009-08-31 15:05:25 +0200" MODIFIED_BY="Tahany Awad" ORDER="1627" O_E="0.0" SE="0.24253562503633297" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.058823529411764705" WEIGHT="2.9940785946061483"/>
<DICH_DATA CI_END="1.8114653786433421" CI_START="0.7772151428580296" EFFECT_SIZE="1.1865489130434783" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="32" LOG_CI_END="0.25803003806261365" LOG_CI_START="-0.10945874642066486" LOG_EFFECT_SIZE="0.07428564582097438" MODIFIED="2009-08-31 15:05:25 +0200" MODIFIED_BY="Tahany Awad" ORDER="1628" O_E="0.0" SE="0.21586473110429905" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.04659758213473133" WEIGHT="5.852189206294318"/>
<DICH_DATA CI_END="83.9933069646434" CI_START="0.23740991935762087" EFFECT_SIZE="4.4655172413793105" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9242446805364994" LOG_CI_START="-0.6245011394998705" LOG_EFFECT_SIZE="0.6498717705183146" MODIFIED="2009-08-31 16:01:13 +0200" MODIFIED_BY="Tahany Awad" ORDER="2041" O_E="0.0" SE="1.4971459111846492" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="2.2414458793769136" WEIGHT="0.107527280797001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.6717294919589174" CI_END="1.392799393366698" CI_START="0.9804724477820841" DF="5" EFFECT_SIZE="1.1685895046951467" ESTIMABLE="YES" EVENTS_1="301" EVENTS_2="153" I2="0.0" ID="CMP-002.02.07" LOG_CI_END="0.14388856895250213" LOG_CI_START="-0.008564605916980841" LOG_EFFECT_SIZE="0.06766198151776064" MODIFIED="2013-09-13 21:31:06 +0200" MODIFIED_BY="Tahany Awad" NO="7" P_CHI2="0.8924420116730524" P_Z="0.08190329102691642" STUDIES="6" TAU2="0.0" TOTAL_1="1541" TOTAL_2="983" WEIGHT="100.0" Z="1.739747919463915">
<NAME>Weight loss</NAME>
<DICH_DATA CI_END="2.129735917976483" CI_START="0.6190758107716594" EFFECT_SIZE="1.1482456140350876" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="15" LOG_CI_END="0.3283257553279916" LOG_CI_START="-0.20825616489942522" LOG_EFFECT_SIZE="0.06003479521428317" MODIFIED="2009-08-31 15:05:52 +0200" MODIFIED_BY="Tahany Awad" ORDER="1629" O_E="0.0" SE="0.3151908760649272" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.09934528835457627" WEIGHT="7.898424152680643"/>
<DICH_DATA CI_END="5.112766459279568" CI_START="0.7694772554616476" EFFECT_SIZE="1.9834710743801653" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.7086559554954395" LOG_CI_START="-0.11380421270512754" LOG_EFFECT_SIZE="0.29742587139515597" MODIFIED="2009-08-31 15:05:52 +0200" MODIFIED_BY="Tahany Awad" ORDER="1630" O_E="0.0" SE="0.4831171740445058" STUDY_ID="STD-Mangia-2005" TOTAL_1="121" TOTAL_2="120" VAR="0.2334022038567493" WEIGHT="3.1933506516395878"/>
<DICH_DATA CI_END="1.4105832478732427" CI_START="0.9315995725349007" EFFECT_SIZE="1.146341463414634" ESTIMABLE="YES" EVENTS_1="235" EVENTS_2="101" LOG_CI_END="0.14939872184559433" LOG_CI_START="-0.03077071941363046" LOG_EFFECT_SIZE="0.05931400121598193" MODIFIED="2009-08-31 15:05:52 +0200" MODIFIED_BY="Tahany Awad" ORDER="1631" O_E="0.0" SE="0.10583242164878648" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.01120050147204653" WEIGHT="71.72669828125119"/>
<DICH_DATA CI_END="2.5227538324347907" CI_START="0.6699028570571735" EFFECT_SIZE="1.3" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" LOG_CI_END="0.4018748746035569" LOG_CI_START="-0.1739881699898834" LOG_EFFECT_SIZE="0.11394335230683679" MODIFIED="2009-08-31 15:05:52 +0200" MODIFIED_BY="Tahany Awad" ORDER="1632" O_E="0.0" SE="0.33826480296223094" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.11442307692307693" WEIGHT="5.300258312983063"/>
<DICH_DATA CI_END="1.7782324952306054" CI_START="0.5785382468059485" EFFECT_SIZE="1.0142857142857142" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.24998854223299927" LOG_CI_START="-0.23766792482336238" LOG_EFFECT_SIZE="0.006160308704818433" MODIFIED="2009-08-31 15:05:52 +0200" MODIFIED_BY="Tahany Awad" ORDER="1633" O_E="0.0" SE="0.28645182268735025" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.08205464672090514" WEIGHT="11.557673883389704"/>
<DICH_DATA CI_END="45.74203636498408" CI_START="0.08007085678437215" EFFECT_SIZE="1.9137931034482758" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6603154948223207" LOG_CI_START="-1.0965255243748804" LOG_EFFECT_SIZE="0.28189498522372014" MODIFIED="2009-08-31 16:01:50 +0200" MODIFIED_BY="Tahany Awad" ORDER="2042" O_E="0.0" SE="1.6193820612595702" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="2.6223982603292946" WEIGHT="0.32359471805580803"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.8477848033427238" CI_END="1.2457243174012225" CI_START="0.8811250729403951" DF="2" EFFECT_SIZE="1.0476826475769159" ESTIMABLE="YES" EVENTS_1="265" EVENTS_2="162" I2="29.76997427430597" ID="CMP-002.02.08" LOG_CI_END="0.0954219422601878" LOG_CI_START="-0.05496244047274539" LOG_EFFECT_SIZE="0.020229750893721213" MODIFIED="2009-09-14 10:12:56 +0200" MODIFIED_BY="Tahany Awad" NO="8" P_CHI2="0.24077533096906367" P_Z="0.5979784371927647" STUDIES="3" TAU2="0.0" TOTAL_1="1331" TOTAL_2="795" WEIGHT="99.99999999999999" Z="0.5273098502299144">
<NAME>Asthenia</NAME>
<DICH_DATA CI_END="2.1193086369366454" CI_START="0.9157258078991886" EFFECT_SIZE="1.393092105263158" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="24" LOG_CI_END="0.3261942080358941" LOG_CI_START="-0.03823454591995011" LOG_EFFECT_SIZE="0.143979831057972" MODIFIED="2009-08-31 15:06:17 +0200" MODIFIED_BY="Tahany Awad" ORDER="1634" O_E="0.0" SE="0.21406725402508872" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.045824789245841865" WEIGHT="12.253966438958667"/>
<DICH_DATA CI_END="1.1857622470446472" CI_START="0.7484333278467198" EFFECT_SIZE="0.9420530688823372" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="91" LOG_CI_END="0.07399761892074003" LOG_CI_START="-0.1258468815439512" LOG_EFFECT_SIZE="-0.025924631311605596" MODIFIED="2009-08-31 15:06:17 +0200" MODIFIED_BY="Tahany Awad" ORDER="1635" O_E="0.0" SE="0.11738964881919128" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.013780329649893059" WEIGHT="62.66385524089198"/>
<DICH_DATA CI_END="1.59999779486806" CI_START="0.8162898981317971" EFFECT_SIZE="1.1428307123034227" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="47" LOG_CI_END="0.20411938410761643" LOG_CI_START="-0.0881555780108871" LOG_EFFECT_SIZE="0.05798190304836464" MODIFIED="2009-08-31 15:06:17 +0200" MODIFIED_BY="Tahany Awad" ORDER="1636" O_E="0.0" SE="0.1716837595328049" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.029475313287317978" WEIGHT="25.082178320149335"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.476337196041328" CI_END="1.0254724003528244" CI_START="0.9057208333311284" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9637384069370861" ESTIMABLE="YES" EVENTS_1="1681" EVENTS_2="1168" I2="33.27793574996258" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.010923976224842893" LOG_CI_START="-0.0430056425291958" LOG_EFFECT_SIZE="-0.016040833152176463" METHOD="MH" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="Tahany Awad" NO="3" P_CHI2="0.07468077204316115" P_Q="0.4518114281165754" P_Z="0.24363714454953578" Q="1.588981515892519" RANDOM="NO" SCALE="102.59" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="5466" TOTAL_2="3855" WEIGHT="300.0" Z="1.1659439093634447">
<NAME>Psychiatric symptoms</NAME>
<GROUP_LABEL_1>PEG + RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF + RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEG + RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INF + RBV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="18.331394978527157" CI_END="1.0222370030646264" CI_START="0.8177412634599341" DF="11" EFFECT_SIZE="0.914289548470048" ESTIMABLE="YES" EVENTS_1="528" EVENTS_2="403" I2="39.993655622580455" ID="CMP-002.03.01" LOG_CI_END="0.009551597550465632" LOG_CI_START="-0.08738408707018927" LOG_EFFECT_SIZE="-0.038916244759861815" MODIFIED="2013-08-28 22:07:34 +0200" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="0.07420288953978826" P_Z="0.1155539838747722" STUDIES="12" TAU2="0.0" TOTAL_1="2140" TOTAL_2="1603" WEIGHT="100.0" Z="1.573712269972917">
<NAME>Depression</NAME>
<DICH_DATA CI_END="5.6416496128421665" CI_START="0.31511665909399916" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7514061098352028" LOG_CI_START="-0.501528636618603" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2009-08-31 15:07:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="1637" O_E="0.0" SE="0.7359800721939871" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.5416666666666665" WEIGHT="0.6485966730720191"/>
<DICH_DATA CI_END="15.439679023172555" CI_START="0.06476818582168423" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.188638267507881" LOG_CI_START="-1.188638267507881" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-31 15:45:06 +0200" MODIFIED_BY="Tahany Awad" ORDER="2032" O_E="0.0" SE="1.3964240043768943" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="1.9500000000000002" WEIGHT="0.21619889102400636"/>
<DICH_DATA CI_END="3.1926804832940405" CI_START="0.6404962885262414" EFFECT_SIZE="1.43" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.5041554574415233" LOG_CI_START="-0.19348338251139985" LOG_EFFECT_SIZE="0.1553360374650618" MODIFIED="2009-08-31 15:07:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="1638" O_E="0.0" SE="0.40979650795630007" STUDY_ID="STD-Esmat-2003" TOTAL_1="100" TOTAL_2="99" VAR="0.1679331779331779" WEIGHT="1.9555678585086"/>
<DICH_DATA CI_END="0.9146244560781033" CI_START="0.5849478239510169" EFFECT_SIZE="0.7314421271127804" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="134" LOG_CI_END="-0.03875719023090104" LOG_CI_START="-0.23288287029513832" LOG_EFFECT_SIZE="-0.1358200302630197" MODIFIED="2009-08-31 15:07:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="1639" O_E="0.0" SE="0.11403038540734714" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.013002928796148129" WEIGHT="29.261326829295953"/>
<DICH_DATA CI_END="78.99765620166416" CI_START="0.14418940444159714" EFFECT_SIZE="3.375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8976142063058348" LOG_CI_START="-0.8410666519717473" LOG_EFFECT_SIZE="0.5282737771670437" MODIFIED="2009-08-31 15:07:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="1640" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="0.1017406545995324"/>
<DICH_DATA CI_END="4.212761734302506" CI_START="1.074548341738478" EFFECT_SIZE="2.1276315789473683" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="10" LOG_CI_END="0.6245668969612089" LOG_CI_START="0.031225958290010777" LOG_EFFECT_SIZE="0.3278964276256098" MODIFIED="2009-08-31 15:07:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="1641" O_E="0.0" SE="0.34853140446047687" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.12147413989519251" WEIGHT="2.1478582637679065"/>
<DICH_DATA CI_END="1.0250444046608929" CI_START="0.7544182803471495" EFFECT_SIZE="0.8793817356778219" ESTIMABLE="YES" EVENTS_1="307" EVENTS_2="172" LOG_CI_END="0.010742679324930577" LOG_CI_START="-0.12238779673187898" LOG_EFFECT_SIZE="-0.055822558703474176" MODIFIED="2009-08-31 15:07:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="1642" O_E="0.0" SE="0.07820150064225471" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.006115474702700565" WEIGHT="49.82465946082656"/>
<DICH_DATA CI_END="3.031136242063711" CI_START="0.5453602518916572" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.481605457267226" LOG_CI_START="-0.26331651841708975" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2009-08-31 15:07:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="1643" O_E="0.0" SE="0.4375708559402168" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.19146825396825395" WEIGHT="1.5133922371680444"/>
<DICH_DATA CI_END="1.6510158932768468" CI_START="0.7612034553318174" EFFECT_SIZE="1.1210526315789473" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="38" LOG_CI_END="0.2177512539588636" LOG_CI_START="-0.11849924898704613" LOG_EFFECT_SIZE="0.04962600248590873" MODIFIED="2009-08-31 15:07:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="1644" O_E="0.0" SE="0.19751520989726112" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.03901225814075912" WEIGHT="8.530827573588331"/>
<DICH_DATA CI_END="1.1596557001422818" CI_START="0.22014366737854985" EFFECT_SIZE="0.5052631578947369" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.06432906705160084" LOG_CI_START="-0.6572938028781219" LOG_EFFECT_SIZE="-0.29648236791326055" MODIFIED="2009-08-31 15:59:20 +0200" MODIFIED_BY="Tahany Awad" ORDER="2036" O_E="0.0" SE="0.42388484588753517" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="0.17967836257309944" WEIGHT="2.65017995448782"/>
<DICH_DATA CI_END="2.809554919092495" CI_START="0.6823713429787182" EFFECT_SIZE="1.3846153846153846" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.4486375257798094" LOG_CI_START="-0.1659792201868708" LOG_EFFECT_SIZE="0.1413291527964693" MODIFIED="2009-08-31 16:10:00 +0200" MODIFIED_BY="Tahany Awad" ORDER="1645" O_E="0.0" SE="0.36102891898278777" STUDY_ID="STD-Scotto-2005" TOTAL_1="26" TOTAL_2="52" VAR="0.13034188034188032" WEIGHT="1.873723722208055"/>
<DICH_DATA CI_END="3.8231959952886934" CI_START="0.6284009511834052" EFFECT_SIZE="1.55" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="6" LOG_CI_END="0.5824265625993318" LOG_CI_START="-0.20176316625874868" LOG_EFFECT_SIZE="0.1903316981702915" MODIFIED="2013-08-28 22:07:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="1646" O_E="0.0" SE="0.4606369285329992" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="30" TOTAL_2="31" VAR="0.21218637992831543" WEIGHT="1.2759278814531523"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.953184807599261" CI_END="1.1041561337713066" CI_START="0.9138170276244694" DF="4" EFFECT_SIZE="1.0044882658330168" ESTIMABLE="YES" EVENTS_1="678" EVENTS_2="459" I2="42.47240493840566" ID="CMP-002.03.02" LOG_CI_END="0.04303048937223444" LOG_CI_START="-0.039140753771614856" LOG_EFFECT_SIZE="0.0019448678003097808" MODIFIED="2009-09-14 10:14:44 +0200" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="0.13838314305836652" P_Z="0.926079367439969" STUDIES="5" TAU2="0.0" TOTAL_1="1816" TOTAL_2="1271" WEIGHT="100.0" Z="0.09277870694071724">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="1.1180745123609428" CI_START="0.8009748055578195" EFFECT_SIZE="0.9463347796300525" ESTIMABLE="YES" EVENTS_1="168" EVENTS_2="174" LOG_CI_END="0.04847074740448818" LOG_CI_START="-0.09638114431438603" LOG_EFFECT_SIZE="-0.023955198454948916" MODIFIED="2009-08-31 15:08:11 +0200" MODIFIED_BY="Tahany Awad" ORDER="1647" O_E="0.0" SE="0.08508671822409483" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.007239749618146512" WEIGHT="32.987081480436665"/>
<DICH_DATA CI_END="2.777240074567005" CI_START="1.1319231438686885" EFFECT_SIZE="1.7730263157894737" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="20" LOG_CI_END="0.4436134233415899" LOG_CI_START="0.05381693981438014" LOG_EFFECT_SIZE="0.24871518157798495" MODIFIED="2009-08-31 15:08:11 +0200" MODIFIED_BY="Tahany Awad" ORDER="1648" O_E="0.0" SE="0.22896838394759542" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.052426520847573474" WEIGHT="3.7294178322934766"/>
<DICH_DATA CI_END="1.1099149583511636" CI_START="0.857970476277228" EFFECT_SIZE="0.9758454106280193" ESTIMABLE="YES" EVENTS_1="410" EVENTS_2="207" LOG_CI_END="0.04528970443197936" LOG_CI_START="-0.06652765645256739" LOG_EFFECT_SIZE="-0.010618976010293983" MODIFIED="2009-08-31 15:08:11 +0200" MODIFIED_BY="Tahany Awad" ORDER="1649" O_E="0.0" SE="0.06568207128844596" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.004314134488740496" WEIGHT="52.05850187939924"/>
<DICH_DATA CI_END="2.1005224567858125" CI_START="0.5665650661260463" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.32232732896185906" LOG_CI_START="-0.24675020718305954" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2009-08-31 15:08:11 +0200" MODIFIED_BY="Tahany Awad" ORDER="1650" O_E="0.0" SE="0.33427896171076077" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.11174242424242425" WEIGHT="2.0646744117598423"/>
<DICH_DATA CI_END="1.4755206486863437" CI_START="0.7391188301275282" EFFECT_SIZE="1.0443108233117484" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="47" LOG_CI_END="0.16894529146918072" LOG_CI_START="-0.1312857332967478" LOG_EFFECT_SIZE="0.018829779086216435" MODIFIED="2009-08-31 15:08:11 +0200" MODIFIED_BY="Tahany Awad" ORDER="1651" O_E="0.0" SE="0.17635719011504758" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.03110185850527504" WEIGHT="9.160324396110772"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.4239339467615082" CI_END="1.0913071718240672" CI_START="0.8567011627904944" DF="2" EFFECT_SIZE="0.9669147444647249" ESTIMABLE="YES" EVENTS_1="475" EVENTS_2="306" I2="0.0" ID="CMP-002.03.03" LOG_CI_END="0.0379470092976491" LOG_CI_START="-0.06717064363591933" LOG_EFFECT_SIZE="-0.014611817169135101" MODIFIED="2009-09-14 10:14:54 +0200" MODIFIED_BY="Tahany Awad" NO="3" P_CHI2="0.4906781652650223" P_Z="0.5858310553481774" STUDIES="3" TAU2="0.0" TOTAL_1="1510" TOTAL_2="981" WEIGHT="100.0" Z="0.5448872687119006">
<NAME>Irritability</NAME>
<DICH_DATA CI_END="1.0846169324924535" CI_START="0.6955621305298584" EFFECT_SIZE="0.8685726592365262" ESTIMABLE="YES" EVENTS_1="109" EVENTS_2="123" LOG_CI_END="0.035276380138746684" LOG_CI_START="-0.1576640709327194" LOG_EFFECT_SIZE="-0.061193845396986336" MODIFIED="2009-08-31 15:09:28 +0200" MODIFIED_BY="Tahany Awad" ORDER="1652" O_E="0.0" SE="0.11333417603001518" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.012844635456402466" WEIGHT="33.97237002515647"/>
<DICH_DATA CI_END="1.175467851854453" CI_START="0.8747297547079016" EFFECT_SIZE="1.0140102098695405" ESTIMABLE="YES" EVENTS_1="354" EVENTS_2="172" LOG_CI_END="0.07021075600189013" LOG_CI_START="-0.05812610031163575" LOG_EFFECT_SIZE="0.006042327845127153" MODIFIED="2009-08-31 15:09:28 +0200" MODIFIED_BY="Tahany Awad" ORDER="1653" O_E="0.0" SE="0.07538570467624946" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.005683004469534699" WEIGHT="63.01963113209493"/>
<DICH_DATA CI_END="2.1005224567858125" CI_START="0.5665650661260463" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.32232732896185906" LOG_CI_START="-0.24675020718305954" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2009-08-31 15:09:28 +0200" MODIFIED_BY="Tahany Awad" ORDER="1654" O_E="0.0" SE="0.33427896171076077" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.11174242424242425" WEIGHT="3.007998842748604"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="61.753933139495764" CI_END="1.247277630394144" CI_START="1.0998117271129804" CI_STUDY="95" CI_TOTAL="95" DF="18" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1712260946858932" ESTIMABLE="YES" EVENTS_1="2001" EVENTS_2="1071" I2="70.85205899462329" I2_Q="93.54900158177226" ID="CMP-002.04" LOG_CI_END="0.09596313345290797" LOG_CI_START="0.0413183461817422" LOG_EFFECT_SIZE="0.06864073981732506" METHOD="MH" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="Tahany Awad" NO="4" P_CHI2="1.0620765318325454E-6" P_Q="4.430372735342303E-10" P_Z="8.482597984217692E-7" Q="46.50442932249514" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="6415" TOTAL_2="4256" WEIGHT="400.0" Z="4.923923566452618">
<NAME>Dermatological symptoms</NAME>
<GROUP_LABEL_1>PEG + RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF + RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEG + RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INF + RBV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="5.645988201872565" CI_END="1.0933277593146402" CI_START="0.8789918908993177" DF="4" EFFECT_SIZE="0.980319455347434" ESTIMABLE="YES" EVENTS_1="555" EVENTS_2="390" I2="29.15323488148012" ID="CMP-002.04.01" LOG_CI_END="0.03875037487153076" LOG_CI_START="-0.056015131472217046" LOG_EFFECT_SIZE="-0.008632378300343148" MODIFIED="2009-09-14 10:15:36 +0200" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="0.22719196776925976" P_Z="0.7210363873001606" STUDIES="5" TAU2="0.0" TOTAL_1="1816" TOTAL_2="1271" WEIGHT="100.0" Z="0.35707402877637656">
<NAME>Alopecia</NAME>
<DICH_DATA CI_END="1.0104913047284032" CI_START="0.6831294370851557" EFFECT_SIZE="0.8308407525985703" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="151" LOG_CI_END="0.004532580765998058" LOG_CI_START="-0.16549699985302427" LOG_EFFECT_SIZE="-0.08048220954351311" MODIFIED="2009-08-31 15:10:24 +0200" MODIFIED_BY="Tahany Awad" ORDER="1655" O_E="0.0" SE="0.09987621731561193" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.00997525878527534" WEIGHT="34.05600228728551"/>
<DICH_DATA CI_END="1.8371505143315874" CI_START="0.8964668009488893" EFFECT_SIZE="1.2833333333333334" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="30" LOG_CI_END="0.2641447387042089" LOG_CI_START="-0.04746578912653234" LOG_EFFECT_SIZE="0.10833947478883828" MODIFIED="2009-08-31 15:10:24 +0200" MODIFIED_BY="Tahany Awad" ORDER="1656" O_E="0.0" SE="0.18304156654476725" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.03350421508316245" WEIGHT="6.6550967920763355"/>
<DICH_DATA CI_END="1.1820303054309524" CI_START="0.8676905189687892" EFFECT_SIZE="1.0127371273712737" ESTIMABLE="YES" EVENTS_1="333" EVENTS_2="162" LOG_CI_END="0.07262861132756555" LOG_CI_START="-0.06163514794641111" LOG_EFFECT_SIZE="0.005496731690577217" MODIFIED="2009-08-31 15:10:24 +0200" MODIFIED_BY="Tahany Awad" ORDER="1657" O_E="0.0" SE="0.07886719681386109" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.006220034733276302" WEIGHT="48.46836940018752"/>
<DICH_DATA CI_END="2.3653566660228886" CI_START="0.5219373124436117" EFFECT_SIZE="1.1111111111111112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.3738966361548852" LOG_CI_START="-0.28238165503353485" LOG_EFFECT_SIZE="0.04575749056067514" MODIFIED="2009-08-31 15:10:24 +0200" MODIFIED_BY="Tahany Awad" ORDER="1658" O_E="0.0" SE="0.38550111687401256" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.1486111111111111" WEIGHT="2.009664097080946"/>
<DICH_DATA CI_END="1.6510158932768468" CI_START="0.7612034553318174" EFFECT_SIZE="1.1210526315789473" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="38" LOG_CI_END="0.2177512539588636" LOG_CI_START="-0.11849924898704613" LOG_EFFECT_SIZE="0.04962600248590873" MODIFIED="2009-08-31 15:10:24 +0200" MODIFIED_BY="Tahany Awad" ORDER="1659" O_E="0.0" SE="0.19751520989726112" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.03901225814075912" WEIGHT="8.810867423369684"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.470056105677515" CI_END="1.2532769221946194" CI_START="0.9643530409096553" DF="4" EFFECT_SIZE="1.0993640939289744" ESTIMABLE="YES" EVENTS_1="453" EVENTS_2="271" I2="26.87460744966958" ID="CMP-002.04.02" LOG_CI_END="0.09804704265670981" LOG_CI_START="-0.015763945713028235" LOG_EFFECT_SIZE="0.0411415484718408" MODIFIED="2009-09-14 10:15:40 +0200" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="0.24237435165811783" P_Z="0.1564784678344671" STUDIES="5" TAU2="0.0" TOTAL_1="1797" TOTAL_2="1230" WEIGHT="100.0" Z="1.417015253589656">
<NAME>Pruritus</NAME>
<DICH_DATA CI_END="1.450333187799998" CI_START="0.8725275616671249" EFFECT_SIZE="1.124924744130042" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="88" LOG_CI_END="0.16146778499388126" LOG_CI_START="-0.05922084552535753" LOG_EFFECT_SIZE="0.05112346973426187" MODIFIED="2009-08-31 15:10:50 +0200" MODIFIED_BY="Tahany Awad" ORDER="1660" O_E="0.0" SE="0.12963359399334037" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.016804868691630212" WEIGHT="27.614266046417377"/>
<DICH_DATA CI_END="1.1700520081303931" CI_START="0.8298313739982166" EFFECT_SIZE="0.9853658536585366" ESTIMABLE="YES" EVENTS_1="282" EVENTS_2="141" LOG_CI_END="0.06820516631201666" LOG_CI_START="-0.08101014953027767" LOG_EFFECT_SIZE="-0.006402491609130536" MODIFIED="2009-08-31 15:10:50 +0200" MODIFIED_BY="Tahany Awad" ORDER="1661" O_E="0.0" SE="0.08764981515348955" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.007682490096440885" WEIGHT="58.69439369873171"/>
<DICH_DATA CI_END="4.2342714917737405" CI_START="0.3690127104593066" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.6267787005419575" LOG_CI_START="-0.43295867452584486" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-08-31 15:10:50 +0200" MODIFIED_BY="Tahany Awad" ORDER="1662" O_E="0.0" SE="0.6224949798994366" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.3875" WEIGHT="1.2427250975133648"/>
<DICH_DATA CI_END="2.2255519050852675" CI_START="1.0930966468470753" EFFECT_SIZE="1.559725400457666" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="38" LOG_CI_END="0.3474377275015991" LOG_CI_START="0.03865856207484459" LOG_EFFECT_SIZE="0.19304814478822188" MODIFIED="2009-08-31 15:10:50 +0200" MODIFIED_BY="Tahany Awad" ORDER="1663" O_E="0.0" SE="0.18137841025319554" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.03289812770597651" WEIGHT="12.258936063506555"/>
<DICH_DATA CI_END="45.74203636498408" CI_START="0.08007085678437215" EFFECT_SIZE="1.9137931034482758" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6603154948223207" LOG_CI_START="-1.0965255243748804" LOG_EFFECT_SIZE="0.28189498522372014" MODIFIED="2009-08-31 16:04:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="2043" O_E="0.0" SE="1.6193820612595702" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="2.6223982603292946" WEIGHT="0.18967909383098727"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.3564376605799406" CI_END="1.251432274594138" CI_START="0.9301552559330759" DF="4" EFFECT_SIZE="1.0789005086930035" ESTIMABLE="YES" EVENTS_1="366" EVENTS_2="224" I2="0.0" ID="CMP-002.04.03" LOG_CI_END="0.09740735129468475" LOG_CI_START="-0.031444555567068634" LOG_EFFECT_SIZE="0.03298139786380804" MODIFIED="2009-09-14 10:15:45 +0200" MODIFIED_BY="Tahany Awad" NO="3" P_CHI2="0.670513621933063" P_Z="0.31568775383327774" STUDIES="5" TAU2="0.0" TOTAL_1="1634" TOTAL_2="1106" WEIGHT="100.00000000000001" Z="1.003358872169514">
<NAME>Skin rash</NAME>
<DICH_DATA CI_END="5.415841769036187" CI_START="0.7385740150070608" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.7336659673760731" LOG_CI_START="-0.13160597604811078" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2009-08-31 15:11:19 +0200" MODIFIED_BY="Tahany Awad" ORDER="1664" O_E="0.0" SE="0.5082650227325636" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.2583333333333334" WEIGHT="1.8931046991553844"/>
<DICH_DATA CI_END="1.5202058225349413" CI_START="0.8911162866601735" EFFECT_SIZE="1.163907284768212" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="80" LOG_CI_END="0.1819023915893484" LOG_CI_START="-0.05006561879196413" LOG_EFFECT_SIZE="0.06591838639869213" MODIFIED="2009-08-31 15:11:19 +0200" MODIFIED_BY="Tahany Awad" ORDER="1665" O_E="0.0" SE="0.13625915755815327" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.018566558018457635" WEIGHT="30.593584970965942"/>
<DICH_DATA CI_END="1.9201875581176557" CI_START="0.5993186352501337" EFFECT_SIZE="1.0727554179566563" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="17" LOG_CI_END="0.2833436513479471" LOG_CI_START="-0.22234221811450183" LOG_EFFECT_SIZE="0.030500716616722642" MODIFIED="2009-08-31 15:11:19 +0200" MODIFIED_BY="Tahany Awad" ORDER="1666" O_E="0.0" SE="0.29704238290766716" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.08823417724346516" WEIGHT="6.394486983813743"/>
<DICH_DATA CI_END="1.2182159805724335" CI_START="0.8247432326231852" EFFECT_SIZE="1.0023549201009252" ESTIMABLE="YES" EVENTS_1="236" EVENTS_2="116" LOG_CI_END="0.08572429228320252" LOG_CI_START="-0.08368123934304972" LOG_EFFECT_SIZE="0.0010215264700763986" MODIFIED="2009-08-31 15:11:19 +0200" MODIFIED_BY="Tahany Awad" ORDER="1667" O_E="0.0" SE="0.09950964784816642" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.009902170014866091" WEIGHT="58.84709770707848"/>
<DICH_DATA CI_END="3.090342669524393" CI_START="0.4404401895407242" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.4900066383997234" LOG_CI_START="-0.35611305913849695" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2009-08-31 15:11:19 +0200" MODIFIED_BY="Tahany Awad" ORDER="1668" O_E="0.0" SE="0.49701489869400245" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.24702380952380953" WEIGHT="2.271725638986461"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.125647709672419" CI_END="1.9346060040015187" CI_START="1.5039111949310153" DF="3" EFFECT_SIZE="1.7057185076086385" ESTIMABLE="YES" EVENTS_1="627" EVENTS_2="186" I2="57.89856414136539" ID="CMP-002.04.04" LOG_CI_END="0.2865925312615188" LOG_CI_START="0.17722219217976024" LOG_EFFECT_SIZE="0.23190736172063953" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NO="4" P_CHI2="0.0679990791484072" P_Z="9.4291936995412E-17" STUDIES="4" TAU2="0.0" TOTAL_1="1168" TOTAL_2="649" WEIGHT="99.99999999999999" Z="8.311761315513117">
<NAME>Injection site reaction</NAME>
<DICH_DATA CI_END="222.30510540610646" CI_START="0.7602164587775486" EFFECT_SIZE="13.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.346949436717161" LOG_CI_START="-0.11906273210348774" LOG_EFFECT_SIZE="1.1139433523068367" MODIFIED="2009-08-31 15:38:36 +0200" MODIFIED_BY="Tahany Awad" ORDER="2028" O_E="0.0" SE="1.4485477549223562" STUDY_ID="STD-Derbala-2005" TOTAL_1="35" TOTAL_2="35" VAR="2.0982905982905984" WEIGHT="0.20092184280108855"/>
<DICH_DATA CI_END="293.1986886666408" CI_START="1.011448033139046" EFFECT_SIZE="17.22077922077922" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.4671620235880694" LOG_CI_START="0.004943574204475659" LOG_EFFECT_SIZE="1.2360527988962724" MODIFIED="2009-08-31 15:11:58 +0200" MODIFIED_BY="Tahany Awad" ORDER="1669" O_E="0.0" SE="1.4463193053458159" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="2.0918395330160036" WEIGHT="0.19962557284753313"/>
<DICH_DATA CI_END="1.84136798247089" CI_START="1.4279247027548763" EFFECT_SIZE="1.6215223800589653" ESTIMABLE="YES" EVENTS_1="599" EVENTS_2="182" LOG_CI_END="0.2651405874104995" LOG_CI_START="0.15470530685175016" LOG_EFFECT_SIZE="0.20992294713112483" MODIFIED="2009-08-31 15:11:58 +0200" MODIFIED_BY="Tahany Awad" ORDER="1670" O_E="0.0" SE="0.06487023046366461" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.004208146800408959" WEIGHT="97.99207784194266"/>
<DICH_DATA CI_END="9.488600411843576" CI_START="1.2910228556689638" EFFECT_SIZE="3.5" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="4" LOG_CI_END="0.9772021578182927" LOG_CI_START="0.11093393088225859" LOG_EFFECT_SIZE="0.5440680443502757" MODIFIED="2009-08-31 15:11:58 +0200" MODIFIED_BY="Tahany Awad" ORDER="1671" O_E="0.0" SE="0.5088502445991073" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.2589285714285714" WEIGHT="1.6073747424087084"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3536648605632795" CI_END="1.997853311551163" CI_START="0.7265888391081242" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2048310746109934" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.3005635978426287" LOG_CI_START="-0.13871127747658246" LOG_EFFECT_SIZE="0.08092616018302312" METHOD="MH" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="Tahany Awad" NO="5" P_CHI2="0.7633260922777209" P_Q="1.0" P_Z="0.47019895236303266" Q="0.0" RANDOM="NO" SCALE="60.546035898842575" SORT_BY="EFFECT_SIZE" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="621" TOTAL_2="601" WEIGHT="99.99999999999999" Z="0.7221553896092265">
<NAME>Thyroid malfunction</NAME>
<GROUP_LABEL_1>PEG + RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF + RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEG + RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INF + RBV</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-31 16:00:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="2040" O_E="0.0" SE="0.0" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="3.7781065604215764" CI_START="0.11763682080868876" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.57727420291097" LOG_CI_START="-0.9294567210223325" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2009-08-31 15:44:16 +0200" MODIFIED_BY="Tahany Awad" ORDER="2031" O_E="0.0" SE="0.8850612031567835" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.7833333333333332" WEIGHT="11.62136571440758"/>
<DICH_DATA CI_END="1.8773867335107455" CI_START="0.2606943092371831" EFFECT_SIZE="0.6995884773662552" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.2735537446135515" LOG_CI_START="-0.5838684490536279" LOG_EFFECT_SIZE="-0.15515735222003824" MODIFIED="2009-08-31 15:20:35 +0200" MODIFIED_BY="Tahany Awad" ORDER="1676" O_E="0.0" SE="0.5036540408684111" STUDY_ID="STD-Esmat-2003" TOTAL_1="81" TOTAL_2="85" VAR="0.25366739288307916" WEIGHT="34.023998416880026"/>
<DICH_DATA CI_END="6.706930006003608" CI_START="0.1490995133548233" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.8265237740363401" LOG_CI_START="-0.82652377403634" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-08-31 15:39:09 +0200" MODIFIED_BY="Tahany Awad" ORDER="2029" O_E="0.0" SE="0.9710083124552245" STUDY_ID="STD-Derbala-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.9428571428571428" WEIGHT="7.747577142938386"/>
<DICH_DATA CI_END="5.755043074929529" CI_START="0.2976416141898375" EFFECT_SIZE="1.30879345603272" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7600485785538547" LOG_CI_START="-0.5263063488333208" LOG_EFFECT_SIZE="0.11687111486026695" MODIFIED="2009-08-31 15:20:35 +0200" MODIFIED_BY="Tahany Awad" ORDER="1673" O_E="0.0" SE="0.7556112519068121" STUDY_ID="STD-Bruno-2004" TOTAL_1="163" TOTAL_2="160" VAR="0.5709483640081799" WEIGHT="11.729304095655946"/>
<DICH_DATA CI_END="5.139023492068215" CI_START="0.43061947445821375" EFFECT_SIZE="1.487603305785124" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.7108806029843119" LOG_CI_START="-0.36590633341059986" LOG_EFFECT_SIZE="0.17248713478685596" MODIFIED="2009-08-31 15:20:35 +0200" MODIFIED_BY="Tahany Awad" ORDER="1675" O_E="0.0" SE="0.6325099766196703" STUDY_ID="STD-Mangia-2005" TOTAL_1="121" TOTAL_2="120" VAR="0.40006887052341594" WEIGHT="15.559449531876261"/>
<DICH_DATA CI_END="8.841359714338122" CI_START="0.26122679586337555" EFFECT_SIZE="1.519736842105263" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.946519060377764" LOG_CI_START="-0.5829822764830206" LOG_EFFECT_SIZE="0.18176839194737174" MODIFIED="2009-08-31 15:20:35 +0200" MODIFIED_BY="Tahany Awad" ORDER="1674" O_E="0.0" SE="0.8984366564257483" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.8071884256094781" WEIGHT="7.696939383834214"/>
<DICH_DATA CI_END="9.449677036533028" CI_START="0.7525242485662867" EFFECT_SIZE="2.6666666666666665" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.9754169657951463" LOG_CI_START="-0.12347950125058385" LOG_EFFECT_SIZE="0.4259687322722811" MODIFIED="2009-08-31 15:20:35 +0200" MODIFIED_BY="Tahany Awad" ORDER="1672" O_E="0.0" SE="0.6454972243679028" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.4166666666666667" WEIGHT="11.62136571440758"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.389023338612336" CI_END="1.1862864155864852" CI_START="1.0189726577065672" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0994514185226003" ESTIMABLE="YES" EVENTS_1="1342" EVENTS_2="795" I2="38.1093116944031" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="0.07418955723347292" LOG_CI_START="0.008162530653653232" LOG_EFFECT_SIZE="0.04117604394356306" METHOD="MH" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="Tahany Awad" NO="6" P_CHI2="0.07956278450933241" P_Q="0.6511120835511259" P_Z="0.01450283570918213" Q="0.8581470203031002" RANDOM="NO" SCALE="694.67" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="4954" TOTAL_2="3331" WEIGHT="300.0" Z="2.4445614874890724">
<NAME>Gastrointestinal symptoms</NAME>
<GROUP_LABEL_1>PEG + RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF + RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEG + RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INF + RBV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="7.597823207846175" CI_END="1.1869414422528777" CI_START="0.9321416129701102" DF="5" EFFECT_SIZE="1.0518543199904948" ESTIMABLE="YES" EVENTS_1="504" EVENTS_2="327" I2="34.19167749472554" ID="CMP-002.06.01" LOG_CI_END="0.0744292935681007" LOG_CI_START="-0.03051810367658713" LOG_EFFECT_SIZE="0.021955594945756777" MODIFIED="2009-09-14 10:17:13 +0200" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="0.17983771392939618" P_Z="0.4121754578770177" STUDIES="6" TAU2="0.0" TOTAL_1="1839" TOTAL_2="1297" WEIGHT="100.0" Z="0.8200713211115125">
<NAME>Decreased appetite</NAME>
<DICH_DATA CI_END="1.231798510434754" CI_START="0.7483765597786188" EFFECT_SIZE="0.9601297472631437" ESTIMABLE="YES" EVENTS_1="96" EVENTS_2="98" LOG_CI_END="0.09053967457940361" LOG_CI_START="-0.12587982368168052" LOG_EFFECT_SIZE="-0.017670074551138476" MODIFIED="2009-08-31 15:22:59 +0200" MODIFIED_BY="Tahany Awad" ORDER="1677" O_E="0.0" SE="0.1271258845723548" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.016160990528303675" WEIGHT="26.299336962635998"/>
<DICH_DATA CI_END="8.777517355740464" CI_START="0.01602104493795524" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.94337169686651" LOG_CI_START="-1.795309161411072" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2009-08-31 15:22:59 +0200" MODIFIED_BY="Tahany Awad" ORDER="1678" O_E="0.0" SE="1.6087146928411398" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="2.587962962962963" WEIGHT="0.3750984672886557"/>
<DICH_DATA CI_END="1.9266687314682953" CI_START="0.977962967720394" EFFECT_SIZE="1.3726655348047538" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="31" LOG_CI_END="0.284807049132427" LOG_CI_START="-0.009677590221790362" LOG_EFFECT_SIZE="0.1375647294553183" MODIFIED="2009-08-31 15:22:59 +0200" MODIFIED_BY="Tahany Awad" ORDER="1679" O_E="0.0" SE="0.17298173487914192" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.029922680601797747" WEIGHT="8.182703601222896"/>
<DICH_DATA CI_END="1.3450549013275521" CI_START="0.9558854970754409" EFFECT_SIZE="1.1338952654232424" ESTIMABLE="YES" EVENTS_1="313" EVENTS_2="136" LOG_CI_END="0.1287400113696458" LOG_CI_START="-0.019594127563407386" LOG_EFFECT_SIZE="0.05457294190311921" MODIFIED="2009-08-31 15:22:59 +0200" MODIFIED_BY="Tahany Awad" ORDER="1680" O_E="0.0" SE="0.08713220747510524" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.007592021579484786" WEIGHT="48.4154873518876"/>
<DICH_DATA CI_END="2.371745990672961" CI_START="0.6071476480461607" EFFECT_SIZE="1.2" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.37506817509858015" LOG_CI_START="-0.2167056830033305" LOG_EFFECT_SIZE="0.07918124604762482" MODIFIED="2009-08-31 15:22:59 +0200" MODIFIED_BY="Tahany Awad" ORDER="1681" O_E="0.0" SE="0.3476108935769035" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.12083333333333335" WEIGHT="2.6569474766279777"/>
<DICH_DATA CI_END="1.0740122586035463" CI_START="0.5160855005643943" EFFECT_SIZE="0.7445012787723785" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="51" LOG_CI_END="0.031009238359340472" LOG_CI_START="-0.2872783422734525" LOG_EFFECT_SIZE="-0.12813455195705606" MODIFIED="2009-08-31 15:22:59 +0200" MODIFIED_BY="Tahany Awad" ORDER="1682" O_E="0.0" SE="0.18696370041263685" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.03495542527198623" WEIGHT="14.070426140336876"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="11.011159675022043" CI_END="1.2582069047177407" CI_START="1.00854879679975" DF="3" EFFECT_SIZE="1.1264826052266474" ESTIMABLE="YES" EVENTS_1="606" EVENTS_2="354" I2="72.75491330122779" ID="CMP-002.06.02" LOG_CI_END="0.09975206415258457" LOG_CI_START="0.003696915605983157" LOG_EFFECT_SIZE="0.05172448987928384" MODIFIED="2009-09-14 10:17:44 +0200" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="0.01166572972310509" P_Z="0.034786760612891106" STUDIES="4" TAU2="0.0" TOTAL_1="1784" TOTAL_2="1239" WEIGHT="99.99999999999999" Z="2.1108319296996143">
<NAME>Nausea</NAME>
<DICH_DATA CI_END="1.0703553103132548" CI_START="0.7214267943147825" EFFECT_SIZE="0.8787394382279059" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="145" LOG_CI_END="0.02952796805312082" LOG_CI_START="-0.14180773170582114" LOG_EFFECT_SIZE="-0.05613988182635018" MODIFIED="2009-08-31 15:23:38 +0200" MODIFIED_BY="Tahany Awad" ORDER="1683" O_E="0.0" SE="0.10064343816379473" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.010129101645429574" WEIGHT="35.45210750426266"/>
<DICH_DATA CI_END="2.5339045480791893" CI_START="0.8371045865815172" EFFECT_SIZE="1.4564144736842106" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="16" LOG_CI_END="0.4037902510275828" LOG_CI_START="-0.07722027852086558" LOG_EFFECT_SIZE="0.16328498625335863" MODIFIED="2009-08-31 15:23:38 +0200" MODIFIED_BY="Tahany Awad" ORDER="1684" O_E="0.0" SE="0.2825479660972808" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.07983335314571012" WEIGHT="3.847781838999813"/>
<DICH_DATA CI_END="1.3817854617969334" CI_START="1.0331693420374226" EFFECT_SIZE="1.1948298524901417" ESTIMABLE="YES" EVENTS_1="405" EVENTS_2="167" LOG_CI_END="0.140440619021935" LOG_CI_START="0.014171510566012147" LOG_EFFECT_SIZE="0.07730606479397358" MODIFIED="2009-08-31 15:23:38 +0200" MODIFIED_BY="Tahany Awad" ORDER="1685" O_E="0.0" SE="0.07417109934917644" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.005501351978665403" WEIGHT="54.16480726075601"/>
<DICH_DATA CI_END="2.6529773787372544" CI_START="1.101807607781484" EFFECT_SIZE="1.7096989966555185" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="26" LOG_CI_END="0.4237335468796271" LOG_CI_START="0.0421057667722011" LOG_EFFECT_SIZE="0.23291965682591412" MODIFIED="2009-08-31 15:23:38 +0200" MODIFIED_BY="Tahany Awad" ORDER="1686" O_E="0.0" SE="0.22417004712308042" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.050252210027164096" WEIGHT="6.535303395981512"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.39451826553822156" CI_END="1.4086919810677365" CI_START="0.9328029328386163" DF="2" EFFECT_SIZE="1.14631235333404" ESTIMABLE="YES" EVENTS_1="232" EVENTS_2="114" I2="0.0" ID="CMP-002.06.03" LOG_CI_END="0.14881604240215676" LOG_CI_START="-0.030210097111620954" LOG_EFFECT_SIZE="0.05930297264526788" MODIFIED="2009-09-15 19:17:37 +0200" MODIFIED_BY="Tahany Awad" NO="3" P_CHI2="0.8209779325968182" P_Z="0.19411952981932587" STUDIES="3" TAU2="0.0" TOTAL_1="1331" TOTAL_2="795" WEIGHT="100.0" Z="1.2984884875087639">
<NAME>Diarrhoea</NAME>
<DICH_DATA CI_END="3.604404402407721" CI_START="0.5811987536307034" EFFECT_SIZE="1.4473684210526316" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="7" LOG_CI_END="0.55683351146386" LOG_CI_START="-0.23567532570899255" LOG_EFFECT_SIZE="0.16057909287743372" MODIFIED="2009-08-31 15:24:03 +0200" MODIFIED_BY="Tahany Awad" ORDER="1687" O_E="0.0" SE="0.46552361393734665" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.21671223513328775" WEIGHT="4.829712251401774"/>
<DICH_DATA CI_END="1.3994621496477895" CI_START="0.8826335387217987" EFFECT_SIZE="1.111401020986954" ESTIMABLE="YES" EVENTS_1="194" EVENTS_2="86" LOG_CI_END="0.14596115687763828" LOG_CI_START="-0.05421957405054507" LOG_EFFECT_SIZE="0.045870791413546594" MODIFIED="2009-08-31 15:24:03 +0200" MODIFIED_BY="Tahany Awad" ORDER="1688" O_E="0.0" SE="0.11758715225781419" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.013826738376102375" WEIGHT="80.02615318817037"/>
<DICH_DATA CI_END="2.1066708173014566" CI_START="0.7237429209231141" EFFECT_SIZE="1.2347826086956522" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="21" LOG_CI_END="0.3235966792253855" LOG_CI_START="-0.14041567116649586" LOG_EFFECT_SIZE="0.09159050402944478" MODIFIED="2009-08-31 15:24:03 +0200" MODIFIED_BY="Tahany Awad" ORDER="1689" O_E="0.0" SE="0.27256315151836946" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.07429067156562563" WEIGHT="15.144134560427863"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="Tahany Awad" NO="3">
<NAME>Subgroup and sensitivity analysis</NAME>
<DICH_OUTCOME CHI2="71.52516562416294" CI_END="1.5394037415947261" CI_START="1.2319348984508753" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3771148071516754" ESTIMABLE="YES" EVENTS_1="1673" EVENTS_2="1081" I2="63.64915792489047" I2_Q="27.084897079430924" ID="CMP-003.01" LOG_CI_END="0.18735253779833963" LOG_CI_START="0.09058775816072465" LOG_EFFECT_SIZE="0.1389701479795321" METHOD="MH" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="3.968843961810187E-6" P_Q="0.24156172406363685" P_Z="1.8056346667341443E-8" Q="1.3714579832512364" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.042354742720552035" TOTALS="SUB" TOTAL_1="3300" TOTAL_2="2804" WEIGHT="200.0" Z="5.629661659668677">
<NAME>Sustanied virological response according to trial methodological quality</NAME>
<GROUP_LABEL_1>PEG + RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF + RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEG + RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours INF + RBV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="32.83635023965714" CI_END="1.507481310588617" CI_START="1.1681847796673643" DF="13" EFFECT_SIZE="1.3270330525886056" ESTIMABLE="YES" EVENTS_1="1263" EVENTS_2="759" I2="60.40972914127457" ID="CMP-003.01.01" LOG_CI_END="0.1782519365610791" LOG_CI_START="0.06751154349797601" LOG_EFFECT_SIZE="0.12288174002952754" MODIFIED="2013-01-18 01:13:06 +0100" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="0.001803048075742164" P_Z="1.3632344212412397E-5" STUDIES="14" TAU2="0.02799179450996123" TOTAL_1="2424" TOTAL_2="1861" WEIGHT="100.0" Z="4.349700739787841">
<NAME>Lower risk of bias trials</NAME>
<DICH_DATA CI_END="1.213964321130765" CI_START="0.9715225770566696" EFFECT_SIZE="1.0859989621172808" ESTIMABLE="YES" EVENTS_1="518" EVENTS_2="235" LOG_CI_END="0.08420592284819177" LOG_CI_START="-0.012547102447421674" LOG_EFFECT_SIZE="0.035829410200385034" MODIFIED="2009-09-14 10:55:39 +0200" MODIFIED_BY="Tahany Awad" ORDER="172" O_E="0.0" SE="0.05683320599384272" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.00323001330353856" WEIGHT="13.552807796255122"/>
<DICH_DATA CI_END="1.5453227913002832" CI_START="0.770119130661838" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.18901920986974008" LOG_CI_START="-0.11344208809094057" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2009-09-14 10:55:40 +0200" MODIFIED_BY="Tahany Awad" ORDER="397" O_E="0.0" SE="0.1776672636296754" STUDY_ID="STD-Hinrichsen-2002" TOTAL_1="36" TOTAL_2="36" VAR="0.031565656565656575" WEIGHT="7.104789622556722"/>
<DICH_DATA CI_END="1.4477692368960238" CI_START="1.111778062982932" EFFECT_SIZE="1.2686993646418125" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="197" LOG_CI_END="0.16069934423037288" LOG_CI_START="0.04601810051792744" LOG_EFFECT_SIZE="0.10335872237415017" MODIFIED="2009-09-14 10:55:40 +0200" MODIFIED_BY="Tahany Awad" ORDER="290" O_E="0.0" SE="0.06736433023800226" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.004537952988414626" WEIGHT="13.007883334142258"/>
<DICH_DATA CI_END="1.6490129785229268" CI_START="0.850420578189295" EFFECT_SIZE="1.1842105263157894" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="38" LOG_CI_END="0.21722407376380887" LOG_CI_START="-0.07036623944674189" LOG_EFFECT_SIZE="0.07342891715853349" MODIFIED="2009-09-14 10:55:41 +0200" MODIFIED_BY="Tahany Awad" ORDER="169" O_E="0.0" SE="0.16893197357488735" STUDY_ID="STD-Esmat-2003" TOTAL_1="100" TOTAL_2="100" VAR="0.02853801169590643" WEIGHT="7.485310648456775"/>
<DICH_DATA CI_END="2.587460148665582" CI_START="0.8695786101905303" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.4128736696348625" LOG_CI_START="-0.06069115152350007" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-09-14 10:55:42 +0200" MODIFIED_BY="Tahany Awad" ORDER="167" O_E="0.0" SE="0.2781743201320934" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.07738095238095238" WEIGHT="4.015679317784465"/>
<DICH_DATA CI_END="1.8820793587258766" CI_START="1.0156744853200899" EFFECT_SIZE="1.3825989960959286" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="44" LOG_CI_END="0.27463793170022405" LOG_CI_START="0.006754542711053098" LOG_EFFECT_SIZE="0.1406962372056386" MODIFIED="2009-09-14 10:55:41 +0200" MODIFIED_BY="Tahany Awad" ORDER="168" O_E="0.0" SE="0.15735602873640067" STUDY_ID="STD-Bruno-2004" TOTAL_1="163" TOTAL_2="148" VAR="0.024760919779690957" WEIGHT="8.021258546519597"/>
<DICH_DATA CI_END="2.603101809315667" CI_START="1.47378725784399" EFFECT_SIZE="1.9586776859504131" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="40" LOG_CI_END="0.4154911540329175" LOG_CI_START="0.1684347973543901" LOG_EFFECT_SIZE="0.29196297569365376" MODIFIED="2009-09-14 10:55:45 +0200" MODIFIED_BY="Tahany Awad" ORDER="171" O_E="0.0" SE="0.14512212686165601" STUDY_ID="STD-Mangia-2005" TOTAL_1="121" TOTAL_2="120" VAR="0.021060431704850578" WEIGHT="8.626380350097277"/>
<DICH_DATA CI_END="1.32831790191945" CI_START="0.83714450752687" EFFECT_SIZE="1.0545112781954886" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="49" LOG_CI_END="0.12330202573004048" LOG_CI_START="-0.07719956780781415" LOG_EFFECT_SIZE="0.023051228961113182" MODIFIED="2009-09-14 10:55:46 +0200" MODIFIED_BY="Tahany Awad" ORDER="170" O_E="0.0" SE="0.11777562854303061" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.013871098678705927" WEIGHT="10.107833647353583"/>
<DICH_DATA CI_END="2.128278660395544" CI_START="0.5393838715932618" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.328028490516341" LOG_CI_START="-0.2681020437614546" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2009-09-14 10:55:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="178" O_E="0.0" SE="0.35017002672851316" STUDY_ID="STD-Tsubota-2005" TOTAL_1="28" TOTAL_2="20" VAR="0.12261904761904761" WEIGHT="2.80951327518325"/>
<DICH_DATA CI_END="2.3142093919110254" CI_START="0.8091645396612035" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.3644026517796553" LOG_CI_START="-0.0919631577436773" LOG_EFFECT_SIZE="0.136219747017989" MODIFIED="2009-09-14 10:55:45 +0200" MODIFIED_BY="Tahany Awad" ORDER="176" O_E="0.0" SE="0.2680715355611962" STUDY_ID="STD-Scotto-2005" TOTAL_1="26" TOTAL_2="52" VAR="0.07186234817813765" WEIGHT="4.237612471118951"/>
<DICH_DATA CI_END="2.9224114694732757" CI_START="1.0479359364655019" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.4657413636656654" LOG_CI_START="0.02033473370692358" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2009-09-14 10:55:43 +0200" MODIFIED_BY="Tahany Awad" ORDER="173" O_E="0.0" SE="0.26163405923614175" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.06845238095238093" WEIGHT="4.387441318456816"/>
<DICH_DATA CI_END="2.138945474742073" CI_START="0.595420689890192" EFFECT_SIZE="1.128526645768025" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3301997138279745" LOG_CI_START="-0.22517607840776227" LOG_EFFECT_SIZE="0.052511817710106094" MODIFIED="2009-09-14 10:55:46 +0200" MODIFIED_BY="Tahany Awad" ORDER="177" O_E="0.0" SE="0.32623048951378114" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="29" TOTAL_2="30" VAR="0.10642633228840126" WEIGHT="3.147962037759433"/>
<DICH_DATA CI_END="2.274740625322729" CI_START="0.7610986148420958" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.3569318838885388" LOG_CI_START="-0.11855906845012143" LOG_EFFECT_SIZE="0.11918640771920867" MODIFIED="2009-09-14 10:55:47 +0200" MODIFIED_BY="Tahany Awad" ORDER="175" O_E="0.0" SE="0.2793057391219034" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="0.07801169590643274" WEIGHT="3.9917851637320974"/>
<DICH_DATA CI_END="2.465187633311933" CI_START="1.4892241124860108" EFFECT_SIZE="1.9160419790104948" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="58" LOG_CI_END="0.3918499804127436" LOG_CI_START="0.17296005939892112" LOG_EFFECT_SIZE="0.2824050199058324" MODIFIED="2009-09-14 10:55:42 +0200" MODIFIED_BY="Tahany Awad" ORDER="174" O_E="0.0" SE="0.12857702312610314" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.016532050875970462" WEIGHT="9.503742470583653"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="39.35761151037615" CI_END="1.951681115026239" CI_START="1.2343048222863637" DF="12" EFFECT_SIZE="1.5520855040371049" ESTIMABLE="YES" EVENTS_1="410" EVENTS_2="322" I2="69.51034491298755" ID="CMP-003.01.02" LOG_CI_END="0.2904088597969731" LOG_CI_START="0.09142242573374042" LOG_EFFECT_SIZE="0.19091564276535675" MODIFIED="2009-09-14 10:55:23 +0200" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="9.186649902914734E-5" P_Z="1.692776375116506E-4" STUDIES="13" TAU2="0.10243681425321907" TOTAL_1="876" TOTAL_2="943" WEIGHT="100.00000000000001" Z="3.7609376304166267">
<NAME>High risk of bias trials</NAME>
<DICH_DATA CI_END="3.5357884851784527" CI_START="1.4846729778611794" EFFECT_SIZE="2.291176470588235" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="17" LOG_CI_END="0.5484862771364655" LOG_CI_START="0.17163080412415313" LOG_EFFECT_SIZE="0.3600585406303093" MODIFIED="2009-07-08 16:59:49 +0200" MODIFIED_BY="Tahany Awad" ORDER="179" O_E="0.0" SE="0.22136677031210955" STUDY_ID="STD-Cariti-2002" TOTAL_1="60" TOTAL_2="57" VAR="0.04900324699841427" WEIGHT="9.021554270837122"/>
<DICH_DATA CI_END="2.6453240320969122" CI_START="1.0500708964473708" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.42247887740424933" LOG_CI_START="0.021218621828463496" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2009-07-08 17:00:40 +0200" MODIFIED_BY="Tahany Awad" ORDER="191" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Shobokshi-2003" TOTAL_1="60" TOTAL_2="60" VAR="0.05555555555555555" WEIGHT="8.6474095743618"/>
<DICH_DATA CI_END="8.136576897762474" CI_START="2.1715317787493897" EFFECT_SIZE="4.203431372549019" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" LOG_CI_END="0.9104417332569528" LOG_CI_START="0.336766189320866" LOG_EFFECT_SIZE="0.6236039612889093" MODIFIED="2009-08-20 14:19:54 +0200" MODIFIED_BY="Tahany Awad" ORDER="192" O_E="0.0" SE="0.3369798542477986" STUDY_ID="STD-Thakeb-2003" TOTAL_1="51" TOTAL_2="49" VAR="0.11355542216886758" WEIGHT="6.325341845577569"/>
<DICH_DATA CI_END="2.1462413599066443" CI_START="0.7112332211862739" EFFECT_SIZE="1.2355072463768115" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.3316785598393653" LOG_CI_START="-0.14798796598480524" LOG_EFFECT_SIZE="0.09184529692728" MODIFIED="2009-07-08 17:00:13 +0200" MODIFIED_BY="Tahany Awad" ORDER="183" O_E="0.0" SE="0.2817584916567142" STUDY_ID="STD-Fargion-2004" TOTAL_1="92" TOTAL_2="93" VAR="0.07938784762066668" WEIGHT="7.5139682223532835"/>
<DICH_DATA CI_END="2.965569021857373" CI_START="0.6732913166880276" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4721080364330698" LOG_CI_START="-0.17179698651050676" LOG_EFFECT_SIZE="0.1501555249612815" MODIFIED="2009-07-08 17:00:13 +0200" MODIFIED_BY="Tahany Awad" ORDER="187" O_E="0.0" SE="0.37823299785832587" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="0.14306020066889633" WEIGHT="5.565137856335835"/>
<DICH_DATA CI_END="2.7902971569505266" CI_START="0.5599762004229086" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.44565045658963615" LOG_CI_START="-0.2518304305735233" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-07-08 16:59:49 +0200" MODIFIED_BY="Tahany Awad" ORDER="180" O_E="0.0" SE="0.4097037257057139" STUDY_ID="STD-Derbala-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.16785714285714284" WEIGHT="5.054588515283284"/>
<DICH_DATA CI_END="2.7755764012248623" CI_START="0.7696039905850021" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.44335318633323517" LOG_CI_START="-0.11373268904125085" LOG_EFFECT_SIZE="0.16481024864599217" MODIFIED="2009-07-08 17:00:29 +0200" MODIFIED_BY="Tahany Awad" ORDER="188" O_E="0.0" SE="0.32723500081453055" STUDY_ID="STD-PRETTY-2005" TOTAL_1="89" TOTAL_2="89" VAR="0.1070827457580858" WEIGHT="6.520750288358719"/>
<DICH_DATA CI_END="3.2554443304763296" CI_START="0.3212990204096413" EFFECT_SIZE="1.0227272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5126102731205879" LOG_CI_START="-0.4930905985422754" LOG_EFFECT_SIZE="0.00975983728915624" MODIFIED="2009-07-08 16:59:49 +0200" MODIFIED_BY="Tahany Awad" ORDER="182" O_E="0.0" SE="0.5907536703143696" STUDY_ID="STD-Dollinger-2005" TOTAL_1="22" TOTAL_2="18" VAR="0.34898989898989896" WEIGHT="3.026459647337532"/>
<DICH_DATA CI_END="5.180388604362314" CI_START="1.489473082428314" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" LOG_CI_END="0.7143623393591298" LOG_CI_START="0.1730326591062955" LOG_EFFECT_SIZE="0.44369749923271273" MODIFIED="2009-08-20 13:37:56 +0200" MODIFIED_BY="Tahany Awad" ORDER="181" O_E="0.0" SE="0.3179797338056486" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.10111111111111112" WEIGHT="6.712054317994664"/>
<DICH_DATA CI_END="3.9220926091785993" CI_START="1.1603782889930911" EFFECT_SIZE="2.1333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.593517844094743" LOG_CI_START="0.06459959443370657" LOG_EFFECT_SIZE="0.32905871926422475" MODIFIED="2009-07-08 17:00:59 +0200" MODIFIED_BY="Tahany Awad" ORDER="193" O_E="0.0" SE="0.3106891980384542" STUDY_ID="STD-Wakil-2006" TOTAL_1="18" TOTAL_2="32" VAR="0.0965277777777778" WEIGHT="6.8666726949469625"/>
<DICH_DATA CI_END="1.6137622339028166" CI_START="0.8924743107464483" EFFECT_SIZE="1.2001005530417295" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="51" LOG_CI_END="0.20783954766570586" LOG_CI_START="-0.04940427590106791" LOG_EFFECT_SIZE="0.07921763588231896" MODIFIED="2009-09-14 10:55:23 +0200" MODIFIED_BY="Tahany Awad" ORDER="399" O_E="0.0" SE="0.15110629534058637" STUDY_ID="STD-Rahman-2007b" TOTAL_1="156" TOTAL_2="154" VAR="0.022833112491556513" WEIGHT="10.90624674942174"/>
<DICH_DATA CI_END="1.2131071622648262" CI_START="0.8569730573893487" EFFECT_SIZE="1.0196078431372548" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="85" LOG_CI_END="0.08389916683905466" LOG_CI_START="-0.06703283176532913" LOG_EFFECT_SIZE="0.008433167536862764" MODIFIED="2009-09-14 10:55:23 +0200" MODIFIED_BY="Tahany Awad" ORDER="398" O_E="0.0" SE="0.08865820310565761" STUDY_ID="STD-Rahman-2007a" TOTAL_1="132" TOTAL_2="130" VAR="0.007860276977924036" WEIGHT="12.386770277535167"/>
<DICH_DATA CI_END="1.4710974778935566" CI_START="0.8843842405219245" EFFECT_SIZE="1.1406206318143697" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="73" LOG_CI_END="0.16764145091153848" LOG_CI_START="-0.05335900502971767" LOG_EFFECT_SIZE="0.057141222940910424" MODIFIED="2009-07-08 17:00:13 +0200" MODIFIED_BY="Tahany Awad" ORDER="186" O_E="0.0" SE="0.1298167617897941" STUDY_ID="STD-Horsmans-2008" TOTAL_1="98" TOTAL_2="160" VAR="0.016852391641588145" WEIGHT="11.453045739656325"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="70.94310717742026" CI_END="1.5522786030763325" CI_START="1.23601628239466" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="1.385150399131872" ESTIMABLE="YES" EVENTS_1="1604" EVENTS_2="1002" I2="63.3509145081888" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.19096967112312146" LOG_CI_START="0.09202419187543164" LOG_EFFECT_SIZE="0.14149693149927653" METHOD="MH" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="4.831541991046073E-6" P_Q="0.6621045784940028" P_Z="2.0742577449742192E-8" Q="0.8246643714950717" RANDOM="YES" SCALE="61.05" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.044039575946192525" TOTALS="SUB" TOTAL_1="3108" TOTAL_2="2553" WEIGHT="300.0" Z="5.60569096779605">
<NAME>Sustanied virological response according to baseline treatment history</NAME>
<GROUP_LABEL_1>PEG + RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF + RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INF + RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PEG + RBV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="69.01705041230004" CI_END="1.616208747439213" CI_START="1.2499206461351897" DF="21" EFFECT_SIZE="1.421313716914238" ESTIMABLE="YES" EVENTS_1="1523" EVENTS_2="942" I2="69.57273619410222" ID="CMP-003.02.01" LOG_CI_END="0.20849745297698527" LOG_CI_START="0.0968824417764098" LOG_EFFECT_SIZE="0.15268994737669753" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="5.046621579518629E-7" P_Z="8.208571542097497E-8" STUDIES="22" TAU2="0.0505665568705721" TOTAL_1="2886" TOTAL_2="2337" WEIGHT="100.0" Z="5.3624829570970896">
<NAME>Naive participants</NAME>
<DICH_DATA CI_END="2.587460148665582" CI_START="0.8695786101905303" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.4128736696348625" LOG_CI_START="-0.06069115152350007" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-06-03 15:18:51 +0200" MODIFIED_BY="Tahany Awad" ORDER="157" O_E="0.0" SE="0.2781743201320934" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.07738095238095238" WEIGHT="3.359607812187382"/>
<DICH_DATA CI_END="1.8820793587258766" CI_START="1.0156744853200899" EFFECT_SIZE="1.3825989960959286" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="44" LOG_CI_END="0.27463793170022405" LOG_CI_START="0.006754542711053098" LOG_EFFECT_SIZE="0.1406962372056386" MODIFIED="2009-06-03 15:31:17 +0200" MODIFIED_BY="Tahany Awad" ORDER="159" O_E="0.0" SE="0.15735602873640067" STUDY_ID="STD-Bruno-2004" TOTAL_1="163" TOTAL_2="148" VAR="0.024760919779690957" WEIGHT="5.70646291030164"/>
<DICH_DATA CI_END="3.5357884851784527" CI_START="1.4846729778611794" EFFECT_SIZE="2.291176470588235" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="17" LOG_CI_END="0.5484862771364655" LOG_CI_START="0.17163080412415313" LOG_EFFECT_SIZE="0.3600585406303093" MODIFIED="2009-07-06 11:36:27 +0200" MODIFIED_BY="Tahany Awad" ORDER="179" O_E="0.0" SE="0.22136677031210955" STUDY_ID="STD-Cariti-2002" TOTAL_1="60" TOTAL_2="57" VAR="0.04900324699841427" WEIGHT="4.317106541627206"/>
<DICH_DATA CI_END="2.866589767711372" CI_START="0.5776073810611648" EFFECT_SIZE="1.286764705882353" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.45736554632394205" LOG_CI_START="-0.23836726569178812" LOG_EFFECT_SIZE="0.10949914031607695" MODIFIED="2009-06-22 14:50:59 +0200" MODIFIED_BY="Tahany Awad" ORDER="141" O_E="0.0" SE="0.40867689771100235" STUDY_ID="STD-Derbala-2005" TOTAL_1="34" TOTAL_2="35" VAR="0.16701680672268907" WEIGHT="1.975580506397926"/>
<DICH_DATA CI_END="5.180388604362314" CI_START="1.489473082428314" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" LOG_CI_END="0.7143623393591298" LOG_CI_START="0.1730326591062955" LOG_EFFECT_SIZE="0.44369749923271273" MODIFIED="2009-06-03 15:42:11 +0200" MODIFIED_BY="Tahany Awad" ORDER="164" O_E="0.0" SE="0.3179797338056486" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.10111111111111112" WEIGHT="2.833993015262132"/>
<DICH_DATA CI_END="1.6490129785229268" CI_START="0.850420578189295" EFFECT_SIZE="1.1842105263157894" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="38" LOG_CI_END="0.21722407376380887" LOG_CI_START="-0.07036623944674189" LOG_EFFECT_SIZE="0.07342891715853349" MODIFIED="2009-06-03 16:16:45 +0200" MODIFIED_BY="Tahany Awad" ORDER="169" O_E="0.0" SE="0.16893197357488735" STUDY_ID="STD-Esmat-2003" TOTAL_1="100" TOTAL_2="100" VAR="0.02853801169590643" WEIGHT="5.433990216002446"/>
<DICH_DATA CI_END="1.4477692368960238" CI_START="1.111778062982932" EFFECT_SIZE="1.2686993646418125" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="197" LOG_CI_END="0.16069934423037288" LOG_CI_START="0.04601810051792744" LOG_EFFECT_SIZE="0.10335872237415017" MODIFIED="2009-06-03 16:50:51 +0200" MODIFIED_BY="Tahany Awad" ORDER="516" O_E="0.0" SE="0.06736433023800226" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.004537952988414626" WEIGHT="7.8006945843696"/>
<DICH_DATA CI_END="1.5453227913002832" CI_START="0.770119130661838" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.18901920986974008" LOG_CI_START="-0.11344208809094057" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2009-06-03 20:37:45 +0200" MODIFIED_BY="Tahany Awad" ORDER="518" O_E="0.0" SE="0.1776672636296754" STUDY_ID="STD-Hinrichsen-2002" TOTAL_1="36" TOTAL_2="36" VAR="0.031565656565656575" WEIGHT="5.233676698182467"/>
<DICH_DATA CI_END="2.965569021857373" CI_START="0.6732913166880276" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4721080364330698" LOG_CI_START="-0.17179698651050676" LOG_EFFECT_SIZE="0.1501555249612815" MODIFIED="2009-06-04 16:19:04 +0200" MODIFIED_BY="Tahany Awad" ORDER="103" O_E="0.0" SE="0.37823299785832587" STUDY_ID="STD-Horsmans-2008" TOTAL_1="23" TOTAL_2="26" VAR="0.14306020066889633" WEIGHT="2.220010586830793"/>
<DICH_DATA CI_END="1.32831790191945" CI_START="0.83714450752687" EFFECT_SIZE="1.0545112781954886" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="49" LOG_CI_END="0.12330202573004048" LOG_CI_START="-0.07719956780781415" LOG_EFFECT_SIZE="0.023051228961113182" MODIFIED="2009-06-03 20:46:56 +0200" MODIFIED_BY="Tahany Awad" ORDER="524" O_E="0.0" SE="0.11777562854303061" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.013871098678705927" WEIGHT="6.670842506096657"/>
<DICH_DATA CI_END="2.603101809315667" CI_START="1.47378725784399" EFFECT_SIZE="1.9586776859504131" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="40" LOG_CI_END="0.4154911540329175" LOG_CI_START="0.1684347973543901" LOG_EFFECT_SIZE="0.29196297569365376" MODIFIED="2009-06-04 15:04:30 +0200" MODIFIED_BY="Tahany Awad" ORDER="85" O_E="0.0" SE="0.14512212686165601" STUDY_ID="STD-Mangia-2005" TOTAL_1="121" TOTAL_2="120" VAR="0.021060431704850578" WEIGHT="6.001277733164874"/>
<DICH_DATA CI_END="1.213964321130765" CI_START="0.9715225770566696" EFFECT_SIZE="1.0859989621172808" ESTIMABLE="YES" EVENTS_1="518" EVENTS_2="235" LOG_CI_END="0.08420592284819177" LOG_CI_START="-0.012547102447421674" LOG_EFFECT_SIZE="0.035829410200385034" MODIFIED="2009-06-04 15:44:06 +0200" MODIFIED_BY="Tahany Awad" ORDER="95" O_E="0.0" SE="0.05683320599384272" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.00323001330353856" WEIGHT="7.990350504504911"/>
<DICH_DATA CI_END="2.9224114694732757" CI_START="1.0479359364655019" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.4657413636656654" LOG_CI_START="0.02033473370692358" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2009-06-04 15:54:09 +0200" MODIFIED_BY="Tahany Awad" ORDER="97" O_E="0.0" SE="0.26163405923614175" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.06845238095238093" WEIGHT="3.611639118060092"/>
<DICH_DATA CI_END="2.6685353150485716" CI_START="1.5143339462398608" EFFECT_SIZE="2.0102372034956306" ESTIMABLE="YES" EVENTS_1="97" EVENTS_2="45" LOG_CI_END="0.42627295457420905" LOG_CI_START="0.18022165786991562" LOG_EFFECT_SIZE="0.3032473062220623" MODIFIED="2009-06-04 16:35:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="437" O_E="0.0" SE="0.1445317496576639" STUDY_ID="STD-Nevens-2010" TOTAL_1="178" TOTAL_2="166" VAR="0.020889426659105634" WEIGHT="6.015639704305636"/>
<DICH_DATA CI_END="1.6137622339028166" CI_START="0.8924743107464483" EFFECT_SIZE="1.2001005530417295" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="51" LOG_CI_END="0.20783954766570586" LOG_CI_START="-0.04940427590106791" LOG_EFFECT_SIZE="0.07921763588231896" MODIFIED="2009-07-22 12:25:13 +0200" MODIFIED_BY="Tahany Awad" ORDER="440" O_E="0.0" SE="0.15110629534058637" STUDY_ID="STD-Rahman-2007a" TOTAL_1="156" TOTAL_2="154" VAR="0.022833112491556513" WEIGHT="5.856340435412462"/>
<DICH_DATA CI_END="1.2131071622648262" CI_START="0.8569730573893487" EFFECT_SIZE="1.0196078431372548" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="85" LOG_CI_END="0.08389916683905466" LOG_CI_START="-0.06703283176532913" LOG_EFFECT_SIZE="0.008433167536862764" MODIFIED="2009-07-22 12:25:13 +0200" MODIFIED_BY="Tahany Awad" ORDER="441" O_E="0.0" SE="0.08865820310565761" STUDY_ID="STD-Rahman-2007b" TOTAL_1="132" TOTAL_2="130" VAR="0.007860276977924036" WEIGHT="7.357123830224512"/>
<DICH_DATA CI_END="2.274740625322729" CI_START="0.7610986148420958" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.3569318838885388" LOG_CI_START="-0.11855906845012143" LOG_EFFECT_SIZE="0.11918640771920867" MODIFIED="2009-06-04 17:02:17 +0200" MODIFIED_BY="Tahany Awad" ORDER="447" O_E="0.0" SE="0.2793057391219034" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="0.07801169590643274" WEIGHT="3.34312718012151"/>
<DICH_DATA CI_END="2.3142093919110254" CI_START="0.8091645396612035" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.3644026517796553" LOG_CI_START="-0.0919631577436773" LOG_EFFECT_SIZE="0.136219747017989" MODIFIED="2009-06-04 17:17:52 +0200" MODIFIED_BY="Tahany Awad" ORDER="451" O_E="0.0" SE="0.2680715355611962" STUDY_ID="STD-Scotto-2005" TOTAL_1="26" TOTAL_2="52" VAR="0.07186234817813765" WEIGHT="3.511045463163432"/>
<DICH_DATA CI_END="2.138945474742073" CI_START="0.595420689890192" EFFECT_SIZE="1.128526645768025" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3301997138279745" LOG_CI_START="-0.22517607840776227" LOG_EFFECT_SIZE="0.052511817710106094" MODIFIED="2009-06-04 17:33:23 +0200" MODIFIED_BY="Tahany Awad" ORDER="457" O_E="0.0" SE="0.32623048951378114" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="29" TOTAL_2="30" VAR="0.10642633228840126" WEIGHT="2.7380440855258286"/>
<DICH_DATA CI_END="8.136576897762474" CI_START="2.1715317787493897" EFFECT_SIZE="4.203431372549019" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" LOG_CI_END="0.9104417332569528" LOG_CI_START="0.336766189320866" LOG_EFFECT_SIZE="0.6236039612889093" MODIFIED="2009-06-04 17:39:03 +0200" MODIFIED_BY="Tahany Awad" ORDER="461" O_E="0.0" SE="0.3369798542477986" STUDY_ID="STD-Thakeb-2003" TOTAL_1="51" TOTAL_2="49" VAR="0.11355542216886758" WEIGHT="2.619109604619392"/>
<DICH_DATA CI_END="2.128278660395544" CI_START="0.5393838715932618" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.328028490516341" LOG_CI_START="-0.2681020437614546" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2009-06-04 17:41:37 +0200" MODIFIED_BY="Tahany Awad" ORDER="463" O_E="0.0" SE="0.35017002672851316" STUDY_ID="STD-Tsubota-2005" TOTAL_1="28" TOTAL_2="20" VAR="0.12261904761904761" WEIGHT="2.4820391561880837"/>
<DICH_DATA CI_END="3.9220926091785993" CI_START="1.1603782889930911" EFFECT_SIZE="2.1333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.593517844094743" LOG_CI_START="0.06459959443370657" LOG_EFFECT_SIZE="0.32905871926422475" MODIFIED="2009-06-04 17:56:51 +0200" MODIFIED_BY="Tahany Awad" ORDER="469" O_E="0.0" SE="0.3106891980384542" STUDY_ID="STD-Wakil-2006" TOTAL_1="18" TOTAL_2="32" VAR="0.0965277777777778" WEIGHT="2.9222978074510166"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="1.8324339508206309" CI_END="1.6128632051356233" CI_START="0.9570037834672361" DF="3" EFFECT_SIZE="1.2423832699814839" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="52" I2="0.0" ID="CMP-003.02.02" LOG_CI_END="0.20759753429901986" LOG_CI_START="-0.019086345257957816" LOG_EFFECT_SIZE="0.09425559452053103" MODIFIED="2009-06-04 16:35:28 +0200" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="0.6079026750850469" P_Z="0.10311975606418237" STUDIES="4" TAU2="0.0" TOTAL_1="199" TOTAL_2="190" WEIGHT="100.0" Z="1.629913613289977">
<NAME>Non-responders and relapsers</NAME>
<DICH_DATA CI_END="3.2554443304763296" CI_START="0.3212990204096413" EFFECT_SIZE="1.0227272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5126102731205879" LOG_CI_START="-0.4930905985422754" LOG_EFFECT_SIZE="0.00975983728915624" MODIFIED="2009-06-03 16:05:05 +0200" MODIFIED_BY="Tahany Awad" ORDER="165" O_E="0.0" SE="0.5907536703143696" STUDY_ID="STD-Dollinger-2005" TOTAL_1="22" TOTAL_2="18" VAR="0.34898989898989896" WEIGHT="5.080466831457498"/>
<DICH_DATA CI_END="1.5453227913002832" CI_START="0.770119130661838" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.18901920986974008" LOG_CI_START="-0.11344208809094057" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2009-06-03 16:57:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="173" O_E="0.0" SE="0.1776672636296754" STUDY_ID="STD-Fargion-2004" TOTAL_1="36" TOTAL_2="36" VAR="0.031565656565656575" WEIGHT="56.16964128859407"/>
<DICH_DATA CI_END="2.7827587474494333" CI_START="0.9189300198750407" EFFECT_SIZE="1.599112426035503" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="13" LOG_CI_END="0.44447555660602706" LOG_CI_START="-0.03671756058267834" LOG_EFFECT_SIZE="0.20387899801167442" MODIFIED="2009-06-04 16:35:28 +0200" MODIFIED_BY="Tahany Awad" ORDER="100" O_E="0.0" SE="0.28265521898099116" STUDY_ID="STD-Nevens-2010" TOTAL_1="52" TOTAL_2="47" VAR="0.07989397281719206" WEIGHT="22.192307427104847"/>
<DICH_DATA CI_END="2.7755764012248623" CI_START="0.7696039905850021" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.44335318633323517" LOG_CI_START="-0.11373268904125085" LOG_EFFECT_SIZE="0.16481024864599217" MODIFIED="2009-06-04 15:27:11 +0200" MODIFIED_BY="Tahany Awad" ORDER="89" O_E="0.0" SE="0.32723500081453055" STUDY_ID="STD-PRETTY-2005" TOTAL_1="89" TOTAL_2="89" VAR="0.1070827457580858" WEIGHT="16.557584452843585"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.965569021857373" CI_START="0.6732913166880276" DF="0" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" I2="0.0" ID="CMP-003.02.03" LOG_CI_END="0.4721080364330698" LOG_CI_START="-0.17179698651050676" LOG_EFFECT_SIZE="0.1501555249612815" MODIFIED="2009-09-24 16:09:32 +0200" MODIFIED_BY="Tahany Awad" NO="3" P_CHI2="1.0" P_Z="0.3606600205753411" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="26" WEIGHT="100.0" Z="0.9141081697373418">
<NAME>Unknown</NAME>
<DICH_DATA CI_END="2.965569021857373" CI_START="0.6732913166880276" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4721080364330698" LOG_CI_START="-0.17179698651050676" LOG_EFFECT_SIZE="0.1501555249612815" MODIFIED="2009-09-24 16:09:32 +0200" MODIFIED_BY="Tahany Awad" ORDER="391" O_E="0.0" SE="0.37823299785832587" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="0.14306020066889633" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="88.54062011358172" CI_END="1.264839238692054" CI_START="1.1141136354758374" CI_STUDY="95" CI_TOTAL="95" DF="33" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1870866196329966" ESTIMABLE="YES" EVENTS_1="1626" EVENTS_2="1033" I2="62.72897122510897" I2_Q="89.05723951611085" ID="CMP-003.03" LOG_CI_END="0.10203533010813622" LOG_CI_START="0.046929489529986525" LOG_EFFECT_SIZE="0.07448240981906136" METHOD="MH" MODIFIED="2014-02-06 15:47:10 +0100" MODIFIED_BY="Tahany Awad" NO="3" P_CHI2="5.663167977898453E-7" P_Q="1.0745333517037103E-4" P_Z="1.169043219095195E-7" Q="18.276923843344367" RANDOM="YES" SCALE="14.052775232250953" SORT_BY="YEAR" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04437019221376974" TOTALS="SUB" TOTAL_1="3209" TOTAL_2="2719" WEIGHT="300.0" Z="5.298271079635691">
<NAME>Sustained virological response according to genotype</NAME>
<GROUP_LABEL_1>PEG + RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF + RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INF + RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PEG + RBV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="29.13907036867299" CI_END="1.6982481842833497" CI_START="1.265336995519648" DF="15" EFFECT_SIZE="1.4658977642208857" ESTIMABLE="YES" EVENTS_1="838" EVENTS_2="489" I2="48.5227228932935" ID="CMP-003.03.01" LOG_CI_END="0.23000115892821815" LOG_CI_START="0.1022062059889698" LOG_EFFECT_SIZE="0.166103682458594" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="0.015433951066633367" P_Z="3.48752989505153E-7" STUDIES="16" TAU2="0.034560076173605854" TOTAL_1="1960" TOTAL_2="1588" WEIGHT="100.0" Z="5.09499362581379">
<NAME>Genotype one</NAME>
<DICH_DATA CI_END="1.356140598229831" CI_START="0.9504291782959912" EFFECT_SIZE="1.1353041858591961" ESTIMABLE="YES" EVENTS_1="263" EVENTS_2="114" LOG_CI_END="0.13230471745878214" LOG_CI_START="-0.02208023926268941" LOG_EFFECT_SIZE="0.05511223909804637" MODIFIED="2009-06-04 18:22:51 +0200" MODIFIED_BY="Tahany Awad" ORDER="92" O_E="0.0" SE="0.09068648779605332" STUDY_ID="STD-Manns-2001" TOTAL_1="697" TOTAL_2="343" VAR="0.008224039068783728" WEIGHT="13.171039536451548"/>
<DICH_DATA CI_END="3.5357884851784527" CI_START="1.4846729778611794" EFFECT_SIZE="2.291176470588235" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="17" LOG_CI_END="0.5484862771364655" LOG_CI_START="0.17163080412415313" LOG_EFFECT_SIZE="0.3600585406303093" MODIFIED="2009-08-24 13:54:05 +0200" MODIFIED_BY="Tahany Awad" ORDER="217" O_E="0.0" SE="0.22136677031210955" STUDY_ID="STD-Cariti-2002" TOTAL_1="60" TOTAL_2="57" VAR="0.04900324699841427" WEIGHT="6.74352397677616"/>
<DICH_DATA CI_END="1.5601828439623722" CI_START="1.052362629030561" EFFECT_SIZE="1.2813579201146803" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="103" LOG_CI_END="0.1931754980151351" LOG_CI_START="0.022165417241503428" LOG_EFFECT_SIZE="0.10767045762831924" MODIFIED="2009-06-03 16:43:29 +0200" MODIFIED_BY="Tahany Awad" ORDER="512" O_E="0.0" SE="0.10045216795998349" STUDY_ID="STD-Fried-2002" TOTAL_1="298" TOTAL_2="285" VAR="0.010090638047860733" WEIGHT="12.620431346173067"/>
<DICH_DATA CI_END="2.965569021857373" CI_START="0.6732913166880276" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4721080364330698" LOG_CI_START="-0.17179698651050676" LOG_EFFECT_SIZE="0.1501555249612815" MODIFIED="2009-06-03 20:36:13 +0200" MODIFIED_BY="Tahany Awad" ORDER="520" O_E="0.0" SE="0.37823299785832587" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="0.14306020066889633" WEIGHT="3.1725616208181235"/>
<DICH_DATA CI_END="1.8820793587258766" CI_START="1.0156744853200899" EFFECT_SIZE="1.3825989960959286" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="44" LOG_CI_END="0.27463793170022405" LOG_CI_START="0.006754542711053098" LOG_EFFECT_SIZE="0.1406962372056386" MODIFIED="2009-06-03 15:34:30 +0200" MODIFIED_BY="Tahany Awad" ORDER="160" O_E="0.0" SE="0.15735602873640067" STUDY_ID="STD-Bruno-2004" TOTAL_1="163" TOTAL_2="148" VAR="0.024760919779690957" WEIGHT="9.499356245354726"/>
<DICH_DATA CI_END="3.2554443304763296" CI_START="0.3212990204096413" EFFECT_SIZE="1.0227272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5126102731205879" LOG_CI_START="-0.4930905985422754" LOG_EFFECT_SIZE="0.00975983728915624" MODIFIED="2009-06-03 16:05:40 +0200" MODIFIED_BY="Tahany Awad" ORDER="166" O_E="0.0" SE="0.5907536703143696" STUDY_ID="STD-Dollinger-2005" TOTAL_1="22" TOTAL_2="18" VAR="0.34898989898989896" WEIGHT="1.4691990871577854"/>
<DICH_DATA CI_END="2.3142093919110254" CI_START="0.8091645396612035" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.3644026517796553" LOG_CI_START="-0.0919631577436773" LOG_EFFECT_SIZE="0.136219747017989" MODIFIED="2009-06-04 17:20:49 +0200" MODIFIED_BY="Tahany Awad" ORDER="452" O_E="0.0" SE="0.2680715355611962" STUDY_ID="STD-Scotto-2005" TOTAL_1="26" TOTAL_2="52" VAR="0.07186234817813765" WEIGHT="5.295042626797484"/>
<DICH_DATA CI_END="4.111604533897573" CI_START="0.7997949603007863" EFFECT_SIZE="1.8134057971014492" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="8" LOG_CI_END="0.6140113362874512" LOG_CI_START="-0.09702133678721175" LOG_EFFECT_SIZE="0.25849499975011975" MODIFIED="2009-06-04 15:26:27 +0200" MODIFIED_BY="Tahany Awad" ORDER="88" O_E="0.0" SE="0.4176641118325532" STUDY_ID="STD-PRETTY-2005" TOTAL_1="69" TOTAL_2="77" VAR="0.17444331031287552" WEIGHT="2.6961825014546412"/>
<DICH_DATA CI_END="2.128278660395544" CI_START="0.5393838715932618" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.328028490516341" LOG_CI_START="-0.2681020437614546" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2009-06-04 17:40:58 +0200" MODIFIED_BY="Tahany Awad" ORDER="462" O_E="0.0" SE="0.35017002672851316" STUDY_ID="STD-Tsubota-2005" TOTAL_1="28" TOTAL_2="20" VAR="0.12261904761904761" WEIGHT="3.5851534210928775"/>
<DICH_DATA CI_END="3.837992449754306" CI_START="1.5305900969052286" EFFECT_SIZE="2.423714759535655" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="18" LOG_CI_END="0.5841041160395603" LOG_CI_START="0.1848588990670476" LOG_EFFECT_SIZE="0.38448150755330396" MODIFIED="2009-06-04 18:22:54 +0200" MODIFIED_BY="Tahany Awad" ORDER="86" O_E="0.0" SE="0.23451861674535127" STUDY_ID="STD-Mangia-2005" TOTAL_1="67" TOTAL_2="79" VAR="0.05499898160015296" WEIGHT="6.292063442797003"/>
<DICH_DATA CI_END="2.4915325367013956" CI_START="1.032132634215539" EFFECT_SIZE="1.6036184210526316" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.39646656295704985" LOG_CI_START="0.013735509894553995" LOG_EFFECT_SIZE="0.2051010364258019" MODIFIED="2009-06-03 20:47:56 +0200" MODIFIED_BY="Tahany Awad" ORDER="525" O_E="0.0" SE="0.22481811511817762" STUDY_ID="STD-Lee-2005" TOTAL_1="38" TOTAL_2="39" VAR="0.05054318488529016" WEIGHT="6.621500355898612"/>
<DICH_DATA CI_END="10.899399543348853" CI_START="1.2016722221112393" EFFECT_SIZE="3.619047619047619" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="1.0374025729687673" LOG_CI_START="0.07978602212497707" LOG_EFFECT_SIZE="0.5585942975468721" MODIFIED="2009-06-04 18:22:48 +0200" MODIFIED_BY="Tahany Awad" ORDER="98" O_E="0.0" SE="0.5625087022440192" STUDY_ID="STD-Napoli-2005" TOTAL_1="21" TOTAL_2="19" VAR="0.3164160401002506" WEIGHT="1.6055544729713775"/>
<DICH_DATA CI_END="1.6137622339028166" CI_START="0.8924743107464483" EFFECT_SIZE="1.2001005530417295" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="51" LOG_CI_END="0.20783954766570586" LOG_CI_START="-0.04940427590106791" LOG_EFFECT_SIZE="0.07921763588231896" MODIFIED="2009-07-22 12:24:20 +0200" MODIFIED_BY="Tahany Awad" ORDER="443" O_E="0.0" SE="0.15110629534058637" STUDY_ID="STD-Rahman-2007a" TOTAL_1="156" TOTAL_2="154" VAR="0.022833112491556513" WEIGHT="9.818434669611998"/>
<DICH_DATA CI_END="2.138945474742073" CI_START="0.595420689890192" EFFECT_SIZE="1.128526645768025" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3301997138279745" LOG_CI_START="-0.22517607840776227" LOG_EFFECT_SIZE="0.052511817710106094" MODIFIED="2009-07-22 12:23:59 +0200" MODIFIED_BY="Tahany Awad" ORDER="458" O_E="0.0" SE="0.32623048951378114" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="29" TOTAL_2="30" VAR="0.10642633228840126" WEIGHT="3.9969191323961346"/>
<DICH_DATA CI_END="2.339116459574322" CI_START="0.4019946117649081" EFFECT_SIZE="0.9696969696969697" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.3690518449350159" LOG_CI_START="-0.39577976805097886" LOG_EFFECT_SIZE="-0.01336396155798149" MODIFIED="2009-06-04 17:04:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="448" O_E="0.0" SE="0.44926587544551705" STUDY_ID="STD-Roffi-2008" TOTAL_1="33" TOTAL_2="28" VAR="0.20183982683982682" WEIGHT="2.3837204085383776"/>
<DICH_DATA CI_END="2.465187633311933" CI_START="1.4892241124860108" EFFECT_SIZE="1.9160419790104948" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="58" LOG_CI_END="0.3918499804127436" LOG_CI_START="0.17296005939892112" LOG_EFFECT_SIZE="0.2824050199058324" MODIFIED="2009-08-24 13:54:21 +0200" MODIFIED_BY="Tahany Awad" ORDER="218" O_E="0.0" SE="0.12857702312610314" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.016532050875970462" WEIGHT="11.029317155710107"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="8.338008908670837" CI_END="1.1860591706328314" CI_START="1.0264352213055552" DF="8" EFFECT_SIZE="1.1033643583558395" ESTIMABLE="YES" EVENTS_1="602" EVENTS_2="437" I2="4.053832424181455" ID="CMP-003.03.02" LOG_CI_END="0.07410635583963947" LOG_CI_START="0.0113315460911539" LOG_EFFECT_SIZE="0.04271895096539664" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="0.4011680988339451" P_Z="0.0076405552264486795" STUDIES="9" TAU2="5.65923765698287E-4" TOTAL_1="887" TOTAL_2="772" WEIGHT="100.0" Z="2.667554252572786">
<NAME>Genotypes two and three</NAME>
<DICH_DATA CI_END="1.1370458035704378" CI_START="0.9300410309744036" EFFECT_SIZE="1.0283478260869565" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="115" LOG_CI_END="0.05577795970728458" LOG_CI_START="-0.031497891088334326" LOG_EFFECT_SIZE="0.01214003430947516" MODIFIED="2009-06-04 15:42:04 +0200" MODIFIED_BY="Tahany Awad" ORDER="93" O_E="0.0" SE="0.05126626677977556" STUDY_ID="STD-Manns-2001" TOTAL_1="300" TOTAL_2="146" VAR="0.0026282301095351193" WEIGHT="42.56867969448431"/>
<DICH_DATA CI_END="1.4656791664868822" CI_START="1.0619092518959576" EFFECT_SIZE="1.2475649350649352" ESTIMABLE="YES" EVENTS_1="106" EVENTS_2="88" LOG_CI_END="0.16603891472978852" LOG_CI_START="0.026087404612888495" LOG_EFFECT_SIZE="0.09606315967133851" MODIFIED="2009-06-03 16:44:09 +0200" MODIFIED_BY="Tahany Awad" ORDER="513" O_E="0.0" SE="0.08220820981381505" STUDY_ID="STD-Fried-2002" TOTAL_1="140" TOTAL_2="145" VAR="0.006758189760792236" WEIGHT="18.564828728816757"/>
<DICH_DATA CI_END="1.5453227913002832" CI_START="0.770119130661838" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.18901920986974008" LOG_CI_START="-0.11344208809094057" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2009-06-08 11:35:18 +0200" MODIFIED_BY="Tahany Awad" ORDER="517" O_E="0.0" SE="0.1776672636296754" STUDY_ID="STD-Hinrichsen-2002" TOTAL_1="36" TOTAL_2="36" VAR="0.031565656565656575" WEIGHT="4.231690810334112"/>
<DICH_DATA CI_END="2.1462413599066443" CI_START="0.7112332211862739" EFFECT_SIZE="1.2355072463768115" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.3316785598393653" LOG_CI_START="-0.14798796598480524" LOG_EFFECT_SIZE="0.09184529692728" MODIFIED="2009-08-24 13:53:38 +0200" MODIFIED_BY="Tahany Awad" ORDER="220" O_E="0.0" SE="0.2817584916567142" STUDY_ID="STD-Fargion-2004" TOTAL_1="92" TOTAL_2="93" VAR="0.07938784762066668" WEIGHT="1.7006191309306349"/>
<DICH_DATA CI_END="1.8666595998634221" CI_START="0.7482318763304381" EFFECT_SIZE="1.1818181818181819" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.27106512813682554" LOG_CI_START="-0.12596379383960205" LOG_EFFECT_SIZE="0.07255066714861175" MODIFIED="2009-06-04 15:55:44 +0200" MODIFIED_BY="Tahany Awad" ORDER="99" O_E="0.0" SE="0.2332167540938137" STUDY_ID="STD-Napoli-2005" TOTAL_1="11" TOTAL_2="13" VAR="0.05439005439005437" WEIGHT="2.474178747657748"/>
<DICH_DATA CI_END="1.99252357495428" CI_START="1.0544595983812015" EFFECT_SIZE="1.4494949494949494" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="22" LOG_CI_END="0.2994034685434249" LOG_CI_START="0.02302994440149745" LOG_EFFECT_SIZE="0.1612167064724612" MODIFIED="2009-06-08 11:35:31 +0200" MODIFIED_BY="Tahany Awad" ORDER="87" O_E="0.0" SE="0.16234317615197666" STUDY_ID="STD-Mangia-2005" TOTAL_1="54" TOTAL_2="41" VAR="0.02635530684311172" WEIGHT="5.050694568368283"/>
<DICH_DATA CI_END="1.2131071622648262" CI_START="0.8569730573893487" EFFECT_SIZE="1.0196078431372548" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="85" LOG_CI_END="0.08389916683905466" LOG_CI_START="-0.06703283176532913" LOG_EFFECT_SIZE="0.008433167536862764" MODIFIED="2009-07-22 12:24:25 +0200" MODIFIED_BY="Tahany Awad" ORDER="442" O_E="0.0" SE="0.08865820310565761" STUDY_ID="STD-Rahman-2007b" TOTAL_1="132" TOTAL_2="130" VAR="0.007860276977924036" WEIGHT="16.136680972456205"/>
<DICH_DATA CI_END="2.0547542337425915" CI_START="0.625108552327895" EFFECT_SIZE="1.1333333333333333" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.3127598839676193" LOG_CI_START="-0.20404455932243387" LOG_EFFECT_SIZE="0.054357662322592676" MODIFIED="2009-06-08 11:35:10 +0200" MODIFIED_BY="Tahany Awad" ORDER="449" O_E="0.0" SE="0.30357348821183" STUDY_ID="STD-Roffi-2008" TOTAL_1="24" TOTAL_2="8" VAR="0.09215686274509807" WEIGHT="1.4664239323078865"/>
<DICH_DATA CI_END="1.4710974778935566" CI_START="0.8843842405219245" EFFECT_SIZE="1.1406206318143697" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="73" LOG_CI_END="0.16764145091153848" LOG_CI_START="-0.05335900502971767" LOG_EFFECT_SIZE="0.057141222940910424" MODIFIED="2009-08-24 13:53:53 +0200" MODIFIED_BY="Tahany Awad" ORDER="219" O_E="0.0" SE="0.1298167617897941" STUDY_ID="STD-Horsmans-2008" TOTAL_1="98" TOTAL_2="160" VAR="0.016852391641588145" WEIGHT="7.806203414644065"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="18.145497324169476" CI_END="2.3867335768233793" CI_START="1.2986769325828746" DF="8" EFFECT_SIZE="1.760566908822706" ESTIMABLE="YES" EVENTS_1="186" EVENTS_2="107" I2="55.91192758688325" ID="CMP-003.03.03" LOG_CI_END="0.3778039428554505" LOG_CI_START="0.11350112655658105" LOG_EFFECT_SIZE="0.24565253470601575" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NO="3" P_CHI2="0.02016176802245173" P_Z="2.6914189148193957E-4" STUDIES="9" TAU2="0.11462821549511913" TOTAL_1="362" TOTAL_2="359" WEIGHT="100.00000000000001" Z="3.6433219098984395">
<NAME>Genotype four</NAME>
<DICH_DATA CI_END="2.4525473255679677" CI_START="0.5325574904766074" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.38961739649427657" LOG_CI_START="-0.27363350253890306" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2009-06-04 15:43:21 +0200" MODIFIED_BY="Tahany Awad" ORDER="94" O_E="0.0" SE="0.38959686123698983" STUDY_ID="STD-Manns-2001" TOTAL_1="28" TOTAL_2="16" VAR="0.1517857142857143" WEIGHT="9.047359696701207"/>
<DICH_DATA CI_END="2.6453240320969122" CI_START="1.0500708964473708" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.42247887740424933" LOG_CI_START="0.021218621828463496" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2009-06-08 11:35:56 +0200" MODIFIED_BY="Tahany Awad" ORDER="454" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Shobokshi-2003" TOTAL_1="60" TOTAL_2="60" VAR="0.05555555555555555" WEIGHT="14.163175701525521"/>
<DICH_DATA CI_END="4.883056228880013" CI_START="0.9164039612200572" EFFECT_SIZE="2.1153846153846154" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.6886917252572371" LOG_CI_START="-0.037913042210385293" LOG_EFFECT_SIZE="0.3253893415234259" MODIFIED="2009-06-03 16:45:08 +0200" MODIFIED_BY="Tahany Awad" ORDER="514" O_E="0.0" SE="0.426811237162088" STUDY_ID="STD-Fried-2002" TOTAL_1="13" TOTAL_2="11" VAR="0.18216783216783214" WEIGHT="8.12120872201149"/>
<DICH_DATA CI_END="8.136576897762474" CI_START="2.1715317787493897" EFFECT_SIZE="4.203431372549019" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" LOG_CI_END="0.9104417332569528" LOG_CI_START="0.336766189320866" LOG_EFFECT_SIZE="0.6236039612889093" MODIFIED="2009-06-08 11:35:57 +0200" MODIFIED_BY="Tahany Awad" ORDER="460" O_E="0.0" SE="0.3369798542477986" STUDY_ID="STD-Thakeb-2003" TOTAL_1="51" TOTAL_2="49" VAR="0.11355542216886758" WEIGHT="10.563170416663546"/>
<DICH_DATA CI_END="1.5902666738308422" CI_START="0.7938711670312022" EFFECT_SIZE="1.1235955056179776" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="34" LOG_CI_END="0.20146995781861515" LOG_CI_START="-0.10024997110844061" LOG_EFFECT_SIZE="0.05060999335508724" MODIFIED="2009-06-03 16:34:02 +0200" MODIFIED_BY="Tahany Awad" ORDER="511" O_E="0.0" SE="0.1772317797894882" STUDY_ID="STD-Esmat-2003" TOTAL_1="89" TOTAL_2="85" VAR="0.03141110376734964" WEIGHT="16.504751344443864"/>
<DICH_DATA CI_END="2.5851996292044426" CI_START="0.6827720462576079" EFFECT_SIZE="1.3285714285714285" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.4124940849597192" LOG_CI_START="-0.1657242678803626" LOG_EFFECT_SIZE="0.12338490853967826" MODIFIED="2009-06-03 16:33:45 +0200" MODIFIED_BY="Tahany Awad" ORDER="509" O_E="0.0" SE="0.33964832268527195" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="28" TOTAL_2="31" VAR="0.11536098310291862" WEIGHT="10.480242835888827"/>
<DICH_DATA CI_END="2.7902971569505266" CI_START="0.5599762004229086" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.44565045658963615" LOG_CI_START="-0.2518304305735233" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-06-22 14:51:33 +0200" MODIFIED_BY="Tahany Awad" ORDER="142" O_E="0.0" SE="0.4097037257057139" STUDY_ID="STD-Derbala-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.16785714285714284" WEIGHT="8.532628611261252"/>
<DICH_DATA CI_END="5.180388604362314" CI_START="1.489473082428314" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" LOG_CI_END="0.7143623393591298" LOG_CI_START="0.1730326591062955" LOG_EFFECT_SIZE="0.44369749923271273" MODIFIED="2009-06-08 11:35:54 +0200" MODIFIED_BY="Tahany Awad" ORDER="510" O_E="0.0" SE="0.3179797338056486" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.10111111111111112" WEIGHT="11.172476937124594"/>
<DICH_DATA CI_END="3.9220926091785993" CI_START="1.1603782889930911" EFFECT_SIZE="2.1333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.593517844094743" LOG_CI_START="0.06459959443370657" LOG_EFFECT_SIZE="0.32905871926422475" MODIFIED="2009-06-04 17:57:07 +0200" MODIFIED_BY="Tahany Awad" ORDER="470" O_E="0.0" SE="0.3106891980384542" STUDY_ID="STD-Wakil-2006" TOTAL_1="18" TOTAL_2="32" VAR="0.0965277777777778" WEIGHT="11.414985734379718"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="77.4190318080047" CI_END="1.5207960976231891" CI_START="1.234974203927047" CI_STUDY="95" CI_TOTAL="95" DF="31" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3704539211507833" ESTIMABLE="YES" EVENTS_1="1681" EVENTS_2="1081" I2="59.95816625958532" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.182070989455171" LOG_CI_START="0.09165788617127789" LOG_EFFECT_SIZE="0.1368644378132244" METHOD="MH" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="Tahany Awad" NO="4" P_CHI2="7.612735035578133E-6" P_Q="0.8774598279499695" P_Z="2.958933555938908E-9" Q="1.7893241905239776" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.040001661406545375" TOTALS="SUB" TOTAL_1="3315" TOTAL_2="2802" WEIGHT="600.0" Z="5.933860450203788">
<NAME>Sustained virological response according to baseline viral load</NAME>
<GROUP_LABEL_1>PEG + RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF + RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INF + RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PEG + RBV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="12.536904835005842" CI_END="1.753593296543901" CI_START="1.0146706015324545" DF="4" EFFECT_SIZE="1.3339113782584957" ESTIMABLE="YES" EVENTS_1="494" EVENTS_2="284" I2="68.0941982678922" ID="CMP-003.04.01" LOG_CI_END="0.24392887663116955" LOG_CI_START="0.006325077564666296" LOG_EFFECT_SIZE="0.1251269770979179" MODIFIED="2009-08-17 16:56:40 +0200" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="0.013774888311253508" P_Z="0.0389879989996594" STUDIES="5" TAU2="0.04874357142254805" TOTAL_1="1071" TOTAL_2="706" WEIGHT="99.99999999999999" Z="2.0643135300849758">
<NAME>High viral load</NAME>
<DICH_DATA CI_END="1.5563680935897253" CI_START="1.0966635706562866" EFFECT_SIZE="1.306450225141251" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="119" LOG_CI_END="0.19211231894489272" LOG_CI_START="0.0400734171675867" LOG_EFFECT_SIZE="0.1160928680562397" MODIFIED="2009-08-17 16:56:40 +0200" MODIFIED_BY="Tahany Awad" ORDER="229" O_E="0.0" SE="0.08930840350869115" STUDY_ID="STD-Fried-2002" TOTAL_1="293" TOTAL_2="292" VAR="0.007975990937271199" WEIGHT="34.343859079418955"/>
<DICH_DATA CI_END="3.3307177735595603" CI_START="1.0981585648102024" EFFECT_SIZE="1.9125" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.5225378345589323" LOG_CI_START="0.04066505309237805" LOG_EFFECT_SIZE="0.2816014438256552" MODIFIED="2009-08-17 16:56:40 +0200" MODIFIED_BY="Tahany Awad" ORDER="236" O_E="0.0" SE="0.283054457142192" STUDY_ID="STD-Mangia-2005" TOTAL_1="24" TOTAL_2="27" VAR="0.080119825708061" WEIGHT="15.116539685490293"/>
<DICH_DATA CI_END="1.1619681485196443" CI_START="0.8584270982230139" EFFECT_SIZE="0.9987316686484344" ESTIMABLE="YES" EVENTS_1="293" EVENTS_2="145" LOG_CI_END="0.06519422348309943" LOG_CI_START="-0.06629658132289426" LOG_EFFECT_SIZE="-5.511789198974208E-4" MODIFIED="2009-08-17 16:55:08 +0200" MODIFIED_BY="Tahany Awad" ORDER="237" O_E="0.0" SE="0.0772383496330219" STUDY_ID="STD-Manns-2001" TOTAL_1="696" TOTAL_2="344" VAR="0.005965762654032933" WEIGHT="35.6057826257805"/>
<DICH_DATA CI_END="7.383987199556376" CI_START="1.1520800638651614" EFFECT_SIZE="2.9166666666666665" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="4" LOG_CI_END="0.8682909351512724" LOG_CI_START="0.061482661454029135" LOG_EFFECT_SIZE="0.4648867983026508" MODIFIED="2009-08-17 16:55:07 +0200" MODIFIED_BY="Tahany Awad" ORDER="276" O_E="0.0" SE="0.47392317373512616" STUDY_ID="STD-Napoli-2005" TOTAL_1="36" TOTAL_2="21" VAR="0.22460317460317458" WEIGHT="7.126364901189053"/>
<DICH_DATA CI_END="3.2086911883830402" CI_START="0.5540507557144057" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.5063279216343763" LOG_CI_START="-0.2564504484177765" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2009-08-17 16:55:04 +0200" MODIFIED_BY="Tahany Awad" ORDER="285" O_E="0.0" SE="0.4480597903824619" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="22" TOTAL_2="22" VAR="0.2007575757575757" WEIGHT="7.807453708121191"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.029817186001432" CI_END="1.5767464520218692" CI_START="1.054838167275534" DF="4" EFFECT_SIZE="1.289655898954814" ESTIMABLE="YES" EVENTS_1="399" EVENTS_2="211" I2="55.702314702438926" ID="CMP-003.04.02" LOG_CI_END="0.19776186242162333" LOG_CI_START="0.023185835510160294" LOG_EFFECT_SIZE="0.1104738489658918" MODIFIED="2009-08-17 16:53:46 +0200" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="0.06035856964783415" P_Z="0.013116939588556798" STUDIES="5" TAU2="0.0252207964436377" TOTAL_1="604" TOTAL_2="423" WEIGHT="100.0" Z="2.480578450974565">
<NAME>Low viral Load</NAME>
<DICH_DATA CI_END="1.4561567469541787" CI_START="0.9846033894371243" EFFECT_SIZE="1.197387518142235" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="78" LOG_CI_END="0.1632081268130189" LOG_CI_START="-0.006738673528420384" LOG_EFFECT_SIZE="0.07823472664229926" MODIFIED="2009-08-17 15:31:28 +0200" MODIFIED_BY="Tahany Awad" ORDER="230" O_E="0.0" SE="0.09982759177079063" STUDY_ID="STD-Fried-2002" TOTAL_1="159" TOTAL_2="150" VAR="0.009965548078755625" WEIGHT="29.8861701081798"/>
<DICH_DATA CI_END="2.75695508412916" CI_START="1.4240774431294674" EFFECT_SIZE="1.9814432989690722" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="30" LOG_CI_END="0.4404296907072409" LOG_CI_START="0.15353360742532252" LOG_EFFECT_SIZE="0.2969816490662817" MODIFIED="2009-08-17 15:44:00 +0200" MODIFIED_BY="Tahany Awad" ORDER="235" O_E="0.0" SE="0.16852417947831513" STUDY_ID="STD-Mangia-2005" TOTAL_1="97" TOTAL_2="93" VAR="0.028400399068839375" WEIGHT="19.611369493553628"/>
<DICH_DATA CI_END="1.4294141559222393" CI_START="1.0470848953971204" EFFECT_SIZE="1.2234042553191489" ESTIMABLE="YES" EVENTS_1="225" EVENTS_2="90" LOG_CI_END="0.1551580787365158" LOG_CI_START="0.019981894771310165" LOG_EFFECT_SIZE="0.087569986753913" MODIFIED="2009-08-17 16:53:46 +0200" MODIFIED_BY="Tahany Awad" ORDER="238" O_E="0.0" SE="0.07940315959406404" STUDY_ID="STD-Manns-2001" TOTAL_1="329" TOTAL_2="161" VAR="0.0063048617535204025" WEIGHT="33.35648287831983"/>
<DICH_DATA CI_END="1.6791398559395172" CI_START="0.633346030551434" EFFECT_SIZE="1.03125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.22508687013045794" LOG_CI_START="-0.19835894701449494" LOG_EFFECT_SIZE="0.013363961557981502" MODIFIED="2009-08-17 16:22:41 +0200" MODIFIED_BY="Tahany Awad" ORDER="277" O_E="0.0" SE="0.24873416908154553" STUDY_ID="STD-Napoli-2005" TOTAL_1="12" TOTAL_2="11" VAR="0.06186868686868688" WEIGHT="12.074765377927681"/>
<DICH_DATA CI_END="2.11037392695491" CI_START="0.39609964692517674" EFFECT_SIZE="0.9142857142857143" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.3243594126556842" LOG_CI_START="-0.40219554471642355" LOG_EFFECT_SIZE="-0.03891806603036967" MODIFIED="2009-08-17 16:42:03 +0200" MODIFIED_BY="Tahany Awad" ORDER="286" O_E="0.0" SE="0.42678197846541877" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="7" TOTAL_2="8" VAR="0.18214285714285716" WEIGHT="5.071212142019062"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.587460148665582" CI_START="0.8695786101905303" DF="0" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" I2="0.0" ID="CMP-003.04.03" LOG_CI_END="0.4128736696348625" LOG_CI_START="-0.06069115152350007" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NO="3" P_CHI2="1.0" P_Z="0.14495259535770766" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="48" WEIGHT="100.0" Z="1.4575935978404688">
<NAME>Predominantly high viral load (more than 65% of total participants)</NAME>
<DICH_DATA CI_END="2.587460148665582" CI_START="0.8695786101905303" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.4128736696348625" LOG_CI_START="-0.06069115152350007" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-08-17 15:18:26 +0200" MODIFIED_BY="Tahany Awad" ORDER="221" O_E="0.0" SE="0.2781743201320934" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.07738095238095238" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.002952591990804" CI_END="2.0571533269387454" CI_START="1.2203949780477192" DF="5" EFFECT_SIZE="1.58446823548792" ESTIMABLE="YES" EVENTS_1="223" EVENTS_2="140" I2="44.46266434360552" ID="CMP-003.04.04" LOG_CI_END="0.3132666624102338" LOG_CI_START="0.08650041184266428" LOG_EFFECT_SIZE="0.19988353712644907" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NO="4" P_CHI2="0.10894659104554705" P_Z="5.498279282056466E-4" STUDIES="6" TAU2="0.04327512070308227" TOTAL_1="454" TOTAL_2="466" WEIGHT="100.0" Z="3.455227864726553">
<NAME>Predominantly low viral load (more than 65% of total participants)</NAME>
<DICH_DATA CI_END="2.7902971569505266" CI_START="0.5599762004229086" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.44565045658963615" LOG_CI_START="-0.2518304305735233" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-08-17 15:21:08 +0200" MODIFIED_BY="Tahany Awad" ORDER="224" O_E="0.0" SE="0.4097037257057139" STUDY_ID="STD-Derbala-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.16785714285714284" WEIGHT="8.403833490084612"/>
<DICH_DATA CI_END="5.180388604362314" CI_START="1.489473082428314" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" LOG_CI_END="0.7143623393591298" LOG_CI_START="0.1730326591062955" LOG_EFFECT_SIZE="0.44369749923271273" MODIFIED="2009-08-17 15:24:19 +0200" MODIFIED_BY="Tahany Awad" ORDER="225" O_E="0.0" SE="0.3179797338056486" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.10111111111111112" WEIGHT="12.288709006743206"/>
<DICH_DATA CI_END="1.6490129785229268" CI_START="0.850420578189295" EFFECT_SIZE="1.1842105263157894" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="38" LOG_CI_END="0.21722407376380887" LOG_CI_START="-0.07036623944674189" LOG_EFFECT_SIZE="0.07342891715853349" MODIFIED="2009-08-17 15:27:54 +0200" MODIFIED_BY="Tahany Awad" ORDER="227" O_E="0.0" SE="0.16893197357488735" STUDY_ID="STD-Esmat-2003" TOTAL_1="100" TOTAL_2="100" VAR="0.02853801169590643" WEIGHT="24.707464053883516"/>
<DICH_DATA CI_END="2.965569021857373" CI_START="0.6732913166880276" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4721080364330698" LOG_CI_START="-0.17179698651050676" LOG_EFFECT_SIZE="0.1501555249612815" MODIFIED="2009-08-17 15:39:15 +0200" MODIFIED_BY="Tahany Awad" ORDER="233" O_E="0.0" SE="0.37823299785832587" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="0.14306020066889633" WEIGHT="9.522190287276452"/>
<DICH_DATA CI_END="2.465187633311933" CI_START="1.4892241124860108" EFFECT_SIZE="1.9160419790104948" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="58" LOG_CI_END="0.3918499804127436" LOG_CI_START="0.17296005939892112" LOG_EFFECT_SIZE="0.2824050199058324" MODIFIED="2009-08-17 16:32:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="281" O_E="0.0" SE="0.12857702312610314" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.016532050875970462" WEIGHT="29.667351598453468"/>
<DICH_DATA CI_END="2.3142093919110254" CI_START="0.8091645396612035" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.3644026517796553" LOG_CI_START="-0.0919631577436773" LOG_EFFECT_SIZE="0.136219747017989" MODIFIED="2009-08-17 16:39:20 +0200" MODIFIED_BY="Tahany Awad" ORDER="283" O_E="0.0" SE="0.2680715355611962" STUDY_ID="STD-Scotto-2005" TOTAL_1="26" TOTAL_2="52" VAR="0.07186234817813765" WEIGHT="15.410451563558736"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.691096779889271" CI_END="1.7043597292015262" CI_START="1.0094696367710558" DF="3" EFFECT_SIZE="1.3116780842738356" ESTIMABLE="YES" EVENTS_1="155" EVENTS_2="115" I2="47.28608357880765" ID="CMP-003.04.05" LOG_CI_END="0.23156126409202868" LOG_CI_START="0.004093260594074268" LOG_EFFECT_SIZE="0.11782726234305141" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NO="5" P_CHI2="0.12764547392605574" P_Z="0.04230547329081884" STUDIES="4" TAU2="0.0322987211351795" TOTAL_1="314" TOTAL_2="293" WEIGHT="100.0" Z="2.0305026380680413">
<NAME>Similar proportions of high and low baseline viral loads</NAME>
<DICH_DATA CI_END="1.8820793587258766" CI_START="1.0156744853200899" EFFECT_SIZE="1.3825989960959286" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="44" LOG_CI_END="0.27463793170022405" LOG_CI_START="0.006754542711053098" LOG_EFFECT_SIZE="0.1406962372056386" MODIFIED="2009-08-17 15:18:46 +0200" MODIFIED_BY="Tahany Awad" ORDER="222" O_E="0.0" SE="0.15735602873640067" STUDY_ID="STD-Bruno-2004" TOTAL_1="163" TOTAL_2="148" VAR="0.024760919779690957" WEIGHT="31.288648283734982"/>
<DICH_DATA CI_END="1.32831790191945" CI_START="0.83714450752687" EFFECT_SIZE="1.0545112781954886" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="49" LOG_CI_END="0.12330202573004048" LOG_CI_START="-0.07719956780781415" LOG_EFFECT_SIZE="0.023051228961113182" MODIFIED="2009-08-17 15:40:43 +0200" MODIFIED_BY="Tahany Awad" ORDER="234" O_E="0.0" SE="0.11777562854303061" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.013871098678705927" WEIGHT="38.66852941983254"/>
<DICH_DATA CI_END="2.274740625322729" CI_START="0.7610986148420958" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.3569318838885388" LOG_CI_START="-0.11855906845012143" LOG_EFFECT_SIZE="0.11918640771920867" MODIFIED="2009-08-17 16:36:00 +0200" MODIFIED_BY="Tahany Awad" ORDER="282" O_E="0.0" SE="0.2793057391219034" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="0.07801169590643274" WEIGHT="16.18450082650057"/>
<DICH_DATA CI_END="3.9220926091785993" CI_START="1.1603782889930911" EFFECT_SIZE="2.1333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.593517844094743" LOG_CI_START="0.06459959443370657" LOG_EFFECT_SIZE="0.32905871926422475" MODIFIED="2009-08-17 16:49:13 +0200" MODIFIED_BY="Tahany Awad" ORDER="289" O_E="0.0" SE="0.3106891980384542" STUDY_ID="STD-Wakil-2006" TOTAL_1="18" TOTAL_2="32" VAR="0.0965277777777778" WEIGHT="13.858321469931909"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="30.519513014883668" CI_END="1.7054873623323532" CI_START="1.1085971898646076" DF="10" EFFECT_SIZE="1.3750267260061706" ESTIMABLE="YES" EVENTS_1="389" EVENTS_2="317" I2="67.23407744047807" ID="CMP-003.04.06" LOG_CI_END="0.231848505631626" LOG_CI_START="0.044773773383412416" LOG_EFFECT_SIZE="0.1383111395075192" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NO="6" P_CHI2="7.040572409887647E-4" P_Z="0.003753769715003416" STUDIES="11" TAU2="0.07523092687173953" TOTAL_1="824" TOTAL_2="866" WEIGHT="100.0" Z="2.8981450229820798">
<NAME>Unknown baseline viral load</NAME>
<DICH_DATA CI_END="3.5357884851784527" CI_START="1.4846729778611794" EFFECT_SIZE="2.291176470588235" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="17" LOG_CI_END="0.5484862771364655" LOG_CI_START="0.17163080412415313" LOG_EFFECT_SIZE="0.3600585406303093" MODIFIED="2009-08-17 15:20:24 +0200" MODIFIED_BY="Tahany Awad" ORDER="223" O_E="0.0" SE="0.22136677031210955" STUDY_ID="STD-Cariti-2002" TOTAL_1="60" TOTAL_2="57" VAR="0.04900324699841427" WEIGHT="9.719958088126088"/>
<DICH_DATA CI_END="3.2554443304763296" CI_START="0.3212990204096413" EFFECT_SIZE="1.0227272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5126102731205879" LOG_CI_START="-0.4930905985422754" LOG_EFFECT_SIZE="0.00975983728915624" MODIFIED="2009-08-17 15:25:03 +0200" MODIFIED_BY="Tahany Awad" ORDER="226" O_E="0.0" SE="0.5907536703143696" STUDY_ID="STD-Dollinger-2005" TOTAL_1="22" TOTAL_2="18" VAR="0.34898989898989896" WEIGHT="2.846515044795826"/>
<DICH_DATA CI_END="2.1462413599066443" CI_START="0.7112332211862739" EFFECT_SIZE="1.2355072463768115" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.3316785598393653" LOG_CI_START="-0.14798796598480524" LOG_EFFECT_SIZE="0.09184529692728" MODIFIED="2009-08-17 15:30:10 +0200" MODIFIED_BY="Tahany Awad" ORDER="228" O_E="0.0" SE="0.2817584916567142" STUDY_ID="STD-Fargion-2004" TOTAL_1="92" TOTAL_2="93" VAR="0.07938784762066668" WEIGHT="7.809859876946384"/>
<DICH_DATA CI_END="1.5453227913002832" CI_START="0.770119130661838" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.18901920986974008" LOG_CI_START="-0.11344208809094057" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2009-08-17 15:34:04 +0200" MODIFIED_BY="Tahany Awad" ORDER="231" O_E="0.0" SE="0.1776672636296754" STUDY_ID="STD-Hinrichsen-2002" TOTAL_1="36" TOTAL_2="36" VAR="0.031565656565656575" WEIGHT="11.307018672921572"/>
<DICH_DATA CI_END="1.4710974778935566" CI_START="0.8843842405219245" EFFECT_SIZE="1.1406206318143697" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="73" LOG_CI_END="0.16764145091153848" LOG_CI_START="-0.05335900502971767" LOG_EFFECT_SIZE="0.057141222940910424" MODIFIED="2009-08-17 15:35:52 +0200" MODIFIED_BY="Tahany Awad" ORDER="232" O_E="0.0" SE="0.1298167617897941" STUDY_ID="STD-Horsmans-2008" TOTAL_1="98" TOTAL_2="160" VAR="0.016852391641588145" WEIGHT="13.11367772824227"/>
<DICH_DATA CI_END="2.7755764012248623" CI_START="0.7696039905850021" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.44335318633323517" LOG_CI_START="-0.11373268904125085" LOG_EFFECT_SIZE="0.16481024864599217" MODIFIED="2009-08-17 16:28:04 +0200" MODIFIED_BY="Tahany Awad" ORDER="280" O_E="0.0" SE="0.32723500081453055" STUDY_ID="STD-PRETTY-2005" TOTAL_1="89" TOTAL_2="89" VAR="0.1070827457580858" WEIGHT="6.623479993092503"/>
<DICH_DATA CI_END="1.6137622339028166" CI_START="0.8924743107464483" EFFECT_SIZE="1.2001005530417295" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="51" LOG_CI_END="0.20783954766570586" LOG_CI_START="-0.04940427590106791" LOG_EFFECT_SIZE="0.07921763588231896" MODIFIED="2009-08-17 16:24:10 +0200" MODIFIED_BY="Tahany Awad" ORDER="278" O_E="0.0" SE="0.15110629534058637" STUDY_ID="STD-Rahman-2007a" TOTAL_1="156" TOTAL_2="154" VAR="0.022833112491556513" WEIGHT="12.313901925427244"/>
<DICH_DATA CI_END="1.2131071622648262" CI_START="0.8569730573893487" EFFECT_SIZE="1.0196078431372548" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="85" LOG_CI_END="0.08389916683905466" LOG_CI_START="-0.06703283176532913" LOG_EFFECT_SIZE="0.008433167536862764" MODIFIED="2009-08-17 16:24:10 +0200" MODIFIED_BY="Tahany Awad" ORDER="279" O_E="0.0" SE="0.08865820310565761" STUDY_ID="STD-Rahman-2007b" TOTAL_1="132" TOTAL_2="130" VAR="0.007860276977924036" WEIGHT="14.532837498848606"/>
<DICH_DATA CI_END="2.6453240320969122" CI_START="1.0500708964473708" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.42247887740424933" LOG_CI_START="0.021218621828463496" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2009-08-17 16:40:50 +0200" MODIFIED_BY="Tahany Awad" ORDER="284" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Shobokshi-2003" TOTAL_1="60" TOTAL_2="60" VAR="0.05555555555555555" WEIGHT="9.232995189714263"/>
<DICH_DATA CI_END="8.136576897762474" CI_START="2.1715317787493897" EFFECT_SIZE="4.203431372549019" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" LOG_CI_END="0.9104417332569528" LOG_CI_START="0.336766189320866" LOG_EFFECT_SIZE="0.6236039612889093" MODIFIED="2009-08-17 16:56:54 +0200" MODIFIED_BY="Tahany Awad" ORDER="287" O_E="0.0" SE="0.3369798542477986" STUDY_ID="STD-Thakeb-2003" TOTAL_1="51" TOTAL_2="49" VAR="0.11355542216886758" WEIGHT="6.396389194809448"/>
<DICH_DATA CI_END="2.128278660395544" CI_START="0.5393838715932618" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.328028490516341" LOG_CI_START="-0.2681020437614546" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2009-08-17 16:46:06 +0200" MODIFIED_BY="Tahany Awad" ORDER="288" O_E="0.0" SE="0.35017002672851316" STUDY_ID="STD-Tsubota-2005" TOTAL_1="28" TOTAL_2="20" VAR="0.12261904761904761" WEIGHT="6.103366787075799"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="71.02988234317876" CI_END="1.2666831636961646" CI_START="1.1057272606550548" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1834720548925683" ESTIMABLE="YES" EVENTS_1="1632" EVENTS_2="1016" I2="63.39568764258713" I2_Q="93.21063625148686" ID="CMP-003.05" LOG_CI_END="0.10266799809890319" LOG_CI_START="0.04364801684238573" LOG_EFFECT_SIZE="0.07315800747064444" METHOD="MH" MODIFIED="2009-09-24 16:49:33 +0200" MODIFIED_BY="Tahany Awad" NO="5" P_CHI2="4.692139984552313E-6" P_Q="1.2412823527263583E-4" P_Z="1.180202114248241E-6" Q="14.72892066239637" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04419964863795049" TOTALS="SUB" TOTAL_1="3225" TOTAL_2="2670" WEIGHT="200.0" Z="4.85893274685991">
<NAME>Sustained virological response according to the type of peginterferon</NAME>
<GROUP_LABEL_1>PEG + RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF + RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INF + RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PEG + RBV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="30.771983970132588" CI_END="2.354523634192557" CI_START="1.459655801000349" DF="8" EFFECT_SIZE="1.853859239867361" ESTIMABLE="YES" EVENTS_1="626" EVENTS_2="378" I2="74.00232624661174" ID="CMP-003.05.01" LOG_CI_END="0.3719030541535116" LOG_CI_START="0.16425045759978374" LOG_EFFECT_SIZE="0.26807675587664764" MODIFIED="2009-08-20 19:49:07 +0200" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="1.5425462744800278E-4" P_Z="4.1799363278637336E-7" STUDIES="9" TAU2="0.0840909360478105" TOTAL_1="1196" TOTAL_2="1165" WEIGHT="100.00000000000003" Z="5.060575165739562">
<NAME>Peginterferon alpha-2a</NAME>
<DICH_DATA CI_END="3.5357884851784527" CI_START="1.4846729778611794" EFFECT_SIZE="2.291176470588235" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="17" LOG_CI_END="0.5484862771364655" LOG_CI_START="0.17163080412415313" LOG_EFFECT_SIZE="0.3600585406303093" MODIFIED="2009-07-08 16:48:17 +0200" MODIFIED_BY="Tahany Awad" ORDER="180" O_E="0.0" SE="0.22136677031210955" STUDY_ID="STD-Cariti-2002" TOTAL_1="60" TOTAL_2="57" VAR="0.04900324699841427" WEIGHT="11.178688675298405"/>
<DICH_DATA CI_END="2.6453240320969122" CI_START="1.0500708964473708" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.42247887740424933" LOG_CI_START="0.021218621828463496" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2009-07-08 16:47:28 +0200" MODIFIED_BY="Tahany Awad" ORDER="453" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Shobokshi-2003" TOTAL_1="60" TOTAL_2="60" VAR="0.05555555555555555" WEIGHT="10.654176984214784"/>
<DICH_DATA CI_END="1.4477692368960238" CI_START="1.111778062982932" EFFECT_SIZE="1.2686993646418125" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="197" LOG_CI_END="0.16069934423037288" LOG_CI_START="0.04601810051792744" LOG_EFFECT_SIZE="0.10335872237415017" MODIFIED="2009-06-03 16:47:02 +0200" MODIFIED_BY="Tahany Awad" ORDER="515" O_E="0.0" SE="0.06736433023800226" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.004537952988414626" WEIGHT="16.78705953494252"/>
<DICH_DATA CI_END="8.136576897762474" CI_START="2.1715317787493897" EFFECT_SIZE="4.203431372549019" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" LOG_CI_END="0.9104417332569528" LOG_CI_START="0.336766189320866" LOG_EFFECT_SIZE="0.6236039612889093" MODIFIED="2009-08-20 19:49:07 +0200" MODIFIED_BY="Tahany Awad" ORDER="459" O_E="0.0" SE="0.3369798542477986" STUDY_ID="STD-Thakeb-2003" TOTAL_1="51" TOTAL_2="49" VAR="0.11355542216886758" WEIGHT="7.527679488715105"/>
<DICH_DATA CI_END="2.1462413599066443" CI_START="0.7112332211862739" EFFECT_SIZE="1.2355072463768115" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.3316785598393653" LOG_CI_START="-0.14798796598480524" LOG_EFFECT_SIZE="0.09184529692728" MODIFIED="2009-07-07 17:29:57 +0200" MODIFIED_BY="Tahany Awad" ORDER="174" O_E="0.0" SE="0.2817584916567142" STUDY_ID="STD-Fargion-2004" TOTAL_1="92" TOTAL_2="93" VAR="0.07938784762066668" WEIGHT="9.10098792870952"/>
<DICH_DATA CI_END="2.7755764012248623" CI_START="0.7696039905850021" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.44335318633323517" LOG_CI_START="-0.11373268904125085" LOG_EFFECT_SIZE="0.16481024864599217" MODIFIED="2009-07-07 17:29:58 +0200" MODIFIED_BY="Tahany Awad" ORDER="90" O_E="0.0" SE="0.32723500081453055" STUDY_ID="STD-PRETTY-2005" TOTAL_1="89" TOTAL_2="89" VAR="0.1070827457580858" WEIGHT="7.7825484277566375"/>
<DICH_DATA CI_END="2.603101809315667" CI_START="1.47378725784399" EFFECT_SIZE="1.9586776859504131" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="40" LOG_CI_END="0.4154911540329175" LOG_CI_START="0.1684347973543901" LOG_EFFECT_SIZE="0.29196297569365376" MODIFIED="2009-07-07 17:29:57 +0200" MODIFIED_BY="Tahany Awad" ORDER="84" O_E="0.0" SE="0.14512212686165601" STUDY_ID="STD-Mangia-2005" TOTAL_1="121" TOTAL_2="120" VAR="0.021060431704850578" WEIGHT="14.14930179763899"/>
<DICH_DATA CI_END="5.180388604362314" CI_START="1.489473082428314" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" LOG_CI_END="0.7143623393591298" LOG_CI_START="0.1730326591062955" LOG_EFFECT_SIZE="0.44369749923271273" MODIFIED="2009-08-20 19:49:00 +0200" MODIFIED_BY="Tahany Awad" ORDER="162" O_E="0.0" SE="0.3179797338056486" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.10111111111111112" WEIGHT="8.033488072031034"/>
<DICH_DATA CI_END="2.465187633311933" CI_START="1.4892241124860108" EFFECT_SIZE="1.9160419790104948" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="58" LOG_CI_END="0.3918499804127436" LOG_CI_START="0.17296005939892112" LOG_EFFECT_SIZE="0.2824050199058324" MODIFIED="2009-07-07 17:29:58 +0200" MODIFIED_BY="Tahany Awad" ORDER="101" O_E="0.0" SE="0.12857702312610314" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.016532050875970462" WEIGHT="14.786069090693022"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="13.908333073830057" CI_END="1.2212577583540491" CI_START="1.0598600658409367" DF="17" EFFECT_SIZE="1.1377004562616109" ESTIMABLE="YES" EVENTS_1="1006" EVENTS_2="638" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.08680733570300116" LOG_CI_START="0.025248528807351657" LOG_EFFECT_SIZE="0.056027932255176445" MODIFIED="2009-07-22 12:24:39 +0200" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="0.6735798025928472" P_Z="3.60081538639767E-4" STUDIES="18" TAU2="0.0" TOTAL_1="2029" TOTAL_2="1505" WEIGHT="99.99999999999999" Z="3.567734167900403">
<NAME>Peginterferon alpha-2b</NAME>
<DICH_DATA CI_END="1.213964321130765" CI_START="0.9715225770566696" EFFECT_SIZE="1.0859989621172808" ESTIMABLE="YES" EVENTS_1="518" EVENTS_2="235" LOG_CI_END="0.08420592284819177" LOG_CI_START="-0.012547102447421674" LOG_EFFECT_SIZE="0.035829410200385034" MODIFIED="2009-06-04 15:35:28 +0200" MODIFIED_BY="Tahany Awad" ORDER="91" O_E="0.0" SE="0.05683320599384272" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.00323001330353856" WEIGHT="40.481004523557196"/>
<DICH_DATA CI_END="1.5453227913002832" CI_START="0.770119130661838" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.18901920986974008" LOG_CI_START="-0.11344208809094057" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2009-06-03 16:58:06 +0200" MODIFIED_BY="Tahany Awad" ORDER="519" O_E="0.0" SE="0.1776672636296754" STUDY_ID="STD-Hinrichsen-2002" TOTAL_1="36" TOTAL_2="36" VAR="0.031565656565656575" WEIGHT="4.142292522245677"/>
<DICH_DATA CI_END="1.6490129785229268" CI_START="0.850420578189295" EFFECT_SIZE="1.1842105263157894" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="38" LOG_CI_END="0.21722407376380887" LOG_CI_START="-0.07036623944674189" LOG_EFFECT_SIZE="0.07342891715853349" MODIFIED="2009-06-03 16:18:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="170" O_E="0.0" SE="0.16893197357488735" STUDY_ID="STD-Esmat-2003" TOTAL_1="100" TOTAL_2="100" VAR="0.02853801169590643" WEIGHT="4.581755188307323"/>
<DICH_DATA CI_END="1.8820793587258766" CI_START="1.0156744853200899" EFFECT_SIZE="1.3825989960959286" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="44" LOG_CI_END="0.27463793170022405" LOG_CI_START="0.006754542711053098" LOG_EFFECT_SIZE="0.1406962372056386" MODIFIED="2009-06-03 15:30:43 +0200" MODIFIED_BY="Tahany Awad" ORDER="158" O_E="0.0" SE="0.15735602873640067" STUDY_ID="STD-Bruno-2004" TOTAL_1="163" TOTAL_2="148" VAR="0.024760919779690957" WEIGHT="5.280667451575837"/>
<DICH_DATA CI_END="2.965569021857373" CI_START="0.6732913166880276" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4721080364330698" LOG_CI_START="-0.17179698651050676" LOG_EFFECT_SIZE="0.1501555249612815" MODIFIED="2009-06-03 20:37:06 +0200" MODIFIED_BY="Tahany Awad" ORDER="522" O_E="0.0" SE="0.37823299785832587" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="0.14306020066889633" WEIGHT="0.9139801464022588"/>
<DICH_DATA CI_END="2.587460148665582" CI_START="0.8695786101905303" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.4128736696348625" LOG_CI_START="-0.06069115152350007" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-06-03 15:18:01 +0200" MODIFIED_BY="Tahany Awad" ORDER="155" O_E="0.0" SE="0.2781743201320934" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.07738095238095238" WEIGHT="1.689746366883435"/>
<DICH_DATA CI_END="2.3142093919110254" CI_START="0.8091645396612035" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.3644026517796553" LOG_CI_START="-0.0919631577436773" LOG_EFFECT_SIZE="0.136219747017989" MODIFIED="2009-06-04 17:16:24 +0200" MODIFIED_BY="Tahany Awad" ORDER="450" O_E="0.0" SE="0.2680715355611962" STUDY_ID="STD-Scotto-2005" TOTAL_1="26" TOTAL_2="52" VAR="0.07186234817813765" WEIGHT="1.8195089148432966"/>
<DICH_DATA CI_END="2.7902971569505266" CI_START="0.5599762004229086" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.44565045658963615" LOG_CI_START="-0.2518304305735233" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-06-22 14:49:24 +0200" MODIFIED_BY="Tahany Awad" ORDER="140" O_E="0.0" SE="0.4097037257057139" STUDY_ID="STD-Derbala-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.16785714285714284" WEIGHT="0.7789610911164772"/>
<DICH_DATA CI_END="2.9224114694732757" CI_START="1.0479359364655019" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.4657413636656654" LOG_CI_START="0.02033473370692358" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2009-06-04 15:53:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="96" O_E="0.0" SE="0.26163405923614175" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.06845238095238093" WEIGHT="1.9101480669117097"/>
<DICH_DATA CI_END="3.2554443304763296" CI_START="0.3212990204096413" EFFECT_SIZE="1.0227272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5126102731205879" LOG_CI_START="-0.4930905985422754" LOG_EFFECT_SIZE="0.00975983728915624" MODIFIED="2009-06-03 16:06:12 +0200" MODIFIED_BY="Tahany Awad" ORDER="167" O_E="0.0" SE="0.5907536703143696" STUDY_ID="STD-Dollinger-2005" TOTAL_1="22" TOTAL_2="18" VAR="0.34898989898989896" WEIGHT="0.37466466373423285"/>
<DICH_DATA CI_END="2.128278660395544" CI_START="0.5393838715932618" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.328028490516341" LOG_CI_START="-0.2681020437614546" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2009-06-04 17:42:07 +0200" MODIFIED_BY="Tahany Awad" ORDER="464" O_E="0.0" SE="0.35017002672851316" STUDY_ID="STD-Tsubota-2005" TOTAL_1="28" TOTAL_2="20" VAR="0.12261904761904761" WEIGHT="1.0663447946351774"/>
<DICH_DATA CI_END="1.32831790191945" CI_START="0.83714450752687" EFFECT_SIZE="1.0545112781954886" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="49" LOG_CI_END="0.12330202573004048" LOG_CI_START="-0.07719956780781415" LOG_EFFECT_SIZE="0.023051228961113182" MODIFIED="2009-06-03 20:45:21 +0200" MODIFIED_BY="Tahany Awad" ORDER="523" O_E="0.0" SE="0.11777562854303061" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.013871098678705927" WEIGHT="9.426375385276462"/>
<DICH_DATA CI_END="3.9220926091785993" CI_START="1.1603782889930911" EFFECT_SIZE="2.1333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.593517844094743" LOG_CI_START="0.06459959443370657" LOG_EFFECT_SIZE="0.32905871926422475" MODIFIED="2009-06-04 17:56:36 +0200" MODIFIED_BY="Tahany Awad" ORDER="468" O_E="0.0" SE="0.3106891980384542" STUDY_ID="STD-Wakil-2006" TOTAL_1="18" TOTAL_2="32" VAR="0.0965277777777778" WEIGHT="1.3545757103484881"/>
<DICH_DATA CI_END="1.2131071622648262" CI_START="0.8569730573893487" EFFECT_SIZE="1.0196078431372548" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="85" LOG_CI_END="0.08389916683905466" LOG_CI_START="-0.06703283176532913" LOG_EFFECT_SIZE="0.008433167536862764" MODIFIED="2009-07-22 12:24:39 +0200" MODIFIED_BY="Tahany Awad" ORDER="439" O_E="0.0" SE="0.08865820310565761" STUDY_ID="STD-Rahman-2007b" TOTAL_1="132" TOTAL_2="130" VAR="0.007860276977924036" WEIGHT="16.634806065857955"/>
<DICH_DATA CI_END="2.138945474742073" CI_START="0.595420689890192" EFFECT_SIZE="1.128526645768025" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3301997138279745" LOG_CI_START="-0.22517607840776227" LOG_EFFECT_SIZE="0.052511817710106094" MODIFIED="2009-06-04 17:31:47 +0200" MODIFIED_BY="Tahany Awad" ORDER="456" O_E="0.0" SE="0.32623048951378114" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="29" TOTAL_2="30" VAR="0.10642633228840126" WEIGHT="1.2285886428686452"/>
<DICH_DATA CI_END="1.6137622339028166" CI_START="0.8924743107464483" EFFECT_SIZE="1.2001005530417295" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="51" LOG_CI_END="0.20783954766570586" LOG_CI_START="-0.04940427590106791" LOG_EFFECT_SIZE="0.07921763588231896" MODIFIED="2009-07-22 12:24:39 +0200" MODIFIED_BY="Tahany Awad" ORDER="438" O_E="0.0" SE="0.15110629534058637" STUDY_ID="STD-Rahman-2007a" TOTAL_1="156" TOTAL_2="154" VAR="0.022833112491556513" WEIGHT="5.726515962291437"/>
<DICH_DATA CI_END="2.274740625322729" CI_START="0.7610986148420958" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.3569318838885388" LOG_CI_START="-0.11855906845012143" LOG_EFFECT_SIZE="0.11918640771920867" MODIFIED="2009-06-04 17:00:21 +0200" MODIFIED_BY="Tahany Awad" ORDER="446" O_E="0.0" SE="0.2793057391219034" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="0.07801169590643274" WEIGHT="1.6760843567421095"/>
<DICH_DATA CI_END="2.965569021857373" CI_START="0.6732913166880276" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4721080364330698" LOG_CI_START="-0.17179698651050676" LOG_EFFECT_SIZE="0.1501555249612815" MODIFIED="2009-06-04 16:18:31 +0200" MODIFIED_BY="Tahany Awad" ORDER="102" O_E="0.0" SE="0.37823299785832587" STUDY_ID="STD-Horsmans-2008" TOTAL_1="23" TOTAL_2="26" VAR="0.14306020066889633" WEIGHT="0.9139801464022588"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="71.02988234317877" CI_END="1.300859237235092" CI_START="1.1551023833577791" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="1.2258163016305654" ESTIMABLE="YES" EVENTS_1="1632" EVENTS_2="1016" I2="63.39568764258714" I2_Q="87.44081149650987" ID="CMP-003.06" LOG_CI_END="0.1142303051707825" LOG_CI_START="0.06262047994824171" LOG_EFFECT_SIZE="0.08842539255951211" METHOD="MH" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NO="6" P_CHI2="4.692139983997201E-6" P_Q="2.0537888396621184E-6" P_Z="1.8654305430824212E-11" Q="31.849191521318584" RANDOM="YES" SCALE="10.0" SORT_BY="YEAR" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.044199648637950506" TOTALS="SUB" TOTAL_1="3225" TOTAL_2="2670" WEIGHT="500.0" Z="6.716185687052701">
<NAME>Sustained virological response according to the type of peginterferon and the type of interferon</NAME>
<GROUP_LABEL_1>PEG + RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF + RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INF + RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PEG + RBV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.82926610023203" CI_END="2.4049078195674904" CI_START="1.634145902236718" DF="7" EFFECT_SIZE="1.9824152588706672" ESTIMABLE="YES" EVENTS_1="371" EVENTS_2="181" I2="35.36034727367151" ID="CMP-003.06.01" LOG_CI_END="0.38109843446435687" LOG_CI_START="0.21329082925118037" LOG_EFFECT_SIZE="0.2971946318577686" MODIFIED="2009-09-15 15:54:23 +0200" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="0.14624182688345166" P_Z="3.855909294630473E-12" STUDIES="8" TAU2="0.025669439260219813" TOTAL_1="743" TOTAL_2="721" WEIGHT="100.00000000000003" Z="6.942364430979061">
<NAME>Peginterferon alpha-2a versus interferon alpha-2a</NAME>
<DICH_DATA CI_END="3.5357884851784527" CI_START="1.4846729778611794" EFFECT_SIZE="2.291176470588235" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="17" LOG_CI_END="0.5484862771364655" LOG_CI_START="0.17163080412415313" LOG_EFFECT_SIZE="0.3600585406303093" MODIFIED="2009-09-14 10:08:26 +0200" MODIFIED_BY="Tahany Awad" ORDER="366" O_E="0.0" SE="0.22136677031210955" STUDY_ID="STD-Cariti-2002" TOTAL_1="60" TOTAL_2="57" VAR="0.04900324699841427" WEIGHT="13.011779901235794"/>
<DICH_DATA CI_END="2.6453240320969122" CI_START="1.0500708964473708" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.42247887740424933" LOG_CI_START="0.021218621828463496" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2009-09-14 10:08:26 +0200" MODIFIED_BY="Tahany Awad" ORDER="367" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Shobokshi-2003" TOTAL_1="60" TOTAL_2="60" VAR="0.05555555555555555" WEIGHT="11.962137522262717"/>
<DICH_DATA CI_END="8.136576897762474" CI_START="2.1715317787493897" EFFECT_SIZE="4.203431372549019" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" LOG_CI_END="0.9104417332569528" LOG_CI_START="0.336766189320866" LOG_EFFECT_SIZE="0.6236039612889093" MODIFIED="2009-09-14 10:08:26 +0200" MODIFIED_BY="Tahany Awad" ORDER="372" O_E="0.0" SE="0.3369798542477986" STUDY_ID="STD-Thakeb-2003" TOTAL_1="51" TOTAL_2="49" VAR="0.11355542216886758" WEIGHT="6.9788150496832575"/>
<DICH_DATA CI_END="2.1462413599066443" CI_START="0.7112332211862739" EFFECT_SIZE="1.2355072463768115" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.3316785598393653" LOG_CI_START="-0.14798796598480524" LOG_EFFECT_SIZE="0.09184529692728" MODIFIED="2009-09-14 10:08:26 +0200" MODIFIED_BY="Tahany Awad" ORDER="368" O_E="0.0" SE="0.2817584916567142" STUDY_ID="STD-Fargion-2004" TOTAL_1="92" TOTAL_2="93" VAR="0.07938784762066668" WEIGHT="9.248521326588271"/>
<DICH_DATA CI_END="2.7755764012248623" CI_START="0.7696039905850021" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.44335318633323517" LOG_CI_START="-0.11373268904125085" LOG_EFFECT_SIZE="0.16481024864599217" MODIFIED="2009-09-14 10:08:26 +0200" MODIFIED_BY="Tahany Awad" ORDER="369" O_E="0.0" SE="0.32723500081453055" STUDY_ID="STD-PRETTY-2005" TOTAL_1="89" TOTAL_2="89" VAR="0.1070827457580858" WEIGHT="7.319085242155531"/>
<DICH_DATA CI_END="2.603101809315667" CI_START="1.47378725784399" EFFECT_SIZE="1.9586776859504131" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="40" LOG_CI_END="0.4154911540329175" LOG_CI_START="0.1684347973543901" LOG_EFFECT_SIZE="0.29196297569365376" MODIFIED="2009-09-14 10:08:26 +0200" MODIFIED_BY="Tahany Awad" ORDER="371" O_E="0.0" SE="0.14512212686165601" STUDY_ID="STD-Mangia-2005" TOTAL_1="121" TOTAL_2="120" VAR="0.021060431704850578" WEIGHT="20.792365529056358"/>
<DICH_DATA CI_END="5.180388604362314" CI_START="1.489473082428314" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" LOG_CI_END="0.7143623393591298" LOG_CI_START="0.1730326591062955" LOG_EFFECT_SIZE="0.44369749923271273" MODIFIED="2009-09-14 10:08:26 +0200" MODIFIED_BY="Tahany Awad" ORDER="370" O_E="0.0" SE="0.3179797338056486" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.10111111111111112" WEIGHT="7.6638297860796785"/>
<DICH_DATA CI_END="2.465187633311933" CI_START="1.4892241124860108" EFFECT_SIZE="1.9160419790104948" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="58" LOG_CI_END="0.3918499804127436" LOG_CI_START="0.17296005939892112" LOG_EFFECT_SIZE="0.2824050199058324" MODIFIED="2009-09-14 10:08:26 +0200" MODIFIED_BY="Tahany Awad" ORDER="365" O_E="0.0" SE="0.12857702312610314" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.016532050875970462" WEIGHT="23.02346564293841"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4477692368960238" CI_START="1.111778062982932" DF="0" EFFECT_SIZE="1.2686993646418125" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="197" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="0.16069934423037288" LOG_CI_START="0.04601810051792744" LOG_EFFECT_SIZE="0.10335872237415017" MODIFIED="2009-09-15 15:55:49 +0200" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="1.0" P_Z="4.110091945297119E-4" STUDIES="1" TAU2="0.0" TOTAL_1="453" TOTAL_2="444" WEIGHT="100.0" Z="3.5329120400779948">
<NAME>Peginterferon alpha-2a versus interferon alpha-2b</NAME>
<DICH_DATA CI_END="1.4477692368960238" CI_START="1.111778062982932" EFFECT_SIZE="1.2686993646418125" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="197" LOG_CI_END="0.16069934423037288" LOG_CI_START="0.04601810051792744" LOG_EFFECT_SIZE="0.10335872237415017" MODIFIED="2009-09-14 10:25:46 +0200" MODIFIED_BY="Tahany Awad" ORDER="391" O_E="0.0" SE="0.06736433023800226" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.004537952988414626" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="9.322254529397227" CI_END="1.247787156776514" CI_START="1.0583768902870914" DF="12" EFFECT_SIZE="1.1491862732948468" ESTIMABLE="YES" EVENTS_1="818" EVENTS_2="475" I2="0.0" ID="CMP-003.06.03" LOG_CI_END="0.09614051121116204" LOG_CI_START="0.024640348441002883" LOG_EFFECT_SIZE="0.06039042982608248" MODIFIED="2009-09-15 15:55:57 +0200" MODIFIED_BY="Tahany Awad" NO="3" P_CHI2="0.6751870755429701" P_Z="9.301388474443959E-4" STUDIES="13" TAU2="0.0" TOTAL_1="1658" TOTAL_2="1141" WEIGHT="99.99999999999999" Z="3.3108474969630226">
<NAME>Peginterferon alpha-2b versus interferon alpha-2b</NAME>
<DICH_DATA CI_END="1.213964321130765" CI_START="0.9715225770566696" EFFECT_SIZE="1.0859989621172808" ESTIMABLE="YES" EVENTS_1="518" EVENTS_2="235" LOG_CI_END="0.08420592284819177" LOG_CI_START="-0.012547102447421674" LOG_EFFECT_SIZE="0.035829410200385034" MODIFIED="2009-09-14 10:08:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="378" O_E="0.0" SE="0.05683320599384272" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.00323001330353856" WEIGHT="54.611606703219955"/>
<DICH_DATA CI_END="1.5453227913002832" CI_START="0.770119130661838" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.18901920986974008" LOG_CI_START="-0.11344208809094057" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2009-09-14 10:08:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="384" O_E="0.0" SE="0.1776672636296754" STUDY_ID="STD-Hinrichsen-2002" TOTAL_1="36" TOTAL_2="36" VAR="0.031565656565656575" WEIGHT="5.588232128551227"/>
<DICH_DATA CI_END="1.6490129785229268" CI_START="0.850420578189295" EFFECT_SIZE="1.1842105263157894" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="38" LOG_CI_END="0.21722407376380887" LOG_CI_START="-0.07036623944674189" LOG_EFFECT_SIZE="0.07342891715853349" MODIFIED="2009-09-14 10:08:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="380" O_E="0.0" SE="0.16893197357488735" STUDY_ID="STD-Esmat-2003" TOTAL_1="100" TOTAL_2="100" VAR="0.02853801169590643" WEIGHT="6.181096919387652"/>
<DICH_DATA CI_END="2.587460148665582" CI_START="0.8695786101905303" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.4128736696348625" LOG_CI_START="-0.06069115152350007" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-09-14 10:08:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="374" O_E="0.0" SE="0.2781743201320934" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.07738095238095238" WEIGHT="2.2795818706211306"/>
<DICH_DATA CI_END="1.8820793587258766" CI_START="1.0156744853200899" EFFECT_SIZE="1.3825989960959286" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="44" LOG_CI_END="0.27463793170022405" LOG_CI_START="0.006754542711053098" LOG_EFFECT_SIZE="0.1406962372056386" MODIFIED="2009-09-14 10:08:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="386" O_E="0.0" SE="0.15735602873640067" STUDY_ID="STD-Bruno-2004" TOTAL_1="163" TOTAL_2="148" VAR="0.024760919779690957" WEIGHT="7.123976724148075"/>
<DICH_DATA CI_END="2.965569021857373" CI_START="0.6732913166880276" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4721080364330698" LOG_CI_START="-0.17179698651050676" LOG_EFFECT_SIZE="0.1501555249612815" MODIFIED="2009-09-14 10:08:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="376" O_E="0.0" SE="0.37823299785832587" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="0.14306020066889633" WEIGHT="1.2330208915844723"/>
<DICH_DATA CI_END="2.3142093919110254" CI_START="0.8091645396612035" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.3644026517796553" LOG_CI_START="-0.0919631577436773" LOG_EFFECT_SIZE="0.136219747017989" MODIFIED="2009-09-14 10:08:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="387" O_E="0.0" SE="0.2680715355611962" STUDY_ID="STD-Scotto-2005" TOTAL_1="26" TOTAL_2="52" VAR="0.07186234817813765" WEIGHT="2.4546403040122233"/>
<DICH_DATA CI_END="2.128278660395544" CI_START="0.5393838715932618" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.328028490516341" LOG_CI_START="-0.2681020437614546" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2009-09-14 10:08:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="377" O_E="0.0" SE="0.35017002672851316" STUDY_ID="STD-Tsubota-2005" TOTAL_1="28" TOTAL_2="20" VAR="0.12261904761904761" WEIGHT="1.4385710834016843"/>
<DICH_DATA CI_END="1.32831790191945" CI_START="0.83714450752687" EFFECT_SIZE="1.0545112781954886" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="49" LOG_CI_END="0.12330202573004048" LOG_CI_START="-0.07719956780781415" LOG_EFFECT_SIZE="0.023051228961113182" MODIFIED="2009-09-14 10:08:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="382" O_E="0.0" SE="0.11777562854303061" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.013871098678705927" WEIGHT="12.716816473219161"/>
<DICH_DATA CI_END="2.7902971569505266" CI_START="0.5599762004229086" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.44565045658963615" LOG_CI_START="-0.2518304305735233" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-09-14 10:08:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="390" O_E="0.0" SE="0.4097037257057139" STUDY_ID="STD-Derbala-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.16785714285714284" WEIGHT="1.0508710751090318"/>
<DICH_DATA CI_END="3.9220926091785993" CI_START="1.1603782889930911" EFFECT_SIZE="2.1333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.593517844094743" LOG_CI_START="0.06459959443370657" LOG_EFFECT_SIZE="0.32905871926422475" MODIFIED="2009-09-14 10:08:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="381" O_E="0.0" SE="0.3106891980384542" STUDY_ID="STD-Wakil-2006" TOTAL_1="18" TOTAL_2="32" VAR="0.0965277777777778" WEIGHT="1.827414038113547"/>
<DICH_DATA CI_END="2.274740625322729" CI_START="0.7610986148420958" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.3569318838885388" LOG_CI_START="-0.11855906845012143" LOG_EFFECT_SIZE="0.11918640771920867" MODIFIED="2009-09-14 10:08:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="389" O_E="0.0" SE="0.2793057391219034" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="0.07801169590643274" WEIGHT="2.2611508970473575"/>
<DICH_DATA CI_END="2.965569021857373" CI_START="0.6732913166880276" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4721080364330698" LOG_CI_START="-0.17179698651050676" LOG_EFFECT_SIZE="0.1501555249612815" MODIFIED="2009-09-14 10:08:34 +0200" MODIFIED_BY="Tahany Awad" ORDER="388" O_E="0.0" SE="0.37823299785832587" STUDY_ID="STD-Horsmans-2008" TOTAL_1="23" TOTAL_2="26" VAR="0.14306020066889633" WEIGHT="1.2330208915844723"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9831314781272508" CI_END="1.231693867461427" CI_START="0.9220480458798255" DF="3" EFFECT_SIZE="1.0656833130039025" ESTIMABLE="YES" EVENTS_1="167" EVENTS_2="151" I2="0.0" ID="CMP-003.06.04" LOG_CI_END="0.09050277910018807" LOG_CI_START="-0.03524644823396842" LOG_EFFECT_SIZE="0.02762816543310984" MODIFIED="2009-09-15 15:56:04 +0200" MODIFIED_BY="Tahany Awad" NO="4" P_CHI2="0.8053335606728301" P_Z="0.38910520885965005" STUDIES="4" TAU2="0.0" TOTAL_1="339" TOTAL_2="332" WEIGHT="100.00000000000003" Z="0.8612412235967868">
<NAME>Peginterferon alpha-2b versus consensus interferon</NAME>
<DICH_DATA CI_END="3.2554443304763296" CI_START="0.3212990204096413" EFFECT_SIZE="1.0227272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5126102731205879" LOG_CI_START="-0.4930905985422754" LOG_EFFECT_SIZE="0.00975983728915624" MODIFIED="2009-09-14 10:45:31 +0200" MODIFIED_BY="Tahany Awad" ORDER="393" O_E="0.0" SE="0.5907536703143696" STUDY_ID="STD-Dollinger-2005" TOTAL_1="22" TOTAL_2="18" VAR="0.34898989898989896" WEIGHT="1.5634104026492484"/>
<DICH_DATA CI_END="2.138945474742073" CI_START="0.595420689890192" EFFECT_SIZE="1.128526645768025" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3301997138279745" LOG_CI_START="-0.22517607840776227" LOG_EFFECT_SIZE="0.052511817710106094" MODIFIED="2009-09-14 10:45:21 +0200" MODIFIED_BY="Tahany Awad" ORDER="396" O_E="0.0" SE="0.32623048951378114" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="29" TOTAL_2="30" VAR="0.10642633228840126" WEIGHT="5.126686476630385"/>
<DICH_DATA CI_END="1.6137622339028166" CI_START="0.8924743107464483" EFFECT_SIZE="1.2001005530417295" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="51" LOG_CI_END="0.20783954766570586" LOG_CI_START="-0.04940427590106791" LOG_EFFECT_SIZE="0.07921763588231896" MODIFIED="2009-09-14 10:45:11 +0200" MODIFIED_BY="Tahany Awad" ORDER="394" O_E="0.0" SE="0.15110629534058637" STUDY_ID="STD-Rahman-2007a" TOTAL_1="156" TOTAL_2="154" VAR="0.022833112491556513" WEIGHT="23.895753971434335"/>
<DICH_DATA CI_END="1.2131071622648262" CI_START="0.8569730573893487" EFFECT_SIZE="1.0196078431372548" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="85" LOG_CI_END="0.08389916683905466" LOG_CI_START="-0.06703283176532913" LOG_EFFECT_SIZE="0.008433167536862764" MODIFIED="2009-09-14 10:45:11 +0200" MODIFIED_BY="Tahany Awad" ORDER="395" O_E="0.0" SE="0.08865820310565761" STUDY_ID="STD-Rahman-2007b" TOTAL_1="132" TOTAL_2="130" VAR="0.007860276977924036" WEIGHT="69.41414914928605"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.9224114694732757" CI_START="1.0479359364655019" DF="0" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" I2="0.0" ID="CMP-003.06.05" LOG_CI_END="0.4657413636656654" LOG_CI_START="0.02033473370692358" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2009-09-15 15:56:11 +0200" MODIFIED_BY="Tahany Awad" NO="5" P_CHI2="1.0" P_Z="0.03244169412580488" STUDIES="1" TAU2="0.0" TOTAL_1="32" TOTAL_2="32" WEIGHT="100.0" Z="2.1389256030704056">
<NAME>Peginterferon alpha-2b versus leucocyte interferon</NAME>
<DICH_DATA CI_END="2.9224114694732757" CI_START="1.0479359364655019" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.4657413636656654" LOG_CI_START="0.02033473370692358" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2009-09-14 10:28:20 +0200" MODIFIED_BY="Tahany Awad" ORDER="392" O_E="0.0" SE="0.26163405923614175" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.06845238095238093" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="71.52516562416292" CI_END="1.5641721538928692" CI_START="1.2634763796743973" CI_STUDY="95" CI_TOTAL="95" DF="26" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4058074442070887" ESTIMABLE="YES" EVENTS_1="1673" EVENTS_2="1081" I2="63.64915792489047" I2_Q="41.50445672179541" ID="CMP-003.07" LOG_CI_END="0.19428455011205759" LOG_CI_START="0.10156712732205446" LOG_EFFECT_SIZE="0.14792583871705606" METHOD="MH" MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Tahany Awad" NO="7" P_CHI2="3.968843961588142E-6" P_Q="0.19104620117976479" P_Z="3.9996402969882813E-10" Q="1.709531947150236" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.04235474272055201" TOTALS="SUB" TOTAL_1="3300" TOTAL_2="2804" WEIGHT="200.0" Z="6.25404174412775">
<NAME>Sustained virological response in trials with or without amantadine</NAME>
<GROUP_LABEL_1>PEG + RBV</GROUP_LABEL_1>
<GROUP_LABEL_2>INF + RBV</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours INF + RBV</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours PEG + RBV</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="61.531837922232626" CI_END="1.5326229800120688" CI_START="1.2174435872827856" DF="23" EFFECT_SIZE="1.3659729202066657" ESTIMABLE="YES" EVENTS_1="1553" EVENTS_2="1010" I2="62.620976755043976" ID="CMP-003.07.01" LOG_CI_END="0.185435333042157" LOG_CI_START="0.08544884643746536" LOG_EFFECT_SIZE="0.13544208973981117" MODIFIED="2009-07-22 12:25:23 +0200" MODIFIED_BY="Tahany Awad" NO="1" P_CHI2="2.287584943960752E-5" P_Z="1.0965536675084609E-7" STUDIES="24" TAU2="0.03858557818431171" TOTAL_1="2998" TOTAL_2="2502" WEIGHT="100.00000000000001" Z="5.309949912139743">
<NAME>Trial without amantadine</NAME>
<DICH_DATA CI_END="2.587460148665582" CI_START="0.8695786101905303" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.4128736696348625" LOG_CI_START="-0.06069115152350007" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2009-07-09 18:02:20 +0200" MODIFIED_BY="Tahany Awad" ORDER="360" O_E="0.0" SE="0.2781743201320934" STUDY_ID="STD-Al_x002d_Faleh-2004" TOTAL_1="48" TOTAL_2="48" VAR="0.07738095238095238" WEIGHT="2.9745765913912563"/>
<DICH_DATA CI_END="1.8820793587258766" CI_START="1.0156744853200899" EFFECT_SIZE="1.3825989960959286" ESTIMABLE="YES" EVENTS_1="67" EVENTS_2="44" LOG_CI_END="0.27463793170022405" LOG_CI_START="0.006754542711053098" LOG_EFFECT_SIZE="0.1406962372056386" MODIFIED="2009-07-09 18:02:20 +0200" MODIFIED_BY="Tahany Awad" ORDER="361" O_E="0.0" SE="0.15735602873640067" STUDY_ID="STD-Bruno-2004" TOTAL_1="163" TOTAL_2="148" VAR="0.024760919779690957" WEIGHT="5.445467994147294"/>
<DICH_DATA CI_END="3.5357884851784527" CI_START="1.4846729778611794" EFFECT_SIZE="2.291176470588235" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="17" LOG_CI_END="0.5484862771364655" LOG_CI_START="0.17163080412415313" LOG_EFFECT_SIZE="0.3600585406303093" MODIFIED="2009-07-09 18:02:20 +0200" MODIFIED_BY="Tahany Awad" ORDER="362" O_E="0.0" SE="0.22136677031210955" STUDY_ID="STD-Cariti-2002" TOTAL_1="60" TOTAL_2="57" VAR="0.04900324699841427" WEIGHT="3.9383029340177007"/>
<DICH_DATA CI_END="2.7902971569505266" CI_START="0.5599762004229086" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.44565045658963615" LOG_CI_START="-0.2518304305735233" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-07-09 18:02:20 +0200" MODIFIED_BY="Tahany Awad" ORDER="363" O_E="0.0" SE="0.4097037257057139" STUDY_ID="STD-Derbala-2005" TOTAL_1="35" TOTAL_2="35" VAR="0.16785714285714284" WEIGHT="1.670929958024655"/>
<DICH_DATA CI_END="5.180388604362314" CI_START="1.489473082428314" EFFECT_SIZE="2.7777777777777777" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="9" LOG_CI_END="0.7143623393591298" LOG_CI_START="0.1730326591062955" LOG_EFFECT_SIZE="0.44369749923271273" MODIFIED="2009-07-09 18:02:20 +0200" MODIFIED_BY="Tahany Awad" ORDER="364" O_E="0.0" SE="0.3179797338056486" STUDY_ID="STD-Derbala-2006" TOTAL_1="40" TOTAL_2="40" VAR="0.10111111111111112" WEIGHT="2.4692877758527922"/>
<DICH_DATA CI_END="3.2554443304763296" CI_START="0.3212990204096413" EFFECT_SIZE="1.0227272727272727" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5126102731205879" LOG_CI_START="-0.4930905985422754" LOG_EFFECT_SIZE="0.00975983728915624" MODIFIED="2009-07-09 18:02:20 +0200" MODIFIED_BY="Tahany Awad" ORDER="365" O_E="0.0" SE="0.5907536703143696" STUDY_ID="STD-Dollinger-2005" TOTAL_1="22" TOTAL_2="18" VAR="0.34898989898989896" WEIGHT="0.8900236148048182"/>
<DICH_DATA CI_END="1.6490129785229268" CI_START="0.850420578189295" EFFECT_SIZE="1.1842105263157894" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="38" LOG_CI_END="0.21722407376380887" LOG_CI_START="-0.07036623944674189" LOG_EFFECT_SIZE="0.07342891715853349" MODIFIED="2009-07-09 18:02:20 +0200" MODIFIED_BY="Tahany Awad" ORDER="366" O_E="0.0" SE="0.16893197357488735" STUDY_ID="STD-Esmat-2003" TOTAL_1="100" TOTAL_2="100" VAR="0.02853801169590643" WEIGHT="5.139047655524056"/>
<DICH_DATA CI_END="1.4477692368960238" CI_START="1.111778062982932" EFFECT_SIZE="1.2686993646418125" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="197" LOG_CI_END="0.16069934423037288" LOG_CI_START="0.04601810051792744" LOG_EFFECT_SIZE="0.10335872237415017" MODIFIED="2009-07-09 18:03:19 +0200" MODIFIED_BY="Tahany Awad" ORDER="367" O_E="0.0" SE="0.06736433023800226" STUDY_ID="STD-Fried-2002" TOTAL_1="453" TOTAL_2="444" VAR="0.004537952988414626" WEIGHT="7.999143804402994"/>
<DICH_DATA CI_END="1.5453227913002832" CI_START="0.770119130661838" EFFECT_SIZE="1.0909090909090908" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="22" LOG_CI_END="0.18901920986974008" LOG_CI_START="-0.11344208809094057" LOG_EFFECT_SIZE="0.037788560889399754" MODIFIED="2009-07-09 18:03:19 +0200" MODIFIED_BY="Tahany Awad" ORDER="368" O_E="0.0" SE="0.1776672636296754" STUDY_ID="STD-Hinrichsen-2002" TOTAL_1="36" TOTAL_2="36" VAR="0.031565656565656575" WEIGHT="4.9172523966792925"/>
<DICH_DATA CI_END="1.4710974778935566" CI_START="0.8843842405219245" EFFECT_SIZE="1.1406206318143697" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="73" LOG_CI_END="0.16764145091153848" LOG_CI_START="-0.05335900502971767" LOG_EFFECT_SIZE="0.057141222940910424" MODIFIED="2009-07-09 18:03:19 +0200" MODIFIED_BY="Tahany Awad" ORDER="369" O_E="0.0" SE="0.1298167617897941" STUDY_ID="STD-Horsmans-2008" TOTAL_1="98" TOTAL_2="160" VAR="0.016852391641588145" WEIGHT="6.222293642562948"/>
<DICH_DATA CI_END="2.965569021857373" CI_START="0.6732913166880276" EFFECT_SIZE="1.4130434782608696" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.4721080364330698" LOG_CI_START="-0.17179698651050676" LOG_EFFECT_SIZE="0.1501555249612815" MODIFIED="2009-07-09 18:03:19 +0200" MODIFIED_BY="Tahany Awad" ORDER="370" O_E="0.0" SE="0.37823299785832587" STUDY_ID="STD-Izumi-2004" TOTAL_1="23" TOTAL_2="26" VAR="0.14306020066889633" WEIGHT="1.8990329936764232"/>
<DICH_DATA CI_END="1.32831790191945" CI_START="0.83714450752687" EFFECT_SIZE="1.0545112781954886" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="49" LOG_CI_END="0.12330202573004048" LOG_CI_START="-0.07719956780781415" LOG_EFFECT_SIZE="0.023051228961113182" MODIFIED="2009-07-09 18:03:19 +0200" MODIFIED_BY="Tahany Awad" ORDER="371" O_E="0.0" SE="0.11777562854303061" STUDY_ID="STD-Lee-2005" TOTAL_1="76" TOTAL_2="77" VAR="0.013871098678705927" WEIGHT="6.575927943454737"/>
<DICH_DATA CI_END="1.213964321130765" CI_START="0.9715225770566696" EFFECT_SIZE="1.0859989621172808" ESTIMABLE="YES" EVENTS_1="518" EVENTS_2="235" LOG_CI_END="0.08420592284819177" LOG_CI_START="-0.012547102447421674" LOG_EFFECT_SIZE="0.035829410200385034" MODIFIED="2009-07-09 18:03:55 +0200" MODIFIED_BY="Tahany Awad" ORDER="372" O_E="0.0" SE="0.05683320599384272" STUDY_ID="STD-Manns-2001" TOTAL_1="1025" TOTAL_2="505" VAR="0.00323001330353856" WEIGHT="8.249347072001136"/>
<DICH_DATA CI_END="2.9224114694732757" CI_START="1.0479359364655019" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.4657413636656654" LOG_CI_START="0.02033473370692358" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2009-07-09 18:03:55 +0200" MODIFIED_BY="Tahany Awad" ORDER="373" O_E="0.0" SE="0.26163405923614175" STUDY_ID="STD-Napoli-2005" TOTAL_1="32" TOTAL_2="32" VAR="0.06845238095238093" WEIGHT="3.222700899629203"/>
<DICH_DATA CI_END="2.465187633311933" CI_START="1.4892241124860108" EFFECT_SIZE="1.9160419790104948" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="58" LOG_CI_END="0.3918499804127436" LOG_CI_START="0.17296005939892112" LOG_EFFECT_SIZE="0.2824050199058324" MODIFIED="2009-07-09 18:04:35 +0200" MODIFIED_BY="Tahany Awad" ORDER="387" O_E="0.0" SE="0.12857702312610314" STUDY_ID="STD-Nevens-2010" TOTAL_1="230" TOTAL_2="213" VAR="0.016532050875970462" WEIGHT="6.258457286452214"/>
<DICH_DATA CI_END="1.6137622339028166" CI_START="0.8924743107464483" EFFECT_SIZE="1.2001005530417295" ESTIMABLE="YES" EVENTS_1="62" EVENTS_2="51" LOG_CI_END="0.20783954766570586" LOG_CI_START="-0.04940427590106791" LOG_EFFECT_SIZE="0.07921763588231896" MODIFIED="2009-07-22 12:25:23 +0200" MODIFIED_BY="Tahany Awad" ORDER="375" O_E="0.0" SE="0.15110629534058637" STUDY_ID="STD-Rahman-2007a" TOTAL_1="156" TOTAL_2="154" VAR="0.022833112491556513" WEIGHT="5.616390115262205"/>
<DICH_DATA CI_END="1.2131071622648262" CI_START="0.8569730573893487" EFFECT_SIZE="1.0196078431372548" ESTIMABLE="YES" EVENTS_1="88" EVENTS_2="85" LOG_CI_END="0.08389916683905466" LOG_CI_START="-0.06703283176532913" LOG_EFFECT_SIZE="0.008433167536862764" MODIFIED="2009-07-22 12:25:23 +0200" MODIFIED_BY="Tahany Awad" ORDER="376" O_E="0.0" SE="0.08865820310565761" STUDY_ID="STD-Rahman-2007b" TOTAL_1="132" TOTAL_2="130" VAR="0.007860276977924036" WEIGHT="7.426956097575886"/>
<DICH_DATA CI_END="2.274740625322729" CI_START="0.7610986148420958" EFFECT_SIZE="1.3157894736842106" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.3569318838885388" LOG_CI_START="-0.11855906845012143" LOG_EFFECT_SIZE="0.11918640771920867" MODIFIED="2009-07-09 18:04:48 +0200" MODIFIED_BY="Tahany Awad" ORDER="377" O_E="0.0" SE="0.2793057391219034" STUDY_ID="STD-Roffi-2008" TOTAL_1="57" TOTAL_2="36" VAR="0.07801169590643274" WEIGHT="2.9584853496302768"/>
<DICH_DATA CI_END="2.3142093919110254" CI_START="0.8091645396612035" EFFECT_SIZE="1.368421052631579" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="19" LOG_CI_END="0.3644026517796553" LOG_CI_START="-0.0919631577436773" LOG_EFFECT_SIZE="0.136219747017989" MODIFIED="2009-07-09 18:04:48 +0200" MODIFIED_BY="Tahany Awad" ORDER="378" O_E="0.0" SE="0.2680715355611962" STUDY_ID="STD-Scotto-2005" TOTAL_1="26" TOTAL_2="52" VAR="0.07186234817813765" WEIGHT="3.123203291950364"/>
<DICH_DATA CI_END="2.6453240320969122" CI_START="1.0500708964473708" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="18" LOG_CI_END="0.42247887740424933" LOG_CI_START="0.021218621828463496" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2009-07-09 18:04:48 +0200" MODIFIED_BY="Tahany Awad" ORDER="379" O_E="0.0" SE="0.23570226039551584" STUDY_ID="STD-Shobokshi-2003" TOTAL_1="60" TOTAL_2="60" VAR="0.05555555555555555" WEIGHT="3.6641934667737255"/>
<DICH_DATA CI_END="2.138945474742073" CI_START="0.595420689890192" EFFECT_SIZE="1.128526645768025" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="11" LOG_CI_END="0.3301997138279745" LOG_CI_START="-0.22517607840776227" LOG_EFFECT_SIZE="0.052511817710106094" MODIFIED="2009-07-09 18:04:48 +0200" MODIFIED_BY="Tahany Awad" ORDER="380" O_E="0.0" SE="0.32623048951378114" STUDY_ID="STD-Sj_x00f6_gren-2007" TOTAL_1="29" TOTAL_2="30" VAR="0.10642633228840126" WEIGHT="2.3787792746113983"/>
<DICH_DATA CI_END="8.136576897762474" CI_START="2.1715317787493897" EFFECT_SIZE="4.203431372549019" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="8" LOG_CI_END="0.9104417332569528" LOG_CI_START="0.336766189320866" LOG_EFFECT_SIZE="0.6236039612889093" MODIFIED="2009-07-09 18:04:48 +0200" MODIFIED_BY="Tahany Awad" ORDER="381" O_E="0.0" SE="0.3369798542477986" STUDY_ID="STD-Thakeb-2003" TOTAL_1="51" TOTAL_2="49" VAR="0.11355542216886758" WEIGHT="2.2673133895762816"/>
<DICH_DATA CI_END="2.128278660395544" CI_START="0.5393838715932618" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.328028490516341" LOG_CI_START="-0.2681020437614546" LOG_EFFECT_SIZE="0.029963223377443202" MODIFIED="2009-07-09 18:04:48 +0200" MODIFIED_BY="Tahany Awad" ORDER="382" O_E="0.0" SE="0.35017002672851316" STUDY_ID="STD-Tsubota-2005" TOTAL_1="28" TOTAL_2="20" VAR="0.12261904761904761" WEIGHT="2.1398351659280044"/>
<DICH_DATA CI_END="3.9220926091785993" CI_START="1.1603782889930911" EFFECT_SIZE="2.1333333333333333" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.593517844094743" LOG_CI_START="0.06459959443370657" LOG_EFFECT_SIZE="0.32905871926422475" MODIFIED="2009-07-09 18:04:48 +0200" MODIFIED_BY="Tahany Awad" ORDER="383" O_E="0.0" SE="0.3106891980384542" STUDY_ID="STD-Wakil-2006" TOTAL_1="18" TOTAL_2="32" VAR="0.0965277777777778" WEIGHT="2.5530512860703474"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="2.4760329459367636" CI_END="2.2304163457774315" CI_START="1.2609283716860489" DF="2" EFFECT_SIZE="1.6770197527349175" ESTIMABLE="YES" EVENTS_1="120" EVENTS_2="71" I2="19.22563052797607" ID="CMP-003.07.02" LOG_CI_END="0.34838593919003186" LOG_CI_START="0.10069041673562341" LOG_EFFECT_SIZE="0.22453817796282763" MODIFIED="2009-07-09 18:05:27 +0200" MODIFIED_BY="Tahany Awad" NO="2" P_CHI2="0.2899588737372386" P_Z="3.8021446033834874E-4" STUDIES="3" TAU2="0.014253873919086878" TOTAL_1="302" TOTAL_2="302" WEIGHT="99.99999999999999" Z="3.553449312289374">
<NAME>Trial with amantadine</NAME>
<DICH_DATA CI_END="2.1462413599066443" CI_START="0.7112332211862739" EFFECT_SIZE="1.2355072463768115" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="18" LOG_CI_END="0.3316785598393653" LOG_CI_START="-0.14798796598480524" LOG_EFFECT_SIZE="0.09184529692728" MODIFIED="2009-07-09 18:05:05 +0200" MODIFIED_BY="Tahany Awad" ORDER="384" O_E="0.0" SE="0.2817584916567142" STUDY_ID="STD-Fargion-2004" TOTAL_1="92" TOTAL_2="93" VAR="0.07938784762066668" WEIGHT="22.606957961112204"/>
<DICH_DATA CI_END="2.603101809315667" CI_START="1.47378725784399" EFFECT_SIZE="1.9586776859504131" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="40" LOG_CI_END="0.4154911540329175" LOG_CI_START="0.1684347973543901" LOG_EFFECT_SIZE="0.29196297569365376" MODIFIED="2009-07-09 18:05:17 +0200" MODIFIED_BY="Tahany Awad" ORDER="385" O_E="0.0" SE="0.14512212686165601" STUDY_ID="STD-Mangia-2005" TOTAL_1="121" TOTAL_2="120" VAR="0.021060431704850578" WEIGHT="59.94608770731222"/>
<DICH_DATA CI_END="2.7755764012248623" CI_START="0.7696039905850021" EFFECT_SIZE="1.4615384615384615" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.44335318633323517" LOG_CI_START="-0.11373268904125085" LOG_EFFECT_SIZE="0.16481024864599217" MODIFIED="2009-07-09 18:05:27 +0200" MODIFIED_BY="Tahany Awad" ORDER="386" O_E="0.0" SE="0.32723500081453055" STUDY_ID="STD-PRETTY-2005" TOTAL_1="89" TOTAL_2="89" VAR="0.1070827457580858" WEIGHT="17.44695433157556"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-02-20 09:39:10 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-02-20 09:39:10 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about all methodological quality items presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiMAAADnCAMAAAD7EqYIAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-02-20 09:39:10 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAASgAAARECAIAAABJaxvIAAAxqUlEQVR42u3dsY4cx3bG8QUMGA42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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-02-20 09:39:10 +0100" MODIFIED_BY="Tahany Awad" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: peginterferon plus ribavirin versus non-pegylated interferon plus ribavirin, outcome: 1.2 Adverse events leading to treatment discontinuation.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-01-25 22:46:19 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_MORE_DECIMALS:NO;SHOW_ROB_TABLE:NO;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: pegylated interferon plus ribavirin versus interferon plus ribavirin, outcome: 1.1 Sustained virological response.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuoAAAIwCAMAAADnHL7dAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-01-25 22:46:10 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.03" SETTINGS="SHOW_CI_LINES:YES;DISTINGUISH_SUBGROUPS:YES;SHOW_EFFECT_ESTIMATE:YES;SHOW_AUTOGENERATED_NUM_FOR_STUDY_NAMES:NO;SHOW_STUDY_NAMES:NO;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: pegylated interferon plus ribavirin versus interferon plus ribavirin, outcome: 1.1 Sustained virological response.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAlgAAAGQCAMAAABF6+6qAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Adjusted Boundaries Sketch.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2014-02-20 09:38:06 +0100" MODIFIED_BY="[Empty name]" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis (TSA): pegylated interferon plus ribavirin versus interferon plus ribavirin - sustained virological response.<BR/>
<BR/>Lan-DeMets statistical monitoring boundaries for assessing statistical significance regarding sustained virological response to pegylated interferon plus ribavirin versus interferon plus ribavirin. The diversity-adjusted required information size of n = 14,486 was calculated based on an event proportion of 50.6% of participants in the interferon-treated group (Pc) with a risk ratio (RR) reduction of 10% in pegylated interferon group; an alpha (a, type I error) of 5%, a beta (b, type II error) of 10%, and the observed diversity D = 72%.<BR/>
<BR/>The solid blue curve presents the cumulative meta-analysis test Z-score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two-sided Lan-DeMets trial sequential boundaries. The cumulative Z-score crosses the boundaries for superiority, and this corresponds with superiority of pegylated interferon.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAz0AAAJlCAIAAAB/oAsMAABUS0lEQVR42u3df0hb+cLgf5/H9cm4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</FILE>
</FIGURE>
<FIGURE FILENAME="Adjusted Boundaries Sketch.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2014-02-20 09:39:05 +0100" MODIFIED_BY="[Empty name]" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Trial sequential analysis (TSA): pegylated interferon plus ribavirin versus interferon plus ribavirin - sustained virological response.<BR/>
<BR/>Lan-DeMets statistical monitoring boundaries for assessing statistical significance regarding sustained virological response to pegylated interferon plus ribavirin versus interferon plus ribavirin. The diversity-adjusted required information size of n = 20,513 was calculated based on an event proportion of 50.6% of participants in the interferon-treated group (Pc) with a risk ratio (RR) reduction of 10% in the pegylated interferon group; an alpha (a, type I error) of 1%, a beta (b, type II error) of 10%, and the observed diversity D = 72%.<BR/>
<BR/>The solid blue curve presents the cumulative meta-analysis test Z-score and the inward sloping red curves present the adjusted threshold for statistical significance according to the two-sided Lan-DeMets trial sequential monitoring boundaries. The cumulative Z-score crosses the boundaries for superiority, and this corresponds with the superiority of pegylated interferon.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA5sAAAK7CAIAAADz0gzFAABU60lEQVR42uzdf2gUd+L4f3l7spdv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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-01-23 15:12:13 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2014-01-23 15:12:13 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2014-01-06 13:30:55 +0100" MODIFIED_BY="Sarah Louise Klingenberg">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2014-01-23 15:12:13 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="3" ROWS="7">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search date</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Group Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>September 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(interferon alfa or interferon alpha or intron A or roferon A or pegylated interferon-2a or pegylated interferon-2b or pegasus or pegasys or pegintron or viraferonPeg or peginterferon or peg-ifn) AND (ribavirin OR riba OR copegus OR rebetol OR ribasphere OR vilona OR virazole) AND (hepatitis C OR hep C OR HCV)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Central Register of Controlled Trials (CENTRAL)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 8, 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor: [Interferon-alpha] explode all trees</P>
<P>#2 interferon al*a or intron or roferon or pegylated interferon-2a or pegylated interferon-2b or pegas*s or pegintron or viraferonpeg or peginterferon or peg-ifn</P>
<P>#3 #1 or #2</P>
<P>#4 MeSH descriptor: [Ribavirin] explode all trees</P>
<P>#5 ribavirin or riba or copegus or rebetol or ribasphere or vilona or virazole</P>
<P>#6 #4 or #5</P>
<P>#7 MeSH descriptor: [Hepatitis C, Chronic] explode all trees</P>
<P>#8 hepatitis c or hep c or hcv</P>
<P>#9 #7 or #8</P>
<P>#10 #3 and #6 and #9<BR/>
</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1946 to</P>
<P>September 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Interferon-alpha/</P>
<P>2. (interferon al$a or intron or roferon or pegylated interferon-2a or pegylated interferon-2b or pegas$s or pegintron or viraferonpeg or peginterferon or peg-ifn).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>3. 1 or 2</P>
<P>4. exp Ribavirin/</P>
<P>5. (ribavirin or riba or copegus or rebetol or ribasphere or vilona or virazole).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>6. 4 or 5</P>
<P>7. exp Hepatitis C, Chronic/</P>
<P>8. (hepatitis c or hep c or hcv).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>9. 7 or 8</P>
<P>10. 3 and 6 and 9</P>
<P>11. (random* or blind* or placebo* or meta-analysis).mp. [mp=protocol supplementary concept, rare disease supplementary concept, title, original title, abstract, name of substance word, subject heading word, unique identifier]</P>
<P>12. 10 and 11</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1974 to</P>
<P>September 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1. exp Alpha Interferon/</P>
<P>2. exp peginterferon/ or exp peginterferon alpha2a/ or exp peginterferon alpha2b/ or exp recombinant alpha2a interferon/ or exp recombinant alpha2b interferon/</P>
<P>3. (interferon al$a or intron or roferon or pegylated interferon-2a or pegylated interferon-2b or pegas$s or pegintron or viraferonpeg or peginterferon or peg-ifn).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>4. 1 or 2 or 3</P>
<P>5. exp Ribavirin/</P>
<P>6. (ribavirin or riba or copegus or rebetol or ribasphere or vilona or virazole).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>7. 6 or 5</P>
<P>8. exp Hepatitis C/</P>
<P>9. (hepatitis c or hep c or hcv).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>10. 8 or 9</P>
<P>11. 4 and 7 and 10</P>
<P>12. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]</P>
<P>13. 11 and 12</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index-Expanded </P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to September 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#6 #5 AND #4</P>
<P>#5 TS=(random* or blind* or placebo* or meta-analysis)</P>
<P>#4 #3 AND #2 AND #1</P>
<P>#3 TS=(chronic hepatitis c)</P>
<P>#2 TS=(ribavirin OR riba OR copegus OR rebetol OR ribasphere OR vilona OR virazole)</P>
<P>#1 TS=(interferon al*a or intron or roferon or pegylated interferon-2a or pegylated interferon-2b or pegas*s or pegintron or viraferonpeg or peginterferon or peg-ifn)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>LILACS</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1980 to September 2013</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>interferon AND ribavirin AND hepatitis C</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="AFF_08E2F89082E26AA2002F1D7AD97D8A77_1" NAME="PERSON" REVMAN_VERSION="5.1.0" TYPE="ADDRESS">
<ALIAS ALIAS_ID="08E2F89082E26AA2002F1D7AD97D8A77">
<ADDRESS>
<DEPARTMENT>The Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital</ORGANISATION>
<ADDRESS_1>Department 7812, Rigshospitalet, Copenhagen University Hospital</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>